TMF- 16073217  CONFIDENTIAL  205801  
GlaxoSmithKline group of companies   Protocol Amd 10 
1 TITLE PAGE  
Protocol Title: A Phase 2, Randomized, Open -label Platform Trial Utilizing a Master 
Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC 
Participants  
Protocol Number : 205801/ Amendment 10 
Short Title : Phase 2 NSCLC Master Protocol  
Compound 
Number:  [COMPANY_004]4428859A  
Study Phase:  2 
Sponsor Name [CONTACT_29560]:  
GlaxoSmithKline Research & Development Limited  
[ADDRESS_100187]  
Middlesex,  TW8 9GS  
[LOCATION_006] 
Regulatory Agency Identifying Number(s) :  
IND Number: [ADDRESS_100188] Number: 2018 -001316 -29  
 
Sponsor Signatory:  
Ivan Diaz -Padilla, MD, PhD , 
Global Clinical Head, Immuno - oncology  
Oncology Clinical Development  
 
 
Approval Date:  26 Apr 2023  
 
 
 
 
© [ADDRESS_100189]-2020  2017N337080_03  
Amendment 2  15-Jul-2019  2017N337080_02  
Amendment 1  20-Sep-2018  2017N337080_01  
Original Protocol  23-Jul-2018  2017N337080_00  
 
Amendment 10  26 Apr 2023  
Overall Rationale for the Amendment:  
This amendment is considered substantial  based on the criteria defined in EU Clinical 
Trial Regulation No 536/2014 of the European Parliament and the Council of the 
European Union  because it significantly impacts the s afety of participants . 
Overall rationale for the current amendment: Amendment  [ADDRESS_100190] of main changes in the protocol and their rationale:  
Section # and 
Name  [CONTACT_11029]  
6.[ADDRESS_100191] 
experienced any grade of  
myocarditis with prior 
immunotherapy.   To further ensure participant safety  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
3 TABLE OF CONTENTS  
PAGE  
1. SYNOPSIS  ................................ ................................ ................................ ...............  7 
2. SCHEDULE OF ACTIVITI ES (SOA)  ................................ ................................ ....... 10 
3. INTRODUCTION  ................................ ................................ ................................ .... 11 
3.1. Study Rationale  ................................ ................................ ..........................  11 
3.2. Background  ................................ ................................ ................................  11 
3.3. Benefit /Risk Assessment  ................................ ................................ ............  12 
3.4. Overall Benefit -Risk Conclusion  ................................ ................................ .. 13 
4. OBJECTIVES AND ENDPO INTS  ................................ ................................ ...........  13 
4.1. Objectives and Endpoints: Part 1  ................................ ................................  13 
4.2. Objectives and Endpoints: Part 2  ................................ ................................  13 
5. STUDY DESIGN  ................................ ................................ ................................ .... 15 
5.1. Overall  Design  ................................ ................................ ............................  15 
5.2. Duration of Treatment  ................................ ................................ .................  18 
5.3. Number of Participants  ................................ ................................ ...............  18 
5.3.1.  Sample Size: Part 1  ................................ ................................ ..... 18 
5.3.2.  Sample Size: Part 2  ................................ ................................ ..... 19 
5.4. Participant Completion and End of Study Definitions  ................................ .. 19 
5.4.1.  Participant Completion Definitions  ................................ ...............  19 
5.4.2.  Study Completion Definition  ................................ .........................  19 
5.5. Scientific Rationale for Study Design  ................................ ..........................  19 
5.5.1.  Steering Committee and Data Monitoring Committee (Part 
2) ................................ ................................ ................................ . 20 
5.6. Dose Justification  ................................ ................................ ........................  20 
6. STUDY POPULATION  ................................ ................................ ...........................  21 
6.1. Inclusion Criteria  ................................ ................................ .........................  21 
6.2. Exclusion Criteria  ................................ ................................ ........................  24 
6.3. Lifestyle and Dietary Restrictions  ................................ ................................  27 
6.4. Screen Failures ................................ ................................ ...........................  27 
6.5. Screening under Molecular Disease Characterization Initiative 
Study  ................................ ................................ ................................ ..........  29 
7. TREATMENTS  ................................ ................................ ................................ ....... 29 
7.1. Treatments Administered  ................................ ................................ ............  29 
7.2. Dose Modification  ................................ ................................ .......................  30 
7.2.1.  Dose and Safety Management Guidelines  ................................ ... 30 
7.3. Method of Treatment Assignment  ................................ ...............................  33 
7.4. Blinding  ................................ ................................ ................................ ....... 33 
7.5. Preparati on/Handling/Storage/Accountability  ................................ ..............  33 
7.5.1.  Preparation  ................................ ................................ ..................  33 
7.5.2.  Handling  ................................ ................................ ......................  34 
7.5.3.  Stora ge ................................ ................................ ........................  34 
7.5.4.  Accountability  ................................ ................................ ..............  34 
7.6. Treatment Compliance  ................................ ................................ ................  34 
7.7. Concomitant Therapy ................................ ................................ ..................  35 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
4 7.7.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]  ..........................  35 
7.7.2.  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014]  .........................  36 
7.8. Treatment after the End of the Study  ................................ ..........................  36 
8. DISCONTINUATION CRIT ERIA  ................................ ................................ .............  36 
8.1. Discontinuation of Study Treatment  ................................ ............................  36 
8.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................  38 
8.1.2.  Study Treatment Restart/Rechallenge  ................................ .........  [ADDRESS_100192] to Follow -up ................................ ................................ ........................  42 
9. STUDY ASSESSMENTS AN D PROCEDURES  ................................ .....................  42 
9.1. General Guidance  ................................ ................................ .......................  42 
9.1.1.  General Guidance for Treatment Continuity when 
Participants are Unable to Come into the Clinic  ...........................  43 
9.2. Screening and Critical Baseline Assessments  ................................ ............  44 
9.3. Efficacy Assessments  ................................ ................................ .................  45 
9.3.1.  Tumor Imaging and Disease Assessments  ................................ .. 46 
9.3.2.  Tumor Growth Kinetics  ................................ ................................  48 
9.3.3.  Survival Follow -up ................................ ................................ ....... 48 
9.4. Adverse Events ................................ ................................ ...........................  48 
9.4.1.  Time Peri od and Frequency for Collecting AE and SAE 
Information  ................................ ................................ ...................  48 
9.4.2.  Method of Detecting AEs and SAEs  ................................ .............  49 
9.4.3.  Follow -up of AEs and SAEs  ................................ .........................  49 
9.4.4.  Regulatory Reporting Requirements for SAEs  .............................  49 
9.4.5.  Cardiovascular and Death Events  ................................ ................  50 
9.4.6.  Pregnancy  ................................ ................................ ...................  50 
9.5. Safety Assessments  ................................ ................................ ...................  50 
9.5.1.  Physical Examinations  ................................ ................................ . 51 
9.5.2.  Performance Status  ................................ ................................ ..... 51 
9.5.3.  Vital Signs  ................................ ................................ ....................  51 
9.5.4.  Electrocardiograms  ................................ ................................ ...... 51 
9.5.5.  Echocardiogram ................................ ................................ ...........  52 
9.5.6.  Clinical Safety Laboratory Assessments  ................................ ...... 52 
9.6. Pharmacokinetics  ................................ ................................ .......................  53 
9.6.1.  Blood Sample Collection  ................................ ..............................  53 
9.6.2.  Sample Analysis  ................................ ................................ ..........  53 
9.7. Anti-Drug Antibodies  ................................ ................................ ...................  53 
9.8. Genetics  ................................ ................................ ................................ ..... 53 
9.9. Biomarker s ................................ ................................ ................................ . 54 
9.9.1.  Blood Biomarkers  ................................ ................................ ........  54 
9.9.2.  Tumor Tissue  ................................ ................................ ...............  54 
9.10.  Patient-Reported Outcome Assessments  ................................ ...................  55 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
5 10. STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  59 
10.1.  Primary Endpoint  ................................ ................................ ........................  59 
10.1.1.  Primary Endpoint: Part 1  ................................ ..............................  59 
10.1.2.  Primary Endpoint: Part 2  ................................ ..............................  59 
10.2.  Hypothesis  ................................ ................................ ................................ .. 60 
10.2.1.  Hypothesis: Part 1  ................................ ................................ ....... 60 
10.2.2.  Hypothesis: Part 2  ................................ ................................ ....... 60 
10.3. Sample Size Determination  ................................ ................................ ........  60 
10.3.1.  Sample Size: Part 1  ................................ ................................ ..... 60 
10.3.2.  Sample Size: Part 2  ................................ ................................ ..... 62 
10.3.3.  Interim Analyses  ................................ ................................ ..........  63 
10.3.4. Statistical Operating Characteristics  ................................ ............  65 
10.3.5.  Sample Size Sensitivity  ................................ ................................  67 
10.3.6.  Sample Size Re -estimation  ................................ ..........................  69 
10.4.  Populations for Analyses  ................................ ................................ ............  69 
10.5.  Statistical Analyses  ................................ ................................ .....................  70 
10.5.1.  Analysis  ................................ ................................ .......................  70 
10.5.2.  Other Secondary Analyses  ................................ ..........................  71 
10.5.3.  Safety Analyses  ................................ ................................ ...........  72 
10.5.4. Pharmacokinetic Analyses  ................................ ...........................  72 
10.5.5.  Pharmacokinetic/Pharmacodynamic Analyses  .............................  73 
10.5.6.  Tumor Kinetic Analyses  ................................ ...............................  73 
10.5.7.  Other Analyses  ................................ ................................ ............  73 
11. REFERENCES  ................................ ................................ ................................ ....... 74 
12. APPENDICES  ................................ ................................ ................................ ........  80 
12.1.  Appendix 1: Arms  ................................ ................................ .......................  [ADDRESS_100193] of Care Arm 1: Docetaxel Alone (Part 2 ONLY)  ............  80 
12.1.2.  Substudy 1 (Arm 2): Feladilimab and Docetaxel 
Combination  ................................ ................................ ................  93 
12.1.3.  Arm 3: Feladilimab and Ipi[INVESTIGATOR_90843]  .......................  110 
12.1.4.  Arm 4: [COMPANY_004]4428859A (Anti -TIGIT) and Dostarlimab (Anti -
PD-1) Combination  ................................ ................................ .... 148 
12.1.5.  Arm 5: [COMPANY_004]4428859A (Anti -TIGIT) plus Dostarlimab (Anti -
PD-1) plus [COMPANY_004]6097608 (Anti -CD96) Combination  ...................  197 
12.2.  Appendix 2: Abbreviations and Trademarks  ................................ ..............  252 
12.3.  Appendix  3: Clinical Laboratory Tests  ................................ .......................  256 
12.4.  Appendix 4: Study Governance Considerations  ................................ ........  257 
12.5.  Appendix 5: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ..... 261 
12.6.  Appendix  6: Contraceptive Guidance and Collection of Pregnancy 
Information  ................................ ................................ ................................  267 
12.7.  Appendix  7: Genetics  ................................ ................................ ................  271 
12.8.  Appendix 8: ECOG Performance Status  ................................ ...................  272 
12.9.  Appendix 9: CKD -EPI [INVESTIGATOR_90844] -Gault Formulas  ...............................  273 
12.10.  Appendix 10: Liver Safety: Required Actions and Follow -up 
Assessments and Study Treatment Rechallenge Guidelines  ....................  [ADDRESS_100194] at Baseline:  .............  [ADDRESS_100195] at Baseline:  ................................ .................  277 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
6 12.10.3.  Phase 2 Liver Chemistry Increas ed Monitoring Criteria 
with Continued Therapy  ................................ .............................  279 
12.10.4.  Liver Safety Drug Restart or Rechallenge Guidelines  ................  280 
12.11.  Appendix 11: Country -Specific Requirements  ................................ ...........  283 
12.12.  Appendix 12: Guidelines for Assessment of Disease, Disease 
Progression and Response Criteria  ................................ ..........................  [ADDRESS_100196] Guidelines  ................................ ................................ ... 289 
12.13.  Appendix 13: Supplemental Statistical Information  ................................ ... 295 
12.13.1.  Parameters for Pi[INVESTIGATOR_90845]  ...........................  295 
12.13.2.  Calculation of PoS of Phase 3 Given Data from Phase 2  ...........  295 
12.14.  Appendix 14: Immune -Related Diseases  ................................ ..................  301 
12.15.  Appendix 15: Protocol Amendment History  ................................ ...............  303 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
7 1. SYNOPSIS  
Protocol Title:  A Phase 2, Randomized, Open -label Platform Trial Utilizing a Master 
Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC 
Participants  
Short Title:  Phase 2 NSCLC Master Protocol  
Rationale:  
Study [ADDRESS_100197] of care (SoC) regimens in participants with relapsed/refractory advanced non -
small cell lung cancer (NSCLC) who have prior pl atinum -containing chemotherapy 
regimen and an immuno -oncology agent treatment failure, such as anti -programmed cell 
death protein 1 [PD1] / PD -Ligand 1 [PD -L1] – either in combination or as separate lines.  
NSCLC is considered intrinsically resistant to imm uno-oncology agents owing in part to 
its broad immune escape and suppressive features that include low antigenicity, despi[INVESTIGATOR_90846], and a high presence of 
regulatory T cells (Tregs). However, as shown by  [CONTACT_90975] -agent response rates of anti -
PD-[ADDRESS_100198] the potential to reinstate immunosurveillance; 
these may include regimens containing chemotherapy that posse ss advantageous 
immunological effects to potentially improve clinical efficacy.  
Objectives and Endpoints (Part 1)  
Objectives  Endpoints  
Primary  
To determine the safety and tolerability of novel 
regimen(s)  AEs, SAEs, DLTs, changes in safety/laboratory 
assessment parameters, dose modifications  
Secondary  
To provide a preliminary evaluation of the efficacy of 
experimental regimen(s)  Objective Response Rate (ORR)  
Disease Control Rate (DCR)  
Characterize the pharmacokinetic properties  
of experimental regimen(s)  PK parameters that include Cmax and Cmin for 
experimental regimen(s) (and investigational agent/s 
included in other arms), as data permit.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
8 Objectives and Endpoints (Part 2):  
Objectives  Endpoints  
Primary  
Determine whether experimental 
regimen(s) provide evidence for improved 
survival over SoC therapy  Overall survival as measured by [CONTACT_90976](s) 
versus SoC therapy for NSCLC  Milestone survival rate at 12 and 18 months  
Evaluate other measures of antitumor 
activity of the experimental regimen(s) 
compared with SoC therapy for NSCLC 
(RECIST 1.[ADDRESS_100199])  CR, PR, SD, PD, PFS, ORR, DOR, DCR  
iCR, iPR, iUPD, iCPD, iSD  
iPFS; iORR;  iDOR  
Evaluate the safety and tolerability of the 
experimental regimen(s) compared with 
SoC therapy for NSCLC  
 Frequency and severity of AEs, AESI; SAEs and AE/SAEs leading to 
dose modifications/delays/withdrawals; changes in laboratory, vital 
signs, and safety assessment parameters, including immunogenicity 
(ADA)  
Characterize the pharmacokinetic 
properties SoC or experimental regimen(s)  PK parameters that may include C max and C min for experimental 
regimen(s) and for SoC alone, as data permit.  
Determine immunogenicity of experimental 
regimen(s)  ADA incidence for experimental regimen(s)  (where appropriate)  
Note : The prefix “i”, used for response related abbreviations in the above table indicates immune responses assigned 
using iRECIST.  
ADA= anti -drug antibody; AE = adverse event/s; AESI = adverse event/s of special interest; C max = maximum 
concentration; C min = minimum concentration; CPD = confirmed progression; CR = complete response; DLT = Dose 
Limiting Toxicity’ DOR = duration of response; NSCLC = n on-small cell lung cancer; ORR = objective response rate; 
OS = overall survival; PD = progressive disease; PFS  = progression -free survival; PR  = partial response; RECIST = 
Response Evaluation Criteria In Solid Tumors; SAE = serious adverse event; SD = stab le disease; SoC = standard of 
care; UPD  = unconfirmed progression.  
 
Overall Design:  
This is a randomized Phase 2, open -label, platform trial utilizing a master protocol 
designed to study novel immunotherapy drug combinations compared with the current 
SoC, in the treatment of patients with advanced NSCLC who have progressed on prior 
anti-PD(L)1 and platinum -based combination chemotherapi[INVESTIGATOR_014]. The study will initially 
evaluate 2 treatment regimens/arms, with additional regimens/arms added via protocol 
amendment (s) (see the Study Design schematic below).  
The study will be conducted in two parts; Part 1 is an open -label, optional, non -
randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) 
evaluation. Part [ADDRESS_100200] evaluated in a separate study/arm for safety. This evaluation may occur prior to 
adoption into 205801 platform study (dose finding in a separate study) or as a distinct 
arm within this platform study (Pa rt 1) prior to Part 2. If an experimental regimen meets 
graduation requirements, i.e., passes criteria for safety and preliminary clinical activity, 
they may advance to Part 2. Graduation will be the term used throughout the protocol to 
TMF- [ADDRESS_100201]. Part 1 is open label single arm while Part 2 is randomized.  
For the randomized survival evaluation, participants will be stratified by [CONTACT_27183] 
(squamous vs. non -squamous ) and line of PD(L)1 therapy (1st vs. 2nd line). Patients with 
NSCLC with undetermined histology (i.e. NSCLC not otherwise specified) will be 
considered as non -squamous for stratification purposes.  
Each additional treatment arm/regimen will be analyzed rel ative to the SoC treatment and 
is considered a substudy within the overall master protocol, as depi[INVESTIGATOR_48393].  
Study Design  
 
 
NSCLC: non -small cell lung cancer; PD(L)1: Programmed Cell Death Protein 1 or Programmed Cell Death Ligand 1.  
Note:  Randomizati on of participants to experimental treatment regimens/arms may not occur in parallel. It should 
also be noted that the terms ‘regimen’ and ‘arm’ may be used interchangeably throughout the document.  
Number of Participants:  
As the study uses a master protoco l design, the sample size is not fixed.  
For Part 1, sample size will be defined for each regimen under the corresponding 
appendix in Section 12.1; a minimum of [ADDRESS_100202] 105 
(SoC arm: 35; experimental arm: 70 for substudy 1). Additional substudies and their 
corresponding experimental regimens will be added via protocol amendments. Each 

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
10 additional experimental arm will enroll a maximum of 70 participants. Randomization to 
SoC/Arm 1 will be minimized through an alteration of the randomization ratio once 35 
participants are randomized to that arm.  
Treatment Groups and Duration:  
Study participation begins with the signing of the informed consent form (ICF) within 
[ADDRESS_100203] dose. After a screening period of up to 28 days, eligible 
participants will be assigned a treatment arm if participating in Part 1 and receive study 
treatment (Day 1), or randomly assigned to a treatment arm (SoC or experimental) if 
participa ting in Part 2 and receive study treatment (Day 1).  
Unless otherwise specified in the treatment -specific appendix, investigational 
combination study treatment will continue at the indicated schedule for a maximum 
duration of approximately [ADDRESS_100204], or 
until disease progression, death, unacceptable toxicity, or withdrawal of consent. Single 
agent SoC treatment (i.e. docetaxel) may continue until disease progression, death, 
unacceptable toxicity, withdrawal of consent, or per institutional standard for docetaxel. 
After the study treatment is permanently discontinued, participants will be followed, via 
telephone contact, for survival and subsequent anticancer therapy every 12  weeks until 
death or the participa nt’s withdrawal from further contact. Participants permanently 
discontinuing study treatment prior to documented disease progression by [CONTACT_90977] 12 weeks for disease progression or participant’s withdrawal from 
further contact.  
The study will be considered ‘finished’ once the last participant from all open treatment 
arms has completed their last survival follow -up contact.  
2. SCHEDULE OF ACTIVITI ES (SoA) 
The Schedules of Activities can be found in the corresponding appendix for each 
arm in Section 12.1.  
• The timing and number of planned study assessments, including safety, 
pharmacokinetic, pharmacodynamic/biomarker or other assessments may be 
altered during the course of the study based on n ewly available data (e.g., to 
obtain data closer to the time of peak plasma concentrations) to ensure appropriate 
monitoring.  
• Any changes in the timing or addition of time points for any planned study 
assessments must be documented and approved by [CONTACT_90978] a protocol amendment. The  Institutional review board/  Independent 
ethics committees (IRB/IEC) will be informed of any safety issues that require 
altera tion of the safety monitoring scheme or amendment of the Informed consent 
form (ICF).  
TMF- [ADDRESS_100205] of care (SoC) 
regimen in participants with relapsed/refractory advanced non -small cell lung cancer 
(NSCLC) who have prior platinum -containing regimen and anti‑programmed cell death 
protein 1 [PD‑1] / PD -Ligand 1 [PD -L1] treatment failure. The study will  be conducted in 
two parts; Part 1 is an optional, non -randomized part based on safety and 
pharmacokinetics/pharmacodynamics (PK/PD) evaluation. Part [ADDRESS_100206] frequencies of somatic mutations 
[Lawrence , 2013], and a high presence of regulatory T ce lls (Tregs). However, as shown 
by [CONTACT_90975] -agent response rates of anti -PD-[ADDRESS_100207] some 
degree of prior T -cell immunity [ Brahmer , 2015; Rittmeyer , 2017; Reck , 2016]. Since 
effective anticancer immune response involves stepwise multistep processes [ Chen , 
2013], lung cancers may possess or acquire features that enable them to evade immune 
surveillance, suppress immune reactivity, proliferate, and survive within an inflammatory 
microenvironment the reby [CONTACT_90979]. Therefore, 
treatment modalities that incorporate combinations with agents targeting different 
processes within the immune cascade have the potential to reinstate immunosurveillance; 
these may include regimens containing chemotherapy that possess advantageous 
immunological effects to improve clinical efficacy [ Galluzzi , 2015].  
3.2. Background  
Cancer is one of the l eading causes of death worldwide, accounting for 8.[ADDRESS_100208] common cause of cancer death, accounting for 
1.69 million deaths worldwide [ Cancer Fact Sheet , 2017]. Globally, the incidence and 
mortality rates attributed to cancer vary across regions; nevertheless, lung cancer remains 
the leading cause of cancer death in men and the second leading cause of cancer death in 
women [ Torre , 2015]. Non -small cell lung cancer accounts for the vast majority of lung 
cancer cases (up to 85%), with disease stage, h istological subtype (e.g., adenocarcinoma, 
squamous, large cell, etc.), and molecular features playing a principal role in making 
treatment choices. In advanced -stage metastatic NSCLC positive for a specific molecular 
alteration (i.e., EGFR/ALK/ROS/BRAF), targeted single -agent approaches are 
recommended [ NCCN , 2021; Planchard , 2018; Postmus , 2017]. In metastatic non -
squamous NSCLC, the first -line option for some patients is the approved triplet regimen 
consistin g of pembrolizumab (an anti -PD-1 inhibitor) added to the 
pemetrexed/carboplatin backbone [ Langer , 2016; KEYTRUDA , 2018]. An alternative 
current standard for NSCLC (squamous or non -squamo us) is pembrolizumab as a single -
agent for (a) first -line treatment of metastatic NSCLC patients whose tumors have high 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
12 PD-L1 expression (Tumor Proportion Score [TPS] ≥50%) or, (b) in subsequent lines 
(post -platinum) of treatment of patients with metastati c NSCLC (squamous or non -
squamous) whose tumors express PD -L1 (TPS ≥1%) as determined by [CONTACT_13247] -approved 
test [ Reck , 2016; KEYTRUDA , 2018]. Additional subsequent -line treatment options 
include other single -agent anti -PD-1/PD -L1 inhibitors (e.g., nivolumab and 
atezolizumab) if not administered as first -line [ Brahmer , 2015; Rittmeyer , 2017]. In 
patients with advanced or metastatic non -squamous NSCLC without EGFR/ALK 
alternations and with PD -L1 TPS ≥1%, more durable responses were observed with 
pembrolizumab monotherapy co mpared to platinum -based chemotherapy alone, and 
support pembrolizumab as a standard first -line treatment option for all PD -L1-positive 
cancers [ Lopes , 2016]. Additionally, in patients with previously untreated metastatic 
squamous NSCLC, the addition of pembrolizumab to platinum -based chemotherapy 
show significant improved survival regardless of PD -L1 expression level, and may be 
considered as a  standard first -line treatment for metastatic squamous NSCLC regardless 
of PD -L1 status [ Paz-Ares , 2018]. Recently, ESMO clinical pra ctice guidelines have been 
updated to include the addition of atezolizumab to first -line chemotherapy in the 
metastatic non -small cell lung cancer setting [ Planchard , 2018]. Single -agent 
chemotherapy such as pemetrexed for non -squamous NSCLC (if not used as part of the 
platinum -containing chemotherapy regimen earlier) or gemcitabine for squamous 
NSCLC or docetaxel for all NSCLC sub -types have been relegated to later l ines and can 
be selected based on the patient’s treatment history, disease characteristics, and 
performance status.  
Docetaxel is approved by [CONTACT_90980] a single -agent for patients with 
locally advanced or metastatic NSCLC after platinum -based c hemotherapy [ TAXOTERE  
PI, 2020 and TAXOTERE  SmPC  2020]. With the recent approvals of nivolumab in the 
same line of therapy, i.e., after progression on platinum -based doublet [ OPDIVO  PI, 
2018], docetaxel h as been relegated to the status of a subsequent therapy, as noted in the 
ESMO/NCCN guidelines [ Herbst , 2016; Horn , 2017; Novello , 2016; NCCN , 2019]. The 
clinical activity of older single -agent chemotherapi[INVESTIGATOR_90847] -line 
treatment in NSCLC  is limited with response rates in the range of 9 to 24% [ Shepherd , 
2000; Hanna , 2004].  
Patients with NSCLC that has failed both a platinum -containing chemotherapy regimen 
and an anti -PD(L)1 inhibitor (used either in combination or as separate lines of therapy) 
have a high u nmet medical need for treatment advances with the potential to improve 
progression -free survival (PFS) and overall survival (OS).  
3.3. Benefit/Risk Assessment  
Benefits and risks for each combination partner can be found in the respective 
subsections under Secti on 12.1. Detailed information related to the known and expected 
benefits and risks including expected AEs of each experimental agent may be found in 
the corresponding Investigator’s Brochure (IB). Refer to the latest docetaxel product 
labels [ TAXOTERE  PI, 2020; TAXOTERE  SmPC, 2020] for information on 
contraindications, warnings, and precau tions related to the use of docetaxel.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
13 3.4. Overall Benefit -Risk Conclusion  
There is biologic rationale to study these novel combinations in this setting based on 
complementary modes of action on the immune system, with the potential for antitumor 
activity tha t exceeds either agent’s monotherapy activity in preclinical models. Based on 
the current safety profiles (See Section 12.1 for details) and docetaxel labeling 
[TAXOTERE  PI, 2020; TAXOTERE  SmPC, 2020], potential overlappi[INVESTIGATOR_90848]. However, it is unknown whether 
the combination regimens will have clinical activity in NSCLC that exceeds the SoC 
treatment. Consider ing the overall poor outlook for patients who have failed prior 
therapi[INVESTIGATOR_90849], any potential risks 
are justified by [CONTACT_90981].  
4. OBJECTIVES AND ENDPO INTS 
4.1. Objectives and Endpoints: Part 1  
Objectives  Endpoints  
Primary  
To determine the safety and tolerability of novel 
regimen(s)  AEs, SAEs, DLTs, changes in safety/laboratory 
assessment parameters, dose modifications  
Secondary  
To provide a preliminary evaluation of the efficacy of 
experimental regimen(s)  Objective Response Rate (ORR)  
Disease Control Rate (DCR)  
Characterize the pharmacokinetic properties  
of experimental regimen(s)  PK parameters that include Cmax and Cmin for 
experimental regimen(s) (and investigational agent/s 
included in other arms), as data permit.  
Exploratory  
4.2. Objectives and Endpoints: Part 2  
Objectives  Endpoints  
Primary  
Determine whether experimental 
regimen(s) provide evidence for improved 
survival over SoC therapy  Overall survival as measured by [CONTACT_90976](s) 
versus SoC therapy for NSCLC  Milestone survival rate at 12 and 18 months  
Evaluate other measures of antitumor 
activity of the experimental regimen(s) 
compared with SoC thera py for NSCLC 
(RECIST 1.[ADDRESS_100209])  CR, PR, SD, PD, PFS, ORR, DOR, DCR  
iCR, iPR, iUPD, iCPD, iSD  
iPFS; iORR; iDOR  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
14 Objectives  Endpoints  
Evaluate the safety and tolerability of the 
experimental regimen(s) compared with 
SoC therapy for NSCLC  
 Frequency and severity of AEs, AESI; SAEs and AE/SAEs leading to 
dose modifications/delays/withdrawals; changes in laboratory, vital 
signs, and safety assessment parameters, including immunogenicity 
(ADA)  
Characterize the pharmacokinetic 
properties of SoC or experimental 
regimen(s)  PK parameters that may include C max and C min for experimental 
regimen(s) and for SoC alone, as data permit.  
Determine immunogenicity of experimental 
regimen(s)  ADA incidence for experimental regimen(s) (where appropriate)  
Exploratory  
Note : The prefix “i”, used for response related abbreviations in the above table indicates immune responses assigned 
using iRECIST.  
AE = adverse event/s; AESI = adverse event/s of special interest; C max = maximum concentration; C min = minimum 
concentration; CPD = confirmed progression; CR = complete response; DLT = Dose Limiting Toxicity’ DOR = duration 
of response;  
 
 
; ORR = objective response ra te; OS = overall survival; PFS = progression -
free survival;  
 
; RECIST = Response Evaluation Criteria In 
Solid Tumors; SAE = serious adverse event; SD = stable disease; SoC = standard of care; TMB = Tumor Mutational 
Burden; UPD = unconfirmed p rogression.  
CCI
CCI
CCI
TMF- [ADDRESS_100210] progressed on p rior anti -PD(L)1 and platinum -based 
combination chemotherapi[INVESTIGATOR_014]. Part 1 is a non -randomized, safety and PK/PD evaluation, 
Part 2 is a randomized, Phase 2 comparing the efficacy and safety of novel regimens with 
docetaxel as the SoC control arm (Arm 1). Nove l combinations will be evaluated in 
separate substudies. As shown in Figure 1, the study will initially evaluate  the efficacy of 
feladilimab in combinat ion with SoC (docetaxel) (Arm 2) compared with SoC alone as 
the standard subsequent -line chemotherapy (substudy 1) in NSCLC . Additional arms will 
be added via protocol amendment based on emerging nonclinical and clinical data. No 
treatment crossover is allowed in this study.  
Each novel combination will first be evaluated for safety. This evaluation may occur 
prior to adoption into the 205801 platform study (dose finding in a separate study) or as a 
distinct arm within this platform study (Part 1) prior t o Part 2. Following the initial safety 
evaluation, additional participants for each regimen and/or dose may be enrolled to 
further evaluate safety and PK/PD  (refer to Section 12.1 for details for each experimental 
regimen).  Once an experimental regimen qualifies for transition evaluation, additional 
participants will be enrolled to Part 2. Within Part 2, participants will be randomized to 
receive eithe r SoC or the experimental treatment. Part  2 treatment arms may be dropped 
based on interim OS results (Section 10.3.3 ). Part [ADDRESS_100211]. Data from Part 1 and 2 will not be combined.  
The data generated from each experimental regimen and associated control arm data are 
considered  a substudy within the overall platform study, as depi[INVESTIGATOR_90850] 1.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
16 Figure 1 Study Design  
 
NSCLC: non -small cell lung cancer; PD(L)1: Programmed Cell Death Protein 1 and Programmed Cell Death 
Ligand 1.  
Note:  Randomization of participants to experimental regimens may not occur in parallel. It should be noted that 
the terms ‘regimen’ and ‘arm’ ma y be used interchangeably throughout the document.  Between 10 -20% of newly 
enrolled participants in substudies (depending upon the number of experimental arms in the trial) will be 
randomized to SoC once the initial [ADDRESS_100212] been enrolled on co ntrol arm.  
 
Interim safety and efficacy data for Part 2 will be reviewed by [CONTACT_90982] (IDMC), independent of the study team. Additional details will be 
provided in an IDMC Charter. A Steering Committee of lead investigators o n study will 
also be established to provide guidance for key decisions such as introduction of new 
arms and graduation of existing arms.  
At study start, participants will be randomized 1:2 to Arm 1 (SoC) and Arm 2, i.e., 33% 
and 67%, respectively. As new s ubstudies are initiated, the randomization ratio will be as 
described below in Table 1. Between 10 -20% of newly enrolled participants in 
subsequent substudies (depending upon the number of experimental arms in the trial) will 
be randomized to SoC once the initial [ADDRESS_100213] been enrolled on control.  
The 1:4 randomization for a 2 -arm trial is for subsequent substudies where a new 
experimental arm enters the trial and the SoC arm has already enrolled more than 
35 participants, and all other experimental arms are no longe r enrolling (e.g. completed 
accrual, or stopped due to toxicity findings, or other reason). Similarly, the 1:4:4 
randomization for a 3 -arm trial is for subsequent substudies where 2 new arms enter after 
the SoC arm has already enrolled more than 35 partici pants, and all other experimental 
arms are no longer enrolling (e.g. completed accrual, or stopped due to toxicity findings, 
or other reason).  

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
17 Table 1 Randomization Ratio and Proportion of Participants Randomized to 
the SoC Arm When  There Are Concurrent Arms  
 Randomization Ratio   
 ≤35th participants  >35th participants  
Two arms  
(SoC and one treatment)  1:2 SoC:Each Trt  1:4 SoC:Each Trt  
Three arms  
(SoC + two treatments)  1:2 SoC:Each Trt  1:4 SoC:Each Trt  
Four arms  
(SoC + three treatments)  1:1 SoC:Each Trt  1:3 SoC:Each Trt  
Five arms or more  
(SoC + four or more treatments)  1:1 SoC:Each Trt  1:2 SoC:Each Trt  
 
The study will employ a Bayesian decision -making framework based on the predictive 
probability of observing a significant improvement in OS in a future Phase 3 trial (see 
Section 10.5.1  for details).  
Interim analysis of OS in Part 2 will be performed for each substudy after approximately 
45 events (experimental arm and SoC combined) and a minimum of [ADDRESS_100214] been observed. Note, events from the SoC arm will be counted 
from t he initial study start (i.e. SoC events from substudy 1 will be counted with any 
further events observed in subsequent substudies). Participants will continue to be 
enrolled during interim analyses. The final analysis for each substudy will be performed 
once a minimum number of events have been observed. At the final analysis, the 
experimental regimen within a substudy may be recommended for proceeding to a Phase 
3 trial if it meets the predefined criteria for clinical activity. Details of the interim 
analy sis and predefined criteria are provided in Section 10.3.3  and Section 10.3.4 . 
The requirements for the experimental regimens to advance from earlier Phase 1 studies 
to the current Phase 2 study (205801) include:  
1. Determination of the recommended Phase 2 dose (RP2D) regimen  
2. Adequate safety dat a of the combination at the RP2D  
3. For the novel/novel combinations, evidence of potential antitumor activity in the 
range of the comparator (currently docetaxel) in an unselected solid tumor 
population.  
Additional experimental regimens or populations with  the appropriate SoC arm may be 
introduced to the current design via protocol amendments; these experimental arm(s) may 
include novel agents other than the aforementioned agents ( Figure 1). A biomarker -
driven approach may be implemented for any of the experimental arms as an enrichment 
strategy whereby [CONTACT_90983] a biomarker test result prior to 
treatment allocation. The rationale for the biomarker -driven approach in selecting 
participants most likely to derive clinical benefit from that particular regimen will be 
fully delineated in the amendment(s).  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
18 5.2. Duration of Treatment  
The study consists of 3 pe riods: screening, treatment, and follow -up. The total duration of 
study participation begins with the signing of the informed consent form (ICF). 
Participants will provide informed consent within [ADDRESS_100215] dose. After a 
screening period of  up to 28 days, eligible participants will be assigned a treatment arm if 
participating in Part 1 and receive study treatment (Day 1) or randomly assigned to a 
treatment arm (SoC or experimental) if participating in Part 2 and receive study treatment 
(Day 1) as specified in the SoA  for each arm (Section 12.1).  
Combination study treatment will continue to be administered at the indicated schedule 
for a maximum duration of approximately 2 years or up to 35 treatment visits (unless 
noted otherwise in sections specific to each arm), whichever comes first, or until d isease 
progression as determined by [CONTACT_19393], death, unacceptable toxicity, or other protocol -
defined criteria are met. Single agent SoC treatment (i.e., docetaxel) may continue until 
disease progression, death, unacceptable toxicity, withdrawal of consent,  or per 
institutional standard for docetaxel. After study treatment is permanently discontinued, 
participants will be followed for adverse events (AEs).  
iRECIST is based on RECIST 1.1 but adapted to account for the unique tumor response 
seen with immunoth erapeutic drugs [ Seymour , 2017]. Participants who attain a 
confirmed complete response (CR) per iRECIST, have received at least [ADDRESS_100216] been 
treated for a minimum of 6 months, may discontinue study treatment; and these 
participants will continue with the scheduled disease assessments (Section  9.3.1 ). 
Participants may be permitted to resume study treatment upon disease progression 
following consultation between the treating investigator and the Sponsor/Medical 
Monitor, and upon written consent by [CONTACT_2299]. See Section 8.1 for specific 
conditions under which a participant may continue study treatment beyond disease 
progression.  
Participants who permanently discontinue study treatment will enter the survival 
follow -up period of the study and undergo the assessments as indica ted in Section  9. 
5.3. Number of Participants  
As the study uses a master protocol design, the sample size for the study overall is not 
fixed. Participant s enrolled to Part 1 will be separate from those enrolled to Part 2.  
5.3.1.  Sample Size: Part 1  
For Part 1, sample size will be defined for each regimen under the corresponding 
appendix in Section 12.1; a minimum of 3 participants will be evaluated for safety during 
the 21 day DLT period before further participants will be enrolled.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
19 5.3.2.  Sample Size: Part [ADDRESS_100217] 105 in substudy 1 
(SoC arm: 35; experimental arm: 70). Additional experimental regimens may be added 
via protocol amendments and will be considered as another substudy. Each additiona l 
experimental arm will enroll a maximum of 70 participants. The minimum sample size 
for the SoC arm is 35 with additional participants randomized to SoC concurrently with 
additional experimental arms/substudies. Further randomization to SoC will be 
minimi zed once [ADDRESS_100218] completed the study if the participant dies during 
the study treatment period or follow -up period, whichever is sooner, or is still in follow -
up at the time of the final analysis. The cause of death will be documented in the 
CRF/eCRF. A participant will be considered to  have withdrawn from the study if the 
participant has not died and is lost to follow -up, has withdrawn consent, at the 
investigator’s discretion is no longer being followed or if the study is closed/terminated.  
5.4.2.  Study Completion Definition  
Substudy completi on: A substudy is considered to have completed once the agreed 
number of events has been reached, survival follow up for remaining patients may not be 
needed.  
 
An arm may close during Part [ADDRESS_100219] participant’s required study visit, 
telephone contact, or death, as applicable, in the last substudy.  
5.5. Scientific Rationale for Study Design  
The study will employ a platform design utilizing a master protocol to compare 
experimental therapi[INVESTIGATOR_15128] a common SoC treatment. Novel regimens may enter Part 2 
via protocol amendment(s) once adequate safety and preliminary clinical activity data are 
obtained. If sufficient safety and preliminary clinical activity data are not available for a 
proposed regimen from other studies, these data may be obtained during a safety and 
PK/PD evaluation option in this study in Part 1. Once a regimen has passed criter ia for 
safety and preliminary clinical activity, the treatment arm/regimen will be analyzed 
relative to the SoC treatment (Part 2) and is considered a substudy within the overall 
master protocol. In addition, different disease settings may be investigated via protocol 
amendment(s) and would introduce the SoC treatment for that setting. This design 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
20 provides efficiencies in the evaluation of experimental therapi[INVESTIGATOR_90851] a common 
control arm and discontinuing therapi[INVESTIGATOR_90852]. The SoC arm will remain open to 
random assignment and the anticancer activity of experimental regimens in substu dies 
that enter the study later will be compared with the overall population treated by [CONTACT_90984]. Thus, the SoC population will always include contemporaneous as well as 
historical data.  
5.5.1.  Steering Committee and Data Monitoring Committee (Part 2)  
A Steering Committee of lead investigators on study and representatives of the Sponsor 
study team will be established to provide guidance for key decisions such as introduction 
of new arms and graduation of existing arms. The remit, membership, and roles and 
responsibilities of the Steering Committee will be described in a charter.  
An IDMC, independent of the study team, will be established to monitor efficacy and 
safety during the course of the trial. The remit, membership, and roles and responsibilities 
of the Data Monitoring Committee will be described in a charter.  
Key decisions of the Steering Committee as well as the IDMC will be documented and 
reported to regulatory agencies if requested, all participating principal investigators (PIs) 
and if required, I nstitutional Review Boards (IRBs)/Independent Ethics Committees 
(IECs) as appropriate with impactful decisions communicated as priority.  
5.6. Dose Justification  
Dose justification for all study drugs are located in the arm -specific appendices (Section 
12.1). 
TMF- [ADDRESS_100220] fulfill additional inclusion/exclusion 
criteria for at least one arm. Criteria for each individual arm can be found in the 
respective appendices for each arm, reported in Section 12.1. 
Prospective approval of protocol deviations to recruitment and enrollment criteria 
(waivers or exemptions) is not permitted.  
6.1. Inclusion Criteria  
1. Capable of giving signed informed consent/assent as described in Section 12.4 
which includes compliance with the requirements and restrictions listed in the ICF 
and in this protocol  
2. Male or female, aged 18 years or older at the time consent is obtained  
   Note:  Participants in Korea must be age 19 years or older at the time consent is 
obtained.    
3. Histologically or cytologically confirmed diagnosis of NSCLC (squamous or non -
squamous) and:  
a. Documented disease progression based on radiographic imaging, during or 
after a maximum of 2 lines of systemic treatment for locally/regionally 
advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or metastatic disease  
Two components of treatment must have been received in the same line or as 
separate lines of therapy:  
i. no more t han or less than 1 line of platinum -containing chemotherapy 
regimen, and  
ii. no more than or less than 1 line of PD(L)1 mAb containing regimen.  
Notes : 
o PD(L)1 mAb received during a previous clinical trial may meet 
this requirement upon consultation with study medical monitor.  
o Participants who received a regimen similar to the PACIFIC 
regimen [chemoradiotherapy followed by [CONTACT_4002](L)1] as part of 
SoC AND have relapsed within one year from the first dose of 
chemoradiotherapy would fulfill the protocol requirement for 
platinum -based chemotherapy treatment and PD -1/L1 
treatment. This would be considered a single line of treatment 
for the purpose of PD(L)1 line of therapy stratification.  
o PD(L)1 mAb can be administered with the platinum -based 
chemotherapy regimen and this would count as a single line of 
therapy.  
o PD(L)[ADDRESS_100221] completed 2 years of pembrolizumab or 
another PD(L)1 mAb, discontinue  from that therapy, 
experience disease progression, and are then retreated with 
PD(L)1, will be considered as having had one line of PD(L)[ADDRESS_100222] had disease 
progression after receiving the locally available SoC treatment for the 
molecular alteration.  
c. Particip ants who received prior anti -PD(L)[ADDRESS_100223] fulfill the following 
requirements:  
o Have achieved a CR, PR or SD and subsequently had disease progression 
(per RECIST 1.1 criteria) either on or after completing PD(L)[ADDRESS_100224] 12 weeks of PD(L)[ADDRESS_100225]  1.1 
(see Appendix 12  for definition of a measurable lesion)  
5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 
0 or 1 
6. A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to 
time of study entry is mandatory. Although a fresh tumor tissue sample obtained 
during screening is preferred, archival tumor specimen is acceptable. See Study 
Reference Manu al (SRM) and Section 9.9.2 for further details on tumor tissue 
requirements.  
7. Adequate organ function as defined in Table 2.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
23 Table 2 Definitions of Adequate Organ Function  
System  Laboratory Values 
Hematologica 
ANC (Absolute Neutrophil Count)  1.5 x 109/L (≥1500/µL)  
Hemoglobin  9 g/dL or ≥5.6 mmol/L  
Platelets  100 x 109/L (≥100 000/µL)  
Hepatic  
Albumin  ≥2.5 g/dL  
Total bilirubin  
 
 
Patients with Gilbert’s Syndrome (only if direct bilirubin 35%)  1.[ADDRESS_100226] (isolated bilirubin >1.[ADDRESS_100227] bilirubin <35%)  
3.[ADDRESS_100228]  
ALT (SGPT)  2.[ADDRESS_100229], OR  
≤[ADDRESS_100230] for participants with documented 
liver metastases  
Renal  
Calculated CrClb ≥30 mL/min  
Abbreviations: ALT = alanine aminotransferase; CrCL = creatinine clearance; SGPT = serum glutamate -pyruvate 
transaminase; ULN = upper limit of normal.  
a.   Participants may be transfused or receive growth factor treatment to meet minimum hematologic values up to 7 
days prior to determining eligibility. Absolute Lymphocyte Count will be  included in the baseline assessment, but 
no range limit requirement for eligibility.  
b.   Calculated CrCL is required to be calculated using the Chronic Kidney Disease Epi[INVESTIGATOR_10444] 
(CKD -EPI) or Cockcroft -Gault formula. Either formula is acce ptable and must be consistently utilized for each 
participant throughout the study ( Appendix 9 ). 
 
8. A male participant must agree to use a highly effective cont raception as detailed in 
Appendix  [ADDRESS_100231] dose of study treatment and refrain f rom donating sperm during this 
period.  Unless otherwise specified under each arm in Section 12.1 
Note:  If the participant is randomized to the SoC regimen only, duration of 
contraception should be as per local label.  
9. A female participant is eligible to participate if she is not pregnant (see 
Appendix  6), not breastfeeding, and at least 1 of the following conditions apply:  
i. Not a woman of childbearing potential (WOCBP) as defined in 
Appendix  [ADDRESS_100232] dose of study treatment.  
Note:  If the participant is randomized to the SoC regimen only, duration 
of contraception should be as per local label.  
10. Life expectancy of at least 12 weeks  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
24 6.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Received prior treatment with the following therapi[INVESTIGATOR_014] (calculation is based on 
date of last therapy to date of first dose of study treatment):  
a. Docetaxel at a ny time  
b. Any of the investigational agents being tested in the current study, refer 
to Section 12.[ADDRESS_100233] dose of study drug is administered.  
d. Prior radiation therapy : permissible if at least one non -irradiated 
measurable lesion is available for assessment per RECIST version 1.[ADDRESS_100234] 2 weeks before start of study 
drug for radiation of any intended use is required.  
2. Received >2 prior lines of therapy for NSCLC, including participants with BRAF 
molecular alterations. (See inclusion criterion #3 for eligible lines of therapy 
guidance)  
Note:  Patients with known molecular  alterations with therapeutic options available 
(e.g., EGFR, ALK, ROS1) are excluded from participation in this study, unless no 
other therapeutic options are available locally.  
3. Invasive malignancy or history of invasive malignancy other than disease unde r 
study within the last 2 years, except as noted below:  
• Any other invasive malignancy for which the participant was definitively 
treated, has been disease -free for at least [ADDRESS_100235] the evaluation 
of the effects of the study treatment on the currently targeted malignancy, may 
be included in this clinical trial.  
• Curatively treated non -melanoma skin cancer or successfully treated in situ 
carcinoma of the skin.  
4. Carcinomat ous meningitis (regardless of clinical status) and uncontrolled or 
symptomatic central nervous system (CNS) metastases.  
 
Note : Participants with previously treated brain metastases may participate 
provided they are asymptomatic (any neurologic symptoms ha ve returned to 
baseline [participants may be receiving stable doses of anticonvulsants]), 
radiographically stable (without evidence of progression by [CONTACT_89181] [ADDRESS_100236] dose of study treatment), have no evidence of new or 
enlar ging brain metastases, and are clinically stable off steroids for at least 2 
weeks prior to study treatment.  
5. Major surgery [ADDRESS_100237] dose of study treatment.  
6. Autoimmune disease (current or history) or syndrome that required systemic 
treatment within the past 2 years (Refer to Appendix 14 ). Replacement therapi[INVESTIGATOR_90853] (for example, adrenal insufficiency) are not considered systemic 
treatments.  
Note : Participants with controlled Type 1 diabetes mellitus (T1DM) are eligible.  
7. Receiving sy stemic steroids (>10 mg oral prednisone or equivalent) or other 
immunosuppressive agents within [ADDRESS_100238] dose of study treatment.  
Note:  Steroids as premedication for hypersensitivity reactions (e.g., computed 
tomography [CT] scan premedication ) are permitted. Use of inhaled  
corticosteroids, local steroid injection, or steroid eye drops is allowed.  
8. Prior allogeneic/autologous bone marrow or solid organ transplantation.  
9. Receipt of any live vaccine within [ADDRESS_100239] dose of study tre atment.  
Refer to the SRM for clarity on COVID -19 vaccines.  
10. Toxicity from previous anticancer treatment that includes:  
a. ≥ Grade 3 toxicity considered related to prior immunotherapy and that led to 
treatment discontinuation.  
b. History of myocarditis of any grade during a previous treatment with 
immunotherapy  
c. Toxicity related to prior treatment that has not resolved to ≤Grade 1 (except 
alopecia, hearing loss, endocrinopathy managed with replacement therapy, 
and peripheral neuropathy which must be ≤Grade 2).  
11. History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for past 
pneumonitis exclusion only if steroids were required for treatment), interstitial 
lung disease, or organizing pneumonia.  
 
Note:  post-radiation changes in the lung related to  prior radiotherapy and/or 
asymptomatic radiation -induced pneumonitis not requiring treatment may be 
permitted if agreed upon by [CONTACT_26791].  
12. Recent history (within the past 6 months) of uncontrolled symptomatic ascites, 
pleural or  pericardial effusions  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
26 13. Recent history (within the past 6 months) of gastrointestinal obstruction that 
required surgery, acute diverticulitis, inflammatory bowel disease, or intra -
abdominal abscess  
14. History or evidence of cardiac abnormalities within the 6 m onths prior to 
enrollment which include:  
a. Serious, uncontrolled cardiac arrhythmia or clinically significant 
electrocardiogram abnormalities including second degree (Type II) or third 
degree atrioventricular block.  
b. Cardiomyopathy, myocardial infarction, acu te coronary syndromes (including 
unstable angina pectoris), coronary angioplasty, stenting or by[CONTACT_15806]  
c. Symptomatic pericarditis.  
NOTE:  Participants with Troponin and/or NT -ProBNP/BNP ≥[ADDRESS_100240] review for potentially significant ECG abnormalities suc h 
as AV block (except for first degree), new cardiac arrhythmias, or frequent 
premature ventricular contractions (PVCs). Please inform the Sponsor regarding 
these participants . 
15. Current unstable liver or biliary disease per investigator assessment defined by [CONTACT_90985], encephalopathy, coagulopathy, hypoalbuminemia, esophageal 
or gastric varices, persistent jaundice, or cirrhosis.  
Note:  Stable chronic liver disease ( including Gilbert's syndrome or asymptomatic 
gallstones) is acceptable if participant otherwise meets entry criteria.  
16. Active infection requiring systemic therapy ≤[ADDRESS_100241] dose of study 
treatment.  
17. Known human immunodeficiency virus infection  
18. History of severe hypersensitivity to monoclonal antibodies or hypersensitivity to 
any of the study treatment(s) or their excipi[INVESTIGATOR_840].  
19. Requires ongoing therapy with a medication that is a strong inhibitor or inducer of 
the cytochrome 3A4 (CYP3A4) enzyme ( Flockhart , 2018). This criterion is 
applicable to only those participants in treatment arms containing docetaxel.  
20. Any serious and/or unstable pre -existin g medical (aside from malignancy), 
psychiatric disorder, or other condition that could interfere with participant’s 
safety, obtaining informed consent, or compliance to the study procedures in the 
opi[INVESTIGATOR_90854]- [ADDRESS_100242] dose of study treatment.  
23. Presence of hepatitis B surface antigen (HBsAg) at screening or within [ADDRESS_100243] dose of study intervention.  
NOTE: Participants with positive Hepatitis C antibody due to prior resolved disease 
can be enrolled, only if a c onfirmatory negative Hepatitis C RNA test is obtained.  
25. Positive hepatitis C RNA test result at screening or within [ADDRESS_100244] 
dose of study treatment.  
NOTE: Test is optional and participants with negative Hepatitis C antibody test are 
not required to also undergo Hepatitis C RNA testing.  
 
26. Receipt of transfusion of blood products (including platelets or red blood cells) or 
administration of colony -stimulating factors (including granulocyte colony 
stimulating factor [G -CSF], granulocyte -macrophage colony -stimulating factor, and 
recombinant erythropoietin) within [ADDRESS_100245]. John’s Wort is a CYP3A inducer, 
and the consumption of St. John’s Wort or products containing St. John’s Wort may 
reduce th e levels of docetaxel.  
6.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently randomized/entered in the study. Laboratory results obtained 
during screening should be used to de termine eligibility criteria. In situations where 
laboratory results are outside the permitted range, the investigator may opt to retest the 
participant and the subsequent screening result, if within range, may be used to confirm 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
28 eligibility. Individuals w ho do not meet the criteria for participation in this study (screen 
failure) may be rescreened. Rescreened participants must be assigned a new unique 
participant number that is different from the initial number.  
A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure participants to meet the Consolidated Standards of Reporting Trials 
(CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demograp hy, screen failure details, eligibility 
criteria, and any SAEs.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
29 6.5. Screening under Molecular Disease Characterization 
Initiative Study  
Participants may be initially screened under [COMPANY_004] protocol 213299 (a molecular disease 
characterization initiative study) whe re it is IRB/IEC approved at a site and then referred 
to this study 205801. Screening assessments performed under protocol 213299 may be 
accepted for the enrollment into this [COMPANY_004] protocol 205801 to avoid any repeat screening 
tests.  
Baseline Biopsy:  
If a bi opsy was acquired under [COMPANY_004] protocol 213299, tissue blocks/slides from this 
biopsy may be used for additional screening or baseline analyses required by [CONTACT_47375] (205801). Another biopsy may be needed for treatment specific screening at 
baseline in ca ses where there is not enough remaining material from biopsy acquired 
under [COMPANY_004] protocol 213299.  
Screening/Baseline Imaging and Other Assessments:  
If radiographic imaging was performed under [COMPANY_004] protocol 213299, those images may 
be used for screening/basel ine disease assessment. Images must meet the acceptable 
scanning modalities and anatomical coverage required for this protocol (205801). 
Additional scans may be needed to meet inclusion/exclusion criteria, safety requirements, 
or other anatomical areas as required by [CONTACT_3181] (205801). Additional scans are 
required if imaging falls outside the screening/baseline acceptable visit window.  
Please refer to SRM for more information.  
7. TREATMENTS  
Study treatment is defined as any investigational treatment(s),  marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant per the 
study protocol.  
7.1. Treatments Administered  
The term study treatment(s) is used throughout the protocol as a general descriptor for 
any or all treatm ent arms/regimens or the individual agents.  
All investigational agents utilized in this study will be provided to sites by [CONTACT_1034]. 
Docetaxel will be sourced locally from commercial stock, except in countries where local 
regulations mandate that the Sp onsor supply all study treatment(s) required for the trial.  
As additional substudies are initiated, treatment details for experimental regimens from 
those substudies will be provided in Section 12.1. 
TMF- [ADDRESS_100246] label for SoC (e.g., docetaxel) and 
guidelines provided in the protocol for investigational agents.  
Note : If a participant, randomized to an experimental treatment arm, experiences a 
toxicity attributable to one of the drugs in the combination, the investigator may 
discontinue the responsible drug but continue treatment with the other drug. In all such 
scenarios, the SoA applicable to the active treatment(s) must be followed.  
Additional dose modification guidelines for specific experimental regimens will be 
provided in Section 12.1 as needed when new substudies are initiated.  
7.2.1.  Dose and Safety Management Guidelines  
[IP_ADDRESS].  General Guidelines for Immune -Related Adverse Events (irAEs)  
AEs associated with immunotherapy treatment may be immune -mediated . These 
immune -related AEs (irAEs) may occur shortly after the first dose or several months after 
the last dose of treatment, or during the treatment course, and may affect more than one 
body system simultaneou sly. Therefore, early recognition of and initiation of treatment 
for these events is critical to reduce potential complications.  
For suspected irAEs, ensure adequate evaluation to confirm the etiology or exclude other 
causes . Additional procedures or test s such as, but not limited to, bronchoscopy, 
endoscopy, or skin biopsy may be included as part of the evaluation . Based on the 
severity of irAEs, withhold or permanently discontinue treatment and administer 
corticosteroids and/or immuno -modulators . Dose mo dification and toxicity management 
guidelines for irAEs associated with immunotherapi[INVESTIGATOR_90855] 12.1.  
Note : This guidance does not apply to participants randomized to Arm 1 SoC 
chemotherapy  in Part 2.  
Before administration of study treatment, investigators are to review a participant’s AEs, 
concomitant medications, and clinical evaluation results, e.g., vital signs, laboratory 
results, ECOG PS, physical examination findings, responses, etc. as outlined in the 
Schedule of Activities (Section 12.1) to monitor for new or worsening irAEs and ensure 
continued dosing is appropriate.  
Adverse Events of Special Interest (AESI)  
AESI are considered to be Infusion Related Reactions (IRRs) and those of potential 
immunologic etiology, including irAEs. Such events recently reported after treatment 
with other immune modulatory therapy include, but are not limite d to, the following: 
pneumonitis, nephritis, hepatitis, colitis, immune related endocrinopathies (such as 
thyroiditis or hypophysitis) or immune related cutaneous toxicities, to include rashes 
confirmed via biopsy to be immune -mediated.  
AESIs will be repo rted within 24 hours if the event meets the criteria for a serious event.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
31 Dose modification  and toxicity management guidelines for irAEs are provided for each 
arm in the respective subsections under Section 12.1. 
[IP_ADDRESS].  Dose Modification and Toxicity Management of Infusion -Reactions 
Related to Immunotherapy Treatment   
Infusion reactions are a well -documented AE associated with the administration of 
monoclonal antibodies (mAbs ). Infusion reactions typi[INVESTIGATOR_90856] 30 minutes to 
2 hours after initiation of drug infusion, although symptoms may be delayed for up to 48 
hours. The incidence of infusion reactions varies by [CONTACT_90612], and there are m ultiple 
mechanisms known to lead to infusion -related reactions including both IgE -dependent 
anaphylactic and non -IgE dependent anaphylactoid hypersensitivities. Cytokine release 
syndrome (CRS), and when severe, cytokine “storm”, has been identified as a se quela of 
the immune system activation associated with infusion reactions.  
Infusion reactions may affect any organ system in the body. Most are mild in severity, 
although severe and even fatal reactions occur. As a group, infusion reactions (including 
both cytokine -mediated and allergic) usually occur during or within a few hours of drug 
infusion. Occasionally, a reaction may occur 1 to 2 days after administration . The NCI -
CTCAE (version 5.0) for grading adverse reactions during chemotherapy administration 
has a scale for grading the severity of infusion reactions and separate grading scales for 
allergic reactions and anaphylaxis . While use of these separate grading scales may be 
useful for classifying the nature of an infusion reaction for research purposes,  they are 
less useful for clinical care, since it may not be obvious if the participant is having an 
allergic infusion reaction or a non -allergic infusion reaction.  
Clinically, an acute -onset infusion reaction may present with flushing, itching, urticaria , 
and/or angioedema, repetitive cough, sudden nasal congestion, shortness of breath, chest 
tightness, wheeze, sensation of throat closure or choking, and/or change in voice quality, 
faintness, tachycardia (or less often bradycardia), hypotension, hypertens ion and/or loss 
of consciousness, nausea, vomiting, abdominal crampi[INVESTIGATOR_007], and/or diarrhea, sense of 
impending doom, tunnel vision, dizziness, and/or seizure, severe back, chest, and pelvic 
pain. Dose modification and treatment guidance for immunotherapy infu sion reactions  
are provided for each arm in the respective subsections under Section 12.1. 
To better understand the underlying etiology of these event s, serum tryptase, C -reactive 
protein (CRP), ferritin, and a cytokine panel should be drawn during the occurrence of an 
infusion reaction/CRS of any grade as outlined in Table 3. Only if not possible to collect 
at the occurrence of the event, samples should be drawn as soon as possible after the 
event and within [ADDRESS_100247] be 
performed at the investigator’s designated local laboratory . The serum cytokine panel 
will be performed at a [COMPANY_004] designated laboratory . These data will aid in the classifying 
(albeit retrospectively) the etiology of the infusion reaction AE . Infusion -related reaction 
management guideline s are provided for each study arm in Section 12.1.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
32 Table 3 Infusion -Related Reaction Laboratory Panel  
Biomarker  Relationship to Adverse Event  
Serum tryptasea IgE-related infusion reaction (Allergic/anaphylaxis) 
[Schwartz , 2006]  
Serum CRPa Elevated in CRS [ Lee, 2014 ] 
Serum ferritina Elevated in CRS [Lee, 2014 ] 
Serum cytokine panelb 
(IFN-γ*^, TNF -α*^, IL -2*, IL -4, IL-6*^, IL -8*, IL -10*, IL -
12p70, and IL -13) * Reported to be elevated in CRS [Lee, 2014 ] 
^ Consistently reported as elevated in CRS [Lee, 
2014 ] 
CRP  = C-reactive protein; CRS  = Cytokine release syndrome; IFNγ = Interferon gamma; TNFα = Tumor necrosis 
factor alpha; IL = Interleukin.  
a. Performed by [CONTACT_90986]; otherwise performed by [CONTACT_90987]  
b. Performed by [CONTACT_90988]  
 
[IP_ADDRESS].  Management Guidance of Chemotherapy -related Toxicities  
Refer to Table 4 and Table 5 for guidance on specific chemotherapy -related AEs; refer to 
chemotherapy prescribing information or standard practice guidelines for the 
management of these AEs, other AEs or potential safety -related issues.  
Table 4 Dose Reductions for Docetaxel -related Hematologic Events  
Chemotherapy Regimen  Toxicity  Actiona 
Docetaxel  • ANC <1.5x109/L, platelets 
<75x109/L, or hemoglobin <9g/dL 
(after transfusion if needed)  
 
 
 
 
• Febrile neutropenia  • Hold docetaxel until 
recovery: ANC 1.5x109/L, 
platelets 100x109/L  
• Recovery within 7 days, 
resume 100% of previous 
dose; >7 days, resume 80% 
of previous dose  
• Hold docetaxel; upon 
recovery, if ANC <500/mm3 
for more than 7 days, 
resume at 55 mg/mm2 
a. Resume treatment with chemotherapy after resolution as indicated; treatment with other study treatment may 
continue unless otherwise instructed.  
Table 5 Dose Reductions for Docetaxel -related Non -Hematologic Events  
Chemotherapy Regimen  Toxicity  Actiona 
Docetaxel  • Grade 3/Grade 4 event (including 
severe or cumulative cutaneous 
reactions), except peripheral 
neuropathy  
 
 
• Grade 3/Grade 4 peripheral 
neuropathies  
 • Hold docetaxel upon recovery 
to Grade  1/baseline, resume 
treatment at 55 mg/mm2 
 
• Consider permanent 
discontinuation; discuss with 
Medical Monitor  
a. Resume treatment with chemotherapy after resolution as indicated; treatment with other study treatment may 
continue unless otherwise instructed.  
TMF- [ADDRESS_100248] practice guidelines for the 
management of these AEs, other AEs or potential safety -related issues [ TAXOTERE  PI, 
2020].  
[IP_ADDRESS].  Dose Delay for Toxicity or Other Illness  
If there is a dose delay between 1 and 7 days, the procedures required at the original 
scheduled visit (including dosing) should be performed as soon as pos sible. Refer to the 
SRM for instructions regarding assessments to be collected and how to record data in the 
eCRF.  
If the delay is 8 days, the visit and dose(s) will be considered missed. The procedures at 
the next regularly scheduled visit should be perf ormed (with dosing), and subsequent 
visits will follow Q3W.  
Participants with infusion delays greater than 3 weeks due to toxicity should discontinue 
study drug(s) unless the treating investigator and Sponsor/Medical Monitor agree there is 
strong evidence  supporting continued treatment.  
 
7.3. Method of Treatment Assignment  
Once determined to be eligible for the study, all participants will be centrally randomized 
using an Interactive Web Response System (IWRS). Before the study is initiated, the 
directions for  the IWRS and log in information will be provided to each site. Once 
determined to be eligible for the study, participants must be randomized via IWRS. Study 
drug shipment will be managed via IWRS. Sites must allow up to 7 business days for 
shipment of stu dy drug.  
Study treatment will be dispensed at the study visits summarized in SoA for treatments 
found within the SoA for each arm (Section 12.1). 
7.4. Blinding  
This is an open -label study. Sites will record the treatment assignment on the applicable 
eCRF.  
7.5. Preparation/Handling/Storage/Accountability  
7.5.1.  Preparation  
Refer to the SRM for instructions on the preparation of investigational study treatments. 
Refer to the package insert for docetaxel preparation instructions.  
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study treatment received and any discrepancies 
are reported and resolved before use of the study treatment.  
1. Only participants enrolled in the study may receive study treatment and only 
authorized site staff may supply or administer study treatment. All study treatments 
TMF- [ADDRESS_100249] be stored in a secure, environmentally controlled, and  monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.  
2. The investigator, institution, or the head of the medical institution (where applicable) 
is responsib le for study treatment accountability, reconciliation, and record 
maintenance (i.e., receipt, reconciliation, and final disposition records).  
3. Further guidance and information for the final disposition of unused study treatment 
are provided in the SRM.  
 
7.5.2.  Handling  
• Under normal conditions of handling and administration, study treatment is not 
expected to pose significant safety risks to site staff . Take adequate precautions to 
avoid direct eye or skin contact [CONTACT_90989].  In case of 
unintentional occupational exposure notify the monitor, Medical Monitor , and/or 
[COMPANY_004] study contact.  
• A Material Safety Data Sheet (MSDS) or equivalent document describing 
occupational hazards and recommended handling precautions either will be 
provided to th e investigator, where this is required by [CONTACT_1207], or is available 
upon request from [COMPANY_004].  
7.5.3.  Storage  
All study treatment must be stored in a secure environmentally controlled and monitored 
(manual or automated) area in accordance with the labeled storage c onditions with access 
limited to the investigator and authorized site staff.  
Refer to the SRM for storage condition specifications and temperature monitoring 
requirements.  
7.5.4.  Accountability  
• Only participants enrolled in the study may receive study treatment a nd only 
authorized site staff may supply or administer study treatment.  
• The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study treatment accountability, reconciliation, and 
record maintenance (i.e. , receipt, reconciliation and final disposal records).  
• Further guidance and information for final disposition of unused study treatment 
are provided in the SRM.  
7.6. Treatment Compliance  
Study treatments will be intravenously administered to participants at th e site. 
Administration will be documented in the source documents and reported in the eCRF.  
TMF- [ADDRESS_100250] dose of study treatm ent until discontinuation of 
study treatment. Any permitted concomitant medication(s), including non -prescription 
medication(s) and herbal product(s), taken during the study will be recorded in the eCRF. 
The minimum requirement for reporting is drug name, dose, dates of administration, and 
the reason for medication.  
Questions regarding concomitant medications must be directed to the [COMPANY_004] Medical 
Monitor for clarification.  
If changes are made to the list of permitted/prohibited medications in the future, form al 
documentation will be provided by [CONTACT_90990]. Any such changes 
will be communicated to the investigative sites by [CONTACT_31711].  
Refer to the drug interaction information in the product package inserts for precautions 
and prohibited conc omitant medications related to docetaxel treatment [ TAXOTERE  PI, 
2020; TAXOTERE  SmPC, 2020].  
7.7.1.  Permitted Medications and Non -Drug Therapi[INVESTIGATOR_90857]/supplementation regimens 
according to the approved product label or standard practice. All participants should 
receive full supportive care during the treatment course of the study, including 
transfusion of blood and blood products, and treatment with antibiotics, antiemetics, 
antidiarrheals, and analgesics, as appropriate. Seasonal flu vaccine is permitted as an 
injection only, that is, intra -nasal flu vaccine is not permitted. Refer to the SRM for 
permitted COVID -19 vaccines. Elective palliative surgery or radiation may be permitted 
on a case -by-case basis in consultation with [COMPANY_004] Medical Monitor.  
The following medications are permitted as indicated: Please also refer to Section 12.1 
for medications specific to each experimental combination.  
a. Bisphosphonates and receptor activator of nuclear factor -kappaB ligand (RANKL) 
inhibitors (e.g., denosumab): Participants are required to have been on a stable dose 
for at least [ADDRESS_100251] dose of study treatment. Prophylactic use 
in par ticipants without evidence or history of bone metastasis is not permitted, except 
for the treatment of osteoporosis.  
b. Growth factors: Prophylactic use of growth factors are not permitted during study 
treatment, unless clinically/therapeutically indicated fo r toxicity management.  
c. Steroids: Refer to Section 7.2.[ADDRESS_100252] dose of study treatment ; see exclusion criteria in Section 6.[ADDRESS_100253] dose of study treatment (see 
Section 6.2 for specific time requirements) and while on treatment in this study: Please 
also refer to Section 12.1 for medications specific to each experimental combination.  
• Anticancer therapi[INVESTIGATOR_90858], 
but are not limited to chemotherapy, immunotherapy, biologic therapy, hormonal 
therapy (other than physiologic replacement), surgery, and radiation therapy 
(other than palliative intervention as described in Section 7.7.1 ). 
• Any investigation al drug(s) other than those referred to as Study Treatment.  
• Refer to the SRM for guidance on COVID -19 and other vaccines.  
• Strong CYP3A4 inhibitors and inducers for participants receiving docetaxel alone 
or in combination with another study drug (use as pr emedication is permitted).  
• Herbal preparations or related over the counter (OTC) preparations containing 
herbal ingredients that are known to affect CYP3A isoenzymes (e.g., St. John’s 
Wort) either during or within [ADDRESS_100254]-study care of the participant’s medical 
condition.  
8. DISCONTINUATION CRIT ERIA  
8.1. Discontinuation of Study Treatment  
Participants will receive study treatment for the scheduled time period as indicated in 
Section 12.[ADDRESS_100255] discontinue treatment if one of the following events occurs earlier:  
• Confirmed disease progression (iCPD as determined by [CONTACT_19393])  
• death  
• unacceptable toxicity, including meeting stoppi[INVESTIGATOR_90859] 10  
In addition, study treatment may be permanently discontinued for any of the following 
reasons:  
• deviation(s) from the protocol or non -compliance with study requirements  
• request of the participant or proxy (withdrawal of consent by [CONTACT_90991])  
• discretion of the investigator  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
37 • participant is lost to follow -up 
• closure or term ination of the study  
Continuation of Treatment Upon Disease Progression  
Participants who have disease progression (unequivocal disease progression) by [CONTACT_393] 
1.1 may continue study treatment at the discretion of the Investigator with approval from 
the Medical Monitor, and upon separate written consent of the participant. Continuation 
on study treatment with disease progression is contingent upon the following conditions:  
• Participant has documented clinical benefit,  
• absence of clinical signs or symptoms indicating clinically significant disease 
progression,  
• no decline in ECOG performance status  
• absence of rapid disease progression or threat to vital organs or critical 
anatomical sites (e.g., CNS metastasis, respi[INVESTIGATOR_90860], or  spi[INVESTIGATOR_13377]) requiring urgent alternative medical 
intervention.  
• no significant, unacceptable, or irreversible toxicities related to study treatment.  
Termination of a Substudy/Experimental Arm  
If a substudy/experimental arm is terminated based on interim results and a participant is 
currently active in the substudy, receiving study treatment, and in the opi[INVESTIGATOR_90861], the participant may continue to rec eive study treatment upon agreement 
between the Sponsor and the investigator.  
Study Termination  
If the study is terminated by [CONTACT_90992] a 
participant is currently active in the study, the Sponsor will not ify the investigator of the 
study termination, further enrollment in the study will be terminated, and the Sponsor 
will communicate to investigative sites the discontinuation procedures and plans for 
discontinuation of patients from study treatment.  
Termi nation Due to Toxicity  
If the participant discontinues from treatment due to toxicity, the relevant AE will be 
recorded on the eCRF as the primary reason for permanent discontinuation.  
Termination from Study Treatment  
If a participant discontinues study treatment for reasons other than disease progression, 
does not have evidence of disease progression and chooses to continue in the study, the 
participant will continue study assessments according to the visit schedule de scribed in 
the SoA for the specific arm in Section 12.1. The participant will be followed until 
disease progression by [CONTACT_90993] a new s ystemic anti -cancer therapy, 
whichever comes first.  
TMF- [ADDRESS_100256] be documented 
in the participant’s medical records and eCRF.  
Once a participant has permanently d iscontinued from study treatment, the participant 
will not be allowed to be retreated but will remain on the observational phase of the study 
for survival follow -up.  
All participants who discontinue from study treatment will have safety assessments at the  
time of discontinuation and during post -study treatment follow -up as specified in the SoA 
for the specific substudy in Section 12.1.   
All participants who permanently discontinue study treatment without disease 
progression will be followed for survival according to the protocol schedule until one or 
more of the following occur:  
• death  
• withdrawal of consent for the observational phase of survi val follow -up 
In the observational phase of the study, all participants who permanently discontinue 
study treatment will be followed via telephone contact [INVESTIGATOR_135] [ADDRESS_100257] been designed to 
assure participant safety and evaluate liver event etiology.  
Discontinuation of study treatment for abnormal liver tests is required when a participant 
meets one of the c onditions outlined Figure 2 or Figure 3, based on baseline ALT:  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
39 Figure 2 Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_90862] 2.[ADDRESS_100258] at Baseline  
 

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
40 Figure 3 Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_90863] [ADDRESS_100259] occurred after a clinical event that, in 
the investigator’s opi[INVESTIGATOR_1649], is attribu table to disease progression and is unlikely to reverse 
with continued study treatment or managed by [CONTACT_90994] (e.g., bisphosphonates 
and/or bone directed radiotherapy, thoracentesis, or paracentesis for accumulating 
effusions), study treatment shoul d be discontinued. In these cases, the decision to 
continue treatment must be discussed with the Sponsor’s Medical Monitor and written 
consent by [CONTACT_90995]. Examples of events that may, in the 
investigator’s opi[INVESTIGATOR_1649], indicate a lack of clinical benefit include, but are not limited to, 
the following:  

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
41 • Worsening of ECOG PS from baseline by [CONTACT_2669] 2 points  
• Skeletal related events defined by [CONTACT_716]:  
o pathologic bone fracture in the region of cancer involvement  
o cancer related surger y to bone, and/or  
o spi[INVESTIGATOR_90552]  
• Development of new CNS metastases  
• Any setting where the initiation of new antineoplastic therapy has been deemed 
beneficial to the participant even in the absence of any such documented clinical 
even t. 
See Section 8.1 above for specific requirements when considering continuation of 
treatment.  
8.1.2.  Study Treatment Restart/Rechallenge  
Study treatment restart or rechallenge is not allowed after liver chemistry stoppi[INVESTIGATOR_90864]:  
• [COMPANY_004] Medical Governance approval is granted.  
• Ethics and/or IRB approval is obtained, if required, and  
• Separate consent for treatme nt restart/rechallenge is signed by [CONTACT_2299].  
If [COMPANY_004] Medical Governance approval to restart/rechallenge participant with study 
treatment is not granted, then participant must permanently discontinue study treatment 
and may continue in the study for protocol -specified follow -up assessments.  
Refer to Section 12.10  for additional information.  
8.2. Withdrawal from the Study  
• A participant may withdraw fr om the study at any time at his/her own request, or may 
be withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance or administrative reasons. No further assessments will be required and the 
investigator must document this in the site study records.  
• If the participant withdraws consent for disclosure of future information, the Sponsor 
may retain and continue to use any data collected before such a withdrawal of 
consent.  
• If a participant withdraws from the study after providing study samples, [COMPANY_004] will 
retain those samples and any results from sample testing prior to participant 
withdrawal, as described in the informed consent. However, if a participant requests 
destruction  of their samples at the time of withdrawal, the investigator should alert 
[COMPANY_004] and document this in the site study records. Once notified, [COMPANY_004] will ensure no 
new testing will be performed on the sample and the sample will be destroyed.  
• A participant will be considered to have withdrawn from the study if the participant 
has not died and is lost to follow -up. 
• Refer to the SoA for data to be collected at the time of study discontinuation and for 
any further evaluations that need to be completed.  
TMF- [ADDRESS_100260] be taken if a participant fails to return to the clinic for a r equired study visit:  
• The site must attempt to contact [CONTACT_90996] d/or should 
continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up.  
9. STUDY ASSESSMENTS AN D PROCEDURES  
Study procedures are summarized in the SoA tables within each arm Appendix (Section 
12.1): Table for Screening assessments, Treatment Period assessments, and Treatment 
Discontinuation Visit [TDV] and Follow -Up assessments. Visit windows, as allowable, 
are notated in the SoA tables .  
9.1. General Guidance  
Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct. Protocol waivers or exemptions are not allowed 
except for immediate safety concerns. Therefore, adherence to the study design 
requirements, including those specified in the SoA are essential and required for study 
conduct .  
Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant shoul d continue or discontinue 
study treatment.  
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
Procedures conducted as part of another clinical trial within the screening window (e.g. 
imaging studies) and obtained prior to signing of the study informed consen t may be used 
for screening/baseline assessments provided the procedures fulfill the protocol defined 
specifications and has been performed within the protocol indicated timeframe.  
TMF- [ADDRESS_100261] be noted:  
• Informed consent must be signed by a pa rticipant before any study required 
procedures are performed . However, procedures conducted as part of the routine 
clinical management (e.g., imaging studies) and conducted prior to signing of the 
study informed consent may be used for screening/baseline a ssessments provided 
the procedure fulfills the protocol defined specifications and has been performed 
within the protocol indicated timeframe.  
• If assessments are scheduled for the same nominal time, then the assessments 
must occur in the following order:  
1. 12-lead ECG  
2. Vital signs  
3. Blood draws  
Note:  The timing of the assessments must allow the blood draw to occur at the 
exact nominal time.  
• The timing and number of planned study assessments, including safety, biomarker 
or other assessments may be altered during the course of the study based on 
emerging data to ensure appropriate monitoring.  
• The change in timing or addition of time points for  any planned study assessments 
must be approved by [CONTACT_90997], but this will not constitute a protocol 
amendment.  
• No more than approximately 13 75 mL of blood  will be collected from each 
participant over the full course of study treatment (2 years) . 
9.1.1.  General Guidance for Treatment Continuity when Participants are 
Unable to Come into the Clinic  
Prior to utilization of any of the measures outlined in this section, discussi on and 
approval must be obtained from Sponsor/contract research organization.  
It is expected that sites participating in clinical studies will make every effort to ensure 
proper monitoring and well -being of enrolled participants by [CONTACT_90998] (Section 12.1). The use of local laboratories and local 
radiology centers to reduce the need for a participant to come i nto the clinic is supported, 
if deemed necessary for the well -being of the participant. These local facilities should be 
added to regulatory documents, as required.  
Any restrictions in place at the site that will impact monitoring and/or participant access  
to the site and care providers should be communicated to the Sponsor/contract research 
organization.  
A global telemedicine  platform that allows for continued monitoring of AEs, concomitant 
medications, protocol deviations, etc., may be engaged. Discussio ns around utilization of 
TMF- [ADDRESS_100262] or alternative 
location for assessment (e.g., local laboratories and imaging centers, at -home collection 
of patient reported outcomes [PROs]).  
9.2. Screening and Critical Baseline Assessments  
All screening assessments must be performed within [ADDRESS_100263] dose.  
The term ‘baseline’ refers to the assessment performed during the screening period prior 
to first dos e of study treatment that serves as a comparison or control. For example, the 
baseline laboratory assessment is the laboratory assessment performed prior to first dose.  
Refer to SoA for each arm (Section 12.1) for additional details on assessments required at 
Screening and prior to start of study treatment. All assessments performed must be 
documented in the site source documents.  
The following assessm ents are required during screening:  
• Demographic parameters such as year of birth and sex will be captured.  
 
• Medical history including cardiovascular medical history, tobacco use, and other risk 
factors will be assessed as related to the inclusion/exclusion  criteria.  
• Disease characteristics including medical, surgical, and treatment history including 
radiotherapy, date of initial diagnosis, stage at initial diagnosis according to the 8th 
Edition of TNM for Lung Cancer by [CONTACT_90999] C ontrol 
[UICC], histology, tumor genetic/genomic features sand current sites of disease will 
be taken as part of the medical history and disease status. Scans from imaging studies 
performed prior to screening may be requested for assessment of baseline lesi ons. 
Details concerning prior anticancer therapy (for example, systemic and radiation 
therapy), including best response to prior systemic therapy will be recorded.  
 
• If available, any antibiotic use within [ADDRESS_100264] of antibiotics on clinical outcome 
through its manipulation of the immune system.  
 
• PD-L1 protein expression by [CONTACT_91000] -L1 status prior to initiation of treat ment with a PD -L1 inhibitor. PD -L1 
expression by [CONTACT_91001] (i.e., Ventana SP263, Ventana SP142, 
Dako 28 -8, or Dako 22C3) must be recorded in the eCRF, if known.  
Baseline lesion assessments required within [ADDRESS_100265] dos e of study 
treatment include:  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
45 • Computed tomography (CT) scan with contrast of the chest and abdomen  
Note:  Although a CT scan is preferred, magnetic resonance imaging (MRI) may 
be used as an alternative method of baseline disease assessment, especially for 
those participants where a CT scan is contraindicated due to allergy to contrast, 
provided the method use d to document baseline status is used consistently 
throughout study treatment to facilitate direct comparison. When MRI is used for 
disease assessment, a non -contrast CT of the chest should also be performed, to 
evaluate the lungs. Refer to RECIST 1.1 guid elines for use of 
fluorodeoxyglucose -positron emission tomography (FDG -PET)/CT [ Eisenhauer , 
2009; Seymour , 2017].  
• MRI of brain with and without IV gadolinium (if clinically indicated)  
• Bone scan (if clinically indicated)  
• Clinical disease assessment for palpable/visible lesions  
• Other areas as indicat ed by [CONTACT_2299]’s underlying disease present prior to 
screening  
Refer to Section 9.3.1  for baseline documentation of target and non -target les ions.  
Safety and laboratory assessments (Section 9.5) required at baseline include:  
• Physical examination  
• ECOG Performance Status  
• Vital Signs  
• Concomitant medication  
o Recorded starting from screening through post -study follow -up.  
o Record all medications the participant is taking including prescription 
medications, over -the-counter (OTC) drugs or preparations, and 
herbal preparations including any cannabinoids and/or recreational 
drugs used.  
o At a minimum, the drug name, route of administration, dose, and 
frequency of dosing, along with start and stop dates must be recorded.  
• Electrocardiogram  
• Echocardiogram  
• Laboratory assessments  
9.3. Efficacy Assessment s 
Planned time points for all efficacy assessments are listed in in each specific arm SoA 
Tables within Section 12.1.  
TMF- [ADDRESS_100266] 1.1 will be used in the assessment of disease burden (target and non -target 
lesions determination) at Screening and as the primary measure of tumor response 
endpoints.  
Additionally, iRECIST guidelines will be used in the assessment of respo nse/progression 
to account for the unique tumor kinetics observed with immunotherapeutic agents which 
may manifest as an increase in tumor burden then later is followed by [CONTACT_91002]. Following approval by [CONTACT_91003] -progression (Section 8.1), participants with disease progression 
by [CONTACT_44993] 1.[ADDRESS_100267] guidelines [ Seymour , 2017].  
Refer to the SoA for each arm (Section 12.1) for the frequency of disease assessments 
post screening.  
A description of the adaptations  and iRECIST process is provided in Appendix [ADDRESS_100268] publication [ Seymour , 2017]. A summary of imaging 
and treatment requirements after first radiologic evidence of progression provided in 
Table 54 and illustrated as a flowchart in Figure 11 in Appendix 12 .  
Tumor images will be obtained and transmitted to a central imaging vendor for potential 
central review. The process for tumor imaging and transmission to the central imaging 
vendor are detailed in the Imaging Manual. Tumor imaging is strongly preferred to be 
acquired by [CONTACT_24636]/oral contrast enhanced CT. For the abdomen and pelvis (if performed), 
contrast -enhanced MRI may be used when CT with iodinated contrast is contraindicated, 
or when mandated by [CONTACT_53246]. MRI is the preferred modality for imaging the brain 
and spi[INVESTIGATOR_050]. The same imaging modality, ideally the same scanner, scanning technique and 
the use of contrast should be used for a participant throughout the study to optimize 
reproducibility and accuracy of assessment of existing and new tumor burden.  
Notes:  
• Imaging must include the chest and abdomen.  
• Brain imaging should be conducted, if clinically indicated, at Screening and 
throughout the study for evaluation of brain metastases. MRI is preferred 
however CT imaging is acceptable if MRI is medically  contraindicated.  
• Bone scans are optional for participants with a history of bone metastases or 
for those participants with new bone pain. Any supplemental imaging done to 
support a positive or negative bone scan, such as plain X -rays that may be 
acquired  for correlation, should be submitted to the central imaging vendor.  
All bone scan abnormalities at Screening that could indicate metastases should be 
evaluated by X -ray, CT, or MRI to determine if they represent malignant lesions. If a 
bone scan was perf ormed within [ADDRESS_100269] dose, it does not need to be 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
47 repeated (in the absence of new or worsening clinical symptoms suggesting bone 
involvement). Typi[INVESTIGATOR_90865]. 
However, positron emission tomography (PET) scan ([18F]-fluorodeoxyglucose or [18F]-
fluoride) is acceptable, providing coverage is sufficient to evaluate total spi[INVESTIGATOR_050], clavicle, 
ribs, pelvis (if performed) and long bones.  
In the event a photograph is taken of a particular lesion, the  site will submit the 
photograph to the central imaging vendor. Refer to the site central imaging vendor 
manual technical requirements for photograph submission.  
[IP_ADDRESS].  Initial Tumor Imaging  
Initial tumor imaging at Screening must be performed within [ADDRESS_100270] dose and can be assessed by [CONTACT_11343].  
[IP_ADDRESS].  Tumor Imaging During the Study  
The first on -study imaging assessment must be performed [ADDRESS_100271] ( Appendix 12 ), disease progression should be confirmed by [CONTACT_91004] 
[ADDRESS_100272] met the conditions detailed in Appendix 12 .  
[IP_ADDRESS].  End of Treatment Imaging  
For participants who discontinue study treatment due to disease progression, tumor 
imaging does not need to be repeated at the TDV. If previous imaging was obtained 
within [ADDRESS_100273] of study therapy on the growth rate of individual tumor lesions, 
pre-baseline images (within approximately 12 months before the baseline scan; images 
obtained >12 months prior to the baseline scan may also be accepted upon consultation 
with Medical Monitor) will be requested to support exploratory investigation of tumor 
growth kinet ics. Up to [ADDRESS_100274]/MRI of the ches t and abdomen with IV contrast are preferred, if available, and per 
local standard of practice. The same modality used at study baseline imaging is 
encouraged to be submitted, but not required. If performed, imaging of the brain along 
with any other areas of disease that were imaged in the 6 months prior to baseline scan 
may also be submitted. PET images are not required but may be submitted; and, the CT 
portion (with IV contrast if possible) of a PET/CT examination is acceptable if no other 
CT examinations  are available.  
9.3.3.  Survival Follow -up 
After a participant receives the last dose of study treatment, he or she will enter the 
survival follow -up period. Follow -up for survival and new anticancer therapy (including 
radiotherapy) will occur every [ADDRESS_100275].  
9.4. Adverse Events  
The definitions of AEs and SAEs are provided in Appendix 5 . 
The investigator and any designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study treatment or the study, 
or that caused the participant to discontinue the study treatment (see Section 8). Adverse 
events must be assessed and documented at each patient contact.  
9.4.1.  Time Period and Frequency for Collecting AE and SAE 
Information  
• All AESIs and SAEs will be collected from the start of treatment until [ADDRESS_100276] dose of study treatment a t the time points specified in the SoA (Section 2). 
However, any AESI or SAEs assessed as related to study participation (e.g., study 
treatment, protocol -mandated procedures, invasive tests, or change in existing 
therapy) or related to a [COMPANY_004] product will be recorded from the time a participant 
consents to p articipate in the study. If subsequent anti -cancer treatment is initiated 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
49 during the 90 -day follow -up period yet <[ADDRESS_100277] 
dose of study tr eatment and documentation of the subsequent anticancer treatment 
will be recorded in the eCRF.  
• All AEs will be collected from the start of study treatment until [ADDRESS_100278] 
dose of study treatment at the time points specified in the SoA (Section 2). 
• Medical occurrences that begin before the start of study treatment but after obtaining 
informed consent will be recorded in the Medical History/Current Medical 
Conditions section of the CRF and not in the AE section.  
• All SAEs will be rec orded and reported to the Sponsor or designee immediately and 
under no circumstance should this exceed 24 hours,  as indicated in Appendix 5 . The 
investigator will submit any updated SAE data to the Sponsor within 24  hours of it 
being available.  
• Investigators are not obligated to actively seek AEs or SAEs in former study 
participants. However, if the investigator learns of any SAE, including a death, at 
any time  after a participant has been discharged from the study, and he/she considers 
the event to be reasonably related to the study treatment or study participation, the 
investigator must promptly notify the Sponsor.  
• The method of recording, evaluating, and asse ssing causality of AEs and SAEs and 
the procedures for completing and transmitting SAE reports are provided in 
Appendix 5 . 
9.4.2.  Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrence.  
9.4.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the inv estigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs and non -serious AESIs (Section 7.2.1  
and Section 9.4.1 ), will be followed until the event is resolved, stabilized, otherwise 
explained, or the participant is lost to follow -up (as defi ned in Section 8.3). If subsequent 
anti-cancer treatment is initiated during the 90 -day follow -up period yet <[ADDRESS_100279] dose of study treatment and documentation of the subsequent 
anticancer treatment will be recorded in the eCRF. Further information on follow -up 
procedures is given in Appendix 5 .  
9.4.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_29532] a SAE is essential so 
that legal obligations and ethical responsibilities toward the safety of 
participants and the safety of a study treatment under clinical investigation are 
met.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
50 • The Sponsor has  a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study treatment 
under clinical investigation. The Sponsor will comply with country -specific 
regulatory requirements relating to safety  reporting to the regulatory authority, 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and 
investigators.  
• Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) according to local reg ulatory requirements and 
Sponsor policy and forwarded to investigators as necessary.  
• An investigator who receives an investigator safety report describing a SAE or 
other specific safety information (e.g., summary or listing of SAE) from the 
Sponsor will re view and then file it along with the Investigator’s Brochure and 
will notify the IRB/IEC, if appropriate according to local requirements.  
 
9.4.5.  Cardiovascular and Death Events  
For any cardiovascular events detailed in Appendix 5  and all deaths, if they are 
considered SAEs, specific cardiovascular and death sections of the eCRF will be required 
to be completed. These sections include questions regarding cardiovascular  (including 
sudden cardiac death) and non -cardiovascular death.  
The CV (cardiovascular) eCRFs are presented as queries in response to reporting of 
certain cardiovascular MedDRA terms. The cardiovascular information should be 
recorded in the specific cardi ovascular section of the eCRF within [ADDRESS_100280] be completed within  one 
week of when the death is reported.  
9.4.6.  Pregnancy  
• Details of all pregnancies in female participants and female partners of male 
participants will be collected after the start of study treatment and until [ADDRESS_100281] dose of study treatment (or per institutional standard).  
• If a pregnancy  is reported, the investigator should inform [COMPANY_004] within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Section 9.4.4 . 
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAE.  
9.5. Safety Assessments  
Planned time points for safe ty assessments are provided within each arm SoA Appendix 
(Section 12.1). Additional time points for safety testing may be added during the study 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
51 based on newly available data to ensure appropriate safety monitoring. PK and ADA 
samples will also be collected for safety. See Section 9.6 and Section  9.7 for additional 
information.  
9.5.1.  Physical Examinations  
• A complete physical examination performed at Screening will include, at a 
minimum, assessment of the cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, skin and 
neurological systems.  
• A brief physical examination performed at each subsequent visit (refer to SoA 
tables for each arm in Section 12.1), will include, at a minimum, assessments of 
the skin, lungs, cardiovascular system, and abdomen (liver and spleen).  
• Investigators should pay special attention to clinical signs related to previous 
serious illnesses.  
• Physical examinations may be performed within one day of dosing (i.e., as 
opposed to the day of dosing), if necessary.  
9.5.2.  Performance Status  
Performance status will be assessed using the ECOG scale at each visit, on the day of 
treatment or within 24 hours prior to dosing, if necessary ( Append ix 8). 
9.5.3.  Vital Signs  
• Vital signs will be measured after [ADDRESS_100282] and will include tempera ture, 
systolic and diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], and oxygen 
saturation (measured by [CONTACT_406]). Blood pressure should be taken in the 
same position throughout the study and captured in the eCRF.  
• Vital signs will be measured more frequently if warranted by [CONTACT_91005].  
• On days where vital signs are measured multiple times, temperature does not 
need to be repeated unless clinically indicated.  
• If a participant develops fever and infusion related reacti on or cytokine release 
syndrome is suspected, refer to management guidelines (Section 7.2.1 ). 
• Height will be recorded at Screening only.  
• Weight will be measured and recorded (in kilograms) at baseline and every other 
treatment visit.  
• Vital signs must be recorded prior to dosing on treatment days.  
9.5.4.  Electrocardiograms  
A 12 -lead ECG will be obtained at screening using an ECG machine that autom atically 
calculates the heart rate and measures PR, QRS, QT, and QTcF intervals; manual 
calculation of QTcF is permitted. ECGs may be repeated during the study as clinically 
indicated , unless noted otherwise in the S oA for each arm under Section 12.1. 
TMF- [ADDRESS_100283] review is required if abnormal results are 
obtained and confirmed as described in Table 34 and Table  46 (Cardiac Investigations).   
9.5.5.  Echocardiogram  
Echocardiograms (ECHO) will be per formed locally at baseline to assess cardiac ejection 
fraction for study eligibility, as specified in the SoA (Section 12.1). Additional ECHO 
assessments may be performed if clinically warranted. The evaluation of the 
echocardiography should include an evaluation for LVEF and both right and left -sided 
valvular lesi ons. Multigated Acquisition Scan (MUGA) can be used in lieu of ECHO (if 
not feasible) in the assessment of LVEF; the same modality should be used in any 
subsequent assessments.  
9.5.6.  Clinical Safety Laboratory Assessments  
Refer to Appendix  [ADDRESS_100284] of clinical laboratory tests to be performed and to the 
SoA for each arm (Section 12.1) for the timing and frequency.  
The investigator must review the laboratory report  prior to administration of study 
treatments , document this review, and record any clinically  relevant changes occurring 
during the study in the AE section of the CRF. The laboratory reports must be filed with 
the source documents. Clinically significant abnormal laboratory findings are those 
which are not associated with the underlying disease, u nless judged by [CONTACT_91006]'s condition.  
All protocol required safety laboratory assessments, as defined in Table [ADDRESS_100285] be provided to the site by [CONTACT_91007].  
All study -required safety laboratory assessments wil l be performed at the institution’s 
local laboratory. Laboratory safety assessments required prior to dosing may be 
performed up to [ADDRESS_100286] be 
recorded in the eCRF. If additional non -protocol spec ified laboratory assessments are 
performed at the institution’s local laboratory and result in a change in participant 
management or are considered clinically significant by [CONTACT_093] (for example, 
SAE or AE or dose modification) the results must al so be recorded in the eCRF.  
For all other protocol required blood and tissue sample collections, laboratory requisition 
forms must be completed, and samples must be clearly labeled with the participant 
number, protocol number, site/center number, and visit  date. Details for the preparation 
and shipment of samples that are required to be tested by a central laboratory will be 
provided by [CONTACT_91008].  
Refer to the SRM for appropriate processing and handling of samp les to avoid duplicate 
and/or additional blood draws.  
All laboratory tests with values that are considered clinically significantly abnormal 
during participation in the study or within [ADDRESS_100287] be 
identified, and the Sponsor notified.  
9.6. Pharmacokinetics  
Planned time points for all pharmacokinetics assessments are listed in the SoA for each 
arm (Section 12.1).  
9.6.1.  Blood Sample Collection  
Blood samples for PK analysis are to be collected as indicated in the SoA. The actual 
date and time of each blood sample collection will be recorded. The timing of PK 
samples may be altered and/or PK samples may be obtained at additional time points to 
ensure adequate PK monitoring.  
Details on PK blood sample collection, processing, storage, and shippi[INVESTIGATOR_90866]/laboratory manual. If additional study drugs are added to this study 
for which PK samples are required, details will be provided in the SRM.  
9.6.2.  Sample Analysis  
PK analysis  will be performed for participants as indicated in each SoA. Concentrations 
of the study treatments will be determined using validated bioanalytical methodologies. 
Once the analysis has been completed, for any remaining samples may be analyzed for 
other c ompound -related metabolites. Refer to the SRM for further details.  
9.7. Anti-Drug Antibodies  
The actual date and time of each blood sample collection will be recorded for each 
specific analyte. Details of blood sample collection (including volume to be collecte d), 
processing, storage, and shippi[INVESTIGATOR_42232].  
The timing and number of planned immunogenicity samples may be altered during the 
course of the study, based on newly -available data to ensure appropriate safety 
monitoring. In the e vent of a hypersensitivity reaction that is either clinically significant 
in the opi[INVESTIGATOR_871], or leads to the participant withdrawing from the study 
treatment, blood samples must be taken from the participant for immunogenicity testing 
at the timepoints indicated in the arm specific SoAs (Section 12.1).  
9.8. Genetics  
Planned time points for all genetics -related assessments are listed in in the SoA for each 
arm (Section 12.1). 
A whole blood sample for DNA isolation will be collected from participants who have 
consented to participate in the genetics analysis component of the study. Participation is 
optional. Participants who do not wish to participate in the genetic research may still 
participate in the study.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
54 In the event of DNA extraction failure, a replacement genetic blood sample may be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.  
See Appendix  7 for further information regarding genetic research. Details on processes 
for collection and shipment and destruction of these samples can be found in the SRM.  
9.9. Biomarkers  
Planned time points for all biomarker assessments are listed in the SoA for  each arm 
(Section 12.1). 
9.9.2.  Tumor Tissue  
[IP_ADDRESS].  Screening Biopsies  
Part 1: All participants are required to provide fresh tumor tissue AND archival tumor 
tissue samples at screening prior to start of study treatment, unless specified otherwise in 
the SoA of each regimen in the respective subsections under Section 12.1.  
Part 2: Tumor tissue at screening (either archival or fresh biopsy if archival tissue is 
unavailable) is required for all participants in Part 2. Fresh tumor tissue AND an archival 
tissue sample obtained during screeni ng are required for at least [ADDRESS_100288] been obtained at any time from the time of 
initial diagnosis to time of study entry. Sufficient and evaluable tumor tissue for protocol 
specified te sting needs to be provided (reference SRM for more details).  
[IP_ADDRESS].  On-Treatment Biopsies  
Part 1: All participants are required to provide paired fresh biopsies at screening and on -
treatment at week 7 (± 8 days), unless specified otherwise in the SoA of each regi men in 
the respective subsections under Section 12.1.  
Part 2: Fresh biopsy collected at week 7 (± 8 days) is optional for participants in Part 2, if  
tumor is amenable to biopsy and upon participant’s consent; However, paired fresh tumor 
biopsies collected at screening and week 7 (± 8 days) is required for at least 20 
participants for each arm.  
Enrollment may become limited during the study, as required, to ensure collection of 
fresh tissue samples as noted.  
 
Additional optional fresh tumor tissue sample will be collected at Week 19 (± 8 days) at 
the time of imaging assessment and/or at the time of confirmed PR or PD, upon 
participant consent (± 8 days).  
When feasible, tumor imaging should be completed prior t o tissue collection to avoid 
potential radiographic alterations due to the biopsy procedure.  
 
These tissues will be evaluated by [CONTACT_91009], including image 
analysis, for expression of phenotypic and functional immune cell markers on tu mor 
infiltrating lymphocytes (TIL) and other immune cells as well as immune signaling 
markers on tumor cells to understand the anti -tumor responses. In addition, when 
possible, similar analyses will be performed on tumor tissue obtained upon progression. 
Additionally, tumor tissue may be sequenced to assess T -cell diversity (TCR diversity) as 
well as evaluated for any DNA/RNA/protein changes correlating with response, 
including tumor mutational load assessments. These samples may also be evaluated for 
predi ctive measures of response to include in the biomarker selected population. If a 
predictive biomarker is identified, these tissues may be used for the development of a 
diagnostic test.  
Other biomarkers may be evaluated as determined by [CONTACT_91010]. De tails for the 
samples collection, processing, storage, and shipment will be provided in the SRM.  
9.10.  Patient -Reported Outcome Assessments  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
56 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
57 Table 6 PRO Outcomes Assessed in Study 205801  
Instrument  Role  Rationale & Overview  
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
58 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
59 10. STATISTICAL CONSIDER ATIONS  
10.1.  Primary Endpoint  
10.1.1.  Primary Endpoint: Part 1  
The primary endpoint for Part 1 is the incidence of AEs, SAEs, DLTs, changes in 
safety/laboratory assessment parameters, and d ose modifications.  
A key secondary endpoint for Part 1 is Objective Response Rate (ORR) using RECIST 
1.[ADDRESS_100289] overall response of CR or PR at any time.  
10.1.2.  Primary Endpoint: P art [ADDRESS_100290].  
10.2.  Hypothesis  
10.2.1.  Hypothesis: Part 1  
The primary objective of Part 1 is to establish the safety and tolerability of the 
experimental combination regimen of each arm.  
10.2.2.  Hypothesis: Part [ADDRESS_100291] of care. The null hypothesis is that there is no 
difference in overall survival between each experimental arm and the SoC and altern ative 
hypothesis is that the experimental regimen improves overall survival over the SoC. The 
predictive probability inference approach will be used as the basis for both interim and 
final decision making. The predictive probability of success (PoS) in fut ure Phase 3 study 
(phase [ADDRESS_100292] with 1 -sided 
alpha=0.025) will be calculated as a measure of the improvement in OS in the 
experimental arm compared with the SoC arm. A cutoff of 43% or greater f or the PoS of 
future Phase 3 study, approximately corresponding to an observed HR no greater than 0.8 
in a substudy, will be implemented as the criteria for an experimental regimen to be 
considered for proceeding to Part 2. As this is a signal finding stud y and not 
confirmatory, each experimental arm will be compared to control in a pairwise fashion 
with no adjustment for multiple comparisons.  
10.3.  Sample Size Determination  
10.3.1.  Sample Size: Part 1  
For Part 1, sample size will be defined for each regimen under the co rresponding 
appendix in Section 12.1.   
The FDA approved dose of docetaxel provides the following outcomes, based on the 
validated data.  
  Study  
  TAX 317  Control for 317  TAX320  Control for 320  
  Docetaxel 75 
mg/m2 n=[ADDRESS_100293] Supportive 
Care n=49  Docetaxel 75 
mg/m2 n=125  Vinorelbine or 
Ifosfamide n=123  
95% CI (Risk Ratio)  (0.35, 0.88)  (0.63, 1.06)  
Median Survival  
(95% CI)  7.5 months  
(5.5, 12.8)  4.6 months  
(3.7, 6.1)  5.7 months  
(5.1, 7.1)  5.6 months  
(4.4, 7.9)  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
61   Study  
  TAX 317  Control for 317  TAX320  Control for 320  
  Docetaxel 75 
mg/m2 n=[ADDRESS_100294] Supportive 
Care n=49  Docetaxel 75 
mg/m2 n=125  Vinorelbine or 
Ifosfamide n=123  
% 1-year Survival  
(95% CI)  37% (24, 50)  12% (2, 23)  30% (22, 39)  20% (13, 27)  
Time to Progression  
(95% CI)  12.3 weeks  
(9.0, 18.3)  7.0 weeks  
(6.0, 9.3)  8.3 weeks  
(7.0, 11.7)  7.6 weeks  
(6.7, 10.1)  
Response Rate  
(95% CI)  5.5%  
(1.1, 15.1)  N/A 5.7%  
(2.3, 11.3)  0.8%  
(0.0, 4.5)  
 
Additional information is available from the control arm of the FDA approved label for 
pembrolizumab where docetaxel was used as a control. The following table summarize 
those data.  
Endpoint   Docetaxel 75 mg/m2 every 3 weeks n=152  
OS Deaths (%)  86 (57%)  
OS Median in months  8.2 (6.4, 10.7)  
PFS Events  118 (78%)  
PFS Median in months  4.1 (3.6, 4.3)  
ORR  8% (4, 13)  
Median duration of response in months (range)  8.1 (2.1+, 8.8+)  
 
Examining the confidence intervals for docetaxel response rates across not only the FDA 
approved package inserts, but other published studies show that while the point estimates 
for response rate may vary, the 95% Confidence Intervals around the point estimates 
remain i n the 5% -15% range. Consequently, using a 10% Response Rate as a benchmark 
is reasonable based on available data. Data from 205801 platform study Substudy 1, if 
available, may be used to calibrate this assumption of the docetaxel monotherapy 
response rate for the futility analysis.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
62 10.3.2.  Sample Size: Part 2  
In Part 2, 70 participants in each experimental arm and a minimum of 35 participants in 
the SoC arm will be randomized. Sample size and associated operating characteristics 
were evaluated via simulation.  
The 8-month milestone survival in the SoC arm is estimated to be ~40% in squamous cell 
lung cancer ( Brahmer , 2015), ~60% in non -squamous lung cancer ( Borghaei , 2015), and 
~50% in PD -L1 positive population ( Herbst , 2016). The participant population i n the 
current study is expected to be a mixed population with both squamous and non -
squamous lung cancer participants; therefore, mean target rate is assumed to be ~50% 
(Figure 4). 
For the target effect of experimental regimens, there is a potential delayed effect at 
treatment start and sustained effect after prolonged follow -up (Brahmer , 2015; Borghaei , 
2015). The survival probability in these arms is expected to overlap in  the SoC arm for up 
to 4 months from start of treatment followed by a separation. It is hypothesized that 
percentage of surviving participants is maintained at 20% after 24 months (Figure 4).  
Under the alternative hypothesis three -pi[INVESTIGATOR_90867] -pi[INVESTIGATOR_90868] (Refer to 
Appendix 13  for simulation parameters). Details of the pi[INVESTIGATOR_90869] (Section 12.13 ). Using this modeling approach for the 
primary endpoint of OS, the assumed survival curve for the SoC arm is presented using 
blue dashes and the target survival curve for the experimental arm is presented as the 
solid red curve in Figure 4. Based on these two curves, the hazard ratio is approximately 
0.58.      
Sample size was chosen by [CONTACT_91011] 4 experimental arms 
enter the  master protocol at different points in time. Enrollment of 9 participants per 
month is assumed. Interim and final analyses are performed based on predetermined 
decision rules as specified in Section 10.3.3  and Section 10.5.1 , respectively.  The 
planned Phase 3 sample size is 300 (150 participants per arm and a total of 210 events).  
The future phase 3 trial will use the log -rank (frequentist) test and the decisio n rule at 
interim and end of phase 2 will use the (Bayesian) predictive probability, given the 
results in phase 2, that the future log -rank test in phase [ADDRESS_100295]. Simulations 
assess the Operating Characteristics of the predictive probability decision criteria under 
the null and alternative hypotheses, as described in Section 10.3.4 . A cutoff of 43% or 
greater for the PoS of future phase 3 study, approximately corresponding to an observed 
HR ≤ 0.[ADDRESS_100296] 6 months, at the discretion of 
the Sponsor . A minimum of 35 events are needed from the experimental arm for both 
primary and final analysis.  
Assuming the true HR≈0.58, 85 death events will p rovide 94.2% probability (power) of 
achieving the guidance criteria with future phase 3 study success ≥ 43%. In the case of 
primary analysis being performed with 75 death events, it will provide 88.3% probability 
of achieving the guidance criteria. If the true HR is 1, [ADDRESS_100297] 
16.6% and 18.2% Type I error, respectively.  
Figure 4 Assumed Survival Probability Under Alternative Hypothesis in 
Experimental Regimens (Red) and  
Docetaxel (Blue)  
  
10.3.3.  Interim Analyses  
[IP_ADDRESS].  Interim Analyses: Part 1  
An interim evaluation of futility in terms of ORR may be conducted for an arm if  data 
permits. Details for futility analyses are provided in the respective subsection for each 
arm in Appendix Section 12.1.  
 

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
64 [IP_ADDRESS].  Interim Analyses: Part [ADDRESS_100298] the trial at different time points as determined by 
[CONTACT_094]-specified decision criteria.   
Part 2 of the study will be conducted under the auspi[INVESTIGATOR_90870]. The membership and activities are outlined in the IDMC and steering 
committee charters. This committee wil l review all available interim safety and efficacy 
data as the study progresses. Interim analyses will be performed approximately every 6 
months depending on the amount of additional data accrued.   
Interim Analyses for OS  
An interim analysis of OS will be  conducted for each substudy after approximately 45 
events (experimental arm and SoC combined) and a minimum of [ADDRESS_100299] been observed. Note , events from the SoC arm will be counted 
from the initial study start (i.e. SoC events from substudy 1 will be counted with any 
further events observed in subsequent substudies).  Stoppi[INVESTIGATOR_90871]. Final decisions on termination of an arm will be based on 
the totality of the data.  
Final analysis  for Graduation   
The final analysis for each substudy will occur after observing 85 events (experimental 
regimen and SoC combined) and the last participant in a substudy has been randomized 
for at least [ADDRESS_100300] 6 months, at the discretion of the Sponsor. A cutoff of 4 3% or greater for the PoS of 
future phase 3 study is used as graduation criteria for an experimental regimen to be 
considered for proceeding to Part 2. The final decision of proceeding to Part 2 will be 
based on the totality of data. An experimental regime n may be discontinued at any time 
due to safety concerns.  
Additional details of the interim analysis will be provided in the RAP and IDMC charter.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
65 10.3.4.  Statistical Operating Characteristics  
For Part 1, please see details under the corresponding appendix for each arm in Section 
12.1.  
For Part 2, simulations were carried out to determine the operating characteristics for the 
primary comparisons for Part 2. The simulation results are presented i n Table 7 and Table 
8. Since the randomization ratios for subsequent studies range from 1:4 to 1:2 (as shown 
in Table 1), the simulations for subsequent studies were performed for both 1:4 and 1:2 
scenarios. Table 7 shows simulation results for 85 events at final analysis as planned and 
Table 8 shows si mulation results for the primary analysis with 75 events in the case 
primary analysis is decided to be conducted.  
The simulations on OS are based on the following assumptions:  
1. The sample size for the experimental arm is 70 for all substudies. The 
sample s ize for the control arm is 35 for substudy 1, and for subsequent 
studies it follows dynamic randomization ratios as described in Table 1.  
2. The required minimum number of death events in the experimental arm 
are 18 for the interim analysis and 35 for the final (or primary) analysis.  
3. The survival curve for the SoC arm and the experimental arm are assumed 
to be same as presented in  Figure 4, with target HR≈0.58. The Weibull 
parameters of each curve used for the simulations are detailed in Section 
12.13.1 . 
4. The recruitment rate is approximately 9 participants per month.  
5. The start date of Part 2 of subsequent studies is ~34 months after the start 
date of substudy 1.  
6. The futility threshold for interim analysis is 5% or less for the PoS of 
future phase 3 study , as described in Appendix C of the IDMC charter.  
7. A cutoff of 43% or greater for the PoS of future phase [ADDRESS_100301] (HR ≈ 0.58) and 
Null Effect ( HR=1) for [ADDRESS_100302] 
Scenarios  Substudies  Number of Participants in 
SoC Arm  Interim Analysis of OS  Final Analysis (85 events)  
Participants 
from 
Substudy 1  Participants 
from 
Subsequent 
Substudy  Average  
Events  
Prob. of 
Futility  Average 
Events  Power or 
Type I error 
(Pred. 
prob.≥43%)  SoC Trt SoC Trt 
HR ~ 0.58  Substudy 1  35 NA 17.4 27.6 3.4%  33.1 51.9 94.2%  
Subsequent 
substudy 
(ratio 1:4)  35 18 40.8 18 9.3%  47.8 37.3 81.9%  
Subsequent 
substudy 
(ratio 1:2)  35 35 46.1 18 9.2%  58.4 35 76.3%  
HR =1  Substudy 1  35 NA 15 30 19.0%  28.3 56.7 16.6%  
Subsequent 
substudy 
(ratio 1:4)  35 18 39.9 18 22.6%  45.3 39.7 14.9%  
Subsequent 
substudy 
(ratio 1:2)  35 35 44.5 18 22.0%  53 35.4 15.6%  
Note: The simulation did not incorporate the minimum requirement of [ADDRESS_100303] (HR ≈ 0.58) and 
Null Effect (HR=1) for [ADDRESS_100304] 
Scenarios  Substudies  Number of Participants in SoC 
Arm Primary Analysis (75 events)  
Participants 
from 
Substudy 1  Participants 
from 
Subsequent 
Substudy  Average Events  Power or 
Type I error 
(Pred. 
prob.≥43%)  SoC Trt 
HR ~ 0.58  Substudy 1  35 NA 29.8 45.2 88.3%  
Subsequent substudy 
(ratio 1:4)  35 18 47 35 76.7%  
Subsequent substudy 
(ratio 1:2)  35 35 58.4 35 76.3%  
HR =1  Substudy 1  35 NA 25 50 18.2%  
Subsequent substudy 
(ratio 1:4) 35 18 44.2 35 16.2%  
Subsequent substudy 
(ratio 1:2)  35 35 52.8 35 15.6%  
Note: The simulation did not incorporate the minimum requirement of [ADDRESS_100305] 
participant to analysis date.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
67 10.3.5.  Sample Size Sensitivity  
It is expected that the statistical operating characteristics will be dependent on 
assumptions around target treatment effects and survival curve of SoC. Evaluations of 
sensitivity analysis were performed varying one assumption at a time (See Table 9, Table 
10, Figure 5, and Figure 6). Sensitivity analysis with respect to HR was conducted using 
simulations under two scenarios: HR=0.48 and HR=0.70. For the case where HR=0.48, 
the target survival curve for the experimental arm is presented in Figure 6A using the 
thick solid orange curve and the assumed survival curve for SOC is presented using blue 
dashes. For the case where the HR=0.70, the target survival curve for the experimental  
arm in Figure 6B is presented using the thick solid green curve and the assumed survival 
curve for SOC is presented using blue dashes. The experiment al target survival curve 
(with HR=0.58 relative to SOC) is also presented (with notation) in both figures. 
Sensitivity analysis simulation results showing the operating characteristics of the 
predictive probability decision criteria under these 2 scenarios  (HR=0.48 and HR=0.70) 
are presented in Table 9. 
Table [ADDRESS_100306] 
Scenarios  Substudies  Number of Participants in 
SoC Interim Analysis of OS  Final Analysis (85 events)  
Participants 
from 
Substudy 1  Participants 
from 
Subsequent 
Substudy  Average 
Events  
Prob. of 
Futility  Average 
Events  Overall 
Power (Pred. 
prob.≥43%)  SoC Trt SoC Trt 
Greater 
than 
Target 
Effect 
(HR ≈ 
0.48)1 Substudy 1  35 NA 18.3 26.7 1.8%  34.3 50.7 99.2%  
Subsequent 
substudy 
(ratio 1:4)  35 18 41.1 18 6.6%  48.9 36.4 93.9%  
Subsequent 
substudy 
(ratio 1:2)  35 35 46.9 18 6.5%  61.1 35 90.0%  
Lower 
than 
Target 
Effect 
(HR ≈ 
0.7)2 Substudy 1  35 NA 16.6 28.4 6.3%  31.6 53.4 76.8%  
Subsequent 
substudy 
(ratio 1:4)  35 18 40.4 18 12.6%  46.9 38.2 61.7%  
Subsequent 
substudy 
(ratio 1:2)  35 35 45.5 18 13.0%  56.2 35.1 56.3%  
[ADDRESS_100307] as shown in Figure 6A (Solid Orange Curve).  
[ADDRESS_100308] as shown in Figure 6B (Solid Green Curve).  
Note: The simulation did not incorporate the minimum requirement of [ADDRESS_100309] 
participant to analysis date.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
68 Sample size sensitivity analysis is also performed assuming higher survival probability of 
SoC, while the survival probability of experimental arm does not change. The simulation 
results are presented in Table 10. 
 
Table 10 Sensitivity Analysis with Higher Survival Probability in SoC (median 
survival = 9 months as described in solid blue line in Figure 5) 
Substudies  Number of Participants in 
SoC Arm  Interim Analysis of OS  Final Analysis (85 events)  
Participants 
from 
Substudy 1  Participants 
from 
Subsequent 
Substudy  Average Events  
Prob. of 
Futility  Average 
Events  
Power or Type I 
error (Pred. 
prob. ≥43%)  SoC Trt SoC Trt 
Substudy 1  35 NA 16.7 28.3 5.9%  32.3 52.7 83.8%  
Subsequent 
substudy 
(ratio 1:4)  35 18 40.4 18 12.8%  47.1 37.9 66.1%  
Subsequent 
substudy 
(ratio 1:2)  35 35 45.5 18 12.2%  56.8 35.1 61.0%  
Note: The simulation did not incorporate the minimum requirement of [ADDRESS_100310] 
participant to analysis date.  
 
Figure 5 Survival of SoC (solid blue line) is Higher than Target Survival of 
SoC (dotted blue line)  
 

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
69 Figure 6 Survival Curves of Experimental Arms in Greater Than Expected 
Survival (A: Orange Solid Line) and Less Than Expected Survival (B: 
Green Solid Lin e) 
 
10.3.6.  Sample Size Re -estimation  
Sample size re -estimation is not planned for this study.  
10.4.  Populations for Analyses  
For analysis purposes, the following populations are defined:  
The Intent to Treat Population (ITT)  is defined as all participants who were 
randomized to treatment regardless of whether the participants actually received study 
treatment. All efficacy endpoints will be evaluated based on this population.  
The Safety Population  is defined as all participa nts who receive at least [ADDRESS_100311] 1 dose of 
study intervention and are followed for the DLT observation period or are withdrawn 
within the DLT observation period due to meeting the DLT criteria and no 
resolution/recovery per d ose modifications and toxicity management guidelines. (Note: 
participants enrolled in a PK/PD cohort at a previously cleared dose will not be included 
in the DLT evaluable population).  

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
70 10.5.  Statistical Analyses  
This is a platform study utilizing a master protoc ol with different arms for each 
experimental regimen(s), the statistical analyses will be conducted separately for each 
arm. Data will be listed and summarized according to the [COMPANY_004] reporting standards, 
where applicable. Complete details of the analysis wil l be documented in the Reporting 
and Analysis Plan (RAP). Any changes to the analysis plan described in this protocol will 
be documented in the RAP and final clinical study report (CSR).  
10.5.1.  Analysis  
[IP_ADDRESS].  Part 1 Analysis  
The primary objective of Part 1 is to estab lish the safety and tolerability of experimental 
regimens prior to transition to Part 2 of the study.  
 
Safety and tolerability will be guided using the methodology and associated dose decision 
rule as described in the respective subsection for each substu dy in Appendix Section 
12.1. However, to ensure safety of participants, dose recommendations based on the 
statistical methodology can be overridden at  the discretion of the Medical Monitor, 
especially in the event of DLT.  
 
[IP_ADDRESS].  Part 2 Primary Efficacy Analysis  
The primary endpoint for Part 2 is OS. The primary analysis is HR and its 95% 
confidence interval from the Cox model with a single treatment covariate . The PoS of 
future phase 3 study will also be reported. A cutoff of 43% or greater for the PoS of 
future phase 3 study is used as a guide for future development of each experimental arm.  
The theorem and details for the calculation of PoS are provided in A ppendix Section 
12.13.2 . 
[IP_ADDRESS].1.  Sensitivity Analysis  
To evaluate the exchangeability assumption between non -concurrent and concurrent SoC 
data, sensitivity analyses will be conducted to evaluate time -dependency in the SoC arm. 
The exchangeability assumption will be examined by [CONTACT_91012]-concurrent and concurrent SoC data, by [CONTACT_91013]’s proportional hazard model with 
indicator in control data (0: nonconcurrent, 1: concurrent data) as a covariate . If there is a 
difference in OS between non -concurrent and concurrent SoC, this differ ence will be 
further investigated or examined. Sensitivity analysis will be conducted if there is 
evidence of a violation of the exchangeability assumption. An example of a sensitivity 
analysis is one where only the concurrent data will be included (i.e., no non -concurrent 
data are used) in evaluating the treatment effect of the experimental regimen at data 
analysis.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
71 [IP_ADDRESS].  Key Secondary Endpoint  
The key secondary endpoints are the milestone survival rates at 12 and 18 months, which 
will be estimated using the Ka plan-Meier method. The milestone survival and the 
differences between the experimental arm and SoC will be presented. The details of the 
analysis will be further discussed in RAP.  
10.5.2.  Other Secondary Analyses  
[IP_ADDRESS].  Anticancer Activity Analyses  
The ITT Population wi ll be used for anticancer activity analyses. Anticancer activity will 
be evaluated based on clinical evidence and response criteria. The response data will be 
summarized by [CONTACT_91014] (iRECIST will be used for response endpoints and disease 
measurement s for iORR, iDCR, iDOR and iPFS; RECIST 1.1 guidelines will be used for 
response endpoints and disease measurements for ORR, DCR, DOR and PFS).  
ORR, DCR, DOR, PFS, and OS as well as iORR, iDCR, iDOR and iPFS will be 
calculated and summarized.  
• ORR or iORR  is defined as the percentage of participants with a best overall 
confirmed CR or PR at any time as per disease -specific criteria.  
• DCR or iDCR is defined as the percentage of participants with a confirmed CR + PR 
at any time, plus SD 12 weeks.  
• DOR or iDOR  is defined as the first documented evidence of CR or PR until disease 
progression or death due to any cause among participants who achieve an overall 
response (i.e., unconfirmed or confirmed CR or PR). Censoring rules will follow 
those of the PFS anal ysis. TTR is defined as the interval from the first dose of study 
treatment to the date of the first documented CR or PR.  
• PFS or iPFS defined as time from the date of randomization to the date of disease 
progression per clinical or radiological assessment or death due to any cause, 
whichever occurs earlier. For the analysis of PFS, if the participant received 
subsequent anticancer therapy prior to the date of documented events, PFS will be 
censored at the last adequate assessment (e.g., assessment where vis it level response 
is CR, PR or SD) prior to the initiation of therapy. Otherwise, if the participant does 
not have a documented date of event, PFS will be censored at the date of the last 
adequate assessment.  
At each interim analysis, if a participant does  not have an event or is lost to follow -up, 
the participant will be censored at the last contact [CONTACT_568] (OS) or last imaging date (PFS). 
Further details on rules of censoring will be provided in the RAP. PFS and OS will be 
summarized using the Kaplan -Meier m ethod.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
72 10.5.3.  Safety Analyses  
The Safety Population will be used for the analysis of safety data. All safety endpoints 
(e.g., adverse event data, clinical laboratory assessments, vital signs, etc.) will be 
summarized according to the scheduled, nominal visit at which they were collected and 
across all on -treatment time points. Complete details of the safety analyses will be 
provided in the RAP.  
[IP_ADDRESS].  Extent of Exposure  
The number of participants administered study treatment will be summarized according 
to the duration of therapy.  
[IP_ADDRESS].  Adverse Events  
AEs will be coded using the standard MedDRA and grouped by [CONTACT_9313]. AEs 
will be graded by [CONTACT_90639] -CTCAE (version 5.0).  
Events will be summarized by [CONTACT_91015], by [CONTACT_53428]. Separate summaries will be given for all AEs, treatment -
related AEs, SAEs, AESIs and AEs leading to dose modifications for toxicity 
management if irAEs of study treatment. AEs, if listed in the NCI -CTCAE (version 5.0) 
will be summarized by [CONTACT_91016], otherwise, the AEs will be summarized by 
[CONTACT_11196].  
The incidence of deaths and the primary cause of death will be summarized.  
[IP_ADDRESS].  Clinical Laboratory Evaluations  
Hematology and clinical chemistry data will be summarized using frequencies and 
proportions according to NCI -CTCAE (version 5.0) . Laboratory test results outside the 
reference ranges that do not have an associated NCI -CTCAE criteria will be summarized 
using proportions. Further d etails will be provided in the RAP.  
[IP_ADDRESS].  Other Safety Measures  
Data for vital signs will be summarized based on predetermined criteria identified to be 
of potential clinical concern. Further details will be provided in the RAP.  
10.5.4.  Pharmacokinetic Analyses  
PK ana lysis will be the responsibility of the Clinical Pharmacology Modeling and 
Simulation (CPMS) Department, [COMPANY_004].  
PK analysis of drug concentration -time data will be conducted by [CONTACT_105] -compartmental 
methods under the direction of CPMS . The following PK parameter s may be determined 
as data permit:  
• maximum observed concentrations (C max) 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
73 • trough concentrations (C trough or C min) 
• Any additional PK parameters that may be calculated as data permit, e.g., area under 
the plasma or serum concentration -time curve (AUC (0-t)) will be presented in the 
study report  
Statistical analyses of the PK parameters data will be the responsibility of Clinical 
Statistics, [COMPANY_004].  
Drug concentration -time data will be listed for each participant and summarized by 
[CONTACT_91017].   
The data from this study may be combined with the data from other studies for a 
population PK analysis. The details of such analysis will be outlined in a separate RAP; 
results of this analysis may be reported separately.  
10.5.5.  Pharmacok inetic/Pharmacodynamic Analyses  
If deemed appropriate and if data permit, exploratory Pharmacokinetic / 
Pharmacodynamic analyses such as exposure -response relationships between exposure 
(e.g., dose, C max or C min) and safety/efficacy/PD parameters (e.g.: an ti-tumor response, 
biomarkers) may be conducted. The details of such PK/PD analyses will be outlined in a 
separate RAP; results of these analyses may be included in a report separate from the 
clinical study report. The data from this study may be combined with the data from other 
studies, which may be reported separately.  
 
10.5.6.  Tumor Kinetic Analyses  
Exploratory analyses may be performed to evaluate the effect of study treatment on the 
growth kinetics of individual tumor lesions. These analyses may include tumor  lesion 
measurements from imaging scans performed earlier in the disease course (i.e., prior to 
screening scans).  
If deemed necessary, additional statistical analyses will be discussed in a separate RAP. 
The data from this study may be combined with the da ta from other studies, which may 
be reported separately.  
10.5.7.  Other Analyses  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
74 11. REFERENCES  
Aaronson  NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The 
European Organization for Research and Treatment of Cancer QLQ -C30: A quality -of-
life instrument for use in international clinical trials in oncology. Journal of the National 
Cancer Insti tute 1993; 85:365 -376. 
Andrade RJ, Robles M, Lucena MI. Rechallenge in drug -induced liver injury: the 
attractive hazard. Expert Opin Drug Saf. 2009; 8:709 -14. 
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab 
After Chemoradi otherapy in Stage III Non -Small -Cell Lung Cancer. NEJM. 2017; 
377(20):1919 -1929  
Ara G, Baher A, Storm N, Horan T, Baikalov C, Brisan E, et al. Potent activity of soluble 
B7RP -1-FC in therapy of murine tumors in syngeneic hosts. Intl J Cancer. 2003, 
103:[ADDRESS_100312], Steins M, R eady NE, et al. Nivolumab 
versus docetaxel in advanced nonsquamous non –small -cell lung cancer. New England 
Journal of Medicine. 2015;373(17):1627 -39. 
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. 
Nivolumab versus docetaxel in advanced squamous -cell non -small -cell lung cancer. N 
Engl J Med. 2015; 373:123 -35. 
Brennan FR, Morton LD, Spi[INVESTIGATOR_90555] S, Kiessling A, Allenspach R, Hey A, et al. 
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. 
mAbs. 2010; 2:233 -255. 
Brierley JB, Gospodarowicz MK, Wittekind Ch, eds. UICC TNM Classification of 
Malignant Tumors, 8th edition (2017), published by [CONTACT_91018] & Sons, Ltd.  
Carthon BC, Wolchok JD, Yuan J, Kamat A, Tang DS, Sun J, et al. Preoperative CTLA -4 
blockade:  Tolerability and immune monitoring in the setting of a presurgical clinical trial. 
Clin Cancer Res. 2010; 16:2861 -2871.  
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional 
Assessment of Cancer Therapy (FACT) scale: Development  and validation of the general 
measure. Journal of Clinical Oncology 1993; 11(3):570 -579. 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
75 Chen DS, Mellman I. Oncology meets immunology: the cancer -immunity cycle. 
Immunity. 2013; 39:[ADDRESS_100313] JF, Tang DN, et al. An ti-CTLA -4 
therapy results in higher CD4+ICOShi T cell frequency and IFN -gamma levels in both 
nonmalignant and malignant prostate tissues. Proc Natl Sci [LOCATION_003]. 2009;106:2729 -2734.  
Cubas R, Moskalenko M, Cheung J, Luoh S, McNamara E, Belvin M, et al. Second CR I-
CIMT -EATI -AACR International Cancer Immunotherapy Conference: Translating 
Science into Survival; September 25 -28, 2016; [LOCATION_001], NY DOI: 10.1158/2326 -
6066.IMM2016 -A114 Published November 2016.  
Devine BJ. Case Number 25 Gentamycin Therapy: Clinical Pharm acy Case Studies. 
Drug Intelligence and Clinical Pharmacy. 1974; 8:650 -655. 
Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, et al. Long -term 
survival and immunological parameters in metastatic melanoma patients who respond to 
ipi[INVESTIGATOR_43839] 10 mg/kg within an expanded access program. Cancer Immunol Immunother. 
2013; 62:[ADDRESS_100314] R, et al. New 
response evaluation criteria in solid tumours: revised RECIST guidelines (versi on 1.1). 
Eur J Cancer. 2009; 45:228 -47.  
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing 
potential synergies. Cancer Immunology Research. 2015 May 1;3(5):436 -43. 
Flockhart. 2018. http://medicine.iupui.edu/clinpharm/ddis/m ain-table/  
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of 
conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015; 28: [ADDRESS_100315] 
Edition. CRC Press, Taylor & Francis Group, LLC. Boca Raton, FL. 2014.  
[COMPANY_004] Document Number 2017N319717_03. [COMPANY_004]3359609 Investigator’s Brochure. 2020.  
Hanna N, Shepherd FA, Foss ella FV, Pereira JR, De Marinis F, von Pawel J, et al. 
Randomized phase III trial of pemetrexed versus docetaxel in patients with non -small -
cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22:[ADDRESS_100316] RS, Baas P, Kim D -W, Felip E, Perez -Gracia JL, Han J -Y, et al. Pembrolizumab 
versus docetaxel for previously treated, PD -L1-positive, advanced non -small -cell lung 
cancer (KEYNOTE -010): a randomised controlled trial. The Lancet. 
2016;387([ZIP_CODE]):[ADDRESS_100317], Vok es EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus 
docetaxel in previously treated patients with non –small -cell lung cancer: two -year 
outcomes from two randomized, open -label, phase III Trials (CheckMate 017 and 
CheckMate 057). Journal of Clinica l Oncology 2017; 35(35): 3924 -33. 
Horn LA, Long TM, Atkinson R, Clements V, Ostrand -Rosenberg S. Soluble CD80 
Protein delays tumor growth and promotes tumor -infiltrating lymphocytes. Cancer 
Immunol Res. 2018;6:59 -68. 
Hunt  CM. Mitochondrial and immunoallergic injury increase risk of positive drug 
rechallenge after drug -induced liver injury: a systematic review. Hepatol. 2010; 52:[ADDRESS_100318] in adults with acetaminophen overdose and 
acute liver failure. Drug Metab Dispos. 2009; 37:1779 -1784.  
Jensen R, Potosky A, Reeve B, Hahn E, Cella D, Fries J, et al. Validation of the PROMIS 
Physical Function Measures in a D iverse Us Population -Based Cohort of Cancer Patients. 
Quality of Life Research 2015: 24(10): 2333 -2344. http://dx.doi.org/10.1007/s11136 -
015-0992 -9 
Ji Y, Liu P, Li Y, et al. A modified toxicity probability interval method for dose -finding 
trials. Clin Trials. 2010; 7:653 –663. 
KEYTRUDA PI (pembrolizumab). [COMPANY_006] Sharp & Dohme Corporation, November 
2018.  
Kilian D, 2017a. [COMPANY_004] Doc ID: 2018N366551_00. Evaluation of the anti -tumor efficacy 
of the rat anti -mouse ICOS surrogate antibody clone 7E.17G9 alone or in combination 
with paclitaxel in the CT -26 syngeneic mouse tumor model. (CT26 -e326 CRL)  
Kilian D, 2017b. [COMPANY_004] Doc ID: 2018N366552_00. Evaluation of the anti -tumor efficacy 
of the rat anti -mouse ICOS surrogate antibody clone 7E.17G9 alone o r in combination 
with carboplatin in the CT -26 syngeneic mouse tumor model. (CT26 -e334 CRL)  
Kilian D, 2017c. [COMPANY_004] Doc ID: 2018N366554_00. Evaluation of the anti -tumor efficacy 
of the rat anti -mouse ICOS surrogate antibody clone 7E.17G9 alone or in combinati on 
with paclitaxel in the EMT -6 syngeneic mouse tumor model. (EMT -6-e230 CRL)  
Kilian D, 2017d. [COMPANY_004] Doc ID: 2018N366555_00. Evaluation of the anti -tumor efficacy 
of the rat anti -mouse ICOS surrogate antibody clone 7E.17G9 alone or in combination 
with carbop latin in the EMT -6 syngeneic mouse tumor model. (EMT -6-e233 CRL)  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
77 Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et 
al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non -
squamous non -small -cell lung  cancer: a randomised, phase 2 cohort of the open -label 
KEYNOTE -021 study. Lancet Oncol 2016; 17:1497 -508. 
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. 
Mutational heterogeneity in cancer and the search for new cancer -associated genes. 
Nature 2013; 499:214 -18. 
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, Gault E. Quantification of 
Hepatitis Delta Virus RNA in Serum by [CONTACT_31861] -Time PCR Indicates Different 
Patterns of Virological Response to Interferon  Therapy in Chronically Infected Patients. J 
Clin Microbiol. 2005;43(5):2363 –2369.  
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts 
in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124:188 -
195. 
Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A New 
Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009; 150:604 -612. 
Li F, Ravetch JV. Inhibitory Fcγ receptor engagement drives adjuvant and anti -tumor 
activities o f agonistic CD40 antibodies. Science. 2011; 333(6045): 1030 -1034.  
Liakou CI, Kamat A, Tang D, Chen H, Sun J, Troncoso P, et al. CTLA -4 blockade 
increases IFN -gamma producing CD4+ICOShi cells to shift the ratio of effector to 
regulatory T cells in cancer pa tients. Proc Natl Acad Sci [LOCATION_003]. 2008; 105:[ZIP_CODE] -[ZIP_CODE].  
Lopes G, Wu Y, Sadowski, S, Zhang J, Rangwala R, Kush D, et al. Pembrolizumab vs. 
platinum -based chemotherapy for PD -L1+ NSCLC: phase 3, randomized, open -label 
KEYNOTE -042 ([STUDY_ID_REMOVED]). J Thorac Oncol . [ADDRESS_100319]; 11(10S): S244 -S245).  
Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody 
development in cancer. Nat Rev Drug Discov. 2018 Jun 15. doi: 10.1038/nrd.2018.75. 
[Epub ahead of print] Review.  
NCCN. Non -Small Cell Lung Cancer (Version 5.2021). nscl.pdf (nccn.org) . Accessed 
August 27, 2021.  
NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse 
Events), version 5, DCTD, NCI, NIH,  DHHS, November 27, 2017.  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
78 Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non -
small -cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and 
follow -up. Ann Oncol. 2016; 27(5): v1 -27. 
O’Hagan  A, Stevents J, Campbell M. Assurance in Clinical Trials. Pharmaceutical 
Statistics, 2005; 4: 187 -201. 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity 
and response criteria of the Eastern Cooperative Oncology Group. Am J Cli n Oncol. 
1982; 5:649 -655. 
OPDIVO Prescribing Information. Bristol -Myers Squibb, November 2018.  
Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh, JS, et al. Drug -induced liver injury 
following positive drug rechallenge. Regul Tox Pharm. 2009; 54:84 -90. 
Parmar M, Torri V, Stewart L. Extracting Summary Statistics to Perform Meta -Analyses 
of the Published Literature for Survival Endpoints. Statistics in Medicine, 1998; 17: 
2815 -2834.  
Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela -Rohena A, Golovina TN, et al. 
The inducible costimulator (ICOS) is critical for the development of human Th17 cells. 
Sci Transl Med. 2010; 2:55ra78.  
Paz-Ares L, Luft A, Vincente D, Tafreshi A, Gumus M, et al. Pembrolizumab plus 
chemotherapy for squamous non -small -cell lung cance r. N Engl J Med 2018 Nov 22; 
379(21):[ADDRESS_100320] D, Popat S, Kerr K, Novello S, Smit EF, et al. Metastatic non -small cell lung 
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann 
Oncol. 2018; 29(4):iv192 -237. 
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early 
and locally advanced non -small cell lung cancer (NCLC): ESMO clinical practice 
guidelines for diagnosis, treatment and follow -up. Ann Oncol. 2017; 28(4):iv1 -21.  
Reck M, Rodri guez -Abreu D, Robinson AG, Hui R, Csoszi, T, Fulop A, et al. 
Pembrolizumab versus chemotherapy for PD -L1-positive Non -Small -Cell Lung Cancer. 
N Engl J Med. 2016 Nov 10;375(19):1823 -33. 
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J,  et al. 
Atezolizumab versus docetaxel in patients with previously treated non -small -cell lung 
cancer (OAK): a phase 3, open -label, multicentre randomised controlled trial. Lancet. 
2017; 389: 255 –65. 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
79 Schwartz LB. Diagnostic  value of tryptase in anaphylaxis and mastocytosis. Immunol 
Allergy Clin. 2006; 26:[ADDRESS_100321]: 
guidelines for response criteria for use in trials testing immunotherapeutics. L ancet Oncol 
2017; 18: e143 -52. 
Sharpe AH, Freeman GJ. The B7 -CD28 Superfamily. Nat Rev Immunol. 2002; 2:[ADDRESS_100322] FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective 
randomized trial of docetaxel versus best supportive care in patients with non -small -cell 
lung cancer previously treated with platinum -based chemotherapy. Journal of Clinical 
Oncology 2000; 18(10):2095 -103. 
TAXOTERE (docetaxel) Prescribing Information. [COMPANY_011] -Aventis US, 2020.  
TAXOTERE (docetaxel) Summary of Prod uct Characteristics. [COMPANY_011] -Aventis Pharma, 
2020.  
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet -Tieulent J, Jemal A. Global Cancer 
Statistics, 2012. CA Cancer J Clin 2015; 65:[ADDRESS_100323] cancer 
and treatment -associated modulation of inducible costimulator expression on patient T 
cells. Clin Cancer Res. 2010; 16:[ADDRESS_100324] C. Convergent and divergent effects of costimulatory 
molecules in conventional and regulatory CD4+ T cells. PNAS. 2013; 110:[ADDRESS_100325] Sheet [Internet]. [cited 2017 February]. Available from: 
http://www.who.int/mediacentre/factsheets/fs297/en/  
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. 
Nivolumab plus ipi[INVESTIGATOR_15172]. N Engl J Med. 2013; 369:122 -133. 
Zhao X, Suryawanshi, S; Hruska, M. Assessment of nivolumab benefit -risk profile of a 
240-mg flat d ose relative to a 3 mg/kg dosing regimen in patient with advanced tumors. 
Annals of Oncology. 2017;28:2002 -2008  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
80 12. APPENDICES  
12.1.  Appendix 1: Arms  
12.1.1.  Standard of Care Arm 1: Docetaxel Alone (Part 2 ONLY)  
[IP_ADDRESS].  Protocol Amendment 4 Summary of Changes Specific to Docetaxel 
Arm  
Section # and Name  [CONTACT_91084] [IP_ADDRESS]  Added physical exam for 
dosing visits.  To align w ith the changes made 
to the other substudies Schedule 
of Activities.  
Schedule of Activities 
Section [IP_ADDRESS]  Removed details on 
number of slides for tissue 
sample to be sent by [CONTACT_3725].  Decided this detail should be 
included in the SRM instead and 
was remove d from protocol.  
Schedule of Activities 
Section [IP_ADDRESS]  Clarified that Docetaxel 
PK samples do not need to 
be collected after cycles 
have been completed.  To provide clarity and address 
site questions.  
Schedule of Activities 
Section [IP_ADDRESS]  At the follow up visit, 
footnote added: If the 
participant dies before the 
first follow up, any 
subsequent anticancer 
therapy or radiotherapy 
should be recorded in the 
eCRF.  To record any subsequent 
therapy the participant may have 
received after study 
discontinuation, if they die 
before first follow up is 
completed.  
Schedule of Activities 
Section [IP_ADDRESS]  Added footnote:  
Pre: predose sample to be  
collected prior to dosing per 
institutional guidance, as 
long as it is collected prior  
to dosing of the 
corresponding agent ; EOI : 
End of infusion sample is  in 
reference to EOI of the 
corresponding agent.  To clarify the sample collection 
reference for predose and EOI.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
81 Protocol Amendment 3 Summary of Changes Specific to Docetaxel Arm  
Section # and Name  [CONTACT_91084] [IP_ADDRESS]  Added Schedule of 
Activities specific to 
docetaxel only treatment.  To provide individual 
specific Schedule of 
Activities Table specific to 
standard of care arm in Part 
2. 
Study  Treatment Section 
[IP_ADDRESS]  Added required cycles for 
docetaxel.  Provide additional 
guidance to align with 
standard practices for 
docetaxel administration.  
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
82 [IP_ADDRESS].  Schedule of Activities Specific to Arm 1 Docetaxel (Part 2)  
The timing and number of planned study assessments, including [safety, pharmacokinetic, ADA, biomarker or others] assessments  may be 
altered during the course of the study ba sed on newly available data.  
 
Table 11 Schedule of Activities – Screening: Standard of Care Arm 1: Docetaxel Alone  
Screening Study 
Assessments  Screening1  Notes  
Visit Window  ≤[ADDRESS_100326] be performed within 4 weeks (28 days) prior to first dose of study treatment unless otherwise 
specified. The informed consent may be signed within [ADDRESS_100327] dose.  
 
Participant Registration2 X 2. Participants will be registered in RAMOS NG at screening.  
Inclusion/Exclusion Criteria  X Review eligibility prior to randomization.  
Demographics, Medical History 
(including alcohol and tobacco 
use), Prior Medications, 
Disease History12 X 12. All known mutations should be entered in the eCRF as disease history.  
Prior Anticancer Treatment, 
Radiotherapy  X  
Screening Safety  
AE/SAE/AESI Assessment3 X 3. After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/ contacts. 
Refer to Section 9.[ADDRESS_100328] dose of study treatment, and during treatment phase if clinically  
indicated. MUGA scan may be used if ECHO not feasible.  
Screening Local Laboratory Assessments (Safety)  
Hepatitis B and C6 X  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
83 Screening Study 
Assessments  Screening1  Notes  
Visit Window  ≤4 Weeks   
Serum β -hCG (for women of 
childbearing potential)  ≤3d  
Clinical Chemistry6, 
Coagulation6, Hematology6, 
Thyroid function6 X 6. Refer to Appendix  [ADDRESS_100329] dose of SoC, repeat testing at screenin g is not required; otherwise, this testing 
is mandatory.  
Calculated CrCl7 X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90872] -Gault formula. See Appendix 9 . 
Troponin I or Troponin T  X  
Urinalysis6 X  
Screening Other Laboratory As sessments  
PD-L1 expression by [CONTACT_4658]8 X 8. PD -L1 expression by [CONTACT_91001] (i.e., Ventana SP263, Ventana SP142, Dako 28 -8, or Dako 22C3) must be 
recorded in the eCRF, if known . Note: Test is not required to be performed by [CONTACT_91020].  
Screening Disea se Assessments   
Tumor Imaging9 X 9. Diagnostic quality CT scan of chest and abdomen with contrast must be obtained within [ADDRESS_100330] dose. Baseline brai n 
scan (MRI with and without IV gadolinium) should be obtained within [ADDRESS_100331] dose if clinically indicated. See additional information rega rding 
bone scans in Section 9.3.1 . 
Pre-Baseline scans for Tumor 
Growth Kinetics10 X 10. Upon participant consent, up to 3 pre -baseline scans (within 12 months before the baseline scan) will be collected to assess 
tumor growt h rate to support exploratory investigation of tumor growth kinetics (See Section 9.3.2  for details on images for 
submission).  
Screening Tumor Bio psies  
Fresh tumor tissue sample and 
Archival tumor11 X 11. Part 2: Tumor tissue at screening (either archival or fresh biopsy if archival tissue is unavailable), is required for al l participants 
in Part 2: Fresh tumor tissue at screening is required in addition to an archival tissue for at least [ADDRESS_100332] been obtained at any time from the time of initial 
diagnosis to time of study entry. Note: Enrollment may become limited during the study, as required, to ensure collection of fresh 
tissue samples as noted.  
 
Abbreviations : AE = adverse event; AESI = adverse events of special interest; β -hCG = β -human chorionic gonadotropin; CKD -EPI = chronic kidney disease epi[INVESTIGATOR_51962]; CrCl = creatinine clearance; CT = computed tomography; ECG = electrocardiogram; ECHO = ec hocardiography; ECOG PS = Eastern Cooperative Oncology Group 
performance status; eCRF = electronic case report form; IHC = Immunohistochemistry; IWRS = interactive web response system; M RI = magnetic resonance imaging; MUGA = 
multi -gated acquisition; SAE =  serious adverse event.  
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
84 Table 12 Schedule of Activities – Treatment Period: Standard of Care Arm 1: Docetaxel Alone  
On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted  (Visits occur once every 3 weeks during treatment period)  
Inclusion/Exclusion 
Criteria  X            
Concomitant Medications  X X X X X X X X X X X  
Participant 
Randomization1 X           1. Once determined to be eligible, participants must be 
randomized via IWRS. Drug shipments will be managed  via 
IWRS. Sites must allow up to 7 business days for shipment of 
study drug.  Randomization can be done prior to Day 1, but no 
more than 3 days prior to Day 1. (Refer to SRM).  
Study treatments1 
Part 2 ONLY 
Docetaxel/SOC arm2 X X X X X X      2. For those  participants randomized to the SOC arm – 
docetaxel can be discontinued after 6 cycles as according to 
local prescribing information. Participants should receive 
premedication prior to receiving docetaxel as per local 
standards.  
On Treatment Safety  
AE/SAE/AESI 
Assessment3 X X X X X X X X X X X 3. After the initial AE/SAE report, the investigator is required to 
proactively follow each participant at subsequent visits/contacts. 
All SAEs and non -serious AESIs will be followed until the event 
is resolved, stabilized, otherwise explained, or the participant is 
lost to follow -up. 
ECOG PS**  X X X X X X X X X Q6W*  Q6W*  *Q6W procedures are counted starting from Week 25 (i.e. the 
first Q6W visit is Week 31, then Week 37, etc.).  
Physical Examination**  X X X X X X X X X Q6W*  Q6W*  ** Physical examinations and ECOG may be performed within 
one day of dosing (i.e., as opposed to the day of dosing), if 
necessary.  
Vital Signs and Weight4 X X X X X X X X X X X 4. Vital signs include blood pressure, temperature, pulse, 
respi[INVESTIGATOR_697], and oxygen saturation. Weight is to be recorded 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
85 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted  (Visits occur once every 3 weeks during treatment period)  
at every other treatment visit in kilograms. Vital signs are to be 
performed predose on treatment days.  
On Treatment Local Laborat ory Assessments (Safety) – assessments may be performed up to 3 days prior to treatment  
Serum β -hCG (for women 
of childbearing potential)[ADDRESS_100333] 
dose.  
Thyroid function tests    X  X  X  X Q6W*  Q6W*  *Q6W procedures are counted starting from Week 25 (i.e. the 
first Q6W visit is Week 31, then Week 37, etc.).  
Calculated CrCl7 X X X X X X X X X X X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90872] -Gault formula. 
Either formula is acceptable and must be consistently utilized for 
each participant throughout the study. See Appendix 9 . 
Urinalysis   X X X X X X X X X X  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
86 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted  (Visits occur once every 3 weeks during treatment period)  
On Treatment Disease Assessments  
Tumor Imaging/Response 
Assessment8   X  X  X  X X8 8. Diagnostic quality CT scan of chest and abdomen with 
contrast is required every 6 weeks (±1 week) until Week 49 and 
every 12 weeks thereafter. Imaging/clinical assessments should 
be performed as indicated in Section 9.2. The same method of 
assessment is required throughout the study. Brain scan (MRI 
with and without IV gadolinium) and bone scan to be performed 
as clinically indicated during the treatment period. If a participant 
has achieved a PD, CR, or PR in the previous radiologic 
assessment, a repeat scan should be performed after at least 4 
weeks to confirm the response.   
On Treatment Patient -Reported Outcomes/Health -Related Quality of Life: completed in Part 2 ONLY  
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
87 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted  (Visits occur once every 3 weeks during treatment period)  
 
 
 
 
On Treatment Biomarkers  
On Treatment Tumor biopsies  
Fresh tumor tissue 
sample13   X    X13     13. At least [ADDRESS_100334] paired fresh 
tumor biopsies collected at Screening (prior to randomization) 
and Week 7 (±8 days). If tumor is amenable to biopsy and upon 
patient consent.  
Additional optional fresh tumor tissue sample will  be collected at 
Week 19 at the time of imaging assessment and at the time of 
confirmed PR or PD (± 8 days), upon participant consent. Note: 
Enrollment may become limited during the study, as required, to 
ensure collection of fresh tissue samples as noted.  
On Treatment Pharmacokinetics  
Plasma SoC PK14 X X X X X X X X    14. Draw sample  at: predose on Day 1 only; at end of SoC 
infusion (within 5 minutes) for all marked visits; and draw an 
additional sample between 2 and 5 hours after end of SoC 
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
88 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted  (Visits occur once every 3 weeks during treatment period)  
infusion for all marked visits. There is a +[ADDRESS_100335] opportunity 
after a participant has met all eligibility requirements before Day 
1 or on Day 1.  
Abbreviations : ; AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; CKD -EPI = Chronic kidney disease epi[INVESTIGATOR_51962]; CR = complete response; CrCl = Creatinine clearance; CT = computed tomog raphy; CTCAE = Common Terminology Criteria for Adverse Events; ECOG PS = 
Eastern Cooperative Oncology Group performance status; EOI = End of infusion;  
 
r; IRR = infusion related reaction;  
 PD = Progressive Disease; ; PR = P artial response;  Pre = Predose;   
 
 SAE = Serious adverse event.  
Pre: predose sample to be  collected prior to dosing per institutional guidance, as l ong as it is collected prior to dosing of the corresponding agent ; EOI : End of infusion sample is  in 
reference to EOI of the corresponding agent.  
 
 
CCI
CCI
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
89 Table 13 Schedule of Activities – Treatment Discontinuation Visit (TDV) and Follow -Up: Standard of Care Arm 1: Docetaxel 
Alone  
TDV and Follow Up 
Assessments  Treatment 
Discontinuation Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  + 10 days    
Anticancer Treatment   X* *If the participant dies before the first follow up, any subsequent anticancer therapy or radiotherapy should be 
recorded in the eCRF.  
 
*Follow up for survival will no longer be required once 85 events are reached for this arm.  
Concomitant 
Medications  X   
TDV and Follow Up Safety  
AE/SAE/AESI 
Assessment2 X  2. After the initial AE/SAE report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. Refer to Section 9.4.1  and Section 9.4.3  for further details.  
ECOG PS  X   
Physical Examination  X   
Vital Signs and Weight3 X  3. Vital signs include blood pressure, temperature, pulse, respi[INVESTIGATOR_697], and oxygen saturation.  
TDV and Follow Up Local Laboratory Assessments  
Clinical Chemistry  X   
Serum β -hCG (for 
women of childbearing 
potential)  X   
Hematology  X   
Thyroid function tests  X   
Calculated CrCl  X  
Urinalysis  X  
TDV and Follow Up Disease Assessments  
Tumor 
Imaging/Response 
Assessment4 X  4. At the TDV, CT scan is required only if the last disease assessment did not show PD and was performed ≥6 
weeks before TDV. For participants who discontinue study treatment without documented disease 
progression, every effort should be made to continue m onitoring disease status by [CONTACT_91021] a new anticancer treatment, disease 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
90 TDV and Follow Up 
Assessments  Treatment 
Discontinuation Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  + [ADDRESS_100336]. See 
additional information in Section 9.3.1   
Telephone call for 
survival status1a  X  
TDV and Follow Up Tumor Biopsies  
Fresh tumor tissue 
sample  X5  5. If possible and upon participant consent, obtain an optional  tumor tissue sample at time of confirmed PD or 
PR. 
TDV and Follow Up Patient -Reported Outcomes/Health -Related Quality of Life  
  
 
 
 
 
 
 
 
TDV and Follow Up Biomarkers  
Abbreviations : AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; CR = complete response; CrCl = Creatinine 
clearance; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECOG PS = Eastern Cooperative Oncology Grou p performance status; 
eCRF = Electronic case report form;  
 
; PD = Progressive Disease;  
 PR = Partial response;  
; SAE = Serious adverse event; TDV = Treatment Discontinuation Visit  
1. The assessments required at the study treatment discontinuation visit must be completed within [ADDRESS_100337]. Participants will be contact[CONTACT_457] 12 weeks (±7 days) until death or participant’s withdrawal from further contact. Subsequent anticance r treatment 
and death date will be documented in the eCRF  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
92 [IP_ADDRESS].  Study Treatment  
Table 14 Description and Administration of Docetaxel  
Name  [CONTACT_91085]/strength  Refer to package insertb,c  
Dosage  75 mg/m2 
Route of administration  IV infusion  
Dosing instructionsa/frequency  Administer diluted product/once Q3W  
a. Refer to the Study Reference Manual for detailed instructions on dosage and administration requirements.  
b. TAXOTERE  PI, 2020; TAXOTERE  SmPC, 2020.  
c. Docetaxel will be sourced locally from commercial stock, except in countries where regulatory authorities mandate 
that the Sponsor supply all study treatment(s) required for the co nduct of a clinical trial.  
All participants randomly assigned to docetaxel -containing arms should be premedicated 
with oral corticosteroids (such as dexamethasone 16 mg per day or its equivalent) per 
local standards (e.g., 8 mg twice daily) for 3 days  starting 1 day prior to docetaxel 
administration to reduce the incidence and severity of fluid retention as well as the 
severity of hypersensitivity reactions [ TAXOTERE  PI, 2020; TAXOTERE  SmPC, 2020]. 
Intravenous corticosteroid premedication may also be utilized per local standard and at 
the discretion of the investigator.  
Docetaxel should be given for [ADDRESS_100338] handling, storage, preparation, and 
administration. Docetaxel will be administered according to the package insert and/or 
local standard.  
[IP_ADDRESS].  Dose Justification  
The dosage of docetaxel for this study, as a single agent and in combination, will be 
75mg/m2 Q3W, as described in the labels [ TAXOTERE  PI, 2020; TAXOTERE  SmPC, 
2020] which is approved (a) as a single -agent for patients with locally advanced or 
metastatic NSCLC after platinum -based chemotherapy, and (b) in combination with 
cisplatin for unresectable, locally advanced or metastatic NSCLC for patients who hav e 
not received prior chemotherapy.  
[IP_ADDRESS].  Treatment of Overdose  
In the event of docetaxel overdose, refer to the instructions in the approved product label. 
Contact [CONTACT_91022].  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
93 12.1.2.  Substudy 1 (Arm 2): F eladilimab and Docetaxel Combination  
[IP_ADDRESS].  Protocol Amendment 5 Summary of Changes Specific to Feladilimab 
and Docetaxel Combination  
Section # and Name  [CONTACT_91084] [IP_ADDRESS]  Added footnote to TDV 
SoA for survival follow up 
requirements  To remove the survival 
follow up requirement for 
Substudy 1 when 85 events 
are reached as this will 
trigger final analysis   
 
Protocol Amendment 3 Summary of Changes Specific to Feladilimab and Docetaxel 
Combination  
Sectio n # and Name  [CONTACT_91084] [IP_ADDRESS]  Added Schedule of 
Activities specific to 
docetaxel only treatment.  To provide individual 
specific Schedule of 
Activities Table specific to 
standard of care arm in Part 
2. 
Clinical Safety Summary 
Section [IP_ADDRESS].1, 
[COMPANY_004]3359609 PK/PD 
Summary Section 
[IP_ADDRESS].1, [COMPANY_004]3359609 
Dose Rationale Section 
[IP_ADDRESS].2  Updated safety and PK/PD 
for [COMPANY_004]3359609.  To align with 
[COMPANY_004]3359609 IB update 
version 5 and recent 
clinical data.  
 
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
94 [IP_ADDRESS].  Schedule of Activities Specific to Feladilimab and Docetaxel Combination (Substudy 1)  
Table 15 Schedule of Activities – Screening: Substudy 1 (Arm 2): Feladilimab and Docetaxel Combination  
Screening Study 
Assessment  Screening1  Notes  
Visit Window  ≤[ADDRESS_100339] be performed within 4 weeks (28 days) prior to first dose of study treatment unless otherwise 
specified. The informed consent may be signed within [ADDRESS_100340] dose.  
 
Participant Registration2 X 2. Participants will be registered in RAMOS NG at screening.  
Inclusion/Exclusion Criteria12 X 12. All known mutations should be entered in the eCRF as disease history.  
Demographics, Medical History 
(including tobacco use), Prior 
Medications, Disease History  X  
Anticancer Treatment  X 
Screening Safety  
AE/SAE/AESI Assessment3 X 3. After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. 
All SAEs and non -serious AESIs will be followed until the event is resolved, stabilized, otherwise explained, or until the participant 
is lost to fol low-up. 
ECOG PS  X  
Physical Examination  X  
Vital Signs, Height and Weight4 X 4. Vital signs include blood pressure, temperature, pulse, respi[INVESTIGATOR_697], and oxygen saturation. Height is recorded at Scr eening 
only. Record weight in kilograms.  
12-lead ECG  X  
Echocardiogram or MUGA 
scan5 X 5. ECHO required at Screening within [ADDRESS_100341] dose of study treatment, and during treatment phase if clinically  
indicated. MUGA scan may be used if ECHO not feasible.  
Screening Local Laboratory Assessments (Safety)  
Hepatitis B and C6 X  
Serum β -hCG (for women of 
childbearing potential)  ≤3d  
Clinical Chemistry6, 
Coagulation6, Hematology6, 
Thyroid function6 X 6. Refer to Appendix  [ADDRESS_100342] dose of study intervention or SoC, repeat testing at screening is not required; otherwise, this testing  is 
mandatory.  
Calculated CrCl7 X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90872] -Gault formula. See Appendix 9 . 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
95 Screening Study 
Assessment  Screening1  Notes  
Visit Window  ≤4 Weeks   
Troponin I or Troponin T  X  
Urinalysis6 X  
Screening Other Laboratory Assessments  
PD-L1 expression by [CONTACT_4658]8 X 8. PD -L1 expression by [CONTACT_91001] (i.e., Ventana SP263, Ventana SP142, Dako 28 -8, or Dako 22C3) must be 
recorded in the eCRF, if known . Note: Test is not required to be performed by [CONTACT_91023] t previously performed.  
Screening Disease Assessments  
Tumor Imaging9 X 9. Diagnostic quality CT scan of chest and abdomen with contrast must be obtained within [ADDRESS_100343] dose. Baseline brai n 
scan (MRI with or without IV gadolinium) should be obtained within [ADDRESS_100344] dose if clinically indicated. See additional information rega rding 
bone scans in Section 9.3.1 . 
Pre-Baseline scans for Tumor 
Growth Kinetics10 X 10. Upon participant consent, up to 3 pre -baseline scans (within 6 months before the baseline scan) will be collected to assess 
tumor growth rate to support exploratory investigation of tumor growth kinetics (See Section 9.3.2  for details on images for 
submission).  
Screening Tumor Biopsies  
Fresh tumor tissue sample and 
Archival tumor11 X 11. Fresh tumor tissue sample AND an archival tissue sample obtained during screening is mandatory for at least [ADDRESS_100345] been obtained at any time from the time of initial diagnosis to time of study entry. 
If only 10 unstained archival slides are av ailable, participant may be considered eligible upon consultation/approval of the [COMPANY_004] 
Medical Monitor. Note: Enrollment may become limited during the study, as required, to ensure collection of fresh tissue samp les 
as noted.  
 
Abbreviations : AE = adverse event; AESI = adverse events of special interest; β -hCG = β -human chorionic gonadotropin; CKD -EPI = chronic kidney disease epi[INVESTIGATOR_51962]; CrCl = creatinine clearance; CT = computed tomography; ECG = electrocardiogram; ECHO = ec hocardiography; ECOG PS = Eastern Cooperative Oncology Group 
performance status; eCRF = electronic case report form; IHC = Immunohistochemistry; IWRS = interactive web response system; M RI = magnetic resonance imaging; MUGA = 
multi -gated acquisition; SAE =  serious adverse event.  
 
 
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
96 Table 16 Schedule of Activities – Treatment Period: Substudy 1 (Arm 2): Feladilimab and Docetaxel Combination  
On Treatment Study 
Assessment   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
Inclusion/Exclusion 
Criteria  X            
Concomitant Medications  X X X X X X X X X X X  
Participant 
Randomization1 X           1. Once determined to be eligible, participants must be 
randomized via IWRS. Drug shipments will be managed via 
IWRS. Sites must allow up to 7 business days for shipment of 
study drug.  
Study treatments1 
Administer Feladilimab 
([COMPANY_004]3359609)*  X X X X X X X X X Q3W  Q3W  *Feladilimab ([COMPANY_004]3359609) must be administered first. 
Administration of Docetaxel must be started 1 hour and no more 
than 2 hours after the end of feladilimab ([COMPANY_004]3359609) infusion.  
Docetaxel2 X X X X X X X X X Q3W2 Q3W2 2. Docetaxel will be administered according to the package 
insert and/or local standard.  
Chemotherapy premedication indicated on the day of dosing 
should be administered after feladilimab ([COMPANY_004]3359609) EOI.  
On Treatment Safety  
AE/SAE/AESI 
Assessment3 X X X X X X X X X X X 3. After the initial AE/SAE report, the investigator is required to 
proactively follow each participant at subsequent visits/contacts. 
All SAEs and non -serious AESIs will be followed until the event 
is resolved, stabilized , otherwise explained, or the participant is 
lost to follow -up. 
ECOG PS  X X X X X X X X X Q6W*  Q6W*  *Q6W procedures are counted starting from Week 25 (i.e. the 
first Q6W visit is Week 31, then Week 37, etc.).  
Physical Examination**  X   X   X X X Q6W*  Q6W*  ** Physical examinations may be performed within one day of 
dosing (i.e., as opposed to the day of dosing), if necessary.  
Vital Signs and Weight4 X X X X X X X X X X X 4. Vital signs include blood pressure, temperature, pulse, 
respi[INVESTIGATOR_697], and oxygen saturation. Weight is to be recorded 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
97 On Treatment Study 
Assessment   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
at every other treatment visit in kilograms. Vital signs are to be 
performed predose on treatment days.  
On Treatment Local Laboratory Assessments (Safety) – assessments may be performed up to 3 days prior to treatment  
Serum β -hCG (for women 
of childbearing potential)[ADDRESS_100346] dose does not need to be repeated unless clinical ly 
indicated. Laboratory testing may be performed one day prior to 
dosing if necessary.  
Thyroid function tests    X  X  X  X Q6W*  Q6W*  *Q6W procedures are counted starting from Week 25 (i.e. the 
first Q6W visit is Week 31, then Week 37, etc.).  
Calculated CrCl7    X   X X X X X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90872] -Gault formula. 
Either formula is acceptable and must be consistently utilized for 
each participant throughout the study. See Appendix 9 . 
Urinalysis   X X X X X X X X X X  
On Treatment Disease Assessments  
Tumor Imaging/Response 
Assessment8   X  X  X  X X8 8. Diagnostic quality CT scan of chest and abdomen with 
contrast is required every 6 weeks (±1 week) until Week [ADDRESS_100347]. The same method of assessment is 
required throughout the study. Brain scan (MRI with or without IV 
gadolinium) and bone scan to  be performed as clinically 
indicated during the treatment period. If a participant has 
achieved a PD, CR, or PR in the previous radiologic 
assessment, a repeat scan should be performed after at least 4 
weeks to confirm the response.  See additional information in 
Section 9.3.1 . 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
98 On Treatment Study 
Assessment   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
On Treatment Patient -Reported Outcomes/Health -Related Quality of Life  
On Treatment Biomarkers  
On Treatment Tumor biopsies  
Fresh tumor tissue 
sample    X    X13     13. At least [ADDRESS_100348] paired 
fresh tumor biopsies collected at Screening (prior to 
randomization) and Week 7 (± 8 days), if tumor is amenable to 
biopsy and upon participant consent.  
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
99 On Treatment Study 
Assessment   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
Additional optional fresh tumor tissue  sample will be collected at 
Week 19 at the time of imaging assessment and at the time of 
confirmed PR or PD (± 8 days), upon participant consent. Note: 
Enrollment may become limited during the study, as required, to 
ensure collection of fresh tissue sampl es as noted.  
On Treatment Pharmacokinetics and Anti -Drug Antibodies (ADA)  
Plasma SoC PK14 X X X X X X X X    14. For Arm 1 and Arm 2: Draw sample (2 mL) at: predose on 
Day 1 only; at end of SoC infusion (within 5 minutes) for all 
marked visits; and draw an additional sample between 2 and 5 
hours after end of SoC infusion for all marked visits. There is a 
+5 minute window allowance for the EOI time points.  
Plasma Feladilimab 
([COMPANY_004]3359609; ICOS 
Agonist) PK15 X X X X X X X X X X X15 15. For Arm 2 only: Draw sample (2 mL) at predose for all 
marked visits. Additional samples also drawn at the following 
time points: Week 1 (Day 1) at end of infusion (EOI) (within 5 
minutes) and EOI+4h. EOI samples also drawn at Week 13 and 
Week 25. After Week 25, draw samples ev ery 12 weeks at 
predose only. There is a +5 minute window allowance for the 
EOI time points.  
Serum Feladilimab 
([COMPANY_004]3359609; ICOS 
Agonist) ADA16 X X X X X X X X X X X16 16. For Arm 2 only: Draw sample (4 mL) at predose on ALL 
treatment visits; then starting with Week [ADDRESS_100349] dose.  
Serum samples will be collected and tested for the presence of 
antibodies that bind to investigational agents as deemed 
appropriate. Feladilimab serum samples may also be tested for 
presence of antibodies that bind to Chinese Hamster Ovary 
(CHO) host cell proteins such as phospholipase B - like (PLBL2).  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
100 On Treatment Study 
Assessment   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
Serum: IRR lab panel17            17. Assessment ONLY required in participant experiencing 
anaphylaxis, serious hypersensitivity, or AEs related to study 
treatment administration that led to withdrawal from the study. 
Refer to Table [ADDRESS_100350] of analytes. Predose analysis will be 
performed on the serum sample collected for feladilimab 
([COMPANY_004]3359609) immunogenicity assessments.  
On Treatment Pharmacogenetics  
Genetic research18 X           18. Informed consent for optional genetic research must be 
obtained before collecting this sample. It is recommended that 
the optional research sample) be taken at the first opportunity 
after a participant has met all eligibility requirements before Day 
1 or on Day 1.  
Abbreviations : ADA = Anti -drug antibody; AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; CKD -EPI = Chronic 
kidney disease epi[INVESTIGATOR_8261]; CR = complete response; CrCl = Creatinine clearance; CT = computed tomography; CTCAE = Common Terminology Criteria for 
Adverse Events; ECOG PS = Eastern Cooperative Oncology Group performance status; EOI = End of infusion;  
 
 IRR = infusion related reaction;  
; PD = Progressive Disease; ; PR = 
Partial response;  
 SAE = Serious adverse event.  
 
CCI
CCI
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
101 Table 17 Schedule of Activities – Treatment Discontinuation Visit (TDV) and Follow -Up: Substudy 1 (Arm 2): Feladilimab 
and Docetaxel Combination  
TDV and Follow Up 
Assessments  Treatment 
Discontinuation Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  + 10 days    
Anticancer Treatment   X* *Follow up for survival will no longer be required once 85 events are reached for this arm.  
Concomitant 
Medications  X   
TDV and Follow Up Safety  
AE/SAE/AESI 
Assessment2 X  2. After the initial AE/SAE report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs and non -serious AESI will be followed until the event is resolved, 
stabilized, otherwise explained, or the participant is lost to follow -up. 
ECOG PS  X   
Physical Examination  X   
Vital Signs  and Weight3 X  3. Vital signs include blood pressure, temperature, pulse, respi[INVESTIGATOR_697], and oxygen saturation.  
TDV and Follow Up Local Laboratory Assessments  
Clinical Chemistry  X   
Serum β -hCG (for 
women of childbearing 
potential)  X   
Hematology  X   
Thyroid function tests  X   
Calculated CrCl  X  
Urinalysis  X  
TDV and Follow Up Disease Assessments  
Tumor 
Imaging/Response 
Assessment4 X  4. At the TDV, CT scan is required only if the last disease assessment did not show PD and was performed ≥6 
weeks before TDV.  
Telephone call for 
survival status1a  X* *Follow up for survival will no longer be required once 85 events are reached for this arm.  
TDV and Follow Up Tumor Biopsies  
Fresh tumor tissue 
sample  X5  5. If possible, obtain an optional  tumor tissue sample at time of confirmed PD or PR.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
102 TDV and Follow Up 
Assessments  Treatment 
Discontinuation Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  + 10 days    
TDV and Follow Up Patient -Reported Outcomes/Health -Related Quality of Life  
  
 
  
 
 
 
 
 
 
TDV and  Follow Up Biomarkers  
Abbreviations : AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; CR = complete response; CrCl = Creatinine 
clearance; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECOG PS = Eastern Cooperative Oncology Group performance status; 
eCRF = Electronic case report form;  
 
; PD = Progressive Disease;  
 PR = Partial response;  
; SAE = Serious adverse event; TDV = Treatment Discontinuation Visit  
 
1. The assessments required at the study treatment discontinuation visit must be completed within [ADDRESS_100351]. Participants will be contact[CONTACT_457] 12 weeks (±7 days) until death or participant’s withdrawal from further contact.  Subsequent anticancer treatment 
will be documented in the eCRF.  
 
CCI
CCI
CCI
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
103 [IP_ADDRESS].  Study Treatments  
Table 18 Description and Administration of Arm 2 Study Treatments  
Name  [CONTACT_91086] ([COMPANY_004]3359609; 
ICOS Agonist)  
Description  Microtubule stabilizer  
small molecule  Humanized anti -ICOS IgG4 
mAb 
Dosage form/strength  Refer to package inserta Solution for injection/ 
10 mg/mL  
Dosage  75 mg/m2 80 mg  
Route of administration  IV infusion  IV infusionb 
Dosing instructionsa/frequency  Administer diluted 
product/once Q3W  Administer diluted 
product/once Q3W  
a. TAXOTERE  PI, 2020; TAXOTERE  SmPC, [ADDRESS_100352] handling, storage, preparation, and administration.  
In feladilimab (ICOS Agonist) -containing arms, feladilimab will be administered first as 
a 30-minute IV infusion (infusion time may be adjusted based on infusion related 
reactions). The administration of the second agent in these arms must be started 1 hour 
and no more than 2 hours after the end of feladilimab infusion.  Chemotherapy 
premedication indicated on the day  of dosing should be administered after feladilimab 
EOI. Docetaxel will be administered according to the package insert and/or local 
standard. Participants should remain under observation at the study site post -study 
treatment infusion per the judgement of  the investigator or as per institutional guidelines  
to monitor for potential infusion reactions or other adverse events.  
[IP_ADDRESS].  Rationale for ICOS Agonist/Docetaxel Combination  
Cancer immunity is described as a multistep process that elicits an effective antitumor 
response [ Chen , 2013]. Each step can be negatively regulated, thus providing the tumor 
with redundant mechanisms by [CONTACT_91024]. In some 
cases, tumors are highly dependent on a single mechanism, and in these cases, there is the 
potential to achieve significant clinical activity with a single agent immunomodulatory 
therapy. Robust antitumor responses including complete cure  have been achieved in some 
cancers by [CONTACT_91025]’s immune system. Antibodies targeting the checkpoint 
receptors or their cognate ligands engaged in negative regulation of T cell responses, such 
as CTLA -4 and PD -1/PD -L1, have demonstrated effic acy as anticancer immunotherapi[INVESTIGATOR_90873] a broad range of tumors including some solid tumors otherwise considered poorly 
immunogenic.  
However, a majority of tumors are non -responsive to this class of agents. One reason for 
the lack of response could be the exi stence of multiple mechanisms of immune 
suppression in the tumor microenvironment which prohibits effective antitumor immune 
responses. In these instances, combination therapi[INVESTIGATOR_90874]. The clinical 
data generated by [CONTACT_91026] [INVESTIGATOR_125] (anti -CTLA -4) and nivolumab (anti -
PD-1) in patients with metastatic melanoma is an example of the practice changing 
clinical benefit of such combinations [ Wolchok , 2013].  
In some patients, inhibition of negative immune checkpoint pathways alone may not 
elicit an effective antitumor response, and additional co -stimulatory signals may be 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
104 necessary to mount an effective response. Immunomodulatory agents that target other 
components of the cancer immunity cycle are needed to expand the population of patients 
and range of tumor types that may respond to immunotherapy as well as enhance the 
magnitude and duration of antitumor responses in patients who se tumors are already 
sensitive to current immunotherapy approaches. The ultimate aim is to improve the 
survival outcome in all disease settings including the advanced setting.  
Feladilimab is a humanized IgG4 anti -ICOS monoclonal antibody [ Mayes , 2018] selected 
for its nanomolar (nM) binding to and agonist activity in ICOS -expressing CD4+ and 
CD8+ effector T cells. Feladilimab is specifically engineered as an Im munoglobulin 
(Ig)G4 hinge -stabilized isotype, IgG4PE, to markedly decrease binding affinity of the Fc 
(Fragment crystallizable) region of the mAb to activating Fcγ receptors and C1q, and 
thereby [CONTACT_91027] -positive T cells through antibody -dependent or complement -dependent cell 
mediated mechanisms, respectively. Moreover, the IgG4PE isotype retains functional 
binding to the Fc  inhibitor receptor, Fc RIIb, a feature described as cri tical for 
modulating antibody agonist activity [ Li, 2011], which also may be essential for optimal 
ICOS agonist activity and its associated antitumor effects in huma ns. 
ICOS is a co -stimulatory receptor of the CD28/CTLA immunoglobulin super family with 
expression restricted to T cells [ Horn , 2018]. ICOS is weakly expressed on resting TH17, 
follicular helper T and regulatory T (Treg) cells and yet is highly induced on CD4+ and 
CD8+ T cells upon T cell receptor (TCR) engagement and activation [ Parmar , 1998, 
Paulos , 2010; Wakamatsu , 2013]. Upregulation of ICOS leads to both Th1 and Th2 
cytokine secretion and sustained effector T cell proliferation and function [ Sharpe , 2002]. 
A growing body of evidence supports the concept that activating ICOS on CD4+ and 
CD8+ effector T cells has antitumor potential.  
The rationale for targeting ICOS in cancer has been established by [CONTACT_91028]. Engagement  of the ICOS pathway with an ICOS -L-Fc 
fusion protein is shown to have potent antitumor activity in multiple syngeneic mouse 
tumor models [ Ara, 2003]. Emerging da ta from patients treated with anti -CTLA -[ADDRESS_100353] a positive role of ICOS+ effector T cells in mediating an antitumor 
immune response. Patients with metastatic melanoma [ Di Giacomo , 2013], urothelial 
[Carthon , 2010], breast [ Vonderheide , 2010] and prostate cancer [ Chen , 2009] who have 
increased absolute counts of circulating and tumor infiltrating CD4+ICOS+ and 
CD8+ICOS+ T cells after ipi[INVESTIGATOR_90875]. Importantly, it 
was shown that ipi[INVESTIGATOR_90876]+ T effector to Treg ratio, reversing an 
abundance of Tregs pre -treatment to a significant abundance of T effectors vs. Tregs 
following treatment  [Liakou , 2008; Vonderheide , 2010]. As evidence d by [CONTACT_91029], ICOS+ T effector cells may be a positive predictive biomarker of ipi[INVESTIGATOR_90877], and activation of this population of cells with an ICOS agonist antibody may 
confer an advantage by [CONTACT_91030] a more robust immune antitumor respon se. 
Similar to the combination of platinum -containing chemotherapy with immuno -oncology 
agents (anti -PD-1) in metastatic non -squamous disease, i.e., the incorporation of the anti -
PD-1 inhibitor, pembrolizumab, to the pemetrexed/carboplatin backbone in the first-line 
TMF-[ADDRESS_100354]/docetaxel combination has the  potential 
to deliver a similar promise to later line NSCLC participants building on the existing 
docetaxel standard of care.  
Chemotherapy can promote tumor immunity by [CONTACT_91031], as well as  modulating distinct features of tumor 
immunobiology [ Emens , 2015]. In preclinical models, combinations with various 
chemotherapy agents including docetaxel and platinum -based treatments with anti -PD-L1 
treatment showed increased efficacy associated with increased frequency of intratumoral 
subsets without antagonizing functional changes mediated by [CONTACT_14181] -PD-L1 [Cubas , 2016]. 
Combination of anti -ICOS surrogate antibody with carboplatin and paclitaxel showed 
some increase efficacy in the CT26 tumor model [ Kilian , 2017a; Kilian , 2017b; Kilian , 
2017c; Kilian , 2017d].  
[IP_ADDRESS].1.  Clinical Safety Summary  
As of the feladilimab Investigator Brochure data cutoff date of [ADDRESS_100355] 1 dose of monotherapy feladilimab in study 204 691 at the 
following dose levels: 0.001 mg/kg (n=1), 0.003 mg/kg (n=1), 0.01 mg/kg (n=2), 0.03 
mg/kg (n=7), 0.10 mg/kg (n=25), 0.30 mg/kg (n=56), 1.0 mg/kg (n=126), 3.0 mg/kg 
(n=24), and 10 0 mg/kg (n=7). In these [ADDRESS_100356] common AEs 
(occurring in 15% of participants overall regardless of dose level or relationship) were 
anemia (22%), asthenia (21%), nausea (19%), fatigue (18%), diarrhea (16%), and 
vomiting (15%).  
In study 204691, [ADDRESS_100357] 1 dose of feladilimab 8 0 mg in 
combination with docetaxel 75 mg/m2 once every 3 weeks (safety cohort), 9 participants 
(90%) experienced at least 1 ≥Grade 3 AE, 2 of whom experienced Grade 5 events: 1 
participants had Grade 5 aspi[INVESTIGATOR_90878] 5 
methicillin -resistant staphylococcus aureus (MRSA) chest infection and Grade 5 lower 
respi[INVESTIGATOR_4416]. Seven participants (70%) experienced at least 1 serious adverse 
event (SAE) of Grade 3; Grade 3: fatigue, dyspnea (1 event), hyponatremia, asp iration 
pneumonia, respi[INVESTIGATOR_1399], hypotension, and diarrhea Grade 5: aspi[INVESTIGATOR_59499], 
lower respi[INVESTIGATOR_90879]. The Grade 5 events were 
reported in 2 participants (1 participant with aspi[INVESTIGATOR_59499]; [ADDRESS_100358] infection and staphylococcal infection); the 3 events were not 
considered related to study treatment and the primary cause of death in both cases was 
sepsis.  
Refer to [COMPANY_004]3359609 IB [[COMPANY_004] Document Number 2017N319717_03 ] for further 
details.  
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
106 [IP_ADDRESS].  Dose Justification (Substudy 1)  
[IP_ADDRESS].1.  Feladilimab Pharmacokinetics and Pharmacodynamics Summary  
The PK of feladilimab was evaluated after 30 minutes of IV infusion at doses from 0.001 
mg/kg to 10.0 mg/kg every 3 weeks (Q3W) in participants with solid tumors in Study 
204691. The plasma PK samples (received prior to the 2020 IB update cutoff date of 16 
March 2020) were analyzed  with a validated bioanalytical method with a lower limit of 
quantitation (LLOQ) of 0.1 µg/mL.  
As of 16 March 2020, preliminary PK data in monotherapy cohorts were available in 1 
participant at 0.003 mg/kg, 2 participants at 0.01 mg/kg, 7  participants at 0 .03 mg/kg, 25 
participants at 0.1 mg/kg, 52 participants at 0.3 mg/kg, 123  participants at 1.0 mg/kg, 23 
participants at 3.0 mg/kg, and 7 participants at 10.0  mg/kg dose. Preliminary PK data in 
pembrolizumab combination cohorts were available in 5 particip ants at 0.01 mg/kg, 
5 participants at 0.03 mg/kg, 13 participants at 0.1 mg/kg, 244 participants at 0.3  mg/kg, 
38 participants at 1.0 mg/kg, and 18 participants at 3.0 mg/kg dose. Preliminary PK data 
in [COMPANY_004]3174998 combination cohorts were available in 5 pa rticipants each at 8 and 24 mg 
and 1 participant at 80 mg fixed dose. Preliminary PK data in chemotherapy combination 
cohorts of the safety run -in were available in 55  participants at 80 mg fixed dose of 
feladilimab.  
Based on these preliminary data, the m edian plasma concentration -time profiles of 
feladilimab exhibit a bi -exponential decline. There are no changes in [COMPANY_004]3359609 PK 
when co -administered at doses from 0.01 to 3.0 mg/kg with biologic or chemotherapy 
partners. Furthermore, median feladilimab pla sma PK profiles after dosing at 8, 24, and 
80 mg fixed doses were superimposable to the median PK profiles observed with 0.1, 0.3, 
and 1.0 mg/kg doses. Preliminary plasma PK parameters of feladilimab computed using 
noncompartmental analysis methods (AUC, C , and C max) calculated over the first dosing 
interval (up to 503 hours) exhibit approximate dose proportional increases in feladilimab 
exposure over the range of 0.01 to 10.0 mg/kg doses. Observed exposures (AUC and C ) 
from body -weight based dose of 1.0  mg/kg (combined monotherapy and combination 
cohorts) and corresponding fixed dose equivalent of 80 mg (chemotherapy safety run -in) 
overlap with each other, indicating similar exposures can be achieved with a fixed dosing 
regimen. Preliminary population PK estimated geometric mean systemic half -life (t1/2) of 
feladilimab is approximately 19 days.  
Based on the preliminary data, median CD4 and CD8 receptor occupancy (RO) was 
maintained at or above 70% during the dosing interval of first cycle for doses 0.3 mg/kg 
as shown in Figure 7.  
Refer to [COMPANY_004]3359609 IB [[COMPANY_004] Document Number 2017N319717_03 ] for further 
details.  
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
107 Figure 7 Median CD4+ and CD8+ Receptor Occupancy (%RO) During the First 
Cycle of Feladilimab Administration as Monotherapy  
 
Feladilimab Dosing Frequency  
The systemic half -life of feladilimab is approximately [ADDRESS_100359] a different dosing regimen as deemed appropriate.  
Rationale for Fixed Dose  
Therapeutic monoclonal antibodies are often dosed based on body -size due to the concept 
that this reduces inter -participant variability in drug exposure. However, body -weight 
dependency of PK parameters does not always explain all or even a majority of observed 
variability in the exposure of monoclonal antibodies [ Zhao , 2017]. Hence, the selection 
of body -weight based versus fixed dosing in this study was evaluated through population 
PK modelling and simulation efforts.  
A preliminary population PK model (N  = 637 participants; March 2020), which 
characterized the influence of body weight, age, and other participant covariates on 
exposure was developed. Results of this analysis indicate  a feladilimab fixed dose  is 
appropria te for trial participants across the bodyweight spectrum. Simulations show a 
feladilimab body weight -based dose results in  slightly higher exposure in heavier weight 
participants  and a feladilimab fixed dose results in slightly higher exposures in lighter 
participants. However, the range of exposures are similar  between body -weight based and 
fixed dosing across the entire body weight spectrum and the exposures are maintained 
well within established clinical boundaries of safety at doses in the range of 24 t o 80 mg 
Q3W (the highest studied dose in monotherapy deemed tolerable was 10 mg/kg or ~800 
mg). This suggests that there is no advantage of  body -weight  based dosing over fixed 
dosing and that lighter patients will not be more susceptible to treatment -related adverse 
events arising from marginal increases in exposure.  
Overall, these preliminary population PK simulations indicate that using fixed dosing 
would result in a similar range of exposures as that of body weight -based dosing. Also, 
fixed dosing offer s the advantage of reduced dosing errors, reduced drug wastage, 
shortened preparation time, and improved ease of administration. Thus, a feladilimab 
fixed dose for Substudy 1 based on a reference body weight of 80 kg is reasonable and 
appropriate.  
Refer to  [COMPANY_004]3359609 IB [[COMPANY_004] Document Number 2017N319717_03 ] for further 
details.  
[IP_ADDRESS].2.  Feladilimab Dose Rationale (Substudy 1)  
Based on the preliminary PK dat a described above in Section [IP_ADDRESS].1  and target 
engagement shown in Figure 7, median CD4 and CD8 receptor occupancy was 
maintained at or above 70% during the dosing interval of first cycle for doses ≥0.3 
mg/kg. Sufficiently high CD4+ RO is expected at peak exposures (8 9% to >99% RO) as 
well as at trough exposures (69% to >99% RO) at steady -state with the proposed 80 mg 
dose in substudy 1.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
109 Collectively, based on the safety and exposure data from the Phase 1 study and the 
predicted target engagement, the 80 -mg dose will b e evaluated in combination with 
docetaxel in this study. No drug -drug interaction related changes are expected in 
feladilimab PK with docetaxel co -administration. The currently planned 80 mg 
feladilimab dose may be adjusted lower to 24 mg or increased to 2 40 mg based on any 
emerging safety, exposure and/or pharmacodynamic data.  
[IP_ADDRESS].3.  Docetaxel Dose Rationale  
Docetaxel is a semisynthetic taxane approved in different tumor indications. The dosage 
of docetaxel as a single agent and in combination for several tumor i ndications, including 
NSCLC and HNSCC, is 75  mg/m2, every three weeks; thus, this dose and schedule was 
selected in combination with feladilimab. There are no drug -drug interaction related 
changes expected in docetaxel PK on co -administration with feladili mab.  
[IP_ADDRESS].  Treatment of Overdose  
An overdose is defined as administration of a dose that is at least 50% greater than the 
intended dose. In the event of an overdose, the investigator must:  
1. Contact [CONTACT_27465].  
2. Closely monitor the participant for adverse events and laboratory abnormalities 
for at least [ADDRESS_100360] 
dose of study treatment if requested by [CONTACT_1689] (determined on a 
case-by-case basis).  
4. Docume nt the quantity of the excess dose as well as the duration of the 
overdosing in the eCRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_91032].  
There is no specific antidote for overdose with the experimental treatments being 
evaluated in this study. In the event of a suspected overdose, it is recommended that the 
appropriate supportive clinical care be instituted as dictated by  [CONTACT_2299]’s clinical 
status.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
110 12.1.3.  Arm 3: Feladilimab and Ipi[INVESTIGATOR_90843]  
[IP_ADDRESS].  Protocol Amendment 5 Summary of Changes Specific to Feladilimab 
and Ipi[INVESTIGATOR_90880] # and Name  [CONTACT_91084] [IP_ADDRESS]  Added footnote to SoAs (on -
treatment and TDV) for 
biomarker, PK, and ADA 
samples SoA  To align with decision to no 
longer collect samples from 
participants in this arm  
Schedule of Activities 
Section [IP_ADDRESS]  Added footnote to TDV SoA 
for survival follow up 
requirements  To remove the survival follow 
up requirement for this arm   
Dose Modification and 
Management 
Guidelines Section 
[IP_ADDRESS]  Moved dose modification 
guidelines to this section 
from the master protocol  To include the dose 
modification guidelines 
specific to the regimen in this 
arm  
Safety Evaluation 
Section [IP_ADDRESS]  Moved Part 1 Analysis text 
from master protocol  To avoid duplication and 
better clarify the analysis for 
this arm  
Risk-benefit Section 
[IP_ADDRESS]  Moved risk management and 
mitigation strategy to this 
section from the master 
protocol  To include risk management 
and mitigation strategy 
specific to the regimen in this 
arm  
 
Protocol Amendment 4 Summary of Changes Specific to Feladilimab and 
Ipi[INVESTIGATOR_90880] # and Name  [CONTACT_91084] [IP_ADDRESS]  Added physical exam for 
dosing visits.  As this is a new combination 
being tested, decision was 
made to require a physical 
exam at every dosing visit.  
Schedule of Activities 
Section [IP_ADDRESS]  Time window for plasma 
feladilimab end of infusion 
PK was extended from [ADDRESS_100361] the end of 
infusion PK sample  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
111 Schedule of Activities 
Section [IP_ADDRESS]  Removed details on number 
of slides for tissue sample to 
be sent by [CONTACT_3725].  Decided this detail should be 
included in the SRM instead 
and was removed from 
protocol.  
Schedule of Activities 
Section [IP_ADDRESS]  Added creatinine clearance 
to screening assessments  To correct the omission of 
creatinine clearance.  
Schedule of Activities 
Section [IP_ADDRESS]  At the follow up visit, 
footnote added: If the 
participant dies before the 
first follow up, any 
subsequent anticancer 
therapy or radiotherapy 
should be recorded in the 
eCRF.  To record any subsequent 
therapy the participant may 
have received after study 
discontinuation, if they die 
before first follow up is 
completed.  
Futility Evaluati on 
Section [IP_ADDRESS]  Clarify ipi[INVESTIGATOR_90881] 3mg/kg dose.  To align with study strategy.  
Schedule of Activities 
Section [IP_ADDRESS]  Added footnote:  
Pre: predose sample to be  
collected prior to dosing per 
institutional guidance, as 
long as it is collected prior  
to dosing of the 
corresponding agent ; EOI : 
End of infusion sample is  in 
reference to EOI of the 
corresponding agent.  To clarify the sample 
collection reference for 
predose and EOI.  
Schedule of Activities 
Section [IP_ADDRESS]  Added in the TDV SOA:  
In the event of 
hypersensitivity reaction that 
is clinically significant 
and/or leads to study 
treatment discontinuation, an 
additional sample should be 
collected at [ADDRESS_100362] the omission of 
hypersensitivity collection of 
ADA samples at TDV and 
added sample collection for 
feladilimab.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
112 [IP_ADDRESS].  Schedule of Activities Specific to Ipi[INVESTIGATOR_90882] (including safety, pharmacokinetic, ADA, biomarker or other assessments) m ay 
be altered during the course of the study based on n ewly available data.  
Table 19 Schedule of Activities – Screening: Arm 3: Ipi[INVESTIGATOR_90883]1  Notes  
Visit Window ≤[ADDRESS_100363] be performed within 4 weeks (28 days) prior to first dose of study treatment unless otherwise 
specified. The informed consent may be signed within [ADDRESS_100364] dose.  
Participant Registration2 X 2. Participants will be registered in RAMOS NG  at screening.  
Inclusion/Exclusion Criteria  X Review eligibility prior to randomization.  
Demographics, Medical History 
(incl. alcohol & tobacco use), 
Prior Medications, Disease 
History12 X 12. All known mutations should be entered in the eCRF as disease history.  
Prior Anticancer Treatment, 
Radiotherapy  X  
Screening Safety  
AE/SAE/AESI Assessment3 X 3. After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/ contacts. 
Refer to Section 9.[ADDRESS_100365] dose of study treatment, and during treatment phase if clinically  
indicated. MUGA scan may be used if ECHO not feasible.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
113 Screening Study 
Assessments  Screening1  Notes  
Visit Window ≤4 Wk    
Screening Local Laboratory Assessments (Safety)  
Hepatitis B and C6 X  
Serum β -hCG (for women of 
childbearing potential)  ≤3d  
Clinical Chemistry6, 
Coagulation6, Hematology6, 
Thyroid function6 X 6. Refer to Appendix  [ADDRESS_100366] dose of study intervention or SoC, repeat testing 
at screening is not required; otherwise, this testing is mandatory.  
Calculated CrCl7 X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90872] -Gault formula. See Appendix 9 . 
Troponin I or Troponin T  X  
Urinalysis6 X  
Screening Other Laboratory Assessments  
PD-L1 expression by [CONTACT_4658]7 X 7. PD -L1 expression by [CONTACT_91001] (i.e., Ventana SP263, Ventana SP142, Dako 28 -8, or Dako 22C3) must be 
recorded in the eCRF, if known . Note: Test is not required to be performed by [CONTACT_91023] t previously performed.  
Screening Disease Assessments   
Tumor Imaging8 X 8. Diagnostic quality CT scan of chest and abdomen with contrast must be obtained within [ADDRESS_100367] dose. Baseline brai n 
scan (MRI with and without IV gadolinium) should be obtained within [ADDRESS_100368] dose if clinically indicated. See additional information rega rding 
bone scans in Section 9.3.1 . 
Pre-Baseline scans for Tumor 
Growth Kinetics9 X 9. Upon participant consent, up to 3 pre -baseline scans (within 12 months before the baseline scan) will be collected to assess 
tumor growth rate to support exploratory investigation of tumor growth kinetics (See Section 9.3.2  for details on images for 
submission).  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
114 Screening Study 
Assessments  Screening1  Notes  
Visit Window ≤4 Wk    
Screening Tumor Biopsies  
Fresh tumor tissue sample and 
Archival tumor10 X 10. Part 1: All participants are required to have tumor tissue  available (archival or fresh biopsy) prior to start of study treatment. A 
fresh biopsy is required if archival tissue is unavailable. Following Part 1 initial safety evaluation (up to first 10 partic ipants), for the 
additional participants enrolled to ass ess further safety as well as PK/PD, fresh tumor tissue AND archival tumor tissue samples 
at screening are required prior to start of study treatment.  
Part 2: Tumor tissue at screening (either archival or fresh biopsy if archival tissue is unavailable), is  required for all participants in 
Part 2. Fresh  tumor  tissue at screening is required in addition to an archival tissue  for at least  [ADDRESS_100369] been obtained at any time from the time of initial  
diagnosis to time of study entry. Note: Enrollment may become limited during the study, as require d, to ensure collection of fresh 
tissue samples as noted.  
‘Abbreviations : AE = adverse event; AESI = adverse events of special interest; β -hCG = β -human chorionic gonadotropin; CKD -EPI = chronic kidney disease epi[INVESTIGATOR_51962]; CrCl = creatinine clearance; CT = computed tomography; ECG = electrocardiogram; ECHO = echocardiography; ECOG PS = Eastern Cooperati ve Oncology Group 
performance status; eCRF = electronic case report form; IHC = Immunohistochemistry; IWRS = interactive web respon se system; MRI = magnetic resonance imaging; MUGA = 
multi -gated acquisition; SAE = serious adverse event.  
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
115 Table 20 Schedule  of Activities – Treatment Period: Arm 3: Ipi[INVESTIGATOR_90884]  1 4 7 10 13 16 19 22 25 28 - 
49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted.  (Visits occur once every 3 weeks during treatment period)  
Inclusion/Exclusion Criteria  X            
Concomitant Medications  X X X X X X X X X X X  
Participant Randomization1 X           1. Once determined to be eligible, participants must be 
randomized via IWRS. Drug shipments will be managed via 
IWRS. Sites must allow up to 7 business days for shipment 
of study drug. Randomization can be done prior to Day 1, 
but no more than 3 days prior to Day 1. (Refer to SRM) . 
Study treatments1 
Administer Feladilimab 
([COMPANY_004]3359609)*  X X X X X X X X X X Q3W  *Feladilimab ([COMPANY_004]3359609) must be administered within 
±3 days of scheduled visit unless otherwise indicated. 
Refer to Section 5.2 for maximum duration of study 
treatment . 
feladilimab ([COMPANY_004]3359609) will be administered first and 
ipi[INVESTIGATOR_90885] 30 minutes and no 
longer than one hour following feladilimab ([COMPANY_004]3359609) 
EOI. 
Administer Ipi[INVESTIGATOR_125]2 X X X X X X X X X X Q3W  2. Feladilimab ([COMPANY_004]3359609) will be administered first and 
ipi[INVESTIGATOR_90885] 30 minutes and no 
longer than one hour following feladilimab ([COMPANY_004]3359609) 
EOI. Refer to Section 5.2 for maximum duration of study 
treatment.  
Dosing interval can be extended to Q6W for toxicity or 
intolerance  
On Treatment Safety  
AE/SAE/AESI Assessment3 X X X X X X X X X X X 3. After the initial AE/SAE report, the investigator is required 
to proactively follow each participant at subsequent 
visits/contacts. All SAEs and non -serious AESIs will be 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
116 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 
49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted.  (Visits occur once every 3 weeks during treatment period)  
followed until the event is resolved, stabilized, otherwise 
explained, or the part icipant is lost to follow -up. 
ECOG PS**  X X X X X X X X X Q6W*  Q6W*  *Q6W procedures are counted starting from Week 25 (i.e. 
the first Q6W visit is Week 31, then Week 37, etc.), unless 
more frequent assessments are clinically indicated.  
Physical Examination**  X X X X X X X X X Q6W*  Q6W*  ** Physical examinations and ECOG may be performed 
within 24 hours prior to dosing (i.e., as opposed to the day 
of dosing), if necessary.  
Vital Signs and Weight4 X X X X X X X X X X X 4. Vital signs include blood pressure, temperature, pulse, 
respi[INVESTIGATOR_697], and oxygen saturation. Weight is to be 
recorded at every other treatment visit in kilograms. Vital 
signs are to be performed predose on treatment days.  
On Treatment Local Laboratory Assessments (Safety) – assessments may be performed up to 3 days prior to treatment  
Serum β -hCG (for women of 
childbearing potential)[ADDRESS_100370] dose.  
Thyroid function tests    X  X  X  X Q6W*  Q6W*  *Q6W procedures are counted starting from Week 25 (i.e. 
the first Q6W visit is Week 31, then Week 37, etc.).  
Calculated CrCl7    X   X X X X X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90872] -Gault 
formula. Either formula is acceptable and must be 
consistently utilized for each participant throughout the 
study. See Appendix 9 . 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
117 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 
49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted.  (Visits occur once every 3 weeks during treatment period)  
Urinalysis   X X X X X X X X X X  
On Treatment Disease Assessments  
Tumor Imaging/Response 
Assessment8   X  X  X  X X8 8. Diagnostic quality CT scan of chest and abdomen with 
contrast is required every 6 weeks (±1 week) until Week 49 
and every 12 weeks thereafter. Imaging/clinical 
assessments should be performed as indicated in Section 
9.2. The same method of assessment is required 
throughout the study. Brain scan (MRI with and without IV 
gadolinium) and bone scan to be performed as clinically 
indicated during the treatment peri od. If a participant has 
achieved a PD, CR, or PR in the previous radiologic 
assessment, a repeat scan should be performed after at 
least 4 weeks to confirm the response.   
On Treatment Patient -Reported Outcomes/Health -Related Quality of Life: Part 2 ONLY  
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
118 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 
49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted.  (Visits occur once every 3 weeks during treatment period)  
On Treatment Biomarkers21 
On Treatment Tumor biopsies22 
Fresh tumor tissue sample13   X    X13     13.Part 1: For participants in the safety evaluation for each 
substudy, fresh biopsies at week 7 (± 8 days) is optional. 
Following Part 1 initial safety evaluation (up to 10 
participants), the additional participants enrolled to assess 
further safety as well as PK/PD are required to provide a 
fresh biopsy obtained at week 7 (± 8 days).  
22. On treatment biopsy for participants in the PK/PD 
cohort is no longer required for ongoing participants in this 
arm. 
Part 2: Fresh biopsy collected at week 7 (± 8 days) is 
optional for participants in Part 2, if tumor is amenable to 
biopsy and upon participant consent. However, fresh biopsy 
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
119 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 
49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted.  (Visits occur once every 3 weeks during treatment period)  
at week 7 (± 8 days) is required for at least 20 participants 
for this arm who also provided a fresh biopsy at screening.  
Additional opt ional fresh tumor tissue sample will be 
collected at Week 19 at the time of imaging assessment 
and at the time of confirmed PR or PD (± 8 days), upon 
participant consent. Note: Enrollment may become limited 
during the study, as required, to ensure collecti on of fresh 
tissue samples as noted.  
On Treatment Pharmacokinetics and Anti -Drug Antibodies (ADA) 
Plasma Feladilimab 
([COMPANY_004]3359609; ICOS 
Agonist) PK14, 23 X X X X X X X X X X X14 14. Draw sample (2 mL) at predose for all marked visits. 
Additional samples also drawn at the following time points: 
Week 1 (Day 1) at end of infusion (EOI) (within 15 minutes) 
and EOI+4h. EOI samples also drawn at Week 13 and 
Week 25. After Week 25, draw samples every 12 weeks at 
predose only. There is a +15 minutes window allowa nce for 
the EOI time points.  
23. Collection of on treatment ICOS PK is no longer 
required for ongoing participants in this arm.  
Ipi[INVESTIGATOR_90886]24 Pre, 
EOI*  Pre, 
EOI Pre, 
EOI Pre, 
EOI Pre, 
EOI Pre, 
EOI Pre, 
EOI15   Pre15 Pre15 *Part 1 ONLY: Additional collection time points for PKs on 
day 8 (± 2 days) and day 15 (± 3 days).  
15. To be collected predose, EOI every 3 weeks until Week 
19, then predose only every 18 weeks thereafter. If 
ipi[INVESTIGATOR_90887] a differing scheduling frequency, pre 
and EOI sho uld be collected relative to dosing on infusion 
days only.  
24. Collection of on treatment ipi[INVESTIGATOR_90888].  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
120 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 
49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted.  (Visits occur once every 3 weeks during treatment period)  
Serum Feladilimab 
([COMPANY_004]3359609; ICOS 
Agonist) ADA16, 25 X X X X X X X X X X X16 16. Draw sample (4 mL) at predose on ALL treatment visits; 
then starting with Week 25 predose samples to be collected 
every 12 weeks. Draw a sample at any time during visit for 
non-treatment visits. Serum samples will be collected and 
tested for the presence of ant ibodies that bind to 
investigational agents as deemed appropriate. Feladilimab 
serum samples may also be tested for presence of 
antibodies that bind to Chinese Hamster Ovary (CHO) host 
cell proteins such as phospholipase B - like (PLBL2).  
25. Collection of on treatment ICOS ADA is no longer 
required for ongoing participants in this arm.  
  
Serum Ipi[INVESTIGATOR_90889]17, 26 Pre Pre Pre Pre Pre Pre Pre18   Pre18 Pre18 17. Serum samples are required to be collected prior to 
dosing (i.e., predose) on each dosing day and at the 
indicated assessment visits following study treatment 
discontinuation, and one sample collected [ADDRESS_100371] dose of study treatment. In the event of hypersensitivity 
reaction that is clinically significant and/or leads to study 
treatment discontinuation, serum samples should be 
collected [ADDRESS_100372] dose 
of study treatment.  
18. To be collected every 3 weeks until Week 19, then 
every 18 weeks thereafter.  
26. Collection of on treatment ipi[INVESTIGATOR_90890] r 
required for ongoing participants in this arm.  
Serum: IRR lab panel19            19. Assessment ONLY required in participant experiencing 
anaphylaxis, serious hypersensitivity, or AEs related to 
study treatment administration that led to withdrawal from 
the study. Refer to Table [ADDRESS_100373] of analytes. Predose 
analysis will be performed on the serum sample collected 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
121 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 
49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days unless otherwise noted.  (Visits occur once every 3 weeks during treatment period)  
for feladilimab ([COMPANY_004]3359609) and/or ipi[INVESTIGATOR_90891].  
On Treatment Pharmacogenetics  
Genetic research20 X           20. Informed consent for optional genetic research must be 
obtained before collecting this sample. It is recommended 
that the optional research sample be taken at the first 
opportunity after a participant has met all eligibility 
requirements before Day 1 or on Day 1.  
Abbreviations : ADA = Anti -drug antibody; AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; CKD -EPI = Chronic 
kidney disease epi[INVESTIGATOR_8261]; CR = complete response; CrCl = Creatinine clearance; CT = computed tomography; CTCAE = Common Terminology Crit eria for 
Adverse Events; ECOG PS = Eastern Cooperative Oncology Group performance status; EOI = End of infusion;  
 
 ICOS = inducible T Cell co -stimula tor; IRR = infusion related reaction;  
; PD = Progressive Disease;  PR = 
Partial response;  Pre = Predose;   
; SAE = Serious adverse event.  
Pre: predose sample to be  collected pr ior to dosing per institutional guidance, as long as it is collected prior to dosing of the corresponding agent ; EOI : End of infusion sample is  in 
reference to EOI of the corresponding agent.  
 
CCI
CCI
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
122 Table  21 Schedule of Activities – Treat ment Discontinuation Visit and Follow -Up: Arm 3: Ipi[INVESTIGATOR_90892] -Up Notes  
Visit Window  + 10 days    
Anticancer Treatment   X* * Follow up for survival is no longer required for participants in this arm.  
 
  
  
Concomitant 
Medications  X   
TDV and Follow Up Safety  
AE/SAE/AESI 
Assessment2 X  2. After the initial AE/SAE report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. Refer to Section 9.4.1  and Section 9.4.3  for further details..  
ECOG PS  X   
Physical Examination  X   
Vital Signs and Weight3 X  3. Vital signs include blood pressure, temperature, pulse, respi[INVESTIGATOR_697], and oxygen saturation.  
TDV and Follow Up Local Laboratory Assessments  
Clinical Chemistry  X   
Serum β -hCG (for 
women of childbearing 
potential)  X   
Hematology  X   
Thyroid function tests  X   
Calculated CrCl X  
Urinalysis  X  
TDV and Follow Up Disease Assessments  
Tumor 
Imaging/Response 
Assessment4 X  4. At the TDV, CT scan is required only if the last disease assessment did not show PD and was performed ≥[ADDRESS_100374]. See 
additional information in Section 9.3.1 . 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
123 TDV and Follow Up 
Assessments  Treatment 
Discontinuation Visit 
 Survival  
Follow -Up Notes  
Visit Window  + 10 days    
Telephone call for 
survival status1a  X* *Follow up for survival is no longer required for participants in this arm.  
TDV and Follow Up Tumor Biopsies  
Fresh tumor tissue 
sample  X5  5. If possible, obtain an optional  tumor tissue sample at time of confirmed PD or PR.  
TDV and Follow Up Patient -Reported Outcomes/Health -Related Quality of Life: Part 2 ONLY  
  
 
  
 
 
 
 
 
 
TDV and Follow Up Biomarkers10 
TDV and Follow Up Pharmacokinetics and Anti -Drug Antibodies (ADA)9 
Feladilimab 
([COMPANY_004]3359609) ADA   X7,[ADDRESS_100375] dose.  
8. In the event of hypersensitivity reaction that is clinically significant and/or leads to study treatment 
discontinuation, an additional sample should be collected at [ADDRESS_100376] dose of study treatment.  
9. Collection of follow up PK and ADA samples is no longer required for ongoing participants in this arm.  Feladilimab 
([COMPANY_004]3359609) PK   X7 
Ipi[INVESTIGATOR_90889]   X7,8 
Ipi[INVESTIGATOR_90886]   X7 
Abbreviations : ADA = Anti -drug antibody; AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; CR = complete 
response; CrCl = Creatinine clearance; CT = computed tomography; CTCAE = Common Terminology Criteria for Adv erse Events; ECOG PS = Eastern Cooperative Oncology 
Group performance status; eCRF = Electronic case report form;  
 
 PD = Progressive Disease; ,  
CCI
CCI
CCI
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
124  PR = Partial response;  
; SAE = Serious adverse event; TDV = Treatment Discontinuation Visit  
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
125 [IP_ADDRESS].  Rationale for the ICOS Agonist/Ipi[INVESTIGATOR_90893] a recombinant, human monoclonal IgG1 kappa antibody that binds to 
CTLA -4. CTLA -4 is a negative regulator of T -cell activity. Ipi[INVESTIGATOR_142] a monoclonal 
antibody that binds to CTLA -4 and blocks the interaction of CTLA -4 with its ligands, 
CD80/CD86. Bloc kade of CTLA -4 has been shown to augment T -cell activation and 
proliferation, including the activation and proliferation of tumor infiltrating T -effector 
cells. Inhibition of CTLA -4 signaling can also reduce T -regulatory cell function, which 
may contribute  to a general increase in T cell responsiveness, including the anti -tumor 
immune response [ YERVOY  Prescribing Information, 2020]. Yervoy (ipi[INVESTIGATOR_125]) alone 
and in combination with nivolumab  platinum -based chemotherapy is indicated for the 
treatment of patients across a number of indications which include metastatic melanoma 
and NSCLC.  
Inducible t -cell costimulator (ICOS) is a co -stimulatory receptor belonging to the 
CD28/CTLA immunoglobulin super family with expression restricted to T cells [ Hutloff , 
1999]. ICOS is weakly expressed on resting TH17, follicular helper T and Treg cells yet 
is highly induced on CD4+ and CD8+ T cells upon T cell receptor (TCR) engagement 
and activation [ Paulos , 2010; Wakamatsu , 2013]. Upregulation of ICOS leads to both 
Th1 and Th2 cytokine secretion and sustained effector T cell proliferation and function 
[Sharpe , 2002]. A growing body of evidence supports the concept that activating ICOS 
on CD4+ and CD8+ effector T cells has  antitumor potential.  
The rationale for targeting ICOS in cancer has been established by [CONTACT_91028]. Engagement of the ICOS pathway with an ICOS -L-Fc 
fusion protein is shown to have potent antitumor activity in mult iple syngeneic mouse 
tumor models [ Ara, 2003]. Emerging data from patients treated with anti -CTLA -[ADDRESS_100377] a positive role of ICOS+ effector T cells i n mediating an antitumor 
immune response. Patients with metastatic melanoma [ Di Giacomo , 2013], urothelial 
[Carthon , 2010], breast [ Vonderheide , 2010] and prostate cancer [ Chen , 2009] who have 
increased absolute counts of circulating and tumor infiltrating CD4+ICOS+ and 
CD8+ICOS+ T cells after ipi[INVESTIGATOR_90894]. Importantly, it 
was shown that ipi[INVESTIGATOR_90876]+ T effector -to-Treg cell ratio, reversing an 
abundance of Tregs cell pre -treatment to a significant abundance of T effectors v s. Tregs 
cells relative to cells following treatment [ Liakou , 2008; Vonderheide , 2010]. As 
evidenced by [CONTACT_91033], ICOS+ T effector cells may be a positive predictive 
biomarker of ipi[INVESTIGATOR_90895], and activation of this population of cells with an 
ICOS agonist antibody may confer an advantage by [CONTACT_91030] a more robust immune 
antitumor response.  
The T cell activating potential of feladilimab was evaluated in multiple assay formats as a 
single agent and in combination with other immune checkpoint inhibitors. Ex -vivo 
studies were conduct ed with PBMC isolated from healthy human donors pre -activated 
with anti -CD3 alone or anti -CD3/anti -CD28. Soluble feladilimab either alone or in 
combination with ipi[INVESTIGATOR_62468] a more robust pro -inflammatory cytokine 
response than either single age nt alone. A modified allogenic mixed lymphocyte reaction 
(MLR) assay, where lymphocytes from one donor were mixed ex -vivo with peptide -
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
126 stimulated dendritic cells differentiated from freshly isolated monocytes from another 
donor, was also employed to evalua te feladilimab in combination with ipi[INVESTIGATOR_125]. 
Significant increases in IFNγ secretion were observed for feladilimab combined with 
ipi[INVESTIGATOR_90896], supporting clinical evaluation of this 
combination.  
In vivo studies using ICOS -/- and ICOS -ligand (L) -/- mice demonstrated the requirement 
of ICOS signaling in mediating the anti -tumor activity of an anti -CTLA -4 antibody in the 
B16/F10 melanoma syngeneic tumor model [ Fu, 2011]. Mice lacking ICOS or ICOS -L 
had significantly decreased survival rates compared to wild -type mice after anti -CTLA -[ADDRESS_100378] anti -tumor responses. In a separate study, B16 tumors 
engineered to overexpress ICOS -L were found to be significantly more sensitive to anti -
CTLA -4 treatment as compared to a B16/Bl6 tumor cells transduced with a control 
protein [ Fan, 2014]. Treatment with mouse anti -CTLA -4 mouse antibody induced ICOS 
on CD4+ and CD8+ T cells in the tumor, spleen and blood, a pattern comparable to the 
ipi[INVESTIGATOR_79231] r esponse showing that interplay between receptor induction extended 
to CTLA -4.  
To support the combination of feladilimab with ipi[INVESTIGATOR_125] (anti -CTLA -4 mAb), the 
nonclinical toxicology findings of ipi[INVESTIGATOR_188] a single agent was reviewed. The 
nonclinical to xicology profiles of ipi[INVESTIGATOR_90897]. Risk mitigation measures for potential 
clinically rel evant risks associated with feladilimab combination therapy based on these 
nonclinical assessments or clinical safety data are described in this protocol. In 
intravenous repeat -dose toxicology studies in monkeys, ipi[INVESTIGATOR_90898]. Im mune -mediated adverse reactions were observed infrequently and included 
colitis (which resulted in a single fatality), dermatitis and infusion reaction (possibly due 
to acute cytokine release resulting from a rapid injection rate) [ Hanaizi , 2012]. In a 
monkey reproductive toxicology study, administration of ipi[INVESTIGATOR_90899] i ncidences 
of abortion, stillbirth, premature delivery (with corresponding lower birth weight), and 
higher incidences of infant mortality in a dose -related manner. The clinical relevance of 
these findings are well characterized and risk mitigation measures are described in this 
protocol.  
Refer to the [COMPANY_004]3359609 Investigator’s Brochure (IB) [[COMPANY_004] Document Number 
2017N319717_03 ; 2020] for further det ails.  
 
 
 
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
127 [IP_ADDRESS].  Clinical Safety Summary  
[IP_ADDRESS].1.  Feladilimab  
As of the feladilimab Investigator Brochure data cutoff date of [ADDRESS_100379] 1 dose of monotherapy feladilimab in study 204691 at the 
following dose levels: 0.001 mg/kg ( n=1), 0.003 mg/kg (n=1), 0.01 mg/kg (n=2), 0.03 
mg/kg (n=7), 0.10 mg/kg (n=25), 0.30 mg/kg (n=56), 1.0 mg/kg (n=126), 3.0 mg/kg 
(n=24), and 10 .0 mg/kg (n=7). In these [ADDRESS_100380] common AEs 
(occurring in 15% of participants overall regardless of dose level or relationship) were 
anemia (22%), asthenia (21%), nausea (19%), fatigue (18%), diarrhea (16%), and 
vomiting (15%).  
Refer to [COMPANY_004]3359609 IB [[COMPANY_004] Document Number 2017N319717_03 ] for further 
details.  
[IP_ADDRESS].2.  Ipi[INVESTIGATOR_90900] ( 5%) with ipi[INVESTIGATOR_188] a single agent are fatigue, 
diarrhea, pruritis, rash, and colitis. The most common adverse reactions ( 20%) with 
ipi[INVESTIGATOR_90901], rash, pruritis, diarrhea, 
musculoskeletal pain, cough, pyrexia, decreased appetite, nausea, abdominal pain, 
arthralgia, headache, vomiting, dyspnea, dizziness, hypot hyroidism, and decreased 
weight.  
For more details on specific indications, adverse reactions and ipi[INVESTIGATOR_90902] [ YERVOY  Prescribing Information, 2020].  
 
[IP_ADDRESS].  Dose Justification  
[IP_ADDRESS].1.  Feladilimab Pharmacokinetics and Pharmacodynamics  
The PK of feladilimab was evaluated after 30 minutes of IV infusion at doses from 0.001 
mg/kg to 10.0 mg/kg every 3 weeks (Q3W) in participants with solid tumors in Study 
204691. The plasma PK samples (received prior to the 2020 IB update cutoff date of 16 
March 2020) were analyzed with a validated bioanalytical method with a LLOQ of 0.1 
µg/m L. 
As of 16 March 2020, preliminary PK data in monotherapy cohorts were available in 1 
participant at 0.003 mg/kg, 2 participants at 0.01 mg/kg, 7  participants at 0.03 mg/kg, 25 
participants at 0.1 mg/kg, 52 participants at 0.3 mg/kg, 123  participants at 1 .0 mg/kg, 23 
participants at 3.0 mg/kg, and 7 participants at 10.0  mg/kg dose. Preliminary PK data in 
pembrolizumab combination cohorts were available in 5 participants at 0.01 mg/kg, 
5 participants at 0.03 mg/kg, 13 participants at 0.1 mg/kg, 244 particip ants at 0.3  mg/kg, 
38 participants at 1.0 mg/kg, and 18 participants at 3.0 mg/kg dose. Preliminary PK data 
in [COMPANY_004]3174998 combination cohorts were available in 5 participants each at 8 and 24 mg 
and 1 participant at 80 mg fixed dose. Preliminary PK data in  chemotherapy combination 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
128 cohorts of the safety run -in were available in 55  participants at 80 mg fixed dose of 
feladilimab.  
Based on these preliminary data, the median plasma concentration -time profiles of 
feladilimab exhibit a bi -exponential decline. Th ere are no changes in feladilimab PK 
when co -administered at doses from 0.01 to 3.0 mg/kg with biologic or chemotherapy 
partners. Furthermore, median feladilimab plasma PK profiles after dosing at 8, 24, and 
80 mg fixed doses were superimposable to the med ian PK profiles observed with 0.1, 0.3, 
and 1.0 mg/kg doses. Preliminary plasma PK parameters of feladilimab computed using 
noncompartmental analysis methods (AUC, C , and C max) calculated over the first dosing 
interval (up to 503 hours) exhibit approximat e dose proportional increases in feladilimab 
exposure over the range of 0.01 to 10.0 mg/kg doses. Observed exposures (AUC and C ) 
from body -weight based dose of 1.0  mg/kg (combined monotherapy and combination 
cohorts) and corresponding fixed dose equivalen t of 80 mg (chemotherapy safety run -in) 
overlap with each other, indicating similar exposures can be achieved with a fixed dosing 
regimen. Preliminary population PK estimated geometric mean systemic half -life (t1/2) of 
feladilimab is approximately 19 days.   
Based on the preliminary data, median CD4 and CD8 receptor occupancy was maintained 
at or above 70% during the dosing interval of first cycle for doses 0.3 mg/kg as shown 
in Figure 8.  
Refer to [COMPANY_004]3359609 IB [[COMPANY_004] Document Number 2017N319717_03 ] for further 
details .  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
129 Figure 8 Median CD4+ and CD8+ Receptor Occupancy (%RO) During the First 
Cycle of Feladilimab Administration as Monotherapy  
 
Feladilimab Dosing Frequency  
The systemic half -life of feladilimab is approximately [ADDRESS_100381] a different dosing regimen as 
deem ed appropriate.  
Rationale for Fixed Dose  
Therapeutic monoclonal antibodies are often dosed based on body -size due to the concept 
that this reduces inter -participant variability in drug exposure. However, body -weight 
dependency of PK parameters does not al ways explain all or even a majority of observed 
variability in the exposure of monoclonal antibodies [ Zhao , 2017]. Hence, the selection 
of body -weight based vers us fixed dosing in this study was evaluated through population 
PK modelling and simulation efforts.  
A preliminary population PK model (N  = 637 participants; March 2020), which 
characterized the influence of body weight, age, and other participant covariat es on 
exposure was developed. Results of this analysis indicate  a feladilimab  fixed dose  is 
appropriate for trial participants across the bodyweight spectrum. Simulations show a 
feladilimab body weight -based dose results in  slightly higher exposure in heav ier weight 
participants  and a feladilimab fixed dose results in slightly higher exposures in lighter 
participants. However, the range of exposures are similar  between body -weight based and 
fixed dosing across the entire body weight spectrum and the exposur es are maintained 
well within established clinical boundaries of safety at doses in the range of 24 to 80 mg 
Q3W (the highest studied dose in monotherapy deemed tolerable was 10 mg/kg or ~800 
mg). This suggests that there is no advantage of  body -weight  based dosing over fixed 
dosing and that lighter patients will not be more susceptible to treatment -related adverse 
events arising from marginal increases in exposure.  
Overall, these preliminary population PK simulations indicate that using fixed dosing 
would  result in a similar range of exposures as that of body weight -based dosing. Also, 
fixed dosing offers the advantage of reduced dosing errors, reduced drug wastage, 
shortened preparation time, and improved ease of administration. Thus, a feladilimab 
fixed dose based on a reference body weight of 80 kg is reasonable and appropriate.  
Refer to [COMPANY_004]3359609 IB [[COMPANY_004] Document Number 2017N319717_03 ] for fur ther 
details.  
[IP_ADDRESS].2.  Feladilimab Dose Rationale (Arm 3)  
Based on the preliminary PK data described above in Section [IP_ADDRESS].1  and target 
engagement shown in Figure 8, median CD4 and CD8 receptor occupancy was 
maintained at or above 70% during the dosing interval of first cycle for doses ≥0.3 
mg/kg. Sufficiently high CD4+ RO is expected at peak exposures (8 9% to >99% RO) as 
well as at trough exposures (69% to >99% RO) at steady -state with the proposed 24 mg 
dose in arm 3.  
Collectively, based on the safety and exposure data from the Phase 1 study and the 
predicted target engagement, a 24 -mg dose will be evalu ated in combination with 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
131 ipi[INVESTIGATOR_90903]. No drug -drug interaction related changes are expected in 
feladilimab PK with ipi[INVESTIGATOR_90904] -administration. The currently planned feladilimab 
dose for this arm is the same as that used in the phase 2/3 studies for recurrent or 
metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC).  
[IP_ADDRESS].3.  Ipi[INVESTIGATOR_90905] 1  mg/kg or 3 mg/kg administered intravenously 
every 3  weeks.  
The 1 mg/kg or 3 mg/kg doses were s elected based on approvals in multiple tumor types, 
both as monotherapy and in combination with nivolumab. [YERVOY  Prescribing 
Information , 2020].  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
132 [IP_ADDRESS].  Study Trea tments  
Table 22 Description and Administration of Arm 3 Study Treatments  
Name  [CONTACT_383][INVESTIGATOR_90906] ([COMPANY_004]3359609; 
ICOS agonist)  
Description  CTLA -4 inhibitor  Humanized anti -ICOS IgG4 
mAb 
Dosage form/strength  50 mg/ 10 mL Solution;  
5 mg/mL  Solution for injection/ 
10 mg/mL  
Dosage  1 mg/kg,  
3 mg/kg  24 mg  
Route of administration  IV infusion  IV infusiona 
Dosing instructionsa/frequency  Administer diluted 
product/once Q3W (refer to 
SRM for infusion time)  Administer diluted 
product/once Q3W  
a: The study reference manual contains the details on product handling, storage, preparation, and administration.  
In the ipi[INVESTIGATOR_125] + feladilimab containing arm, feladilimab will be administered first as 
a 30minute IV infusion (infusion time may be adjusted in the event an infusion reaction 
occurs) under medical supervision of an investigator or designee . The administ ration of 
the ipi[INVESTIGATOR_90907] [ADDRESS_100382] -study treatment 
infusion per the judgement of the investigator or as per institutional guidelines. Refer to 
Section [IP_ADDRESS] , Table 24 for details on the management of participants experiencing 
infusion reactions.  
 
The date(s), start time(s) and stop time(s) of administration of each study drug will be 
documented in the source documents and reported in the eCRF. The dose of study 
treatment and study participant identification will be confirmed at the time of dosing b y a 
member of the study site staff other than the person administering the study treatment. 
Infusions may be administered up to 72 hours before or after the planned date of 
treatment for administrative reasons only (e.g., scheduling an infusion around a ho liday). 
The 72 -hour window does not apply to completion of study treatment administration 
interrupted by [CONTACT_91034]. Refer to Section [IP_ADDRESS]  for criteria governing dose 
interruptions or delays.  
Details on preparation and administration of feladilimab and ipi[INVESTIGATOR_90908] (SRM) and ipi[INVESTIGATOR_90909], respectively.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
133 [IP_ADDRESS].  Concomitant Therapy  
Please refer to Section 7.7  
[IP_ADDRESS].  Treatment of Overdose  
[IP_ADDRESS].1.  Feladilimab Overdose  
An overdose of feladilimab is defined as administration of a dose that is >240 mg (>10 
times the 24 mg intended dose). In the event of an overdose, the investigator must:  
1. Contact [CONTACT_27465].  
2. Closely monitor the participant for adverse events and laboratory abnormalities 
for at least [ADDRESS_100383] 
dose of study treatment if requested by [CONTACT_1689] (de termined on a 
case-by-case basis).  
4. Document the quantity of the excess dose as well as the duration of the 
overdosing in the eCRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_91035] M onitor based on the clinical evaluation of the 
participant.  
There is no specific antidote for overdose with the experimental treatments being 
evaluated in this study. In the event of a suspected overdose, it is recommended that the 
appropriate supportive clinical care be instituted as dictated by [CONTACT_2299]’s clinical 
status.  
[IP_ADDRESS].2.  Ipi[INVESTIGATOR_90910], no information is available on 
overdosage. In case of overdose symptomatic treatment has to be applied; ther e are no 
known antidotes for the compound.  
In the event of an overdose, the investigator must:  
1. Contact [CONTACT_27465].  
2. Closely monitor the participant for adverse events and laboratory abnormalities 
for at least [ADDRESS_100384] dose of 
study treatment if requested by [CONTACT_1689] (determined on a case -by-
case basis).  
4. Document the quantity of the excess dose as well as the duration of the  
overdosing in the eCRF.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
134 Decisions regarding dose interruptions or modifications will be made by [CONTACT_43208].  
[IP_ADDRESS].   Treatment Duration for Ipi[INVESTIGATOR_90911], intolerable toxicity, 
informed consent withdrawal or death. Combination study treatment will continue to be 
administered at the indicated schedule for a maximum duration of approximately [ADDRESS_100385].  Refer to Section 5.2. for additional 
details regarding follow up after discontinuation of study treatment.  
[IP_ADDRESS].  Dose modification and Management Guidelines  
The dose of feladilimab cannot be reduced or modified.  
No dose reductions are allowed for ipi[INVESTIGATOR_125]. Dose Modification Guidelines for 
immune related Adverse Events are listed in Section [IP_ADDRESS] .  
If either [COMPANY_004]3359606 or ipi[INVESTIGATOR_90912], the other 
study drug must also be held or discontinued, unless discussed ot herwise with Medical 
Monitor.  
[IP_ADDRESS].1.  General Guidelines for Immune -Related Adverse Events (irAEs)  
AEs associated with immunotherapy treatment may be immune -mediated . These 
immune -related AEs (irAEs) may occur shortly after the first dose or several months after 
the last dose of treatment, or during the treatment course, and may affect more than one 
body system simultaneously . Therefore, early recognition of and initiation of treatment 
for these events is critical to reduce potential complications. Based on existi ng data from 
the study 204691, most treatment -related AEs were Grade 1 or 2, managed with 
supportive care and if appropriate the administration of corticosteroids . 
For suspected irAEs, ensure adequate evaluation to confirm the etiology or exclude other 
causes. Additional procedures or tests such as, but not limited to, bronchoscopy, 
endoscopy, or skin biopsy may be included as part of the evaluation . Based on the 
severity of irAEs, withhold or permanently discontinue treatment and administer 
corticosteroids . Dose modification and toxicity management guidelines for irAEs 
associated with immunotherapi[INVESTIGATOR_80152] 23.  
Table 23 Dose Modification and Toxicity Management Guidelines for Immune -
Related AEs  
General instructions : 
• Corticosteroid taper should be initiated upon AE improving to Grade [ADDRESS_100386] 4 weeks.  
• For situations where immunotherapy treatment has been withheld, treatment can be resumed after AE 
has been reduced to Grade [ADDRESS_100387] dose or corticosteroids cannot 
be reduced to ≤ 10 mg prednisone or equivalent per day within 12 weeks.  
• For severe and life -threatening irAEs, IV corticosteroid should be initiated first followed by [CONTACT_44874]. 
Other immunosuppressive t reatment should be initiated if irAEs cannot be controlled by [CONTACT_13216].  
TMF-[ADDRESS_100388] been excluded.
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
137  
[IP_ADDRESS].2.  Dose Modification and Toxicity Management of Infusion -Reactions 
Related to Immunotherapy Treatment  
Table [ADDRESS_100389] been excluded.
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
138 [IP_ADDRESS].3.  Adverse Events of Special Interest (AESI)  
AESI are def ined as events of potential immunologic etiology, including irAEs. Such 
events recently reported after treatment with other immune modulatory therapy include, 
but are not limited to, the following: pneumonitis, nephritis, hepatitis, colitis, immune 
related  endocrinopathies (such as thyroiditis or hypophysitis) or immune related 
cutaneous toxicities, to include rashes confirmed via biopsy to be immune -mediated.  
AESIs will be reported within 24 hours if the event meets the criteria for a serious event.  
[IP_ADDRESS].  Safety Evaluation  
All the regimen qualification activities in Part [ADDRESS_100390] 24 mg feladilimab in 
combination with either 1mg/kg ipi[INVESTIGATOR_90913] 3mg/kg ipi[INVESTIGATOR_125]. The arm assessing 
the combination of 24 mg feladilimab with 1 mg/kg ipi[INVESTIGATOR_90914] g the combination of 3 mg/kg ipi[INVESTIGATOR_43861] [ADDRESS_100391] been excluded.
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
139 (mTPI) approach with some additional modifications due to only one dose level being 
evaluated. The mTPI [INVESTIGATOR_90915] a simple beta -binomial hierarchic model [ Ji, 2010]. Decision rules a re based 
on calculating the unit probability mass (UPM) of three intervals corresponding to under 
dosing, proper dosing, and overdosing in terms of toxicity. Specifically, the under -dosing 
interval is defined as (0, pT – ε1), the overdosing interval as (pT  + ε2, 1), and the proper 
dosing interval as (pT – ε1, pT + ε2), where pT is the target toxicity rate, ε1 and ε2 are 
small fractions, such as 0.05, to account for the uncertainty around the true target toxicity. 
The three dosing intervals are associated wi th three different dose decisions. Given an 
interval and a probability distribution, the UPM of that interval is defined as the 
probability of the interval divided by [CONTACT_91036]. The mTPI [INVESTIGATOR_90916], and the one with the largest UPM 
implies the corresponding dose -finding decision. For example, if the over -dosing interval 
has the largest UPM, decision will be to stop further evaluation.  
 
Initial safety and tolerability of the combination will be  evaluated within the first 21 days 
(DLT period). Evaluation of the available safety data over the first [ADDRESS_100392] three participants treated with 24  mg 
feladilimab + 1 mg/kg ipi[INVESTIGATOR_90917] (DLTs) meeting the criteria 
described in Table 27, an additional 6 -7 participants will be treated with 24  mg 
feladilimab + 1mg/kg ipi[INVESTIGATOR_125].  
If a participant withdraws from the study before the completion of the 21 -day DLT 
evaluation period for reasons other than DLT, then the participant may be replac ed to 
achieve the three -participant required minimum. The decision to declare the combination 
tolerable will occur following review of the safety, PK and PD data and joint discussion 
by [CONTACT_91037]. Membership, roles and accou ntabilities, 
and the process for safety review and meeting frequency is outlined in the Study 
Reference Manual.   
The mTPI [INVESTIGATOR_90918]:  
(i) A maximum of 10 participants will complete the DLT evaluation period;  
(ii) The true underlying to xicity rate for feladilimab falls within the range from 25% 
to 33% and targets at 30%.  
(iii) Maximum probability that the dose exceeds the target toxicity is 95%; however 
an additional safety rule will be applied if the maximum sample size of 10 is 
reached where by [CONTACT_91038] -tolerated if there is greater than 
70% posterior probability that the true DLT rate is >30%  
Participants will be enrolled in cohorts of 3 -4 and decisions will be made after all patients 
within a cohort complete the DLT ev aluation period.  
The monitoring rules guiding dose decision are provided in Table 25. The tolerability 
decision framework using the mTPI [INVESTIGATOR_90919] a beta/binomial 
TMF-[ADDRESS_100393].. In other studies utilizing mTPI, these points are often denoted as 
“E”, “S”, and “D”, denoting the thresholds governing escalating the dose, staying at the 
same dose, or de -escalating the dose, respectively. However in this study, as there is no 
dose escalation or de -escalation, the thresholds mark the criteria used to determine 
whether the doses of the combination are tolerated and therefore, permit continued 
treatment of additional participants  at the same combination dose. If a dose combination 
is not tolerated per Table [ADDRESS_100394] three participants in Part 1 
experience a DLT is represented in the cell marking the intersections of row ‘1’ and 
column ‘3’ in Table 25. According  to the model underlying the mTPI, such a scenario 
predicts the actual rate of toxicity to be within the acceptable, predetermined range, 
therefore allowing treatment of additional three participants at the same dose 
combination. The scenario in which one of these three additional participants experience 
DLT, is represented in the cell marking the intersection of row ‘2’ and column ‘6’, 
allowing treatment of an additional four participants according to the model. If two of 
these four additional participants  experience DLTs, the combination will not be 
considered as tolerated and no additional participants will be treated in this combination. 
not continue because of unacceptable toxicity. If the combination is considered tolerated, 
additional participants wil l be enrolled to further evaluate safety and PK/PD. No formal 
evaluation of DLTs will be performed after the 21 day period, however other measures of 
safety will continue to be monitored.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
141 Table 25 Dose Decision Rules  
  Number Treate d     
#DLTs  3 6 10 
0 Tolerated  Not applicable  Not applicable  
1 Enroll 3  Tolerated  Tolerated  
2 Stop Enroll 4  Tolerated  
3 Stop Stop Tolerated  
4   Stop Stop 
5   Stop Stop 
6   Stop Stop 
7     Stop 
8     Stop 
9     Stop 
10     Stop 
 
[IP_ADDRESS].  Futility evaluation  
Once an arm transitions through the initial safety evaluation as described above, 
additional participants will be enrolled to that arm, up to a maximum of 15 participants to 
provide f urther evaluation of safety and tolerability and:  
1. Preliminary PK/pharmacodynamic characteristics (i.e., measures of target 
engagement and functional effects such as receptor occupancy and cytokine 
release) and  
2. Evaluation of antitumor activity.  
In these participants, tumor biopsy at Screening and Week 7 will be requir ed (refer to 
SOA tables for each arm Section 12.1 or further details).  
An interim evaluation of futility in terms of ORR will be conducted after the first [ADDRESS_100395] assessments.  A maximum of 15 
participants will be enrolled to allow for 10 evaluable participants to be assessed for 
futility. If no objective responses are observed in 10 evaluable participa nts, development 
of the experimental regimen may be stopped. Decisions will be made after evaluation of 
other endpoints and will be based on the totality of data, including the Disease Control 
Rate endpoint.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
142 Table 26 Planned Dose Levels for Feladilimab and Ipi[INVESTIGATOR_90920] (mg/kg)  Feladilimab 
([COMPANY_004]3356909) (mg)  Safety (n)  PK/PD (n)  Total (n)  
1 1 24 3-6 6-19 9-25 
2 3 24 3-10 N/A 3-10 
 
The ipi[INVESTIGATOR_90921] 3mg/kg dose in combination with 
feladilimab 24 mg. If the 3mg/kg ipi[INVESTIGATOR_90922], a second cohort of 3 -10 participants will be dosed at 
1mg/kg ipi[INVESTIGATOR_90923] 24 mg feladilimab to explore a lower dose.  
[IP_ADDRESS].  Dose Limiting Toxicity  
The severity of all toxicities will be graded using National Cancer Institute - Common 
Terminology Criteria for Adverse Events (NCI -CTCAE) (version 5.0) [ NCI, 2017]. The 
DLT observation period is [ADDRESS_100396] one of the criteria listed in Table 27 and is 
considered by [CONTACT_91039] (probably or 
possibly) to the study treatment during the 21 -day DLT observation perio d. An AE 
considered related to the underlying disease under study it is not defined as a DLT. A 
safety event can still be included for DLT consideration after the 21 day window.  
 
Table 27 Dose -Limiting Toxicity  Criteria  
Toxicity  DLT Definition  
Hematologic  • Febrile neutropenia as defined by [CONTACT_3989]  v5 
• Grade 4 neutropenia of >7 days in duration or requiring  G-CSF 
• Grade 4 anemia of any duration  
• Grade  4 thrombocytopenia  of any duration or Grade  3 thrombocytopenia with  bleeding  
Non- hematologic  • Grade 4  toxicity  
• Grade 3 pneumonitis of any  duration  
• Grade  3 toxicity  that does  not resolve  to ≤Grade  1 or baseline  within  3 days despi[INVESTIGATOR_90924] 
• Any Grade 2 ocular toxicity requiring systemic steroids, or any ≥ Grade 3 ocular  toxicity  
• Following events are not considered  DLTs  
o Grade  3 and Grade  4 asymptomatic  electrolyte  abnormalities  that are corrected within 
24 hours without clinical  sequelae  
o Grade 3 nausea, vomiting, or fatigue that resolves to 
 Grade 1 within 7 days with 
optimal supportive care  
o Grade 3 and Grade 4 infusion reactions in participants not receiving prophylaxis for 
IRRs (refer to Section [IP_ADDRESS]  for detail s on IRR management)  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
143 Toxicity  DLT Definition  
Other  • Toxicity that results in permanent discontinuation of feladilimab monotherapy  or feladilimab 
and agent  in combination  during  the first four weeks of  treatment  
• Grade  3/Grade  4 toxicity  that results  in a participant  not receiving  the expected doses of a 
regimen in Cycle 1, defined by 21  days  
• Any other toxicity considered to be dose -limiting that occurs beyond  four weeks will be 
considered in the selection of the dose to recommend for expansion  cohorts  
• Any other  event  which  in the judgment  of the investigator  and [COMPANY_004]  Medical Monitor is 
considered to be a  DLT 
a. Suggested toxicity management guidelines as described in Section [IP_ADDRESS]  may include systemic corticosteroids 
for immune -related toxicities; if systemic corticosteroids use delays administration of the second dose of study 
treatment and the event does not otherwise meet the DLT criteria for  non- hematologic toxicity, the dose delay 
will not be considered a  DLT.  
CTCAE=Common Toxicity Criteria for Adverse Events; DLT = Dose -limiting toxicity; G -CSF =Granulocyte colony -
stimulating factor; [COMPANY_004] =GlaxoSmithKline; IRR=infusion related reaction  
 
If a participant experiences a DLT  during the DLT observation period, the participant 
may resume dosing provided the toxicity did not meet study treatment discontinuation 
criteria and following approval by [CONTACT_1034]. In cases where retreatment is considered, 
refer to Section [IP_ADDRESS].1  for selection of the dose and schedule of ipi[INVESTIGATOR_90925]. Participants may reduce the dose intensity of ipi[INVESTIGATOR_90926].  
 
Toxicity management and dose modification guidelines described in Section [IP_ADDRESS]  are 
provided for those AEs of special interest that, although not observed in nonclinical 
studies, may be expected with the administration of immune directed therapi[INVESTIGATOR_90927].  
 
Guidance for the identification, evaluation, and the established algorithms for the 
treatment management of immune -related adverse events (irAEs) including dose 
modification  algorithms  are provided  in Section  7.1 and Section  7.2. These  guidelines  are 
based on the experience of irAE management following the development of immune 
check -point inhibitors such as ipi[INVESTIGATOR_90928].  
 
If there is a delay in administration of study treatment, refer to Section [IP_ADDRESS]  for 
guidance on planning of subsequent study visits.  
 
[IP_ADDRESS].  Risk -Benefit Assessment for Ipi[INVESTIGATOR_90929] a first -in-class anti -ICOS  agonist antibody for the treatment 
of cancers of different histology. It is expected to differentiate from first generation 
immunomodulatory antibodies directed against Cytotoxic T -Lymphocyte -Associated 
Protein 4 (CTLA -4) and Programmed cell death protein  1 (PD -1)/PD -Ligand -1 (PD -L1) 
by [CONTACT_24096] a different axis in the antitumor T cell response cascade and promoting 
activation of a co -stimulatory receptor instead of blocking an inhibitory checkpoint 
receptor. The effect of ICOS agonist activity is to prom ote the expansion and function of 
cytotoxic CD8+, and effector CD4+ T cells, resulting in improved antitumor immune 
responses that are durable. Due to the restricted expression of ICOS on activated T cells, 
it is expected that feladilimab may result in a m ore favorable safety profile as compared 
TMF-[ADDRESS_100397]. Accordingly, as ICOS agonists stimulate IFN
  production which induces 
PD-L1 expression on tumor cells and within the tumor microenvironment [ Mimura , 
2018], this may facilitate the therapeutic benefit of PD -1/L1 blockade within tumors that 
have low levels of PDL1 expression. Several studies have underscored the co -expression 
of PD -1 and ICOS on tumor --infiltrating lymphocytes (TILs) and anti -PD-1-responsive 
peripheral T cells, as well as complementarity between inhibition of the PD -1/L1 axis and 
co-stimulation  via the ICOS/L axis [ Kamphorst , 2017; Gros , 2014; Beyrend , 2019]. 
Clinical studies and a series of nonclinical studies support the combination approach of 
an anti -ICOS agonist with immune checkpoint inhibitors  or other agents that modulate 
the immune system distinct from ICOS biology.  
Although there is no clinical experience with the combination of feladilimab with 
ipi[INVESTIGATOR_125], given the currently available safety data and the low likelihood of drug -drug 
interac tions between feladilimab with ipi[INVESTIGATOR_125], combination therapy may have an 
acceptable safety profile. Additionally, the combination may provide anti -tumor effect in 
participants with advanced NSCLC. The current nonclinical and clinical safety 
information f or feladilimab and ipi[INVESTIGATOR_125], used as single agents, provide support for 
their use in combination in the target patient population.  
This is the first study testing the combination of feladilimab with ipi[INVESTIGATOR_90930] e been treated with standard therapi[INVESTIGATOR_014]. Study 
participants may benefit from medical tests and screening performed during the study. 
Any potential benefit of the addition of ipi[INVESTIGATOR_90931]. Data 
obtained in this study may help identify  individuals more likely to benefit or have side -
effects from ipi[INVESTIGATOR_90932].  
Based on the status of ipi[INVESTIGATOR_188] a marketed product with documented anticancer 
activity and an acceptable safety profile and feladilimab as an agent with close t o a one 
thousand patient experience with preliminary signals of activity in NSCLC and a 
manageable toxicity profile, the potential benefit to risk is favorable to proceed with the 
combination in the context of a controlled monitored study with an initial s afety 
clearance and rule out futility screening to confirm the potential risks and benefits.  
 
The following sub sections outline the risks and mitigation strategies for this  
protocol for ipi[INVESTIGATOR_125]. Refer to the latest ipi[INVESTIGATOR_90933] (USPI) a nd the 
EU SmPC for additional details. Feladilimab risk assessment and mitigation  
strategies are in the master protocol (Section 3.3). 
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
145 Table 28 Risk Assessment and Mitigation Strategy: Ipi[INVESTIGATOR_90934]/Rationale for Risk  Mitigation Strategy  
Immune -related 
AEs 
 
 
 • Inflammatory AEs such as diarrhea/colitis, 
pneumonitis, nephritis, and hepatotoxicity 
are well established as treatment emergent 
AEs with immune -modulating agents and are 
consistent with the immune -stimulatory 
mechanism of action of these agents. (refer 
to the latest SmPC and/or USPI [INVESTIGATOR_90935] ) 
 • Participants with the following medical 
history are ineligible for this study  
o Toxicity (
 Grade 3) related to prior 
immunotherapy leading to study 
treatment discontinuation  
o Active autoimmune disease (refer to 
Section 6.2 exclusion criterion 6 ) 
o Severe hypersensitivity to another 
mAb 
• Established management algorithms for  
immune -related adverse events (irAEs)   
• Refer to Section [IP_ADDRESS]  for further 
details on the identification, evaluation, 
and management of toxicities with a 
potential immune etiology.  
Infusion and 
hypersensitivity 
reactions and 
potential CRS  • Risk for infusion reactions and 
hypersensitivity is inherent to many mAbs 
[Brennan , 2010] (refer to the latest SmPC 
and/or USPI [INVESTIGATOR_90936] ) 
 • Participants with history of severe 
hypersensitivity to another mAb or to the 
chemotherapi[INVESTIGATOR_90937].  
• Refer to Section [IP_ADDRESS]  for further 
details on management of infusion 
reactions.  
• Refer to Section [IP_ADDRESS]  for further 
details on management of CRS  
Immune complex 
disease  • Immune complex formation and deposition 
findings (refer to the latest SmPC and/or 
USPI [INVESTIGATOR_90936] ) • Clinical laboratory safety assessments 
and immunogenicity testing  
 
Table 29 below provides an outline of the risk assessment and mitigation strategy for 
[COMPANY_004]3359609 (feladilimab). More detailed information about the known and expected 
benefits and risks and reasonably expected adverse events of feladilimab may be found in 
the IB [[COMPANY_004] Document Number 2017N319717_03 ]. 
 
 
 
 
 
 
 
 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
146 Table 29 Risk Assessment and Mitigation Strategy [COMPANY_004]3359609 (feladilimab)  
Potential Risk of 
Clinical 
Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Immune -related 
AEs 
 
 
 • Inflammatory AEs such as diarrhea/colitis, 
pneumonitis, nephritis, and hepatotoxicity 
are well established as treatment emergent 
AEs with immune -modulating agents and are 
consistent with the immune -stimulatory 
mechanism of action of these agents.  
 • Partici pants with the following medical 
history are ineligible for this study  
o Toxicity (Grade 3) related to prior 
immunotherapy leading to study 
treatment discontinuation  
o Active autoimmune disease (refer to 
Section 6.2 exclusion criterion 6 ) 
o Severe hypersensitivity to another 
mAb 
• Established management algorithms for 
immune -related adverse events (irAEs)  
• Refer to Section [IP_ADDRESS]  for further 
details on the identification, evaluation, 
and management of toxicities with a 
potential immune etiology.  
Infusion -related 
reactions (IRRs) 
which include 
hypersensitivity 
and potential 
cytokine release 
syndrome (CRS)  • Risk for infusion reactions and 
hypersensitivity is inherent to many mAbs 
[Brennan , 2010]  
• The overall rate of IRRs with feladilimab is 
low and there have been no cases of CRS 
observed across the clinical program of 
feladilimab [[COMPANY_004] Document Number 
2017N319717_03 , 2020].  
 • Participants with history of severe 
hypersensitivity to another mAb or to the 
chemotherapi[INVESTIGATOR_90937].  
• Refer to Section [IP_ADDRESS]  for further 
details on management of infusion 
reactions and details on CRS 
management.  
Immune complex 
disease  • Immune complex formation and deposition 
findings in nonclinical safety studies [ [COMPANY_004] 
Document Number 2017N319717_03 , 2020]  • Clinical laboratory safety assessments 
and immunogenicity testing  
Abbreviations: AE = adverse event; IB = Investigator’s Brochure; ICOS = inducible T -cell co -stimulator; LPS = 
lipopolysaccharide; mAb = monoclonal antibody; TCR = T -cell receptor.  
 
[IP_ADDRESS].  Additional Study Population Criteria: Arm 3  
None.  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
147 [IP_ADDRESS].  References  
Beyrend, G., et al., PD-L1 blockad e engages tumor -infiltrating lymphocytes to co -express 
targetable activating and inhibitory receptors. J Immunother Cancer, 2019. 7(1): p. 217.  
Fan X, Quezada SA, Sepulveda Ma, Sharma P, Allison JP. Engagement of the ICOS 
pathway markedly enhances efficacy  of CTLA -4 blockade in cancer immunotherapy. J 
Exp Med. 2014; 211:715 -725. 
Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor 
responses mediated by [CONTACT_14181] -CTLA -4 therapy. Cancer Res. 2011; 71:5445 -5454.  
Gros A., et al., PD-1 ident ifies the patient -specific CD8(+) tumor -reactive 
repertoire infiltrating human tumors. J Clin Invest, 2014. 124(5): p. 2246 -59. 
Hanaizi Z, van Zwieten -Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, et al. 
The European Medicines Agency review of ipi[INVESTIGATOR_134] (Yervoy) for the treatment of 
advanced (unresectable or metastatic) melanoma in adults who have received prior 
therapy: summary of the scientific assessment of the Committee for Medicinal Products 
for Human Use. Eur J Cancer, 2012   
Hutloff A, Dittri ch AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, et al. 
ICOS is an inducible T cell co -stimulator structurally and functionally related to CD28. 
Nature. 1999; 397:[ADDRESS_100398], A.O., et al., Proliferation of PD -1+ CD8 T cells in periphe ral blood after 
PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A, 2017. 114(19): 
p. [ADDRESS_100399] in gastric  cancer. Cancer Sci. 
2018; 109: 43 -53. 
Sharpe AH, Freeman GJ. The B7 -CD28 Superfamily. Nat Rev Immunol. 2002; 2:[ADDRESS_100400] C. Convergent and divergent effects of costimulatory 
molecules in conventional and regulatory CD4+ T cells. PNAS. 2013; 110:1023 -1028.  
YERVOY [Prescribing Information]. Princeton, NJ. Bristol -Myers Squibb Company; 
2020.  
YERVOY [ Summa ry of Product Characteristics ]. Dublin, Ireland. Bristol -Myers Squibb 
Company; 2020.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
148 12.1.4.  Arm 4: [COMPANY_004]4428859A (Anti -TIGIT) and Dostarlimab (Anti -PD-1) 
Combination  
[IP_ADDRESS].  Protocol Amendment 9 Summary of Changes Specific to [COMPANY_004]4428859A 
and Dostarlimab Arm  
Section # and Name  [CONTACT_91084] [IP_ADDRESS]  
(Table 30, Table 31 
and Table 32) 
Dose modification and 
Management 
Guidelines (Section 
[IP_ADDRESS]  and Table 
34) 
 
 
 
 
 
 
 
 
 
 Addition of text to clarify 
that the following 
investigations will require a 
Cardiologist or locally 
appropriate specialist 
review;  
1.  
 
  
  
 
 
 
 
 
 
 
  
Addition of text to clarify 
that t he Sponsor will need to 
be informed regarding these 
participants  
Addition of text to clarify 
that investigators are 
required to review all safety 
laboratory assessments 
before dosing. .  Modifications were made to 
provide additional monitoring 
requirements and management 
of cardiac abnormalities in the 
event of  
 
 
 
 
 
Section [IP_ADDRESS]  and 
Table 38  
  
 
  
 
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
149 Protocol Amendment 8 Summary of Changes Specific to [COMPANY_004]4428859A and 
Dostarlimab Arm  
Section # and Name  [CONTACT_91084] [IP_ADDRESS]  
(Table 30, Table 31 
and Table 32) 
Schedule of Activities 
Section [IP_ADDRESS]  
(Table 31 and Table 
32) 
Dose modification and 
Management 
Guidelines (Section 
[IP_ADDRESS]  and Table 
34) 
 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
150 Protocol Amendment 7 Summary of Changes Specific to [COMPANY_004]4428859A and 
Dostarlimab Arm  
 
Section #  and Name  [CONTACT_91084] [IP_ADDRESS] 
(Table 31 and Table 
32) 
 
Protocol Amendment 6 Summary of Changes Specific to [COMPANY_004]4428859A and 
Dostarlimab Arm  
Section  # and Name  [CONTACT_91084] [IP_ADDRESS]  
(Table 31)  Removed the timing 
between infusions  Moved details of timing 
between infusions to the 
Pharmacy Manual to allow 
flexibility as new data from 
ongoing studies become 
available  
Schedule of Activities 
Section [IP_ADDRESS]  
(Table 31)  Updated assessment 
title/heading of whole blood 
to specify flow cytometry  To clarify the intent for the 
whole blood sample  
Schedule of Activities 
Section [IP_ADDRESS]  
(Table 31)  Updated note # 17, under the 
IRR sample  To clarify when an IRR 
sample is required to be taken  
Schedule of Activities 
Section [IP_ADDRESS]  
(Table 32 ) Included a [ADDRESS_100401] from 
regulatory agency to include 
safety lab assessments during 
follow up  
Schedule of Activities 
Section [IP_ADDRESS]  
(Table 32)  Updated the time window 
for treatment discontinuation 
visit to specify it is within To clarify the time window 
and align with the footnote 
included in the SOA  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
151 Section  # and Name  [CONTACT_11029]  
30 days of study treatment 
discontinuation  
Clinical Safety 
Summary: 
[COMPANY_004]4428859A 
Section [IP_ADDRESS] .1 Added number of  
participants ), showing 
favorable results in Phase 1 
dose-finding study of 
[COMPANY_004]4428859A  To include omitted data  
Dose Justification: 
[COMPANY_004]4428859A 
Pharmacokinetics and 
Pharmacodynamics  
Section [IP_ADDRESS].1  Corrected t1/[ADDRESS_100402] typo 
Study Treatments 
Section 12.1.4. 7 Removed the timing for 
observation after completion 
of study treatment 
administration  Moved details of observation 
period to the Pharmacy 
Manual to allow flexibility as 
new data from ongoing studi es 
become available  
Dose Modification and 
Management 
Guidelines Section 
[IP_ADDRESS]  To include the most recent 
safety data from the ongoing 
FTIH study  
Dose Modification and 
Management 
Guideline Section 
[IP_ADDRESS]  Table 34: Corrected Grade 0 
for AEs to AEs resolved  To align with grading of AEs 
as there is no Gra de 0 
[COMPANY_004]4428859A Dose 
Rationale (Arm 4) 
Section [IP_ADDRESS].2  Updated language around 
the dose rationale  for in vitro 
evaluation of [COMPANY_004]4428859  Corrected prior error in 
information reported to align 
with Investigator Brochure  
Dose Limiting 
Toxicity Section 
[IP_ADDRESS]  To clarify that the time 
window is after completion of 
the DLT period  
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
152 Section  # and Name  [CONTACT_91087]-Benefit 
Assessment of 
[COMPANY_004]4428859A and 
Dostarlimab combined  
12.1.[ADDRESS_100403] sample 
in the case of an infusion 
reaction  
Additional Inclusion 
Criteria: Arm 4 
Section [IP_ADDRESS].1  Added inclusion criteria:  
-Male contraception is not 
required for this arm  To update contraception 
requirements for males 
participating in this arm  
All Sections  Defined abbreviations  Added abbreviations that were 
omitted in error  
 
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
153 [IP_ADDRESS].  Schedule of Activities Specific to the [COMPANY_004]4428859A and Dostarlimab Combination  
The timing and number of planned study assessments (including safety, pharmacokinetic, ADA, biomarker or other assessments) m ay 
be altered during the cours e of the study based on newly available data.  
Table 30 Schedule of Activities – Screening Arm 4: [COMPANY_004]4428859A and Dostarlimab Combination  
Screening Study Assessments  Screening1  Notes  
Visit Window  ≤[ADDRESS_100404] be performed within 4 weeks (28 days) prior to first dose of study treatment 
unless otherwise specified. The informed consent may be signed within [ADDRESS_100405] dose.  
Participant Registration2 X 2. Participants will be  registered in RAMOS NG at screening.  
Inclusion/Exclusion Criteria  X Review eligibility prior to randomization.  
Demographics, Medical History (including 
alcohol and tobacco use), Prior Medications, 
Disease History12 X 12. All known mutations should be entered in the eCRF as disease history.  
Prior Anticancer Treatment, Radiotherapy  X  
Screening Safety  
AE/SAE/AESI Assessment3 X 3. Any AESI or SAEs assessed as related to study participation (e.g., study treatment, protocol -mandated 
procedures, invasive tests, or change in existing therapy) or related to a [COMPANY_004] product will be recorded from the time 
a participant consents to participate in the study. After the initial AE/SAE report, the investigator is required to 
proactively follow each participant at sub sequent visits/contacts.  Refer to Section 9.[ADDRESS_100406] review for participants with  potentially significant ECG 
abnormalities such as AV block (except for first degree), new cardiac arrhythmias, or frequent PVCs. Please inform 
the Sponsor regarding these participants.   
Echocardiogram or MUGA scan5 X 5. ECHO required at Screening within [ADDRESS_100407] dose of study treatment, and during treatment phase if 
clinically indicated. MUGA scan may be used if ECHO not feasible.  
Screening Local Laboratory Assessments (Safety)  
Hepatitis B and C6 X  
Serum β -hCG (for women of childbearing 
potential)  ≤3d  
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
154 Screening Study Assessments  Screening1  Notes  
Visit Window  ≤[ADDRESS_100408] dose 
of study intervention or SoC, repeat testing at screening is not required; otherwise, this testing is mandatory.  
Calculated CrCl7 X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90872] -Gault formula. See Appendix 9 . 
Urinalysis6 X  
Screening Other Laboratory Assessments  
PD-L1 expression by [CONTACT_4658]8 X 8. PD -L1 expression by [CONTACT_91001] (i.e., Ventana SP263, Ventana SP142, Dako 28 -8, or Dako 
22C3) must be recorded in the eCRF, if known . Note: Test is not required to be performed by [CONTACT_91040].  
Screening Disease Assessments   
Tumor Imaging9 X 9. Diagnostic quality CT scan of chest and abdomen with contrast must be obtained within [ADDRESS_100409] dose. 
Baseline brain scan (MRI with and without IV gadolinium) should be obtained within [ADDRESS_100410] dose if clinically 
indicated. See additional information regarding bone scans in Section 9.3.1 . 
Pre-Baseline scans for Tumor Growth 
Kinetics10 X 10. Upon participant consent, up to 3 pre -baseline scans (within 12 months before the baseline scan) will be 
collected to assess tumor growth rate to support exploratory investigation of tumor growth kinetics (See Section 
9.3.2  for details on images for submission).  
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
155 Screening Study Assessments  Screening1  Notes  
Visit Window  ≤4 Wks   
Screening Tumor Biopsies  
Fresh tumor tissue sample and Archival 
tumor11 X 
 
Abbreviations : AE = adverse event; AESI = adverse events of special interest; β -hCG = β -human chorionic gonadotropin; BNP = B-type natriuretic peptide; CKD -EPI = chronic 
kidney disease epi[INVESTIGATOR_8261]; CrCl = creatinine clearance; CT = computed tomography; ECG = electrocardiogram; EC HO = echocardiography; ECOG PS = Eastern 
Cooperative Oncology Group performance statu s; eCRF = electronic case report form; IHC = Immunohistochemistry; IWRS = interactive web response system; MRI = magnetic 
resonance imaging; MUGA = multi -gated acquisition; NT-pro-BNP = N-terminal pro -hormone  BNP; SAE = serious adverse event.  
 
CCI
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
156 Table 31  Schedule of Activities – Treatment Period Experimental Arm 4: [COMPANY_004]4428859A (Anti -TIGIT) and Dostarlimab (Anti -
PD-1) Combination  
On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
Inclusion/Exclusion 
Criteria  X            
Concomitant Medications  X X X X X X X X X X X  
Participant 
Randomization1 X           1. Once determined to be eligible, 
participants must be randomized via IWRS. 
Drug shipments will be managed via IWRS. 
Sites must allow up to 7 business days for 
shipment of study drug. Randomization can 
be done prior to Day 1, but no more than 3 
days prior to Day 1. (Refer to SRM).  
Study treatments1 
Administer Dostarlimab2 X X X X X X X X X X Q3W   
 
 
  
 
 
Refer to Section 5.2 for maximum duration 
of study treatment.  
On Treatment Safety  
AE/SAE/AESI 
Assessment3 X X X X X X X X X X X 3. After the initial AE/SAE report, the 
investigator is required to proactively follow 
each participant at subsequent 
visits/contacts. Refer to Section 9.4.1  for 
further details.  
ECOG PS**  X X X X X X X X X* Q6W*  Q6W*  *Q6W procedures are counted starting from 
Week 25 (i.e. the first Q6W visit is Week 31, 
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
157 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
then Week 37, etc.) unless more frequent 
assessments are clinically indicated.  
Physical Examination**  X X X X X X X X X Q6W*  Q6W*  ** Physical examinations and ECOG may be 
performed within 24 hours prior to dosing 
(i.e., as opposed to the day of dosing), if 
necessary.  
Vital Signs and Weight4 X X X X X X X X X X X 4. Vital signs include blood pressure, 
temperature, pulse, respi[INVESTIGATOR_697], and 
oxygen saturation. Weight is to be recorded 
at every other treatment visit in kilograms. 
Vital signs are to be performed predose on 
treatment days. Refer to Section 9.5.3 . 
If a participant experiences an infusion -
related reaction, refer to Section [IP_ADDRESS].1  
for guidance on vital signs monitoring.  
12-lead ECG * X X X X X X X X X X X* * Perform at every dosing visi t (may be 
performed within 24 hours prior to dosing).  
Results must be reviewed before  dosing  
Cardiologist  or locally appropriate specialist 
review may be required if abnormal results 
are obtained and confirmed as described  in 
Table 34 . 
 
On Treatment Local  Laboratory Assessments (Safety) – assessments may be performed up to 3 days prior to treatment  
Serum β -hCG (for 
women of childbearing 
potential)[ADDRESS_100411] of 
required assessments. Laboratory testing 
may be performed one day prior to dosing if 
necessary. Not required to be tested on  Day 
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
158 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
[ADDRESS_100412] dose.  
 
 
Thyroid function tests    X  X  X  X* Q6W*  Q6W*  *Q6W procedures are counted starting from 
Week 25 (i.e. the first Q6W visit is Week 31, 
then Week 37, etc.).  
Calculated CrCl7 X X X X X X X X X X X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90938] -Gault formula. Either formula is 
acceptable and must be consistently utilized 
for each participant throughout the study. 
See Appendix 9 . 
Urinalysis   X X X X X X X X X X  
On Treatment Disease Assessments  
Tumor 
Imaging/Response 
Assessment8   X  X  X  X X8 8. Diagnostic quality CT scan of chest and 
abdomen with contrast is required every 6 
weeks (±1 week) until Week 49 and every 
12 weeks thereafter. Imaging/clinical 
assessments should be performed as 
indicated in Section 9.2. The same method 
of assessment is required throughout the 
study. Brain scan (MRI with and without IV 
gadolinium) and bone scan to be performed 
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
159 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
as clinically indicated during the trea tment 
period. If a participant has achieved a PD, 
CR, or PR in the previous radiologic 
assessment, a repeat scan should be 
performed after at least 4 weeks to confirm 
the response.  
On Treatment Patient -Reported Outcomes/Health -Related Quality of Life: Part 2 ONLY  
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
160 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
On Treatment Biomarkers  
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
161 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
On Treatment Tumor biopsies  
Fresh tumor tissue 
sample13   X13    X19     
On Treatment Pharmacokinetics and Anti -Drug Antibodies (ADA)  
[COMPANY_004]4428859A PK*14 
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
162 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
           17. Assessment required in participant 
experiencing anaphylaxis, serious 
hypersensitivity, or in the occurrence of an 
infusion reaction/CRS of any grade. 
Samples should be drawn during the 
occurrence of the event. Only if not possible 
to collect at the occ urrence of the event, 
samples should be drawn as soon as 
possible after the event and within 24 hours 
(Refer to Section [IP_ADDRESS] ).Refer to Table 3 
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
163 On Treatment Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
for list of analytes. Predose analysis will be 
performed on the serum sample collected 
for [COMPANY_004]4428859A and/or dostarlimab 
immunogenicity assessments.  
On Treatment Pharmacogenetics  
Genetic research18 X           18. Informed consent for optional genetic 
research must be obtained before collecting 
this sample. It is recommended that the 
optional research sample be taken at the 
first opportunity after a participant has met 
all eligibility requirements before Day 1 or on 
Day 1.  
 
Abbreviations : ADA = Anti -drug antibody; AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; BNP = B-type natriuretic 
peptide; CKD -EPI = Chronic kidney disease epi[INVESTIGATOR_8261]; CR = complete response; CrCl = Creatinine clearance; CT = computed t omography; CTCAE = Common 
Terminology Criteria for Adverse Events;  ECG = Electrocardiogram;  ECOG  PS = Eastern Cooperative Oncology Group performance status; EOI = End of infusion; 
 
 IRR = infusion related reaction;  
; NT-pro-BNP =  N-terminal pro -hormone  BNP;  ; PD =  Progressive Disease;  
; PR = Partial response;  Pre =Predose;   
 SAE = Serious adverse event.  
Pre: predose sample to be  collected prior to dosing per institutional guidance, as long as it is collected prior to dosing of the corresponding agent;  EOI: End of infusion sample is  in 
reference to EOI of the corresponding agent.  
 
CCI
CCI
CCI
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
164 Table 32 Schedule of Activities – Treatment  Discontinuation Visit and Follow -Up Arm 4: [COMPANY_004]4428859A (Anti -TIGIT) and 
Dostarlimab (Anti -PD-1) Combination  
TDV and Follow Up 
Assessments  Treatment 
Discontinuation 
Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  within 30 days 
of study 
treatment 
discontinuation    
Anticancer Treatment   Q12W*  *If the participant dies before the first follow up, any subsequent anticancer therapy or radiotherapy should be 
recorded in the eCRF.  
 
 
Concomitant Medications  X   
TDV and  Follow Up Safety  
AE/SAE/AESI Assessment2 X  2. After the initial AE/SAE report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. Refer to Section 9.4.1  and Section 9.4.3  for further details.  
ECOG PS  X   
Physical Examination  X   
Vital Signs and Weight3 X  3. Vital signs include blood pressure, temperature, pulse, respi[INVESTIGATOR_697], and oxygen saturation.  
TDV and Follow Up Local Laboratory Assessments  
Clinical Chemistry  X X^  
Serum β -hCG (for women of 
childbearing potential)  X   Refer to Appendix  [ADDRESS_100413] of required laboratory assessments.  
^Safety laboratory assessments should be collected at TDV (within [ADDRESS_100414] dose of study treatment) 
and at [ADDRESS_100415]  dose of study treatment, unless the participant has started a new anti -cancer 
therapy within the 90 day follow -up period, in which case safety laboratory assessments are not applicable. Hematology  X X^ 
Coagulation  X  
Thyroid function tests  X X^ 
Calculated CrCl  X  
Urinalysis  X  
 
 
12-lead ECGa X  
TDV and Follow Up Disease Assessments  
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
165 TDV and Follow Up 
Assessments  Treatment 
Discontinuation 
Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  within 30 days 
of study 
treatment 
discontinuation    
Tumor Imaging/Response 
Assessment4 X  4. At the TDV, CT scan is required only if the last disease assessment did not show confirmed PD and was 
performed ≥[ADDRESS_100416]. 
See additional information in Section 9.3.1  
Telephone call for survival status1a  Q12W   
TDV and Follow Up Tumor Biopsies  
Fresh tumor tissue sample  X5  5. If possible, obtain an optional  tumor tissue sample at time of confirmed PR or PD.  
TDV and Follow Up Patient -Reported Outcomes/Health -Related Quality of Life: Part 2 ONLY  
  
 
  
 
 
 
 
 
 
TDV and Follow Up Biomarkers  
TDV and Follow Up Pharmacokinetics and Anti -Drug Antibodies (ADA)  
CCI
CCI
CCI
TMF-16073217  CONFIDENTIAL  205801  
  Protocol Amd 10  
166 Abbreviations : ADA = Anti -drug antibody; AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; BNP =  B-type natriuretic 
peptide;  CR = complete response; CrCl = Creatinine clearance; CT = computed tomography; CTCAE = C ommon Terminology Criteria for Adverse Events; ECG = 
Electrocardiogram; ECOG PS = Eastern Cooperative Oncology Group performance status; eCRF = Electronic case report form;  
 
; NT-pro-BNP =  N-terminal pro -hormone  BNP;  PBMC = 
peripheral mononuclear cells; PD = Progressive Disease; ; 
 
; SAE = Serious adverse event; TDV = Treatment Discontinuation Visit  
1. The assessments required at the study treatment discontinuation visit must be completed within [ADDRESS_100417]. Participants will be contact[CONTACT_457] 12 weeks (±7 days) until death or participant’s withdr awal from further contact. Subsequent anticancer 
treatment and death date will be documented in the eCRF  
.
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
167 [IP_ADDRESS].  Rationale for the [COMPANY_004]4428859A (Anti -TIGIT) and Dostarlimab (Anti -PD-
1) Combination  
Multiple immune checkpoints in addition to PD -(L)1 may regulate T cell anergy and 
modulate antitumor immunity [ Topalian , 2011; Mellman , 2011]. Co -regulatory receptors 
expressed on T cells can induce stimulatory or inhibitory signaling cascades that 
modulate T cell proliferation, cytokine production, and cytotoxic T cell activation. 
Proteins of the nectin and nectin -like (Necl1) family, i ncluding TIGIT (T cell 
immunoglobulin and immunoreceptor tyrosine -based inhibition motif  domain), PVRIG 
(Poliovirus Receptor -related Immunoglobulin Domain Containing), and CD96, have 
emerged as immune -suppressing candidates that may prevent immune reactiva tion after 
PD-(L)1 blockade. These co -regulatory receptors modulate the CD226 immune 
checkpoint, which is one of the major activating receptors for natural killer ( NK) cells.  
TIGIT interaction with the ligand CD155 downregulates cytotoxic T and NK cells an d is 
a critical regulator of antitumor T cell immunity [ Harjunpää , 2020]. TIGIT may regulate 
antitumor immunity through a variety of mechanisms: by [CONTACT_91041], impairing T cell priming by [CONTACT_405], or inhibiting CD8+ 
effector tumor cell killing [ Harjunpää , 2020; Johnston , 2014; Joller , 2014]. The 
interaction of TIGIT with its complementary costimulatory receptor, CD226, is 
analogous to the interaction of CTLA -4 and CD28. TIGIT competes with CD226 for its 
main ligand, CD155 [ Stengel , 2012; Johnston , 2014], modulating antitumor  immunity 
through multiple mechanisms. Binding of TIGIT on T  cells with CD155 ligand on 
dendritic cells impairs CD4+ T cell function [ Chauvin , 2020]. In ad dition, binding of 
TIGIT prevents homodimerization and activation of CD226 on CD8+ T cells [ Johnston , 
2014]. TIGIT also interacts weakly with other co-regulatory inhibitors of the CD226 
pathway including CD112, CD113, and CD114.  
TIGIT is highly expressed on murine and human tumor infiltrating T cells [ Johnston , 
2014]. In human tumor specimens from the Cancer Genome Atlas (TCGA [ NCI, 2021]), 
TIGIT expression is upregulated in a broad range of solid tumors [ Johnston , 2014]. 
TIGIT is upregulated on tumor infiltrating CD8+ T cells and a population of infiltrating 
CD4+ T  cells in solid tumors in comparison to per ipheral T  cells from patients and 
normal donors. CD8+ and CD4+ TIGIT -expressing T cells also co -express PD -1. 
In NSCLC, TIGIT was expressed in tumor -infiltrating CD8+ and CD4+ T cells and was 
co-expressed with PD -1 [Johnston , 2014]. Peripheral CD8+ and CD4+ T cells from 
NSCLC tumor donors had higher levels of TIGIT compared with healthy donors. In 
addition, in patients with NSCLC, the expression of PD -1 was higher in TIGIT+ cells 
than in TIGIT - cells in both circulating CD8+ T cells and tumor infiltrating CD8+ T cells 
[Hu, 2020]. TIGIT could act as a checkpoint inhi bitor in exhausted tumor -infiltrating T 
cells.  
 
EOS884448 (also known as EOS -448; hereafter referred to as [COMPANY_004]4428859A) is a fully 
human IgG1 mAb that prevents TIGIT -ligand binding. As an IgG1, [COMPANY_004]4428859A also 
displays a potent affinity for the FcγRs with  the potential to mediate antibody -dependent 
cellular cytotoxicity/phagocytosis ( ADCC/P ) against TIGIT expressing cells. Binding of 
[COMPANY_004]4428859A  to TIGIT was shown to increase T cell activation by [CONTACT_91042]- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
168 TIGIT ligands. [COMPANY_004]4428859A  (or its mouse surr ogate for rodent studies) mediates 
ADCC/P of immunosuppressive cells by [CONTACT_91043] a high level of TIGIT relative to cytotoxic CD8 or NK cells, resulting 
in an increased ratio of effector CD8+/immunosuppre ssive Treg cells. Moreover, this 
effect was abrogated in mice lacking FcγRs, further suggesting the requirement for an 
ADCC/P effect to fully induce tumor growth inhibition. Overall, these data demonstrate 
that [COMPANY_004]4428859A  restores antitumor immunity by [CONTACT_91044], PVR/CD155 and Nectin2/CD112, and induces a strong immune 
response mediated by [CONTACT_91045]/P [ Preillon , 2021].  
Dostarlimab (formerly referred to as TSR -042) is an IgG4 -k humanized monoclonal 
antibody that binds with high affinity to PD -[ADDRESS_100418] antibodies inhibits tumor growth in 
murine tumor models, either alone or in combination with immune c heckpoint inhibitors 
like anti -PD-(L)1 [ Johnston , 2014; Zhang , 2018; Hung , 2018; Guille rey, 2018; Dixon , 
2018; Minnie , 2018; Minnie , 2019]. Activation of PD -1 signaling dephosphorylates and 
inactivat es CD226 via an intracellular SH2 -containing protein tyrosine phosphatase 2 
domain. Combined blockade of TIGIT and PD -1 can synergize to promote antitumor 
immune response and overcome resistance to immunotherapy in a variety of tumor types 
in nonclinical m odel systems. In a nonclinical mouse model system of CT26 CRC, anti -
TIGIT or anti -PD-L1 antibodies alone were insufficient to decrease tumor burden, 
however the combination of anti -PD-1 and anti -TIGIT blocking antibodies caused tumor 
regression with the ma jority of mice achieving a complete response [ Johnston , 2014]. 
Mice bearing CT26 tumors treated with anti -TIGIT and anti -PD-L1 agents in 
combination had improved survival compared with control or monotherapy treated mice. 
Combined TIGIT and PD -1 blockade in mice with established MC38 CRC demonstrated 
tumor regression and tumor clearance compared with monotherapy and control treatment 
[Dixon , 2018]. Combination treatment with anti -TIGIT and anti -PD-1 agents resulted in 
increased production of inflammatory cytokines including IL -2, IFN, and TNF  by 
[CONTACT_398]4+ and CD8+ tumor infiltrating lymphocytes compared with either therapy alone, 
suggesting that combined blockade of TIGIT and PD -[ADDRESS_100419] the potential for synergy between anti -PD-(L)[ADDRESS_100420] tested dose of 
mg/kg.  
 
[IP_ADDRESS].   Clinical Safety Summary  
[IP_ADDRESS].1.   [COMPANY_004]4428859A  
Several mAbs targeting TIGIT are in various stages of clinical development. These 
agents include tiragolumab, vibostolimab, domvanalimab, etigilimab, and 
[COMPANY_004]4428859A , among  an increasing number of others.  
A Phase 1b study of vibostolimab monotherapy in pa rticipants with advanced solid tumor 
types previously treated with anti -PD-(L)1 therapy reported a 3% ORR and 35% DCR 
[Golan , 2018]. In a Phase  1a/Phase  1b st udy of tiragolumab as a single agent and in 
combination with atezolizumab in advanced solid tumors, there were no objective 
responses in 24  participants treated with tiragolumab monotherapy [ Bendell , 2020]. The 
[ADDRESS_100421], ovarian, endometrial, melanoma, and other 
cancer diagnosis [ Bendell , 2020]. The ORR for etigilimab in the dose -escalation phase 
was 0%, with a DCR of 30% in a Phase 1a/Phase 1b study of etigilimab in participants 
with advanced solid tumors [ Sharma , 2018]. A Phase [ADDRESS_100422] 
preliminary ef ficacy in 20 participants with advanced solid tumors, with an ORR of 5% 
[Van den Mooter , 2021].  
The safety profile of anti -TIGIT mAbs has been t olerable and comparable to that of other 
single -agent immune checkpoint inhibitors. In the vibostolimab Phase 1b study of 
immune checkpoint inhibitor -experienced participants, 59% of participants experienced 
any treatment -related adverse event (TRAE) with Grade ≥3 TRAEs in 15% of 
participants in the vibostolimab monotherapy arm. The most common TRAEs reported 
were fatigue (22%) and rash (20%). One participant (2%) had a TRAE that led to 
discontinuation and none experienced a fatal TRAE [ Golan , 2018]. In the Phase 1a 
dose-escalation phase of the tiragolumab study in 24 patients, there were no DLTs 
[Bendell , 2020]. TRAEs occurred in 67% of participants, Grade  3 TRAEs in 4% (Grade 
3 blood creatinine increase) and the most common AE reported was fatigue (38%). There 
were 6 SAEs reported (25%) with no AEs leading to study withdrawal or death [ Bendell , 
2020].  
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
170 [IP_ADDRESS].2.  Dostarlimab  
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
171 • Treatment -emergent SAEs regardless of causality were reported in % of 
participants; the most frequently reported % of partic ipants) were 
abdominal pain %), pneumonia %), and dyspnoea %). Treatment -
related SAEs were reported in 8.5% of participants; the most frequently 
reported % of participants) were pneumonitis %), adrenal 
insufficiency %), and pyrexia  %). 
• TEAEs leading to treatment discontinuation regardless of causality were 
reported in % of participants; the most frequently reported % of 
participants) were alanine aminotransferase increased %), aspartate 
aminotransferase increased %), pneumonitis %), and transaminases 
increased %). Treatment -related events leading to discontinuation were 
reported in % of participants; the most frequently reported % of 
participants) were alanine aminotransferase increased %), as partate 
aminotransferase increased %), pneumonitis %), and transaminases 
increased %).  
• TEAEs leading to death regardless of causality were reported in % of 
participants with respi[INVESTIGATOR_90939] >1 participant 
participants %]); % of the deaths were due to treatment -related 
TEAEs (completed suicide, hepatic ischaemia).  
Of the participants, % who received dostarlimab monotherapy experienced at 
least 1 immune -related TEAE (irAE). The most frequent % ) irAEs were 
hypothyroidism, diarrhea, alanine aminotransferase increased, aspartate aminotransferase 
increased, blood creatinine increased, hyperglycemia and amylase increased.  
participants %) who received dostarlimab monotherapy experien ced at least 1 irAE 
with severity of ≥Grade 3. For  participants with ≥Grade 3 irAEs, the AE was 
assessed as study drug related by [CONTACT_431].  
The safety profile of monotherapy dostarlimab in participants with advanced or recurrent 
solid tum ors was generally similar to the reported safety profiles of other mAbs blocking 
the PD -1 interactions ( KEYTRUDA  USPI, 2021; KEYTRUDA , SmPC, 2021; OPDIVO  
USPI, 2021; OPDIVO , SmPC, 2021).  
[IP_ADDRESS].   Anti-TIGIT and Anti -PD-1/PD -L1 Monoclonal Antibody Combinati ons in 
Clinical Studies  
Combinations with anti -TIGIT mAbs and anti -PD-1/PD -L1 mAbs have demonstrated 
improved antitumor efficacy while preserving acceptable side effect profiles. The 
combination of vibostolimab with pembrolizumab (an anti -PD-1 mAb) demonst rated a 
confirmed ORR of 24%, DCR of 36%, and a median DOR that was not reached 
(95%  CI: 4 to 17+ months) in participants with a variety of advanced solid tumors who 
were naïve to anti -PD-(L)1 therapy [ Niu, 2020]. Notably, even in participants who had 
previously received anti -PD-(L)1 therapy, the DCR was 50%, driven mostly by [CONTACT_91046] [ Ahn, 2020]. In a Phase 1b dose -escalation study, the combination of 
tiragolumab with atezolizumab (an anti -PD-L1 mAb) showed an ORR of 9% in 
participants with advanced solid tumors. In an expansion cohort of anti -PD(L)1 -naïve 
participants with PD -L1+ NSCLC, an ORR of 46% and a DCR of 85% were observed 
[Bendell , 2020].  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
172 The results from the aforementioned Phase 1b study led to th e Phase 2 CITYSCAPE 
study, a randomized, double -blind study of tiragolumab plus atezolizumab versus placebo 
plus atezolizumab in participants with PD -L1+ (TPS  ≥1%), treatment -naïve, locally 
advanced or metastatic NSCLC. In the CITYSCAPE study, a confirmed ORR of 37% for 
the combination arm compared with 21% for the placebo/atezoli zumab arm in the intent -
to-treat population (n=135) was reported [ Rodríguez -Abreu , 2020]. Median PFS was 
improved from 3.88 months (range: 2.73 to 4.53 months) with atezoli zumab to 5.5 
months (range:  4.2 to 10.4 months; HR: 0.58, 95% CI: 0.38, 0.89) for the combination. In 
58 participants with PD -L1-high (TPS ≥50%) tum ors, the confirmed ORR was 66% for 
the combination compared with 24% in the atezolizumab arm. The median PFS was not 
reached with the combination (95% CI: 5.49 to not evaluable [NE]) compared with 
4.11 months (95%  CI: 2.07, 4.73) for the atezolizumab arm ( HR for PFS: 0.3; 
95% CI: 0.15. 0.61). For participants with PD -L1 TPS 1 -49%, the ORR and PFS were 
similar across both arms (ORR: 18% with atezolizumab vs 16% with tiragolumab and 
atezolizumab; PFS: 3.58 months and 4.04 months, respectively [HR:0.89; 
95% CI: 0.53,  1.49]). The rates of TEAEs (99% vs 96%), Grade 3 AEs (48% vs 44%), 
Grade 5 AEs (5% vs 7%), SAEs (37% vs 35%), and AEs leading to treatment withdrawal 
(10% vs 9%) were all similar between the combination and placebo/atezolizumab arms, 
respectively;  there was a modest increase in AEs leading to dose modification in the 
combination arm (40% vs 28%). The overall rate of immune -mediated AEs (69% vs 
47%) and Grade 3 or 4 immune -mediated AEs (18% vs 13%) were higher in the 
combination arm [ Rodríguez -Abreu , 2020].  
Similar results have been observed with other anti -TIGIT mAbs and anti -PD-(L)1 
combinations, suggesting anti -TIGIT mAbs promote enha nced antitumor immune 
responses without a substantial increased risk of toxicity over single -agent immune 
checkpoint blockade [ Niu, 2020]. Vibostolimab in combina tion with pembrolizumab has 
demonstrated responses in participants with advanced NSCLC naïve to anti -PD-(L)1 
therapy both with and without PD -L1 expression [ Niu, 2020]. As a result, multiple 
Phase  [ADDRESS_100423] evaluating anti -TIGT and anti -PD(L)1 combination 
therapy in PD -L1+ NSCLC ([STUDY_ID_REMOVED]; [STUDY_ID_REMOVED]; [STUDY_ID_REMOVED]; 
[STUDY_ID_REMOVED]; [STUDY_ID_REMOVED]).  
The combination of [COMPANY_004]4428859A and dostarlimab is  supported by [CONTACT_91047] -targeting agents administered alone or in combination 
with anti -PD-(L)1 agents. In the dose -escalation phase, tiragolumab (an anti -TIGIT mAb) 
was administered at 2, 8, 30, 100, 400, 600, 1200  mg Q3W in combination with the anti -
PD-L1 agent, atezolizumab (1200 mg Q3W). No DLTs were observed across all doses 
(N=49). TRAEs occurred in 59% of participants and the most frequently reported TRAEs 
were Grade 1 pruritus, Grade 1 -2 fatigue, Grade 1 -2 rash, Grade 1 diarrhea, and Grade 1 
arthralgia. Two Grade 3 TRAEs were reported in the combination: 1 hyperlipasemia and 
1 lymphocyte count decreased. Infusion reactions were seen in 8% of participants, most 
were Grade 1/2. A higher rate of immune -relate d AEs (irAEs) was observed with the 
combination than with tiragolumab monotherapy [ Bendell , 2020]. In the Phase [ADDRESS_100424] -line 
atezolizumab at 1200 mg Q3W in PD -L1–selected metastatic NSCLC demonstrated good 
tolerability with a safety profile similar to placebo plus atezolizumab [ Rodríguez -Abreu , 
2020]. Vibostolimab (an anti -TIGIT mAb) demonstrated a tolerable safety profile across 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
173 the various doses tested alone and in combination with pembrolizumab (anti -PD-1, 200 
mg Q3W) in th e Phase 1b study (see Rationale Section [IP_ADDRESS]  for further details).  
[IP_ADDRESS].  Dose Justification  
[IP_ADDRESS].1.  [COMPANY_004]4428859A Pharmacokinetics and Pharmacodynamics  
[IP_ADDRESS].2.   [COMPANY_004]4428859A Dose Rationale (Arm 4)  
The [COMPANY_004]4428859A RP2D of mg is based on the preliminary safety, PK/PD, 
and efficacy data available from the Phase 1/Phase 2a clinical Study IO -002 
([STUDY_ID_REMOVED]), as well as observations from other clinical studies evaluating anti -
TIGIT mAbs which generally have similar properties [ Bendell , 2020; Rodríguez -Abreu , 
2020; Niu, 2020]. Additionally, Study TIG -[ADDRESS_100425] noted at 4.22 to 133 nM ( 0.623 to 20.0  µg/mL)  [Refer to Section 
[IP_ADDRESS].4  of the iTeos  EOS8844 48 [EOS -448] IB, 2021] . This target level has been 
confirmed in multiple functional assays, including ADCC, and translates to in vivo 
mouse studies  [Refer to Section [IP_ADDRESS].8 and Section [IP_ADDRESS].3 of the iTeos  EOS884448 
[EOS -448] IB, 2021] . Assuming a tumor tissue dilution of 20 -fold [ Shah , 2013] and 
dosing, µg/mL would result in tumor 
concentrations that would saturate TIGIT binding in the tumor. A preliminary population 
PK analysis of [COMPANY_004]4428859A FTIH data was conducted and simulations were 
performed to evaluate a variety of [COMPANY_004]4428859A doses and regimens for future studies. 
The simulated minimum serum concentration after the first dose and at steady state 
following mg is µg/mL and µg/mL, respectively  [Refer to Table 16 
of the iTeos  EOS884448 [EOS -448] IB, 2021] , both of which are within the range 
estimated to result in tumor concentrations that would saturate TIGIT binding.  
 
Based on these data, [COMPANY_004]4 428859A mg is considered an appropriate starting dose to 
combine with dostarlimab to minimize the risk of unacceptable toxicity and maximize the 
potential benefit to participants with NSCLC. Moreover,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
175 [IP_ADDRESS].3.  Dostarlimab Dose Rationale  
No reduction in dostarlimab dose is allowed given that the safety and efficacy profile of 
the included dose regimen for dostarlimab is considered acceptable, whereas the effica cy 
of lower doses is not fully characterized.  
[IP_ADDRESS].  Study Treatments  
Table 33 Description and Administration of Arm 4 [COMPANY_004]4428859A plus 
Dostarlimab (Anti -PD-1) Study Treatments  
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
176  
 
 (see 
pharmacy manual for administration instructions).  
All participants should remain under observation at the study site after the completion of 
study treatment administration  (refer to SRM for details). Section [IP_ADDRESS] , Table 35 for 
details on the management of participants experiencing infusion reactions. Refer to 
Section 5.2 for information on the duration of study treatment.  
The date and time of administration will be documented in the source documents and 
reported in the eCRF. For drug administered by [CONTACT_91048], the dose of 
study treatment and study participant identification will be confirmed at the time of  
dosing by a member of the study site staff other than the person administering the study 
treatment. The specific time of study treatment administration (e.g., time of the week for 
first administration; time of the day for each administration) should take into 
consideration PK sampling time points, study visit procedures, and the post -infusion 
observation time interval. Infusions may be administered up to 72 hours before or after 
the planned date of treatment for administrative reasons only (e.g., schedulin g an infusion 
around a holiday). Both drugs should be administered on the same day. The 72 -hour 
window does not apply to completion of study treatment administration interrupted by [CONTACT_91049]. Refer to Section [IP_ADDRESS]  for criteria governing dose interruptions or 
delays.  
Details on preparation and administration of [COMPANY_004]4428859A and dostarlimab are 
described in the pharmacy manual.  
[IP_ADDRESS].  Concomitan t Therapy  
Please refer to Section 7.7 
[IP_ADDRESS].  Treatment of Overdose  
[IP_ADDRESS].1.  [COMPANY_004]4428859A Overdose  
An overdose of [COMPANY_004]4428859A is defined as administration of a dose tha t is above 
mg.  
In the event of an overdose, the investigator must:  
[ADDRESS_100426] dose of 
study treatment if requested by [CONTACT_1689] (determined on a case -by-
case basis).  
4 Document the quantity of the excess dose as well as the duration of the 
overdosing in the eCRF.  
 
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
177 Decisions regarding dose interruptions or modifications will be made by [CONTACT_43208].  
There is no specific antidote for overdose with the experimental treatments being 
evaluated in this study. In the event of a suspected overdose, it is recommended that the 
appropriate supportive clinical care be instituted as dictated by [CONTACT_2299]’s clinical 
status.  
[IP_ADDRESS].2.  Dostarlimab Overdose  
Human data on overdose are not available. There is no known antidote for dostarlimab.  
 
An overdose of dostarlimab is defined as any dose that is ≥20% than mg
 
In the event of an overdose, the investigator mu st: 
[ADDRESS_100427] dose of 
study treatment if requested by [CONTACT_1689] (determined on a case -by-
case basis).  
4 Document the quantity of the excess dose as well as the duration of the 
overdosing i n the eCRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_43208].  
 
There is no specific antidote for overdose with the experi mental treatments being 
evaluated in this study. In the event of a suspected overdose, it is recommended that the 
appropriate supportive clinical care be instituted as dictated by [CONTACT_2299]’s clinical 
status.  
 
[IP_ADDRESS].  Treatment Duration for [COMPANY_004]4428859A and Dostarlimab  
Participants enrolled will be treated until disease progression, intolerable toxicity, 
informed consent withdrawal or death. Combination study treatment will continue to be 
administered at the indicated schedule for a maximum duration of up to  [ADDRESS_100428]. Refer to Section 5.2 for additional 
details regarding follow up after discontin uation of study treatment.  
 
[IP_ADDRESS].  Dose modification and Management Guidelines  
No dose reductions are allowed for dostarlimab. No dose reductions are allowed for 
[COMPANY_004]4428859A at the participant level. Dose modification guidelines for immune related 
adverse events are listed in Table 34. If study drugs must be held or discontinued for any 
CCI
CCI
TMF- [ADDRESS_100429] be held or discontinued, unless discussed otherwise with 
Medical Monitor.  
 
In case of any unforeseen toxicities for [COMPANY_004]4428859A occurring at the mg
dose cohort in combination, de -escalation to mg or a lower dose  may be 
considered at the cohort level, if needed.  
 
In addition to the immune -related adverse events listed in Table 34, immunotherapy may 
be associated with other irAEs, including events which may be less commonly associated 
with PD -(L)[ADDRESS_100430] current professional guidelines (e.g.: National 
Comprehensive Cancer Network [NCCN ], National Comprehensive Cancer Network 
[SITC ]) should be considered. Patients should receive appropriate supportive care 
measures as deemed necessary by [CONTACT_64372], including but not limited to 
the items outlined below:  
 
Table 34 Dose Modification and Toxicity Management Guidelines for Immune -
Related AEs  
General instructions : 
• Corticosteroid taper should be initiated upon AE improving to Grade [ADDRESS_100431] 4 weeks.  
• For situ ations where immunotherapy treatment has been withheld, treatment can be resumed after AE 
has been reduced to Grade [ADDRESS_100432] dose or corticosteroids 
cannot be reduced to ≤ 10 mg prednisone or equivalent per day within 12 weeks.  
• For severe and life -threatening irAEs, IV corticosteroid should be initiated first followed by [CONTACT_44874]. 
Other immunosuppressive tr eatment should be initiated if irAEs cannot be controlled by [CONTACT_13216].  
 
Immune -related AEs  Severity 
grade or 
conditions 
(CTCAEv5.0)  Action taken  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_90940] -up  
Respi[INVESTIGATOR_90941]- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
179 Immune -related AEs  Severity 
grade or 
conditions 
(CTCAEv5.0)  Action taken  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_90940] -up  
Gastrointestinal  
Diarrhea / colitis  
Hepatobiliary  
Hepatitis with no tumor 
involvement of the liver  
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
180 Immune -related AEs  Severity 
grade or 
conditions 
(CTCAEv5.0)  Action taken  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_90940] -up  
Hepatitis with tumor 
involvement of the liver**  
Endocrine  
Type 1 diabetes mellitus 
(T1DM) or Hyperglycemia  
 
Endocrinopathies (e.g. 
hypophysitis, hypo -
/hyperthyroidism, adrenal 
insufficiency)  
Renal  
Nephritis with renal 
dysfunction  
Cardiovascular  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
181 Immune -related AEs  Severity 
grade or 
conditions 
(CTCAEv5.0)  Action taken  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_90940] -up  
Cardiac Investigations  
i) ECG changes and/or ii) 
troponin and/ or NT -
proBNP/BNP elevations  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
182 Immune -related AEs  Severity 
grade or 
conditions 
(CTCAEv5.0)  Action taken  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_90940] -up  
Myocarditis  
Other  
Neurological Events 
(myasthenia gravis, Guillain -
Barré syndrome, encephalitis, 
transverse myelitis)  
All other immune -related 
AEs 
Skin Toxicities1 
Rash  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
183 Immune -related AEs  Severity 
grade or 
conditions 
(CTCAEv5.0)  Action taken  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_90940] -up  
Pruritis  
Exfoliative dermatologic 
conditions (e.g. SJS, TEN, 
DRESS)  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
184 Immune -related AEs  Severity 
grade or 
conditions 
(CTCAEv5.0)  Action taken  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_90940] -up  
NOTES :  
*Resume in patients with complete resolution or partial resolution  to Grade 1 after corticosteroid taper. Permanently 
discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone 
to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids.  
 
**If AST and ALT are less than or equal to  ULN at baseline in patients with liver involvement, withhold or 
permanently discontinue based on recommendations for hepatitis with no liver involvement.  
***Abnormal troponin and proNTBNP/BNP at screening is defined as any value >ULN at screening  
 
1. For any grade skin toxicities, recent alcohol intake or other potentially related concomitant exposures per 
Investigator assessment, should be recorded in the eCRF. Please refer to SRM for additional details.  
Abbreviations: BNP =  B-type natriuretic peptide;  SJS = Stevens -Johnson syndrome; TEN = toxic epi[INVESTIGATOR_194]; 
DRESS = drug reaction with eosinophilia and systemic symptoms.  
[IP_ADDRESS].1.  Dose Modification and Toxicity Management of Infusion -Reactions 
Related to Immunotherapy Treatment  
Table 35 Immunotherapy Infusion Reaction Dose Modification and Treatment 
Guidelines  
NCI CTCAE Grade  Treatment  Premedication at Subsequent 
Dosing  
Grade 1  
Mild reaction; infusion interruption 
not indicated; intervention not 
indicated  Increase monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_13046].  
Please refer to the pharmacy manual for 
administration details.  Participant may be premedicated 
1h (± 30 minutes) prior to infusion 
of study drugs with: 
Diphenhydramine 50 mg (or 
equivalent dose of antihistamine) 
and/or acetaminophen 325 -1000 
mg (or equivalent dose of 
analgesic)  
Grade 2  
Requires therapy or infusion 
interruption but responds 
promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDs, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hrs.  Stop Infusion.  
Additional appropriate medical therapy 
may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Increase monitor ing of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_13046].  Participant may be premedicated 
1h (± 30 minutes) prior to infusion 
of study drugs with:  
Diphenhydramine 50 mg (or 
equivalent dose of antihistamine).  
Acetaminophen 500 -1000 mg (or 
equivalent dose of analgesic).  
If necessary, corticosteroids (up 
to 25mg of hydrocortisone or 
equivalent) may be used and 
adaptation of the infusion rate 
should be di scussed with Medical 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
185 NCI CTCAE Grade  Treatment  Premedication at Subsequent 
Dosing  
If symptoms resolve within 1 hour of 
stoppi[INVESTIGATOR_13056], the infusion may 
be restarted at 50% of the original 
infusion rate ( e.g. from 100 mL/hr to 50 
mL/hr), unless otherwise specified in the 
pharmacy manual. Otherwise dosing will 
be held until symptoms resolve and the 
participant should be premedicated for 
the next scheduled dose.  
 
Participants who develop Grade 2 toxicity 
despi[INVESTIGATOR_90942].  
 
Please refer to the pharmacy manual for 
administration details.  Monitor.   
Grades 3 or 4  
Grade 3:  
Prolonged (e.g. not rapi[INVESTIGATOR_38194]/or interruption of 
infusion; recurrence of symptoms 
following initial improvement; 
hospi[INVESTIGATOR_38195] (e.g., renal 
impairment, pulmonary 
infiltrates))  
Grade 4:  
Life-threatening; pressor or 
ventilatory support indicated  Stop Infusion.  
Additional appropriate medical therapy 
may include but is not limited to:  
Epi[INVESTIGATOR_238]**  
IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Increase monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_13046].  
Hospi[INVESTIGATOR_13021].  
**In cases of anaphylaxis, epi[INVESTIGATOR_90943].  
 
Participant is permanently discontinued 
from further study drug treatment.  
 
Please refer to the pharmacy manual for 
administration details.  No subsequent dosing  
Appropriate resuscitation equipment shou ld be available at the bedside and a physician readily available 
during the period of drug administration.  
For further information, please refer to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE) at 
http://ctep.cancer.gov  
Abbreviations: NSAIDs = non -steroidal anti -inflammatory drugs.  
If a participant has an infusion related reaction, vital signs will be obtained every 15 
minutes (± 5 minutes) at the start of symptoms until the participant is deemed medically 
stable in the opi[INVESTIGATOR_2511] i nvestigator; pulse oximetry should be performed in 
conjunction with vital signs.  
 
Adverse Events of Special Interest (AESI)  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
186 Refer to Section [IP_ADDRESS]  for details. In addition, for AESIs of immune related cutaneous 
toxicities of any grade, recent alcohol intake or other potentially related concomitant 
exposures per Investigator assessment, should be recorded in the eCRF. Please refer to 
SRM for additiona l details.  
[IP_ADDRESS].  Safety Evaluation  
If a participant withdraws from the study before the completion of the 21 -day DLT 
evaluation period for reasons other than DLT or become s non -evaluable during the DLT 
period, then the participant may be replaced to achieve the three -participant required 
minimum. The decision to declare the combination tolerable will occur following review 
of the safety, PK and PD data (if available) and jo int discussion by [CONTACT_91050]. Membership, roles and accountabilities, and the process for 
safety review and meeting frequency is outlined in the Study Reference Manual.   
The mTPI [INVESTIGATOR_90918]:  
(i) 
(ii) 
The monitoring rules guiding dose decision are provided in Table 36. The tolerability 
decision framework using the mTPI [INVESTIGATOR_90944] a beta/binomial 
model and pre -calculated before study initiation. The rules in Table 36 utilize the mTPI 
[INVESTIGATOR_90945]:  
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
187 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
188 . 
[IP_ADDRESS].  Dose Limiting Toxicity  
The severity of all toxicities will be graded using National Cancer Institute - Common 
Terminology Criteria for Adverse Events (NCI -CTCAE) (version 5.0) [ NCI, 2017]. The 
DLT observation period is [ADDRESS_100433] one of the criteria listed in Table 37 and is 
considered by [CONTACT_91039] (probably, or 
possibly) to the study treatment during the 21 -day DLT observation period. An AE 
considered related  to the underlying disease under study it is not defined as a DLT. A 
safety event can still be included for DLT consideration after the 21 day window. See 
Section 10.4 for the definition of a DLT evaluable participant.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
190 Table 37 Dose -Limiting Toxicity  Criteria  
Toxicity  DLT Definition (Grading per CTCAE v5)  
Hematologic  • Grade 4 neutropenia of any duration or febrile neutropenia   
• Grade 4 anemia of any  duration  
• Grade  4 thrombocytopenia  of any duration  or Grade  3 thrombocytopenia with  bleeding  
Non- hematologic  • Grade 2 uveitis, epi[INVESTIGATOR_227], iritis, eye pain, or blurred vision that does not respond to 
topi[INVESTIGATOR_139] G1 severity or requires systemic treatment.  
• Grade 2 colitis or diarrhea that persists without resolution to ≤ Grade 1 for ≥  7 days 
despi[INVESTIGATOR_90946]  
• Grade 3 diarrhea/colitis lasting ≥72h regardless of medical intervention or G4 
diarrhea/colitis    
• Grade 3 pneumonitis  
• Grade 3 rash if no resolution to ≤Grade [ADDRESS_100434] of care  
• Grade 3 hypersensitivity or IRR   
• ALT ≥ 3x ULN plus bilirubin ≥ 2x ULN (>35% direct) or plus INR >1.5, if measureda 
(possible Hy’s Law)  
• Grade  3 toxicity  that does  not resolve  to ≤Grade  1 or baseline  within  3 days despi[INVESTIGATOR_90947] 4 toxicity  
• Following events are not considered  DLTs  
o ≥ Grade  3 electrolyte  abnormalities  that are corrected to ≤ Grade 1 or 
baseline within 72 hours without clinical  sequelae  
o Grade 3 nausea or vomiting that resolves to ≤Grade 1 or baseline within 7 
days  
o ≥Grade 3 fatigue ≤7 days  
o ≥Grade 3 lymphopenia  
o Grade 3 elevation of amylase or lipase not associated with clinical or 
radiographic evidence of pancreatitis  
 
Other  • Toxicity that results in permanent discontinuation of either agent  in combination   
• Any other toxicity considered to be dose -limiting that occurs after the completion of the DLT 
observation period will be considered in the selection of the dose to recommend for 
expansion  cohorts  
• Any other  event  which  in the judgment  of the investigator  and [COMPANY_004]  Medical Monitor is 
considered to be a  DLT 
a. Not applicable to participants taking anticoagulants.  
b. Suggested toxicity management guidelines as described in Section [IP_ADDRESS]  may include systemic 
corticosteroids for immune -related toxicities; if systemic corticosteroids use delays administration of the 
second dose  of study treatment and the event does not otherwise meet the DLT criteria for  non- hematologic 
toxicity, the dose delay will not be considered a  DLT.  
CTCAE=Common Toxicity Criteria for Adverse Events; DLT = Dose -limiting toxicity; G -CSF =Granulocyte 
colony -stimulating factor; [COMPANY_004] =GlaxoSmithKline; IRR=infusion related reaction  
 
If a participant experiences a DLT during the DLT observation period, the participant 
may resume dosing provided the toxicity did not meet study treatment discontinuation 
criteria and following approval by [CONTACT_1034].  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
191 Toxicity management and dose modification guidelines provided in Section [IP_ADDRESS]  are 
directed for those AEs of special interest that, although not observed in nonclinical 
studies, may be expected with the administration of immune directed therapi[INVESTIGATOR_014].  
 
Guidance for the identification, evaluation, and the established algorithms for the 
treatment management of i mmune -related adverse events (irAEs) including dose 
modification  algorithms  are provided  in Section [IP_ADDRESS] . These  guidelines  are based on 
the experience of irAE management following the development of immune check -point 
inhibitors such as ipi[INVESTIGATOR_90928]. Guidelines are also provided for 
infusion reactions or severe cytokine release ( Section [IP_ADDRESS].1 ). The joint ASCO and 
NCCN guidelines for the diagnosis and management of irAEs treated with immune 
checkpoint inhibitor therapy may be used as a supplement to the guidance provid ed in 
Section  [IP_ADDRESS] . 
 
If there is a delay in administration of study treatment, refer to Section [IP_ADDRESS]  for 
guidance on planning of subsequent study visits.  
 
[IP_ADDRESS].  Risk -Benefit Assessment of [COMPANY_004]4428859A and Dostarlimab combined   
Table 38 Risk Assessment and Mitigation Stra tegy: Dostarlimab and 
[COMPANY_004]4428859A  
Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Immune -related AEs 
(irAEs)  
 
 
 • Inflammatory AEs such as diarrhea/colitis, 
pneumonitis, nephritis, myocarditis  and 
hepatotoxicity are well established as 
treatment emergent AEs with immune -
modulating agents, and are consistent 
with the immune -stimulatory mechanism 
of action of these agents.  
• An anti -PD-1 checkpoint inhibitor 
(dostarlimab) will be used in combination 
with an anti -TIGIT mAb ([COMPANY_004]4428859A).  
• Based on the safety profile of anti PD -1 
antibodies, administered alone or in 
combination, the anticipated adverse 
reactions may be primarily immune 
mediated. Based on emerging data from 
anti-TIGIT mAbs, administered a lone or in 
combination, the anticipated adverse 
reactions are similarly immune mediated.  
 • Participants with the following 
medical history are ineligible for this 
study  
o Toxicity ( ≥Grade 3) related to 
prior immunotherapy leading to 
study treatment discontinuation  
o Active autoimmune disease (refer 
to Section 6.2 exclusion crite rion 
6) 
o Severe hypersensitivity to another 
mAb 
• Established management algorithms 
for immune -related adverse events 
(irAEs)   
• Refer to Section [IP_ADDRESS]  for further 
details on the identification, 
evaluation, and management of 
toxicities with a potential immune 
etiology.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
192 Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Infusion and 
hypersensitivity 
reactions and potential 
CRS  • Risk for infusion reactions and 
hypersensitivity is inherent to many 
mAbs [ Brennan , 2010]  
Dostarlimab : 
• The frequency of IRRs with dostarlimab 
is labelled as common  
 
 [COMPANY_004]4428859A  
• 
 
See Investigator’s Brochures for dostarlimab, 
and [COMPANY_004]4428859A [ iTeos  EOS884448 
[EOS -448] IB, 2021] for d etails.  • Participants with history of severe 
hypersensitivity to another mAb or to 
the chemotherapi[INVESTIGATOR_90948].  
• Refer to Section [IP_ADDRESS]  for further 
details on management and 
monitoring of infusion reactions.   
• Refer to Section [IP_ADDRESS]  for further 
details on management of CRS  
• Refer to Protocol Section [IP_ADDRESS] ; 
Table 3 for details of blood panel 
collection for all participants 
experiencing any grade of infusion 
reaction or CRS  
• For severe (Grade 3) or 
life-threatening (Grade 4) IRRs 
associated with [COMPANY_004]4428859A or 
dostarlimab, infusion should be 
stopped, and treatment sh ould be 
permanently discontinued.  
ADA and Immune 
complex disease  • Immune complex deposition may cause 
clinical symptoms, most commonly renal, 
skin, or vasculitis pathology.  
• For nonclinical immune complex formation 
and deposition findings (refer to individual 
product Investigator’s Brochure  [IBs])  
• [COMPANY_004]4428859A is a  fully human IgG1 mAb 
with a wild -type Fc domain. Based on the 
characteristics of the molecules and 
active pharmace utical ingredients, the risk 
of immunogenicity in humans is 
considered to be low and similar to other 
mAbs.  • Clinical laboratory safety 
assessments and immunogenicity 
testing  
Reproductive toxicity  • Animal studies assessing reproductive 
toxicity have not yet been conducted.  
• Immune -checkpoint inhibitors (such as 
dostarlimab) have been shown to have 
potential to disrupt maternal -fetal 
tolerance leading to failure of 
implantation or spontaneous abortion. A 
similar risk will be assumed for 
[COMPANY_004]4428859A . • Inclusi on of contraception guidelines 
for WOCBP (Section 6.1). 
• Exclusion of lactating or pregnant 
women (Section 6.2). 
• Pregnancy testing for WOCBP 
during Screening and throughout the 
Treatment period, as specified in the 
SoA (Section [IP_ADDRESS] ). 
Abbreviations: AE = adverse event; IB = Investigator’s Brochure; irAEs= immune -related adverse events; IRR= 
infusion -related reactions; mAb = monoclonal antibody.  
 
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
193 [IP_ADDRESS].  Additional Study Population Criteria: Arm 4  
[IP_ADDRESS].1.  Additional Inclusion Criteria: Arm 4  
1. Male contraception is not required for this arm.  
[IP_ADDRESS].2.  Additional Exclusion Criteria: Arm 4  
1. Known hypersensitivity to dostarlimab and/or [COMPANY_004]4428859A components or 
excipi[INVESTIGATOR_840].  
2. Has received prior antibodies or drugs targeting TIGIT, CD96, PVRIG, or other 
therapi[INVESTIGATOR_90949]226 axis pathway.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
194 [IP_ADDRESS].  References  
Ahn MJ, Niu J, Kim D, Rasco D, Mileham KF, Chung HC, et al. Vibostolimab, an 
anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in 
anti-PD-1/PD -L1-refractory NSCLC. Ann Oncol . 2020;31(Suppl  4):S754 -S840.  
Bendell  JC, Bedard P, Bang YJ, LoRusso P, Hodi S, Gordon M, et al. Abstract CT302: 
Phase Ia/Ib dose -escalation study of the anti -TIGIT antibody tiragolumab as a single 
agent and in combination with atezolizumab in patients with advanced solid tumors. 
Cancer Res . 2020;80(Suppl 16):CT302.  
Beyrend, G., et al., PD -L1 blockade engages tumor -infiltrating lymphocytes to co -
express targetable activating and inhibitory receptors. J Immunother Cancer, 2019. 7(1): 
p. 217.  
Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy.  J Immunother Cancer . 
2020;8(2):e000957.  
Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional 
Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor 
Immunity. J Immunol . 2018;200(8):3000 -3007.  
Golan T, Bauer T, Jimeno A, Perets R, Niu J, Lee J, et al. Phase 1 dose -finding study of 
the anti -TIGIT antibody MK -7684 as monotherapy and in combination with 
pembrolizumab in patients with advanced solid tumors. J Immunother Cancer . 
2018;6(suppl  1): O25.  
Gros, A., et al.,  PD-1 identifies the patient -specific CD8(+) tumor -reactive repertoire 
infiltrating human tumors. J Clin Invest, 2014. 124(5): p. 2246 -59. 
[COMPANY_004] Document Number TMF -11850520. Analysis of PD -1 receptor modulation by 
[CONTACT_91051] (TSR -042) using ex vivo IL2 sti mulation ratio. Effective Date: 
[ADDRESS_100435]  2019.  
[COMPANY_004] Document Number RPS -SA-1628635. Population pharmacokinetic analysis and 
exploratory exposure -response analysis of dostarlimab (TSR -042) (Study 4010 -01-001 
GARNET). Effective Date: 09  November  2020.  
Guille rey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, et al. TIGIT immune 
checkpoint blockade restores CD8+ T -cell immunity against multiple myeloma. Blood . 
2018;132(16):1689 -1694.  
Harjunpää  H, Guillery C. TIGIT as an emerging immune checkpoint. Clin Exp  Immunol.  
2020;200(2):108 -119. 
Hu F, Wang W, Fang C, Bai C. TIGIT presents earlier expression dynamic than PD -1 in 
activated CD8+  T cells and is upregulated in non -small cell lung cancer patients. Exp 
Cell Res . 2020;396(1):112260.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
195 Hung AL, Maxwell R, Theo dros D, Belcaid Z, Mathios D, Luksik AS, et al. TIGIT and 
PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. 
Oncoimmunology . 2018;7(8):e1466769.  
iTeos Investigator’s Brochure for EOS884448 (EOS -448) Edition 2.0 02 April 2021.  
Johnston RJ, Comps -Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The 
immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. 
Cancer Cell . 2014;26(6):923 -937. 
Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, et al. Treg cells expressing the 
coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell 
responses. Immunity.  2014; 40(4):[ADDRESS_100436], A.O., et al., Proliferation of PD -1+ CD8 T cells in peripheral blood after PD -
1-targeted therap y in lung cancer patients. Proc Natl Acad Sci U S A, 2017. 114(19): p. 
4993 -4998.  
KEYTRUDA [package insert]. Whitehouse Station, NJ. [COMPANY_006] Sharp & Dohme 
Corporation; 2021.  
KEYTRUDA [Summary of Product Characteristics]. [COMPANY_006] Sharp & Dohme B.V., 2021.  
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature.  2011; 
480(7378):[ADDRESS_100437] in gastric cancer. Cancer S ci. 
2018; 109: 43-53. 
Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L, et al. Myeloma 
escape after stem cell transplantation is a consequence of T -cell exhaustion and is 
prevented by [CONTACT_91052]. Blood . 2018;132(16):[ADDRESS_100438], Gartlan KH, Zhang P, Wilkinson AN, Samson L, et al. Myeloma 
escape after stem cell transplantation is a consequence of T -cell exhaustion and is 
prevented by [CONTACT_91052]. Blood. 2019; 134(21):1878.  
National Cancer Institute (NCI). The Cance r Genome Atlas. 
https://www.cancer.gov/about -nci/organization/ccg/research/structural -genomics/tcga. 
Accessed 04  June 2021.  
Niu J, Nagrial A, Voskoboynik M, Chung HC, Lee DH, Ahn M, et al. Safety and efficacy 
of vibostolimab, an anti -TIGIT antibody, plus p embrolizumab in patients with 
anti-PD-1/PD -L1-naive NSCLC. Ann Oncol . 2020;31(suppl 4): S754 -S840.  
OPDIVO [package insert]. Princeton, NJ. Bristol -Myers Squibb Company; 2021.  
OPDIVO [Summary of Product Characteristics]. Bristol -Myers Squibb Pharma EEIG; 
2021.  
TMF- [ADDRESS_100439] killing of tumor cells: the multiple 
mechanisms of action of a -TIGIT antagonist antibodies. Mol Cancer Ther . 2021; 20(1), 
121–131. 
Rodríguez -Abreu D, Johnson ML, Hussein MA, Cobo M, Patel AJ, Secen NM, et al. 
Primary analysis of a randomized, double -blind, phase II study of the anti -TIGIT 
antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus at ezo as 
first-line (1L) treatment in patients with PD -L1-selected NSCLC (CITYSCAPE). J Clin 
Oncol . 2020;38(15_suppl):9503.  
Shah  DK, Betts AM. Antibody biodistribution coefficients: inferring tissue 
concentrations of monoclonal antibodies based on the plasma  concentrations in several 
preclinical species and human. MAbs . 2013;5(2):297 -305. 
 
Sharma  S, Moore K, Mettu N, Garrido -Laguna I, Ulahannan SV, Khemka V, et al. Initial 
results from a Phase 1a/b study of etigilimab (OMP -313M32), an anti -T cell 
immunorecept or with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors. 
J Immunother Cancer . 2018;6(suppl  1):P289.  
 
Stengel KF, Harden -Bowles K, Yu X, Rouge L, Yin J, Comps -Agrar L, et al. Structure of 
TIGIT immunoreceptor bound to poliovirus receptor reve als a cell -cell adhesion and 
signaling mechanism that requires cis -trans receptor clustering. Proc Natl Acad Sci [LOCATION_003] . 
2012;109(14):5399 -5404.  
TESARO Investigator’s Brochure for Dostarlimab Edition 6.0 19 April 2021.  
Topalian SL, Weiner GJ, Pardoll DM. Canc er immunotherapy comes of age. J Clin 
Oncol.  2011;29(36):[ADDRESS_100440] -in-human study of EOS884448, a novel potent anti -
TIGIT antibody, monotherapy shows favorable tolerability profile and early signs of 
clinical activity in immune -resistant advanced cancers. Cancer Res.  2021;81(13_Suppl): 
Abstract CT118.  
Zhang Q, Bi J, Zheng  X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint 
receptor TIGIT prevents NK cell exhaustion and elicits potent anti -tumor immunity. Nat 
Immunol . 2018;19 (7):723 -732. 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
197 12.1.5.  Arm 5: [COMPANY_004]4428859A (Anti -TIGIT) plus Dostarlimab (Anti -PD-1) 
plus [COMPANY_004]6097608 (Anti -CD96) Combination  
[IP_ADDRESS].  Protocol Amendment 9 Summary of Changes Specific to [COMPANY_004]4428859A 
and Dostarlimab and [COMPANY_004]6097608 Arm  
Section # and Name  [CONTACT_91088] [IP_ADDRESS]  
(Table  30, Table 40 
and Table 41) 
Dose modification and 
Management 
Guidelines (Section 
[IP_ADDRESS]  and Table  
34) 
 
 
 
 
 
 
 
 
 
 Addition of text to clarify 
that the following 
investigations will require a 
Cardiologist or locally 
appropriate specialist 
review;  
Addition of text to clarify 
that the Sponsor will need to 
be informed regarding these 
participants  
Addition of text to clarify 
that investigators are 
required to review all safety 
laboratory assessments 
before dosing. .   
Section [IP_ADDRESS]  and 
Table 50 
 
 
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
198 Protocol Amendment 8 Summary of Changes Specific to [COMPANY_004]4428859A and 
Dostarlimab and [COMPANY_004]6097608 Arm  
Section # and Name  [CONTACT_91084] [IP_ADDRESS]  
(Table 39, Table 40 
and Table 41) 
Schedule of Activities 
Section [IP_ADDRESS]  
(Table 40 and Table 
41) 
 
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
199 Protocol Amendment 7 Summary of Changes Specific to [COMPANY_004]4428859A and 
Dostarlimab and [COMPANY_004]6097608 Arm  
Section # and Name  [CONTACT_91084] [IP_ADDRESS]  
(Table 40 and Table 
41)  
CCI
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
200 [IP_ADDRESS].  Schedule of Activities Specific to the [COMPANY_004]4428859A (Anti -TIGIT) plus Dostarlimab (Anti -PD-1) plus [COMPANY_004]6097608 
(Anti -CD96) Combination  
The timing and number of planned study assessm ents (including safety, pharmacokinetic, ADA, biomarker or other assessments) may  
be altered during the course of the study based on newly available data.  
Table 39 Schedule of Activities – Screening: Arm 5: [COMPANY_004]4428859A (Anti -TIGIT) plus Dostarlimab (Anti -PD-1) plus 
[COMPANY_004]6097608 (Anti -CD96) Combination  
Screening Study Assessments  Screening1  Notes  
Visit Window  ≤[ADDRESS_100441] be performed within 4 weeks (28 days) prior to first dose of study treatment 
unless otherwise specified. The informed consent may be signed within [ADDRESS_100442] dose.  
Participant Registration2 X 2. Participants will be registered in RAMOS NG at screening.  
Inclusion/Exclusion Criteria  X Review eligibility prior to randomization.  
Demographics, Medical History (including 
alcohol and tobacco use), Prior Medications, 
Disease History12 X 12. All known mutations should be entered in the eCRF as disease history.  
Prior Anticancer Treatment, Radiotherapy  X  
Screening Safety  
AE/SAE/AESI Assessment3 X 3. Any AESI or SAEs assessed as related to study participation (e.g., study treatment, protocol -mandated 
procedures, invasive tests, or change in existing therapy) or related to a [COMPANY_004] product will be recorded from the time 
a participant consents to participate in the study. After the initial AE/SAE report, the investigator is required to 
proactively follow each participant at subsequent visits/contacts.  Refer to Section 9.[ADDRESS_100443] review for participants with potentially significant ECG 
abnormalities such as AV block (except for first degree), new cardiac arrhythmias, or frequent PVCs. Please inform 
the Sponsor regarding these participants.    
Echocardiogram or MUGA scan5 X 5. ECHO required at Screening within [ADDRESS_100444] dose of study treatment, and during treatment phase if 
clinically indicated. MUGA scan may be used if ECHO not feasible.  
Screening Local Laboratory Assessments (Safety)  
Hepatitis B and C6 X  
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
201 Screening Study Assessments  Screening1  Notes  
Visit Window  ≤4 Wks   
Serum β -hCG (for women of childbearing 
potential)  ≤3d  
Clinical Chemistry6, Coagulation6, 
Hematology6, Thyroid function6 X 6. Refer to Appendix  [ADDRESS_100445] dose 
of study intervention or SoC, repeat testing at screening is not required; otherwise, this testing is mandatory.  
Calculated CrCl7 X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90872] -Gault formula. See Appendix 9 . 
Urinalysis6 X  
Screening Other Laboratory Assessments  
PD-L1 expression by [CONTACT_4658]8 X 8. PD -L1 expression by [CONTACT_91001] (i.e., Ventana SP263, Ventana SP142, Dako 28 -8, or Dako 
22C3) must be recorded in the eCRF, if known . Note: Test is not required to be performed by [CONTACT_91040].  
Screening Disease Assessments   
Tumor Imaging9 X 9. Diagnostic quality CT scan of chest and abdomen with contrast must be obtained within [ADDRESS_100446] dose. 
Baseline brain scan (MRI with and without IV gadolinium) should be obtained within [ADDRESS_100447] dose if clinically 
indicated. See additional information regarding bone scans in Section 9.3.1 . 
Pre-Baseline scans for Tumor Growth 
Kinetics10 X 10. Upon participant consent, up to 3 pre -baseline scans (within 12 months before the baseline scan) will be 
collected to assess tumor growth rate to support exploratory investigation of tumor growth kinetics (See Section 
9.3.2  for details on images for submission).  
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
202 Screening Study Assessments  Screening1  Notes  
Visit Window  ≤4 Wks   
Screening Tumor Biopsies  
Fresh tumor tissue sample and Archival 
tumor11 X 
 
Abbreviations : AE = adverse event; AESI = adverse events of  special interest; β -hCG = β -human chorionic gonadotropin; BNP = B-type natriuretic peptide CKD -EPI = chronic 
kidney disease epi[INVESTIGATOR_8261]; CrCl = creatinine clearance; CT = computed tomography; ECG = electrocardiogram; EC HO = echocardiograph y; ECOG PS = Eastern 
Cooperative Oncology Group performance status; eCRF = electronic case report form; IHC = Immunohistochemistry; IWRS = interac tive web response system; MRI = magnetic 
resonance imaging; MUGA  = multi -gated acquisition; NT-pro-BNP = N-terminal pro -hormone  BNP ;SAE = serious adverse event.  
CCI
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
203 Table 40  Schedule of Activities – Treatment Period Experimental Arm 5: [COMPANY_004]4428859A (Anti -TIGIT) plus Dostarlimab 
(Anti -PD-1) plus [COMPANY_004]6097608 (Anti -CD96) Combination  
On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
Inclusion/Exclusion 
Criteria  X            
Concomitant Medications  X X X X X X X X X X X  
Participant 
Randomization1 X           1. Once determined to be eligible, 
participants must be randomized via IWRS. 
Drug shipments will be managed via IWRS. 
Sites must allow up to 7 business days for 
shipment of study drug. Randomization can 
be done prior to Day 1, but no more than 3 
days prior to Day 1. (Refer to SRM).  
Study treatments1 
Administer Dostarlimab2 X X X X X X X X X X Q3W  
On Treatment Safety  
AE/SAE/AESI 
Assessment3 X X X X X X X X X X X 3. After the initial AE/SAE report, the 
investigator is required to proactively follow 
CCI
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
204 On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
each participant at subsequent 
visits/contacts. Refer to Section 9.4.1  for 
further details.  
ECOG PS**  X X X X X X X X X* Q6W*  Q6W*  *Q6W procedures are counted starting from 
Week 25 (i.e. the first Q6W visit is Week 31, 
then Week 37, etc.) unless more frequent 
assessments are clinically indicated.  
Physical Examination**  X X X X X X X X X Q6W*  Q6W*  ** Physical examinations and ECOG may be 
performed within 24 hours prior to dosing 
(i.e., as opposed to the day of dosing), if 
necessary.  
Vital Signs and Weight4 X X X X X X X X X X X 4. Vital signs include blood pressure, 
temperature, pulse, respi[INVESTIGATOR_697], and 
oxygen saturation. Weight is to be recorded 
at every other treatment visit in kilograms. 
Vital signs are to be performed predose on 
treatment days. Refer to Section 9.5.3 . 
If a participant experiences an infusion -
related reaction, refer to Section [IP_ADDRESS].1  
for guidance on vital signs monitoring.  
12-lead ECG  X X X X X X X X X X X* *Perform at every dosing visit  (may be 
performed within 24 hours prior to dosing).  
Results must be reviewed before  dosing  
Cardiologist or locally appropriate specialist 
review may be required if abnormal results 
are obtained and confirmed as described  in 
Table  46. 
On Treatment Local Laboratory Assessments (Safety) – assessments may be performed up to 3 days prior to treatment  
Serum β -hCG (for 
women of childbearing 
potential)[ADDRESS_100448] will be required.  
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
205 On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
Clinical Chemistry, 
Hematology, 
Coagulation6 X X X X X X X X X X X 6. Refer to Appendix  [ADDRESS_100449] dose.  
Thyroid function tests    X  X  X  X* Q6W*  Q6W*  *Q6W procedures are counted starting from 
Week 25 (i.e. the first Q6W visit is Week 31, 
then Week 37, etc.).  
Calculated CrCl7 X X X X X X X X X X X 7. CrCl is calculated by [CONTACT_91019] -EPI [INVESTIGATOR_90938] -Gault formula. Either formula is 
acceptable and must be consistently utilized 
for each participant throughout the study. 
See Appendix 9 . 
Urinalysis   X X X X X X X X X X  
On Treatment Disease Assessments  
Tumor 
Imaging/Response 
Assessment8   X  X  X  X X8 8. Diagnostic quality CT scan of chest and 
abdomen with contrast is required every 6 
weeks (±1 week) until Week 49 and every 
12 weeks thereafter. Imaging/clinical 
assessments should be performed as 
indicated in Section 9.2. The same method 
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
206 On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
of assessment is required throughout the 
study. Brain scan (MRI with and without IV 
gadolinium) and bone scan to be performed 
as clinically indicated during the trea tment 
period. If a participant has achieved a PD, 
CR, or PR in the previous radiologic 
assessment, a repeat scan should be 
performed after at least 4 weeks to confirm 
the response.  
On Treatment Patient -Reported Outcomes/Health -Related Quality of Life: Part 2 ONLY  
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
207 On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
On Treatment Biomarkers  
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
208 On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
On Treatment Tumor biopsies  
Fresh tumor tissue 
sample13   X13    X19     
On Treatment Pharmacokinetics and Anti -Drug Antibodies (ADA)  
CCI
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
209 On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
210 On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
21. To be collected at Week 25 and every 
12 weeks thereafter.  
Serum: IRR lab panel17            17. Assessment required in participant 
experiencing anaphylaxis, serious 
hypersensitivity, or in the occurrence of an 
infusion reaction/CRS of any grade. 
Samples should be drawn during the 
occurrence of the event. Only if not possible 
to collect at the occ urrence of the event, 
samples should be drawn as soon as 
possible after the event and within 24 hours 
(Refer to Section [IP_ADDRESS] ). Refer to Table [ADDRESS_100450] of analytes. Predose analysis will be 
performed on the serum sample collected 
for [COMPANY_004]4428859A and/or dostarlimab 
and/or [COMPANY_004]6097608 immunogenicity 
assessments.  
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
211 On Treatment  Study 
Assessments   Notes  
Week  1 4 7 10 13 16 19 22 25 28 - 49 52 - 106  
Day 1 22 43 64 85 106 127 148 169 190 - 
337 358 - 
736  
Visit Window  ±3-day window on treatment days  (Visits occur once every 3 weeks during treatment period)  
On Treatment Pharmacogenetics  
Genetic research18 X           18. Informed consent for optional genetic 
research must be obtained before collecting 
this sample. It is recommended that the 
optional research sample be taken at the 
first opportunity after a participant has met 
all eligibility requirements before Day 1 or on 
Day 1.  
 
Abbreviations : ADA = Anti -drug antibody; AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; BNP = B-type natriuretic 
peptide ; CKD -EPI = Chronic kidney disease epi[INVESTIGATOR_8261]; CR = complete response; Cr Cl = Creatinine clearance; CT = computed tomography; CTCAE = Common 
Terminology Criteria for Adverse Events; ECG = Electrocardiogram;  ECOG PS = Eastern Cooperative Oncology Group performance status; EOI = End of infusion;
 
 IRR = infusion related reaction;  
; NT-pro-BNP = N-terminal pro -hormone  BNP;  PBMC = peripheral mononuclear cells; PD = Progressive Disease;  
; PR = Partial response;  Pre =Predose;   
 – Physical Function; SAE = Serious adverse event.  
Pre: predose sample to be  collected prior to dosing per institutional guidance, as long as it is collected prior to dosing of the corresponding agent; EOI: End of infusion sample is  in 
reference to EOI of the corresponding agent.  
 
CCI
CCI
CCI
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
212 Table 41 Schedule of Activities – Treatment Discontinuation Visit and Follow -Up Arm 5: [COMPANY_004]4428859A (Anti -TIGIT) plus 
Dostarlimab (Anti -PD-1) plus [COMPANY_004]6097608 (Anti -CD96) Combination  
TDV and Follow Up 
Assessments  Treatment 
Discontinuation 
Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  within 30 days 
of study 
treatment 
discontinuation    
Anticancer Treatment   Q12W*  *If the participant dies before the first follow up, any subsequent anticancer therapy or radiotherapy should be 
recorded in the eCRF.  
 
 
Concomitant Medications  X   
TDV and Follow Up Safety  
AE/SAE/AESI Assessment2 X  2. After the initial AE/SAE report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. Refer to Section 9.4.1  and Section 9.4.3  for further details.  
ECOG PS  X   
Physical Examination  X   
Vital Signs and Weight3 X  3. Vital signs include blood pressure, temperature, pulse, respi[INVESTIGATOR_697], and oxygen saturation.  
TDV and Follow Up Local Laboratory Assessments  
Clinical Chemistry  X X^  
Serum β -hCG (for women of 
childbearing potential)  X   Refer to Appendix  [ADDRESS_100451] of required laboratory assessments.  
^Safety laboratory assessments should be collected at TDV (within [ADDRESS_100452] dose of study treatment) 
and at [ADDRESS_100453] dose of study treatment, unless the participant has started a new anti -cancer 
therapy within the 90 day follow -up pe riod, in which case safety laboratory assessments are not applicable. 
Refer to Appendix  3 for the specific laboratory assessments.   
 Hematology  X X^ 
Coagulation  X  
Thyroid function tests  X X^ 
Calculated CrCl  X  
Urinalysis  X  
 
 
12-lead ECGa X  
TDV and Follow Up Disease Assessments  
CCI
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
213 TDV and Follow Up 
Assessments  Treatment 
Discontinuation 
Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  within 30 days 
of study 
treatment 
discontinuation    
Tumor Imaging/Response 
Assessment4 X  4. At the TDV, CT scan is required only if the last disease assessment did not show confirmed PD and was 
performed ≥[ADDRESS_100454]. 
See additional information in Section 9.3.1  
Telephone call for survival status1a  Q12W   
TDV and Follow Up Tumor Biopsies  
Fresh tumor tissue sample  X5  5. If possible, obtain an optional  tumor tissue sample at time of confirmed PR or PD.  
TDV and Follow Up Patient -Reported Outcomes/Health -Related Quality of Life: Part 2 ONLY  
  
 
  
 
 
 
 
 
 
TDV and Follow Up Biomarkers  
TDV and Follow Up Pharmacokinetics and Anti -Drug Antibodies (ADA)  
CCI
CCI
CCI
TMF-16073217  CONFIDNTIAL  205801  
  Protocol Amd 10  
 
214 TDV and Follow Up 
Assessments  Treatment 
Discontinuation 
Visit1 
 Survival  
Follow -
Up1a Notes  
Visit Window  within 30 days 
of study 
treatment 
discontinuation    
Abbreviations:  ADA = Anti -drug antibody; AE = Adverse event; AESI = Adverse events of special interest; β -hCG = Beta -human chorionic gonadotropin; BNP = B-type natriuretic 
peptide  CR = complete response; CrCl = Creatinine clearance; CT = computed tomography; CTCAE = Common Terminology Criteria for Advers e Events; ECG = 
Electrocardiogram;  ECOG PS = Eastern Cooperative Oncology Group performance status; eCRF = Electronic case report f orm;  
 
; NT- pro- BNP = N-terminal pro -hormon e BNP  
; PD = Progressive Disease; ; PR = P artial response; 
 
 SAE = Serious adverse event; TDV = Treatment Discon tinuation Visit.  
 
1. The assessments required at the study treatment discontinuation visit must be completed within [ADDRESS_100455]. Participants will be contact[CONTACT_457] 12 weeks (±7 days) until death or participant’s withdrawal from further contact. Subsequent anticancer treatment 
and death date will be documented in the eCRF.  
CCI
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
215 [IP_ADDRESS].  Study Design Arm 5:  [COMPANY_004]4428859A (Anti -TIGIT) plus Dostarlimab 
(Anti -PD-1) plus [COMPANY_004]6097608 (Anti -CD96) Combination  
 
[COMPANY_004]4428859A will be evaluated at a  
 
 
 
, in accordance to the mTPI [INVESTIGATOR_90950] 48 Section [IP_ADDRESS]  (see Figure 9). A maximum of 9 evaluable 
participants will be assigned to DLT cohorts for each dose combination  per mTPI . 
Further evaluation of a combination dose demonstrated to result in unacceptable  toxicity 
as described in Table 48 will be stopped.  
After the combinations mentioned above are determined to be tolerated per the mTPI 
[INVESTIGATOR_90951] [IP_ADDRESS]  (Table 48), there is an option to open PK/PD cohorts to further 
evaluate safety and PK/PD. If PK/PD cohorts are opened,  
 
 
 
 
   
 
[IP_ADDRESS].  Rationale for the [COMPANY_004]4428859A (Anti -TIGIT) plus Dostarlimab (Anti -PD-
1) plus [COMPANY_004]6097608 (Anti -CD96) Combination  
Anti-TIGIT and Anti -PD-1/PD -L1 Monoclonal Antibody Combinations in Clinical 
Studies  
Combinations with anti -TIGIT mAbs and anti -PD-1/PD -L1 mAbs have demonstrated 
improved antitumor efficacy while preserving acceptable side effect profiles. The 
combination of vibostolimab (an anti -TIGIT mAb) with pe mbrolizumab (an anti -PD-1 
mAb) demonstrated a confirmed ORR of 24%, DCR of 36%, and a median DOR that was 
not reached (95%  CI: 4 to 17+ months) in participants with a variety of advanced solid 
tumors who were naïve to anti -PD-(L)1 therapy [ Niu, 2020]. Notably, even in 
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
216 participants who had previously received anti -PD-(L)1 therapy, the DCR was 50%, 
driven mostly by [CONTACT_91053] [ Ahn, 2020]. Vibostolimab demonstrated a 
tolerable safety profile across the various doses tested alone and in combination with 
pembrolizumab (anti -PD-1, 200 mg Q3W ) in the Phase 1b study (see Rationale Section 
[IP_ADDRESS]  for further details).  
In the dose escalation phase, tiragolumab (an anti -TIGIT mAb) was admini stered at 2, 8, 
30, 100, 400, 600, 1200  mg Q3W in combination with the anti -PDL1 agent, atezolizumab 
(1200 mg Q3W). No DLTs were observed across all doses (N=49). TRAEs occurred in 
59% of participants and the most frequently reported TRAEs were Grade 1 pru ritus, 
Grade 1  to 2 fatigue, Grade 1  to 2 rash, Grade 1 diarrhea, and Grade 1 arthralgia. Two 
Grade 3 TRAEs were reported in the combination: 1 hyperlipasemia and 1 lymphocyte 
count decreased. Infusion reactions were seen in 8% of participants, most were 
Grade 1/2. A higher rate of immune -related AEs (irAEs) was observed with the 
combination than with tiragolumab monotherapy [ Bendell , 2020]. In a Phase 1b dose 
escalation  study, the combination of tiragolumab with atezolizumab (an anti -PD-L1 
mAb) showed an ORR of 9% in participants with advanced solid tumors. In an expansion 
cohort of anti -PD(L)1naïve participants with PD -L1+ NSCLC, an ORR of 46% and a 
DCR of  85% were observed [ Bendell , 2020]. The results from the aforementioned Phase 
1b study led to the Phase 2 CITYSCAPE study, a randomized, double -blind study  of 
tiragolumab plus atezolizumab versus placebo plus atezolizumab in participants with 
PD-L1+ (TPS  ≥1%), treatment -naïve, locally advanced or metastatic NSCLC. In the 
CITYSCAPE study, a confirmed ORR of 37% for the combination arm compared with 
21% for th e placebo/atezoli zumab arm in the intent -to-treat population (n=135) was 
reported [ Rodríguez -Abreu , 2020]. Median PFS was improved from 3.88 months (range: 
2.73 to 4.53 months) with atezoli zumab to 5.5 months (range:  4.2 to 10.4 months; 
HR: 0.58, 95% CI: 0.38, 0.89) for the combination. In 58  participants with PD -L1 high 
(TPS ≥50%) tumors, the confirmed ORR was 66% for the combination compared with 
24% in the atezolizumab arm. The median PFS was not reached with the combination 
(95%  CI: 5.49 to not evaluable [NE]) compared with 4.11  months (95%  CI: 2.07, 4.73) 
for the atezolizumab arm (HR for PFS: 0.3; 95%  CI: 0.15. 0.61). For participants with 
PD-L1 TPS 1 -49%, the ORR and PFS were similar across both arms (ORR: 18% with 
atezolizumab vs 16% with tiragolumab and atezolizumab; PFS: 3.58 months and 4.04 
months, respectively [HR:0.89; 95%  CI: 0.53,  1.49]). The rates of TEAEs (99% vs 96%), 
Grade 3 AE s (48% vs 44%), Grade 5 AEs (5% vs 7%), SAEs (37% vs 35%), and AEs 
leading to treatment withdrawal (10% vs 9%) were all similar between the combination 
and placebo/atezolizumab arms, respectively; there was a modest increase in AEs leading 
to dose modifica tion in the combination arm (40% vs 28%). The overall rate of immune -
mediated AEs (69% vs 47%) and Grade 3 or 4 immune mediated  AEs (18% vs 13%) 
were higher in the combination arm [ Rodríguez -Abreu , 2020].  
As a result, multiple Phase  [ADDRESS_100456] evaluating anti -TIGIT and 
anti-PD(L)1 combination therapy in PD -L1+ NSCLC ([STUDY_ID_REMOVED]; [STUDY_ID_REMOVED]; 
[STUDY_ID_REMOVED]; [STUDY_ID_REMOVED]; [STUDY_ID_REMOVED]).  
 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
217 Triplet Combination of [COMPANY_004]4428859A plus Dostarlimab plus [COMPANY_004]6097608  
Multiple immune checkpoints in addition to PD -(L)1 may regulate T cell anergy and 
modulate antitumor immunity [ Topalian , 2011; Mellman , 2011]. Co -regulatory receptors 
expressed on T cells can induce stimulatory or inhibitory signaling cascades that 
modulate T cell proliferation, cytokine production, and cytotoxic T cell activa tion. 
Proteins of the nectin and nectin -like (Necl1) family, including TIGIT, PVRIG 
(poliovirus receptor -related immunoglobulin domain), and CD96, have emerged as 
immune -suppressing candidates that may prevent immune reactivation after PD(L)1 
blockade. The se co -regulatory receptors modulate the CD226 immune checkpoint, which 
is one of the major activating receptors for NK cells.  
CD96, TIGIT and CD226 (DNAM -1) are cell -surface receptors in the Ig superfamily and 
are known to interact with nectin and nectin -like ligands. CD155 is the primary ligand for 
all 3 receptors (CD96, TIGIT, and CD226). CD226 has been reported to potentiate 
NK-cell cytotoxicity against cancer cells, and is critical for tumor immunosurveillance 
[Gilfillan , 2008; Iguchi -Manaka , 2008; Lakshmikanth , 2009; Chan , 2010]. Conversely, 
both CD96 [ Chan , 2014]  and TIGIT [ Li , 2018 ] 
[Lozano  , 2012] are known to dampen immune responses through inhibition of 
NK- and/or T -cell function. Binding of CD96 and TIGIT with CD155 prevents 
homodimerization and activation of CD226 on CD8+ T cells [ Johnston , 2014].  
In the tumor microenvironment, CD96 is expressed by [CONTACT_33152], effector T cells, and 
regulatory T  cells (Tregs). TIGIT is highly expressed on murine and human tumor 
infiltrating T cells [ Johnston , 2014]. In human tumor specimens from the Cancer Genome 
Atlas (TCGA [ NCI, 2021]), TIGIT expression is upregulated in a broad  range of solid 
tumors [ Johnston , 2014]. TIGIT is upregulated on tumor infiltrating CD8+ T cells and a 
population of infiltrating CD4+ T cells in solid t umors in comparison to peripheral 
T cells from patients and normal donors. CD8+ and CD4+ TIGIT -expressing T cells also 
co-express PD -1. 
 
 
 
 [[COMPANY_004] Document Number 2019N420882_00 ]. In NSCLC, TIGIT 
was expressed in tumor -infiltrating CD8+ and CD4+ T cells and was co -expressed with 
PD-1 [Johnston , 2014]. Peripheral CD8+ and CD4+ T cells from NSCLC tumor donors 
had higher levels of TIGIT compared with healthy donors. In addition, in patients with 
NSCLC, the expression of PD -1 was higher  in TIGIT+ cells than in TIGIT -negative cells 
in both circulating CD8+ T cells and tumor -infiltrating CD8+ T cells [ Hu, 2020]. TIGIT 
could act as a checkpoint inhibi tor in exhausted tumor -infiltrating T  cells.  
CD96 and TIGIT represent novel immune checkpoint receptor targets. As depi[INVESTIGATOR_90952] 10, engagement of CD96 and TIGIT with CD155 functions as an 
‘off switch,’ or immune checkpoint, to downregulate immune responses.  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
218 Figure 10 Mechanism of Action for CD226 Axis  
 
Abbreviations: APC  = antigen -presenting cell; CD  = cluster  of differentiation; NK  = natural killer; TIGIT  = T-cell 
immunoglobulin and immunoreceptor tyrosine -based inhibition motif domain.  
 
EOS884448 (also known as EOS -448; hereafter referred to as [COMPANY_004]4428859A) is a fully 
human IgG1 mAb that prevents TIGIT -ligand  binding. As an IgG1, [COMPANY_004]4428859A also 
displays a potent affinity for the fragment crystallizable (Fc) gamma receptors (FcγRs) 
with the potential to mediate ADCC/P against TIGIT expressing cells. Binding of 
[COMPANY_004]4428859A to TIGIT was shown to increase T cell  activation by [CONTACT_91054]. [COMPANY_004]4428859A (or its mouse surrogate for rodent studies) mediates 
ADCC/P of immunosuppressive cells by [CONTACT_91055] T cells that express a high level of TIGIT relative to cytotoxic CD8 or NK 
cells, resulting in an increased ratio of effector CD8+/immunosuppressive regulatory T 
cell cells. Moreover, this effect was abrogated in mice lacking FcγRs, further suggesting 
the requirement for an ADCC/P effect to fully induce tumor growth inhibition. Overall, 
these data demonstrate that [COMPANY_004]4428859A restores antitumor immunity by [CONTACT_91056], PVR/CD155 and Nectin2/CD112, and 
induces a strong immune response mediated by [CONTACT_30962] T cell de pletion and ADCC/P 
[Preillon , 2021].  
[COMPANY_004]6097608 is a fully human IgG1 mAb checkpoint inhibitor designed to modulate this 
axis by [CONTACT_12789] a high -affinity complex with CD96, disrupting CD96 binding to CD155, 
and subsequently redirecting CD155 -mediated costimulatory signaling through the 
activating receptor CD226 to increase T‑cell and NK -cell antitumor activity. Modulation 

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
219 of this axis via inhibition or dele tion of CD96 has resulted in antitumor activity in mouse 
tumor models both alone and in combination with PD‑1 inhibition [ Blake , 2016; 
Harjunpää , 2018].  
Dostarlimab (formerly referred to as TSR -042) is an IgG4 -k humani zed monoclonal 
antibody that binds with high affinity to PD -[ADDRESS_100457] activity of dostarlimab was confirmed in an MLR demonstrating 
enhanced interleukin -2 production upon addition of dostarlimab. Dostarlimab is an anti -
PD1 agent so nonclinical safety data is expected to be similar t o a large extent to what 
was seen with data supporting pembrolizumab combinations. To support combination 
with dostarlimab, the principal nonclinical toxicology findings associated with 
dostarlimab were reviewed.  
 
 
. 
As a proof of concept, co -inhibition of CD96 and PD -(L)1 has proven efficacious in 
several nonclinical tumor models. For example, dual genetic ablation of CD96  and Pdcd1  
(PD-1) significantly suppressed SM1WT1 (melanoma) tumor growth in mice relative to 
single knockout approaches (i .e., CD96 -/- or Pdcd1 -/-) without overt perturbations in 
immune homeostasis beyond what has been reported for PD -1-deficient mice [ Harjunpää , 
2018]. Combinations of anti -CD96 antibodies with anti -CTLA -[ADDRESS_100458] also been shown to be more effective than anti -CD96 alone with regards to mouse 
survival [ Blake , 2016]. Similar improvements in antitumor responses have been observed 
in mice following antibody -mediated co -blockade of CD96 and PD -1 or PD -L1 [Blake , 
2016; Li, 2018; Mittal , 2019]. Likewise, in nonclinical models, the combination of anti -
PD-L1 and anti -TIGIT agents synergistically improved tumor control over either 
antibody alone [ Johnston , 2014]. Finally, and most importantly, triple combination of 
anti-CD96, -TIGIT, and -PD-1 has been shown to further improve antitumor responses in 
multiple  tumor models [ Mittal , 2019]. Therefore, approaches that block the binding of 
both CD96 and TIGIT to CD155 could have therapeutic benefit. Thus, combined 
blockade of CD96 and TIGIT may potentiate the activity of dost arlimab.  
 
 
 
. Monoclonal 
antibodies, such as [COMPANY_004]6097608 and dostarlimab, are not substrates for cytochrome 
P450 or drug transporters. Although treatments are checkpoint inhibitors and are not 
expected to increas e the potential for CRS based on in vitro cytokine release assays 
(CRAs) and toxicology studies of each individual inhibitor, a combination CRA is being 
conducted and the data will be available to support dosing of the triplet. For additional 
nonclinical t oxicology data for [COMPANY_004]6097608, dostarlimab, and [COMPANY_004]4428859A refer to 
the individual Investigator Brochures[see the iTeos  EOS884448 [EOS -448] IB, 2021; 
Dostarlimab  IB, 2021; [COMPANY_004]6097608  IB, 2021 ].  
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
220 [IP_ADDRESS].  Clinical Safety Summary  
[IP_ADDRESS].1.  [COMPANY_004]4428859A  
Several mAbs targeting TIGIT are in various stages of clinical development. These 
agents include tiragolumab, vibostolimab, domvanalimab, etigilimab, and 
[COMPANY_004]4428859A , among an increasing number of others.  
A Phase 1b study of vibostolimab monotherapy in par ticipants with advanced solid tumor 
types previously treated with anti -PD-(L)1 therapy reported a 3% ORR and 35% DCR 
[Golan , 2018]. In a Phase  1a/Phase  1b stud y of tiragolumab as a single agent and in 
combination with atezolizumab in advanced solid tumors, there were no objective 
responses in 24  participants treated with tiragolumab monotherapy [ Bendell , 2020]. The 
[ADDRESS_100459], ovarian, endometrial, melanoma, and other 
cancer diagnosis [ Bendell , 2020]. The ORR for etigilimab in the dose -escalation phase 
was 0%, with a DCR of 30% in a Phase 1a/Phase 1b study of etigilimab in participants 
with advanced solid tumors [ Sharma , 2018]. A Phase [ADDRESS_100460] 
preliminary efficacy in 20 participants with advanced solid tumors, with an ORR of  5% 
[Van den Mooter , 2021].  
The safety profile of anti -TIGIT mAbs has been tolerable and comparable to that of other 
single -agent immune checkpo int inhibitors. In the vibostolimab Phase 1b study of 
immune checkpoint inhibitor -experienced participants, 59% of participants experienced 
any treatment -related adverse event (TRAE) with Grade ≥3 TRAEs in 15% of 
participants in the vibostolimab monotherap y arm. The most common TRAEs reported 
were fatigue (22%) and rash (20%). One participant (2%) had a TRAE that led to 
discontinuation and none experienced a fatal TRAE [ Golan , 2018]. In the Phase 1a 
dose-escalation phase of the tiragolumab study in 24 patients, there were no DLTs 
[Bendell , 2020]. TRAEs occurred in  67% of participants, Grade 3 TRAEs in 4% 
(Grade  3 blood creatinine increase) and the most common AE reported was fatigue 
(38%). There were 6 SAEs reported (25%) with no AEs leading to study withdrawal or 
death [ Bendell , 2020].  
 
 
 
 
 
 
 
 
 
 There were no AEs that led to 
treatment discontinuations or any TEAEs leading to death. TRAEs were reported by % 
of participants, with % of part icipants having Grade ≥3 TRAEs, and % having serious 
TRAEs. The most frequent TRAEs included pruritus (n= %]), infusion -related 
reaction (n= %]), fatigue (n= %]), and pyrexia (n= %]); at least skin 
CCI
CCI
CC
I
C
CI
CCI
CCI
CCI
CCI
CC
I
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
221 disorder (all confounded) was reported in participants (for additional details, see the 
iTeos  EOS884448 [EOS -448] IB, 2021).  
Overall, the early data from this Phase 1 study  
.  
[IP_ADDRESS].2.  Dostarlimab  
A total of participants with advanced or recurrent solid tumors received at least one 
dose of monotherapy dostarlimab  
prior to the data cut -off date of 1 November 2020 in study 4010 -01-001 (GARNET).  
The data from participants treated with monotherapy dostarlimab in Study 4010 -01-001 
demonstrated an acceptable safety profile with manageable toxicity in p articipants with 
advanced or recurrent solid tumors:  
• Treatment -emergent adverse events (TEAEs) regardless of causality were 
reported in % of participants, and % of participants had treatment 
related events. The most common reported TEAEs %) were anemia 
%), fatigue 0%), nausea %), and diarrhea %).  
• Grade ≥3 TEAEs regardless of causality were reported in % of 
participants; the most frequently reported % of participants) were anaemia 
%), dyspnoea %), abdominal pa in %), and hyponatraemia %). 
Treatment -related Grade 3 events were reported in % of participants; 
the most frequently reported % of participants) were anaemia %), 
fatigue %), alanine aminotransferase increased ( %), and lipase 
increased %).  
• Treatment -emergent SAEs regardless of causality were reported in % of 
participants; the most frequently reported % of participants) were 
abdominal pain %), pneumonia %), and dyspnoea %). Treatment -
related SAEs were repor ted in % of participants; the most frequently 
reported % of participants) were pneumonitis %), adrenal 
insufficiency %), and pyrexia %).  
• TEAEs leading to treatment discontinuation regardless of causality were 
reported in % of participants; the most frequently reported % of 
participants) were alanine aminotransferase increased %), aspartate 
aminotransferase increased %), pneumonitis %), and transaminases 
increased %). Treatment -related events leading to disc ontinuation were 
reported in % of participants; the most frequently reported % of 
participants) were alanine aminotransferase increased %), aspartate 
aminotransferase increased %), pneumonitis %), and transaminases 
increased %).  
• TEA Es leading to death regardless of causality were reported in % of 
participants with respi[INVESTIGATOR_90939] >1 participant 
 participants %]); % of the deaths were due to treatment -related 
TEAEs (completed suicide, hepatic  ischaemia).  
CCI
C
CI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
222 Of the  participants, % who received dostarlimab monotherapy experienced at 
least 1 immune -related TEAE (irAE). The most frequent %) irAEs were 
hypothyroidism, diarrhea, alanine aminotransferase increased, aspartate aminotransferase 
increased, blood creatinine increased, hyperglycemia and amylase increased.  
participants %) who received dostarlimab monotherapy experienced at least 1 irAE 
with severity of ≥Grade 3. For participants with ≥Grade 3 irAEs, the AE was 
assessed as study drug related by [CONTACT_431].  
The safety profile of monotherapy dostarlimab in participants with advanced or recurrent 
solid tumors was generally similar to the reported safety profiles of other mAbs blocking 
the PD -1 interactions  (KEYTRUDA  USPI, 2021; KEYTRUDA , SmPC, 2021; OPDIVO  
USPI, 2021; OPDIVO , SmPC, 2021).  
[IP_ADDRESS].3.  [COMPANY_004]6097608  
An ongoing Phase 1 FTIH study (Study 212214; [STUDY_ID_REMOVED]) in advanced solid 
tumors is assessing the safety, tolerability, PK, PD, and preliminary anticancer activity of 
[COMPANY_004]6097608. The study design allows for the assessment of [COMPANY_004]6097608 as 
monotherapy and  in combination with dostarlimab.  
Arm A consists of dose escalation to determine the RP2D  of [COMPANY_004]6097608 as a single 
agent, and Arm B consists of dose escalation in combination with dostarlimab. Results 
from Arm A and Arm B will be used to establish the RP 2Ds for monotherapy and 
combination therapy.  
As of the preliminary data cut -off date of [ADDRESS_100461] 1 dose of [COMPANY_004]6097608 monotherapy (Arm A ) and participants have received at 
least 1 dose of [COMPANY_004]6097608 in combination with dostarlimab (Arm B). Participants in 
the Arm A population ([COMPANY_004]6097608 monotherapy; n  were enrolled at the following 
dose levels:  mg (n= mg (n=  mg (n= mg (n  mg (n= mg 
(n= and  mg (n= Participants in the Arm B population ([COMPANY_004]6097608 in 
combination with dostarlimab; n were enrolled in dose -escalation cohorts and 
received [COMPANY_004]6097608 at the mg (n= mg (n= and mg (n= and mg 
(n= dose levels. In the study, deaths were reported; deaths were considered 
treatment -related.  
Arm A (GKS6097608 Monotherapy) – Ongoing:   %) participants 
have experienced at least 1 treatment -emergent AE ( TEAE). The most frequently 
reported TEAEs (n>2) across all dose levels were fatigue (n= %); nausea (n=
%); constipation (n= %); diarrhoea  (n= %);  chills , vomiting (n= %] 
each); dizziness, anaemia, and anorexia  (n= %] each). Of th e participants 
enrolled acros dose level participants experienced SAEs event [urinary tract 
infection] at mg vents [disease progression and cerebrovascular accident] a mg, 
event [failure to thrive] at mg; events [pulmonary hemorrhage  and hypovolemic 
shock] at mg; and event [pneumonia] at mg). No SAEs were noted as treatment 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CC
I
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CC
I
CCI
CC
I
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
223 related. Of the  TRAEs reported as of 0 5 November 2021 ( Table 42), the majority  
%) Grade [ADDRESS_100462] been observed to date.  
Arm B ([COMPANY_004]6097608 in Combination with Dostarlimab) – Ongoing:   
participants %) have experienced at least 1 TEAE. Table 43 presents TRAEs for Arm 
B as of the 05 November  2021 .  participants experienced 4 serious adverse 
events (hyponatremia, tumor hemorrhage, meningitis and  CNS necrosis) as a result of 
disease progression.  DLTs have been reported. Of the TRAEs reported were 
Grade 1 or 2 events.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
224  
[IP_ADDRESS].  Dose Justification  
[IP_ADDRESS].1.  [COMPANY_004]4428859A Pharmacokinetics and Pharmacodynamics  
 
 
 
 
 
 
 
 
 
 
 
. PK data 
obtained at Cycle 1 are summarized in the iTeos  EOS884448 [EOS -448] IB, 2021.  
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
225 [IP_ADDRESS].2.  [COMPANY_004]4 428859A Dose Rationale (Arm 5)  
The [COMPANY_004]4428859A RP2D of mg  is based on the preliminary safety, PK/PD, 
and efficacy data available from the Phase 1/Phase 2a clinical Study IO -002 
([STUDY_ID_REMOVED]), as well as observations from other clinical studies eval uating anti -
TIGIT mAbs which generally have similar properties [ Bendell , 2020; Rodríguez -Abreu , 
2020; Niu, 2020]. Additionally, Study TIG -006 is currently evaluating the safety, 
tolerabil ity, PK, PD, and anti -tumor activity of [COMPANY_004]4428859A in combination with 
pembrolizumab in participants with advanced solid tumors. The starting dose level of 
[COMPANY_004]4428859A is mg in combination with pembrolizumab in study IO -006 
([STUDY_ID_REMOVED]). Furtherm ore, [COMPANY_004]4428859A  mg will also be tested in 
combination with dostarlimab in Arm 4 of this platform  study  and will inform the 
safety/tolerability profile of this doublet  (see Section 12.1.4 ).  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
226  
 
 
 
 
TRAEs were Grade 1 pruritus, Grade 1 -2 fatigue, Grade 1 -2 rash, 
diarrhea, and arthralgia. Two  Grade 3 TRAEs were reported in the group receiving 
combination treatment: 1  event of hyperlipasemia and 1 event of lymphocyte count 
decreased. Infusion reactions were seen in 8% of participants. A higher rate of irAEs was 
observed with the combination tha n with tiragolumab monotherapy [ Bendell , 2020]. In 
the Phase [ADDRESS_100463] -line 
atezolizumab at 120 0 mg Q3W in PD -L1–selected metastatic NSCLC demonstrated good 
tolerability, with a safety profile similar to placebo plus atezolizumab [ Rodríguez -Abreu , 
2020]. Vibostolimab (an anti -TIGIT mAb) has also demonstrated a good safety and 
tolerability profile across the various doses tested alone and in combination with 
pembrolizumab (an anti -PD-1 mAb, 200 mg Q3W) in the Phase  1b study [ Ahn, 2020; 
Niu, 2020].  
[IP_ADDRESS].3.  Dostarlimab Dose Rationale  
The anti -PD-1 mAb do starlimab will be administered in combination with 
[COMPANY_004]4428859A and [COMPANY_004]6097608 as a flat dose of  mg
Dostarlimab has been approved in the US and the EU for the treatment of adult patients 
with dMMR/MSI -H (the latter in the EU only) recurrent or adva nced endometrial cancer 
that has progressed on or following prior treatment with a platinum -containing regimen. 
As determined in the GARNET study, the recommended clinical dose of dostarlimab 
deemed safe and effective is mg  for 4 cycles, followed b y mg 
To facilitate combination with the other study intervention regimens of this study, 
dostarlimab dosing  
 
 
 
 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
227 No reduction in dostarlimab dose is allowe d given that the safety and efficacy profile of 
the included dose regimen for dostarlimab is considered acceptable, whereas the efficacy 
of lower doses is not fully characterized.  
[IP_ADDRESS].4.  [COMPANY_004]6097608 Pharmacokinetics and Pharmacodynamics  
 
 
 
 
 
 
 
 
 
 Prelimin ary pharmacokinetic summary statistics are 
presented in Table 44 below.  
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
228 [IP_ADDRESS].5.  [COMPANY_004]609 7608 Dose Rationale  
See associated text under Section [IP_ADDRESS].4  and Section  [IP_ADDRESS].3  for details regarding 
preliminary pharmacokinetic and clinical  safety data from the FTIH Study.  
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
229 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
230 [IP_ADDRESS].  Study Treatments  
Table 45 Description and Administration of Arm 5 [COMPANY_004]4428859A p lus 
Dostarlimab plus [COMPANY_004]6097608 Study Treatments  
Name  [CONTACT_91089]4428859A  [COMPANY_004]6097608  
 
In the  dostarlimab + [COMPANY_004]4428859A +  [COMPANY_004]6097608 combination arm, dostarlimab 
mg will be administered first as an IV infusion  [COMPANY_004]4428859A mg will be 
administered as an IV infusion after completion of dostarlimab infusion. Lastly (3rd 
agent to be infused), [COMPANY_004]6097608 mg, mg or mg will be administered as 
an IV infusion after completion of [COMPANY_004]4428859A infusion (see pharmacy manual 
for administration instructions).  
All participants should  remain under observation at the study site after the completion of 
study treatment administration  (refer to SRM for details). Section [IP_ADDRESS] , Table 47 for 
details on the management of participants experiencing infusion reactions. Refer to 
Section 5.2 for information on the duration of study treatment.  
The date and time of administration will be documented in the source documents and 
reported in the eCRF. For drug administered by [CONTACT_91057], the dose of 
study treatment and study participant identification will be confirmed at the time of 
dosing by a member of the study site staff other than the person administering the study 
treatment. The specific time of study treatment ad ministration (e.g., time of the week for 
first administration; time of the day for each administration) should take into 
consideration PK sampling time points, study visit procedures, and the post -infusion 
observation time interval. Infusions may be admini stered up to 72 hours before or after 
the planned date of treatment for administrative reasons only (e.g., scheduling an infusion 
around a holiday). All drugs should be administered on the same day. The 72 -hour 
window does not apply to completion of study treatment administration interrupted by [CONTACT_91049]. Refer to Section [IP_ADDRESS]  for criteria governing dose interruptions or 
delays.  
Details on preparation and administration of  [COMPANY_004]4428859A , dostarlimab , and 
[COMPANY_004]6097608  are described in the pharmacy manual.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
231 [IP_ADDRESS].  Concomitant Therapy  
Refer to Section 7.7. 
[IP_ADDRESS].  Treatment of Overdose  
[IP_ADDRESS].1.  [COMPANY_004]4428859A Overdose  
An overdose of [COMPANY_004]4428859A is defined as administration of a dose that is above 
mg.  
In the event of an overdose, the investigator must:  
[ADDRESS_100464] dose of 
study treatment if requested by [CONTACT_941] M edical Monitor (determined on a case -by-
case basis).  
4 Document the quantity of the excess dose as well as the duration of the 
overdosing in the eCRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_43208].  
There is no specific antidote for overdose with the experimental treatments being 
evaluated in this study. In the event of a suspected overdose, it is recommended that the 
appro priate supportive clinical care be instituted as dictated by [CONTACT_2299]’s clinical 
status.  
[IP_ADDRESS].2.  Dostarlimab Overdose  
Human data on overdose are not available. There is no known antidote for dostarlimab.  
 
An overdose of dostarlimab is defined as any dose that is ≥20% than mg
 
In the event of an overdose, the investigator must:  
[ADDRESS_100465] dose of 
study treatment if requested by [CONTACT_1689] (determined on a case -by-
case basis).  
4 Document the quantity of the excess dose as well as the duration of the 
overdosing i n the eCRF.  
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
232 Decisions regarding dose interruptions or modifications will be made by [CONTACT_43208].  
There is no specific antidote for overdose with the experime ntal treatments being 
evaluated in this study. In the event of a suspected overdose, it is recommended that the 
appropriate supportive clinical care be instituted as dictated by [CONTACT_2299]’s clinical 
status.  
[IP_ADDRESS].3.  [COMPANY_004]6097608 Overdose  
There is no specific in formation on overdose of [COMPANY_004]6097608. [COMPANY_004] does not recommend 
specific treatment for an overdose of [COMPANY_004]6097608. An overdose of [COMPANY_004]6097608 is 
defined as administration of more than the protocol -specified dose.  
In the event of an overdose, the investigator must:  
[ADDRESS_100466] dose of 
study treatment if reques ted by [CONTACT_1689] (determined on a case -by-
case basis).  
4 Document the quantity of the excess dose as well as the duration of the 
overdosing in the eCRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_43208].  
There is no specific antidote for overdose with the experimental treatments being 
evaluated in this study. In the event of a suspected overdose, it is recommended tha t the 
appropriate supportive clinical care be instituted as dictated by [CONTACT_2299]’s clinical 
status.  
[IP_ADDRESS].  Treatment Duration for [COMPANY_004]4428859A,  Dostarlimab , and [COMPANY_004]6097608  
Participants enrolled will be treated until disease progression, intolerable toxicity , 
informed consent withdrawal or death. Combination study treatment will continue to be 
administered at the indicated schedule for a maximum duration of up to [ADDRESS_100467]. Refer to Section 5.2 for additional 
details regarding follow up after discontinuation of study treatment.  
[IP_ADDRESS].  Dose modification  and Management Guidelines  
No dose reductions are allowed for [COMPANY_004]4428859A, dostarlimab , or [COMPANY_004]6097608  at the 
participant level. Dose modification guidelines for immune related adverse events are 
listed in Table  46. If study treatment must be held or discontinued for any toxicity, all 
TMF- [ADDRESS_100468] be held or discontinued, unless discussed otherwise with Medical 
Monitor.  
In addition to the immune -related adverse events listed in Table  46, immunotherapy may 
be associated with other irAEs, including events which may be less commonly associated 
with PD -(L)[ADDRESS_100469] current professional guidelines (e.g.: NCCN, SITC) 
should be considered. Patients should receive appropriate supportive care measures as 
deemed necessary by [CONTACT_64372], including but not limited to the items 
outlined below:  
 
Table  46 Dose Modification and Toxicity Management Guidelines for Immune -
Related AEs  
General instructions : 
• Corticosteroid taper should be initiated upon AE improving to Grade [ADDRESS_100470] 4 weeks.  
• For situations where immunotherapy treatment has been withheld, treatment can be resumed after AE 
has been reduced to Grade [ADDRESS_100471] dose or corticosteroids 
cannot be reduced to ≤10 mg prednisone or equivalent per day within 12 weeks.  
• For severe and life -threatening irAEs, IV corticosteroid should be initiated first followed by [CONTACT_44874]. 
Othe r immunosuppressive treatment should be initiated if irAEs cannot be controlled by [CONTACT_13216].  
Immune -related AEs  Severity 
grade or 
conditions 
(CTCAEv5.0)  Action taken  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_90940] -up  
Respi[INVESTIGATOR_90953]- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
234 Diarrhea / colitis  
Hepatobiliary  
Hepatitis with no tumor 
involvement of the liver  
Hepatitis with tumor 
involvement of the liver**  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
235 Endocrine  
Type 1 diabetes mellitus 
(T1DM) or Hyperglycemia  
 
Endocrinopathies (e.g. 
hypophysitis, hypo -
/hyperthyroidism, adrenal 
insufficiency)  
Renal  
Nephritis with renal 
dysfunction  
Cardiovascular  
 
 
 
 
 
 
 
Cardiac Investigations  
i) ECG changes and/or ii) 
troponin and/ or NT -
proBNP/BNP elevations  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
236 Myocarditis  
Other  
Neurological Events 
(myasthenia gravis, Guillain -
Barré syndrome, encephalitis, 
transverse myelitis)  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
237 All other immune -related 
AEs 
Skin Toxicities1 
Rash  
Pruritis  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
238 Exfoliative dermatologic 
conditions (e.g. SJS, TEN, 
DRESS)  
NOTES :  
*Resume in patients with complete resolution or partial resolution  to Grade 1 after corticosteroid taper. Permanently 
discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone 
to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids.  
 
**If AST and ALT are  less than or equal to ULN at baseline in patients with liver involvement, withhold or 
permanently discontinue based on recommendations for hepatitis with no liver involvement.  
***Abnormal troponin and proNTBNP/BNP at screening is defined as any value >ULN  at screening  
 
1. For any grade skin toxicities, recent alcohol intake or other potentially related concomitant exposures per 
Investigator assessment, should be recorded in the eCRF. Please refer to SRM for additional details.  
 
Abbreviations: BNP = B-type natriuretic peptide; NT -pro-BNP = N-terminal pro -hormone  BNP; SJS = Stevens -Johnson 
syndrome; TEN = toxic epi[INVESTIGATOR_194]; DRESS = drug reaction with eosinophilia and systemic symptoms.  
 
 
;  
 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
239  
 
[IP_ADDRESS].1.  Dose Modification and Toxicity Management of Infusion -Reactions 
Related to Immunotherapy Treatment  
Table 47 Immunotherapy Infusion Reaction Dose Modification and Treatment 
Guidelines  
NCI CTCAE Grade  Treatment  Premedication at Subsequent 
Dosing  
Grade 1  
Mild reaction; infusion interruption 
not indicated; intervention not 
indicated  Increase monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_13046].  
Please refer to the pharmacy manual for 
administration det ails.  Participant may be premedicated 
1h (± 30 minutes) prior to infusion 
of study drugs with: 
Diphenhydramine 50 mg (or 
equivalent dose of antihistamine) 
and/or acetaminophen 325 -1000 
mg (or equivalent dose of 
analgesic)  
Grade 2  
Requires therapy or infu sion 
interruption but responds 
promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDs, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hrs.  Stop Infusion.  
Additional appropriate medical therapy 
may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_13046].  
If symptoms resolve within 1 hour of 
stoppi[INVESTIGATOR_90954], the infusion may 
be restarted at 50% of the original 
infusion rate (e.g. from 100 mL/hr to 
50 mL/hr), unless otherwise specified in 
the pharmacy manual. Otherwise dosing 
will be held until symptoms resolve and 
the participant should be premedicated 
for the next scheduled dose.  
 
Participants who develop Grade 2 toxicity 
despi[INVESTIGATOR_90942].  
 
Please refer to the pharmacy manual for 
administration details.  Participant may be pr emedicated 
1h (± 30 minutes) prior to infusion 
of study drugs with:  
Diphenhydramine 50 mg (or 
equivalent dose of antihistamine).  
Acetaminophen 500 -1000 mg (or 
equivalent dose of analgesic).  
If necessary, corticosteroids (up 
to 25  mg of hydrocortisone or 
equivalent) may be used and 
adaptation of the infusion rate 
should be discussed with Medical 
Monitor.   
Grades 3 or 4  
Grade 3:  
Prolonged (e.g. not rapi[INVESTIGATOR_38194]/or interruption of 
infusion; recurrence of symptoms 
following initial improvement; 
hospi[INVESTIGATOR_38195] (e.g., renal Stop Infusion.  
Additional appropriate medical therapy 
may include but is not limited to:  
Epi[INVESTIGATOR_238]**  
IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  No subsequent dosing  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
240 NCI CTCAE Grade  Treatment  Premedication at Subsequent 
Dosing  
impairment, pulmonary 
infiltrates))  
Grade 4:  
Life-threatening; pressor or 
ventilatory support indicated  Oxygen  
Pressors  
Corticosteroid s 
Increase monitoring of vital signs as 
medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_13046].  
Hospi[INVESTIGATOR_13021].  
**In cases of anaphylaxis, epi[INVESTIGATOR_90943].  
 
Participant is permanently discontinued 
from further study drug treatment.  
 
Please refer to the pharmacy manual for 
administration details.  
Appropriate resuscitation equipment should be available at the bedside and a physician readily  available 
during the period of drug administration.  
For further information, please refer to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE) at 
http://ctep.cancer.gov  
Abbreviations: NSAIDs = non -steroidal anti -inflammatory drugs.  
If a participant has an infusion related reaction, vital signs will be obtained every 
15 minutes (± 5 minutes) at the start of symptoms until the participant is deemed 
medically stable in the opi[INVESTIGATOR_871]; pulse oximetry should be performed in 
conjunction with vital signs.  
 
Adverse Events of Special Interest (AESI)  
Refer to Section [IP_ADDRESS]  for details. In addition, for AESIs of immune related cutaneous 
toxicities of any grade, recent alcohol intake or other potentially related concomitant 
exposures per Investigator assessment, should be recorded in the eCRF. Please refer to 
SRM for additional details.  
 
[IP_ADDRESS].  Safety Evaluation  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
241 If a participant withdraws from the study before the completion of the 21 -day DLT 
evaluation period for reasons other than DLT or becomes non -evaluable d uring the DLT 
period, then the participant may be replaced to achieve the three -participant required 
minimum. The decision to declare the combination tolerable will occur following review 
of the safety, PK and PD data (if available) and joint discussion by  [CONTACT_91050]. Membership, roles and accountabilities, and the process for 
safety review and meeting frequency is outlined in the Study Reference Manual.   
The mTPI [INVESTIGATOR_90918]:  
(iii) 
(iv) 
The monitoring rules guiding dose decision are provided in Table 48. The tolerability 
decision framework using the mTPI [INVESTIGATOR_90944] a beta/binomial 
model and pre -calculated before study initiation. The rules in Table 48 utilize the mTPI 
[INVESTIGATOR_90945]:  
• A maximum of DLT evaluable participants will be enrolled for DLT evaluatio n 
for each dose combination.  
• To avoid exposing participants to excessive toxicities, if or more DLTs occur at 
a dose combination, that dose combination will stop enrolling more participants 
and will de -escalate to lower dose combination (where applicable ). 
• Re-escalate to a dose combination is not allowed if that dose has been evaluated 
and the mTPI [INVESTIGATOR_90955] “D” or “DU”.  
The entries in the dose decision rules in Table [ADDRESS_100472]. The se points are often 
denoted as “E”, “S”, “D” and “DU”, denoting the thresholds governing escalating the 
dose, staying at the same dose, de -escalating the dose, or de -escalating and no longer re -
visit, respectively. To note, there is no “D” in Table 48 due to the above additional rules 
that re -escalation is not allowed. If a dose combination is not tolerated per Table 48, 
further evaluation of that dose combination will be stopped.  
 
CCI
C
CI
CC
I
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
242 additional participants experience DLTs, the rule indicates "DU" so this combination will 
not be considered acceptable and no additional participants will be treated with this 
combination because of unacceptable toxicity. However, if none of thes e additional 
participants experience DLTs, the rule indicates "S" with a DLT rate of % DLTs out 
of participants), hence the combination will be considered tolerated.  
 
If a combination is considered tolerated and the observed DLT rate is %, addit ional 
participants may be enrolled to further evaluate safety and PK/PD. No formal evaluation 
of DLTs will be performed after the 21 day period, however other measures of safety will 
continue to be monitored.  
 
CCI
CC
I
CCI
C
CI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
243 [IP_ADDRESS].  Dose Limiting Toxicity  
The severity of all toxicities will be graded using National Cancer Institute - Common 
Terminology  Criteria for Adverse Events (NCI -CTCAE) (version 5.0) [ NCI, 2017]. The 
DLT observation period is [ADDRESS_100473] one of the criteria listed in Table 49 and is 
considered by [CONTACT_91039] (probably, or 
possibly) to the study treatment during the 21 -day DLT observation period. An AE 
considered related to the underlying disease under study it is not defined as a D LT. A 
safety event can still be included for DLT consideration after the 21 day window. See 
Section 10.4 for the definition of a DLT evaluable partic ipant.  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
244 Table 49 Dose -Limiting Toxicity  Criteria  
Toxicity  DLT Definition (Grading per CTCAE v5)  
Hematologic  • Grade 4 neutropenia of any duration or febrile neutropenia   
• Grade 4 anemia of any  duration  
• Grade  4 thrombocytopenia  of any duration  or Grade  3 thrombocytopenia with  bleeding  
Non- hematologic  • Grade 2 uveitis, epi[INVESTIGATOR_227], iritis, eye pain, or blurred vision that does not respond to 
topi[INVESTIGATOR_139] G1 severity or requires systemic treatment.  
• Grade 2 colitis or diarrhea that persists without resolution to ≤ Grade 1 for ≥7 days 
despi[INVESTIGATOR_90946]  
• Grade 3 diarrhea/colitis lasting ≥72h regardless of medical intervention or G4 
diarrhea/colitis    
• Grade 3 pneumonitis  
• Grade 3 rash if no resolution to ≤Grade [ADDRESS_100474] of care  
• Grade 3 hypersensitivity or IRR   
• ALT ≥ 3x ULN plus bilirubin ≥ 2x ULN (>35% direct) or plus INR >1.5, if measure da 
(possible Hy’s Law)  
• Grade  3 toxicity  that does  not resolve  to ≤Grade  1 or baseline  within  3 days despi[INVESTIGATOR_90947] 4 toxicity  
• Following events are not considered  DLTs  
o ≥ Grade  3 electrolyte  abnormalities  that are corrected to  ≤ Grade 1 or 
baseline within 72 hours without clinical  sequelae  
o Grade 3 nausea or vomiting that resolves to ≤Grade 1 or baseline within 7 
days  
o ≥Grade 3 fatigue ≤7 days  
o ≥Grade 3 lymphopenia  
o Grade 3 elevation of amylase or lipase not associated with clini cal or 
radiographic evidence of pancreatitis  
 
Other  • Toxicity that results in permanent discontinuation of any agent  in combination   
• Any other toxicity considered to be dose -limiting that occurs after the completion of the DLT 
observation period will be c onsidered in the selection of the dose to recommend for 
expansion  cohorts  
• Any other  event  which  in the judgment  of the investigator  and [COMPANY_004]  Medical Monitor is 
considered to be a  DLT 
a. Not applicable to participants taking anticoagulants.  
b. Suggested toxicity management guidelines as described in Section [IP_ADDRESS]  may include systemic 
corticosteroids for immune -related toxicities; if systemic corticosteroids use delays administration of the 
second dose of study treatment and the event does not otherwise meet the DLT criteria for  non- hematologic 
toxicity, the dose delay will not be considered a  DLT.  
CTCAE=Common Toxicity Criteria for A dverse Events; DLT = Dose -limiting toxicity; G -CSF =Granulocyte 
colony -stimulating factor; [COMPANY_004] =GlaxoSmithKline; IRR=infusion related reaction  
 
If a participant experiences a DLT during the DLT observation period, the participant 
may resume dosing provided  the toxicity did not meet study treatment discontinuation 
criteria in Table  46 and following approval by [CONTACT_1034].  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
245 Toxicity management and dose modi fication guidelines provided in Section [IP_ADDRESS]  are 
directed for those AEs of special interest that, although not observed in nonclinical 
studies, may be expected with the administration of immune directed therapi[INVESTIGATOR_014].  
 
Guidance for the ident ification, evaluation, and the established algorithms for the 
treatment management of immune -related adverse events (irAEs) including dose 
modification  algorithms  are provided  in Section [IP_ADDRESS] . These  guidelines  are based on 
the experience of irAE management following the development of immune check -point 
inhibitors such as ipi[INVESTIGATOR_90928]. Guidelines are also provided for 
infusion reac tions or severe cytokine release ( Section [IP_ADDRESS].1 ). The joint ASCO and 
NCCN guidelines for the diagnosis and management of irAEs treated with immune 
checkpoint inhibitor therapy may be used as a supplement to the guidance provided in 
Section [IP_ADDRESS] . 
 
If there is a delay in administration of study treatment, refer to Section [IP_ADDRESS]  for 
guidance on planning of subsequent study visits.  
 
[IP_ADDRESS].  Risk -Benefit Assessment of [COMPANY_004]4428859A, [COMPANY_004]6097608 and 
Dostarlimab combined   
Table 50 Risk Assessment and Mitigation Strategy: [COMPANY_004]4428859A, 
[COMPANY_004]6097608 and Dostarlimab  
Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Immune -related AEs 
(irAEs)  
 
 
 • Inflammatory AEs such as diarrhea/colitis, 
pneumonitis, nephritis,  myoc arditis   and 
hepatotoxicity are well established as 
treatment emergent AEs with immune -
modulating agents, and are consistent 
with the immune -stimulatory mechanism 
of action of these agents.  
• An anti -PD-1 checkpoint inhibitor 
(dostarlimab) will be used in combinati on 
with an anti -TIGIT mAb ([COMPANY_004]4428859A)  
and anti -CD96 ([COMPANY_004]6097608) .  
• Based on the safety profile of anti PD -1 
antibodies, administered alone or in 
combination, the anticipated adverse 
reactions may be primarily immune 
mediated. Based on emerging data from 
anti-TIGIT mAbs, administered alone or in 
combination, the anticipated adverse 
reactions are similarly immune mediated.  
 • Participants with the following 
medical history are ineligible for this 
study  
o Toxicity ( ≥Grade 3) related to 
prior immunotherapy leadin g to 
study treatment discontinuation  
o Active autoimmune disease (refer 
to Section 6.2 exclusion criterion 
6) 
o Severe hypersensitivity to another 
mAb 
• Established management algorithms 
for immune -related adverse events 
(irAEs)   
• Refer to Section [IP_ADDRESS]  for further 
details on the identification, 
evaluation, and management of 
toxicities with a potential immune 
etiology.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
246 Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Infusion and 
hypersensitivity 
reactions and potential 
CRS  • Risk for infusion reactions and 
hypersensitivity is inherent to many 
mAbs [ Brennan , 2010]  
 
[COMPANY_004]6097608:  
• Manageable infusion reactions have 
been observed with [COMPANY_004]6097608 in the 
ongoing Phase 1 clinical study.  
 
Dostarlimab : 
• The frequency of IRRs with dostarlimab 
is labelled as common  
 
 
 [COMPANY_004]4428859A:  
• 
 
See Investigator’s Brochures for dostarlimab, 
[COMPANY_004]6097608 and [COMPANY_004]4428859A [ iTeos  
EOS884448 [EOS -448] IB, 2021] for details.  • Participants with history of severe 
hypersensitivity to another mAb or to 
the chemotherapi[INVESTIGATOR_90956].  
 
• Refer to Section [IP_ADDRESS]  for further 
details on management and 
monitoring of infusion reactions.   
• Refer to Section [IP_ADDRESS]  for further 
details on management of CRS  
• Refer to Protocol Section [IP_ADDRESS] ; 
Table 3 for details of blood panel 
collection for all participants 
experiencing any grade of infusion 
reaction or CRS  
• For severe (Grade 3) or 
life-threa tening (Grade 4) IRRs 
associated with [COMPANY_004]6097608, 
[COMPANY_004]4428859A or dostarlimab, 
infusion should be stopped, and 
treatment should be permanently 
discontinued.  
ADA and Immune 
complex disease  • Immune complex deposition may cause 
clinical symptoms, most commonly  renal, 
skin, or vasculitis pathology.  
• For nonclinical immune complex formation 
and deposition findings (refer to individual 
product Investigator’s Brochure  [IBs])  
• [COMPANY_004]4428859A and  [COMPANY_004]6097608 are  fully 
human IgG1 mAb with a wild -type Fc 
domain. Based on the characteristics of 
the molecules and active pharmaceutical 
ingredients, the risk of immunogenicity in 
humans is considered to be low and 
similar to other mAbs.  • Clinical laboratory safety 
assess ments and immunogenicity 
testing  
Reproductive toxicity  • 
• Immune -checkpoint inhibitors (such as 
dostarlimab) have been shown to have 
potential to disrupt maternal -fetal 
tolerance leading to failure of 
implantation or spontaneous abortion. A 
similar risk will be assumed for 
[COMPANY_004]6097608 and [COMPANY_004]4428859A . • Inclusion of  contraception guidelines 
for WOCBP (Section 6.1). 
• Exclusion of lactating or pregnant 
women (Section 6.2). 
• Pregnancy testing for WOCBP 
during Screening and throughout the 
Treatment period, as specified in the 
SoA (Section  [IP_ADDRESS]  and Section   
[IP_ADDRESS] ). 
Abbreviations: AE = adverse event; IB = Investigator’s Brochure; irAEs= immune -related adverse events; IRR= 
infusion -related reactions; mAb = monoclonal antibody.  
 
CCI
CCI
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
247 [IP_ADDRESS].  Additional Study Population Criteria: Arm 5  
[IP_ADDRESS].1.  Additional Inclusion Criteria: Arm 5  
1. Male contraception is not required for this arm.  
[IP_ADDRESS].2.  Additional Exclusion Criteria: Arm 5  
1. Known hypersensitivity to components or excipi[INVESTIGATOR_90957], [COMPANY_004]6097608, 
and/or [COMPANY_004]4428859A .  
2. Has received prior antibodies or drugs targeting TIGIT, CD96, PVRIG, or other 
therapi[INVESTIGATOR_90949]226 axis pathway.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
248 [IP_ADDRESS].  References  
Ahn MJ, Niu J, Kim D, Rasco D, Mileham KF, Chung HC, et al. Vibostolimab, an 
anti-TIGIT antibody, as monotherapy and in  combination with pembrolizumab in 
anti-PD-1/PD -L1-refractory NSCLC. Ann Oncol . 2020;31(Suppl  4):S754 -S840.  
Bendell JC, Bedard P, Bang YJ, LoRusso P, Hodi S, Gordon M, et al. Abstract CT302: 
Phase Ia/Ib dose -escalation study of the anti -TIGIT antibody tira golumab as a single 
agent and in combination with atezolizumab in patients with advanced solid tumors. 
Cancer Res . 2020;80(Suppl 16):CT302.  
Beyrend, G., et al., PD -L1 blockade engages tumor -infiltrating lymphocytes to co -
express targetable activating and i nhibitory receptors. J Immunother Cancer , 
2019; 7(1):217.  
Blake  SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, et al. Suppression of 
metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer 
Discov. 2016;6(4):446 -459. 
Chan CJ,  Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, et al. 
DNAM -1/CD155 interactions promote cytokine and NK cell -mediated suppression of 
poorly immunogenic melanoma metastases. J Immunol. 2010;184(2):902 -911. 
Chan CJ, Martinet L, Gilfillan S, So uza-Fonseca -Guimaraes F, Chow MT, Town L, et al. 
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell 
functions. Nat Immunol. 2014;15(5):431 -438. 
Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer . 
2020;8(2):e000957.  
Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional 
Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor 
Immunity. J Immunol . 2018;200(8):3000 -3007.  
Gilfillan S, Chan CJ, Cella M, Haynes NM , Rapaport AS, Boles KS, et al. DNAM -1 
promotes activation of cytotoxic lymphocytes by [CONTACT_91058] -presenting cells 
and tumors. J Exp Med. 2008;205(13):2965 -2973.  
Golan T, Bauer T, Jimeno A, Perets R, Niu J, Lee J, et al. Phase 1 dose -finding s tudy of 
the anti -TIGIT antibody MK -7684 as monotherapy and in combination with 
pembrolizumab in patients with advanced solid tumors. J Immunother Cancer . 
2018;6(suppl  1): O25.  
Gros A, et al. PD -1 identifies the patient -specific CD8(+) tumor -reactive repert oire 
infiltrating human tumors. J Clin Inves. , 2014;124(5):2246 -2259.  
[COMPANY_004] Document Number 2019N420882_00. Expression of CD96, TIGIT, and related 
family member expression in human tumor samples. Effective Date: 29 January 2020.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
249 [COMPANY_004] Document Number TMF -[ZIP_CODE] 520. Analysis of PD -1 receptor modulation by 
[CONTACT_91051] (TSR -042) using ex vivo IL2 stimulation ratio. Effective Date: 
[ADDRESS_100475]  2019.  
[COMPANY_004] Document Number RPS -SA-1628635. Population pharmacokinetic analysis and 
exploratory exposure -response analysis of do starlimab (TSR -042) (Study 4010 -01-001 
GARNET). Effective Date: 09  November  2020.  
[COMPANY_004] Document Number RPS -CLIN -014254. [COMPANY_004]6097608  Investigator's Brochure. 
Effective Date: 09  June 2021.  
Guillerey C , Harjunpää H, Carrié N, Kassem S, Teo T, Miles K,  et al. TIGIT immune 
checkpoint blockade restores CD8+ T -cell immunity against multiple myeloma. Blood. 
2018;132(16):[ADDRESS_100476] CD96 
and PD -1 or TIGIT enhances tumor immunity without significantly compromising 
immune homeostasis. Oncoimmunology. 2018;7(7):e1445949.  
Harjunpää  H, Guillery C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol.  
2020;200(2):108 -119. 
Hu F, Wang W, Fang C, Bai C. TIGIT presents earlier expressio n dynamic than PD -1 in 
activated CD8+  T cells and is upregulated in non -small cell lung cancer patients. Exp 
Cell Res . 2020;396(1):112260.  
Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, et al. TIGIT and 
PD-1 dual checkpoint blockade enha nces antitumor immunity and survival in GBM. 
Oncoimmunology . 2018;7(8):e1466769.  
Iguchi -Manaka A, Kai H, Yamashita Y, Shibata K, Tahara -Hanaoka S, Honda S, et al. 
Accelerated tumor growth in mice deficient in DNAM -1 receptor. J Exp Med. 
2008;205(13):2959 -2964. 
iTeos Investigator’s Brochure for EOS884448 (EOS -448) Edition 2.0 02 April 2021.  
Johnston RJ, Comps -Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The 
immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. 
Cancer C ell. 2014;26(6):923 -937. 
Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, et al. Treg cells expressing the 
coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell 
responses. Immunity.  2014; 40(4):[ADDRESS_100477], A.O., et al., Proliferation of PD -1+ CD8 T cells in peripheral blood after PD -
1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A, 2017. 114(19): p. 
4993 -4998.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
250 KEYTRUDA [package insert]. Whitehouse Station, NJ. [COMPANY_006] Sharp & Doh me 
Corporation; 2021.  
KEYTRUDA [Summary of Product Characteristics]. [COMPANY_006] Sharp & Dohme B.V., 2021.  
Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, et al. NCRs and 
DNAM -[ADDRESS_100478]. 2009;119(5):[ADDRESS_100479]. 
2018;128(6):2613 -2625.  
Lozano E, Dominguez -Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis 
regulates human T cell function. J Immunol. 2012;188(8):3869 –3875.  
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature.  2011; 
480(7378):[ADDRESS_100480] in gastric cancer. Cancer Sci. 
2018;109:[ADDRESS_100481], Gartlan KH, Zhang P, Wilkinson AN, Samson L,  et al. M yeloma 
escape after stem cell transplantation is a consequence of T -cell exhaustion and is 
prevented by [CONTACT_91052]. Blood . 2018;132(16):[ADDRESS_100482], Gartlan KH, Zhang P, Wilkinson AN, Samson L,  et al. Myeloma 
escape after stem cell tr ansplantation is a consequence of T -cell exhaustion and is 
prevented by [CONTACT_91052]. Blood. 2019;134(21):1878.  
Mittal  D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, et al. CD96 is an 
immune checkpoint that regulates CD8+ T -cell antitumor f unction. Cancer Immunol Res. 
2019;7(4):559 -571. 
National Cancer Institute (NCI). The Cancer Genome Atlas. 
https://www.cancer.gov/about -nci/organization/ccg/research/structural -genomics/tcga. 
Accessed 04  June 2021.  
Niu J, Nagrial A, Voskoboynik M, Chung HC,  Lee DH, Ahn M, et al. Safety and efficacy 
of vibostolimab, an anti -TIGIT antibody, plus pembrolizumab in patients with 
anti-PD-1/PD -L1-naive NSCLC. Ann Oncol . 2020;31(suppl 4): S754 -S840.  
OPDIVO [package insert]. Princeton, NJ. Bristol -Myers Squibb Compan y; 2021.  
OPDIVO [Summary of Product Characteristics]. Bristol -Myers Squibb Pharma EEIG; 
2021.  
Preillon J, Cuende J, Rabolli V, Garnero L, Mercier M, Wald N, et al. Restoration of 
T-cell effector function, depletion of Tregs, and direct killing of tumor ce lls: the multiple 
TMF- [ADDRESS_100483] antibodies. Mol Cancer Ther . 2021; 20(1), 
121–131. 
Rodríguez -Abreu D, Johnson ML, Hussein MA, Cobo M, Patel AJ, Secen NM, et al. 
Primary analysis of a randomized, double -blind, phase II study of t he anti -TIGIT 
antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as 
first-line (1L) treatment in patients with PD -L1-selected NSCLC (CITYSCAPE). J Clin 
Oncol . 2020;38(15_suppl):9503.  
Ryman  JT and Meibohm B. Pharmacokinetics of monoclonal anitbodies. CPT 
Pharmacometrics Syst Pharmacol . 2017;6:576 -588.  
Sharma S, Moore K, Mettu N, Garrido -Laguna I, Ulahannan SV, Khemka V, et al. Initial 
results from a Phase 1a/b study of etigilimab (OMP -313M32), an anti -T cell 
immunoreceptor with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors. 
J Immunother Cancer . 2018;6(suppl  1):P289.  
Stengel KF, Harden -Bowles K, Yu X, Rouge L, Yin J, Comps -Agrar L, et al. Structure of 
TIGIT immunoreceptor bound to poliovirus receptor reveals a cel l-cell adhesion and 
signaling mechanism that requires cis -trans receptor clustering. Proc Natl Acad Sci [LOCATION_003] . 
2012;109(14):5399 -5404.  
TESARO Investigator’s Brochure for Dostarlimab  Edition 6.0 19 April 2021.  
Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin 
Oncol.  2011;29(36):[ADDRESS_100484] -in-human study of EOS884448, a no vel potent anti -
TIGIT antibody, monotherapy shows favorable tolerability profile and early signs of 
clinical activity in immune -resistant advanced cancers. Cancer Res.  2021;81(13_Suppl): 
Abstract CT118.  
Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint 
receptor TIGIT prevents NK cell exhaustion and elicits potent anti -tumor immunity. Nat 
Immunol . 2018;19 (7):723 -732. 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
252 12.2.  Appendix 2: Abbreviations and Trademarks  
Abbreviation  Definition  
-hCG Beta-human chorionic gonadotropin  
ADA Anti-drug antibodies  
ADCC/P  Antibody -dependent cellular cytotoxicity/phagocytosis  
AE Adverse event  
AESI  Adverse events of special interest  
AKT V-AKT murine thymoma viral oncogene  
ALT Alanine aminotransferase  
AML Acute myeloid leukemia  
ANC  Absolute neutrophil count  
AST Aspartate aminotransferase  
AUC  Area under the concentration time curve  
AUC (0-) Area under the concentration -time curve over the dosing interval  
BAL Bronchoalveolar lavage  
BARC  Breast Cancer gene  
BCG  Bacillus calmette -guérin  
BNP B-type natriuretic peptide  
cfDNA  Cell-free DNA  
CHO  Chinese hamster ovary  
CIOMS  Council for international organizations of medical sciences  
CKD -EPI [INVESTIGATOR_90958];  
CNS  Central nervous system  
CONSORT  Consolidated standards of reporting trials  
CPK Creatine phosphokinase  
CPMS  Clinical pharmacology modeling and simulation  
CR Complete response  
CRA  Cytokine release assays  
CRC  Colorectal carcinoma  
CrCl Calculated creatinine clearance  
CRF Case report form  
CRP  C-reactive protein  
CRS  Cytokine release syndrome  
CSR  Clinical study  report  
CT Computed tomography  
CTCAE  Common terminology criteria for adverse events  
ct-DNA  Circulating tumor DNA  
CTLA -4 Cytotoxic t -lymphocyte -associated protein 4  
CV Cardiovascular  
DCR  Disease control rate  
DILI Drug -induced liver injury  
dL Deciliter  
DLT Dose limiting toxicity  
DNA  Deoxyribonucleic acid  
DoR Duration of response  
DRESS  Drug reaction with eosinophilia and systemic symptoms  
EC Effective concentration  
ECG  Electrocardiogram(s)  
ECHO  Echocardiography  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EOI End of infusion  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
253 Abbreviation  Definition  
Fc Fragment crystallizable  
FcR Fc-gamma receptor  
FcR Fc region receptor  
FDA Food and Drug Administration  
FDG -PET Fluorodeoxyglucose positron emission tomography  
FSH Follicle stimulating hormone  
FTIH  First-time-in-human  
GCP  Good clinical practice  
%GCV  Percent geometric coefficient of variation  
G-CSF Granulocyte colony -stimulating factor  
GI Gastrointestinal  
GM Geometric mean  
[COMPANY_004]  GlaxoSmithKline  
HIPAA  Health insurance portability and accountability act  
HLA Human leukocyte antigen  
HPLC  High performance liquid chromatography  
HR Hazard ratio  
HRD  Homologous recombination deficiency  
HRQL  Health related quality of life  
HRT Hormonal replacement therapy  
IB Investigator’s Brochure  
ICF Informed consent form  
ICH International council on harmonization of technical requirements for registration of 
pharmaceuticals for human use  
ICOS  Inducible t -cell costimulator  
iCPD  iRECIST Confirmed disease progression   
IDMC  Independent Data Monitoring Committee  
IEC Independent ethics committees  
IFN Interferon, gamma  
Ig Immunoglobulin  
IHC Immunohistochemistry  
IL Interleukin  
INR International normalized ratio  
IO Immunotherapy  
irAE Immune -related adverse event  
IRB Institutional review board  
iRECIST  Modified RECIST 1.[ADDRESS_100485]  
LLOQ  Lower limit of quantitation  
LPS Lipopolysaccharide  
LVEF  Left ventricular ejection fraction  
mAb Monoclonal antibody  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
254 Abbreviation  Definition  
MDS  Myelodysplastic syndrome  
MedDRA  Medical Dictionary for Regulatory Activities  
MLR  Mixed  lymphocyte reaction  
mmol  Millimolar  
MRI Magnetic resonance imaging  
MRSA  Methicillin -resistant Staphylococcus Aureus  
MTD  Maximum tolerated dose  
mTPI  [INVESTIGATOR_90959]-CTCAE  National Cancer Institute - Common Terminology Criteria for Adverse Events  
NCCN  National Comprehensive Cancer Network  
NE Not evaluable  
NIH National Institutes for Health  
NK Natural killer  
nM Nanomolar(s)  
NSAIDs  Non-steroidal anti -inflammatory drugs  
NT-pro-BNP N-terminal pro -hormone  BNP 
NYHA  [LOCATION_001] Heart Association  
ORR  Objective response rate  
OS Overall survival  
OTC  Over the counter  
PARP  Poly(ADP -ribose) polymerase  
PBMC  Peripheral blood mononuclear cells  
PBMC  Peripheral blood mononuclear cell  
PCR  Polymerase chain reaction  
PD Progressive disease  
PD-1 Programmed cell death protein 1  
PD-L1 Programmed cell death ligand 1  
PET Positron emission tomography  
PFS Progression -free survival  
PI [INVESTIGATOR_90960] -reported outcome  
PS Performance status  
PVRIG  Poliovirus Receptor -related Immunoglobulin Domain Containing  
Q1W Every 1 week  
Q2W  Every 2 weeks  
Q3W  Every 3 weeks  
QLQ  Quality of life questionnaire  
QoL Quality of life  
QTc Corrected QT interval duration  
QTcF QT duration corrected for heart rate by [CONTACT_6550]’s  formula  
RANKL  Receptor activator of nuclear factor -kappaB ligand  
RAP Reporting and analysis plan  
CCI
CCI
CCI
TMF- [ADDRESS_100486]  
  Keytruda  
  Opdivo  
  Taxotere  
  Yervoy (ipi[INVESTIGATOR_125])  
 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
256 12.3.  Appendix  3: Clinical Laboratory Tests  
Table [ADDRESS_100487] (SGOT)  
Creatinineb Sodium  Total protein  ALT (SGPT)  
Glucose  Calcium  Albumin  Alkaline phosphatase  
LDH Amylase  Lipase   
Coagulationd PT/INR  
PTT/aPTT  
Cardiac Function  Troponin I or Troponin T  (Troponin I is preferred over Troponin T. High 
sensitivity assays are preferred where available )  
BNP or NT -pro-BNP (NT -pro-BNP is preferred)  
Thyroid Function  Thyroid stimulating hormone  
Free T4  
Free T3 (when clinically indicated)  
Routine Urinalysis  Specific gravity  
pH, glucose, protein, blood and ketones by [CONTACT_5230] (Note: routine urinalysis 
by [CONTACT_91059], in accordance with local 
practice).  
Other Screening Tests  Hepatitis B sur face antigen (HBsAg)  
Hepatitis C (Hep C antibody)c 
Serum -hCG Pregnancy test (for women of child bearing potential)  
 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; -hCG = beta -human chorionic 
BNP = B -type natriuretic peptide; gonadotropin; BUN = blood urea nitrogen; HBsAg = Hepatitis B surface antigen; RBC 
= red blood cells; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic pyruvic transaminase; 
T3 = triiodothyronine; T4 = t hyroxine; WBC = white blood cells; INR = International Normalized Ratio; NT-pro-BNP = N -
terminal pro -hormone BNP; PT = Prothrombin Time; aPTT = Activated Partial Thromboplastin Time  
a.   Required if local laboratory testing is available  
b.   Creatinine cle arance is also required to be calculated using the formula provided in Appendix [ADDRESS_100488].  
d.   Coagulation factors (PT/INR and aPTT/PTT) should be tested per the SOA under each stud y arm in Section 12.[ADDRESS_100489] coagulation factors monitored closely 
throughout the study.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
257 12.4.  Appendix 4: Study Governance Considerations  
Regulatory and Ethical Considerations  
• This stud y will be conducted in accordance with the protocol and with:  
• Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Eth ical 
Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations  
• The protocol, protocol amendments, ICF, Investigator Brochure, and other 
relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by 
[CONTACT_22843]/IEC before the study is 
initiated.  
• Any amendments t o the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by [CONTACT_1201]/EC  
• Notifying the IRB/IEC of SAE or other significant safety findings as 
required by  [CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulati ons 
 
Financial Disclosure  
Investigators and sub -investigators will provide the Sponsor with sufficient, accurate 
financial information as requested to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the  appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
Informed Consent Process  
• The investigator or his/her representa tive will explain the nature of the study to 
the participant or his/her legally authorized representative and answer all 
questions regarding the study.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
258 • Participants must be informed that their participation is voluntary. Participants 
or their legally auth orized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_100490] (HIPAA) 
requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed co nsent 
must also sign the ICF.  
• Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant’s 
legally authorized representat ive.  
The ICF may contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research in accordance with SOP -[COMPANY_004]F -410. The 
investigator or authorized designee will explain to each participant the objectives of  the 
exploratory research. Participants will be told that they are free to refuse to participate 
and may withdraw their consent at any time and for any reason during the storage period. 
A separate signature [CONTACT_22862] a participant's agre ement to allow any 
remaining specimens to be used for exploratory research. Participants who decline to 
participate will not provide this separate signature.  
Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant 
records or datasets that are transferred to the Sponsor will contain the identifier 
only; participant names or any information which would make the participant 
identifiable will not be transferred.  
• The participant must be informed that his/her personal st udy-related data will be 
used by [CONTACT_9324]. The level of 
disclosure must also be explained to the participant.  
The participant must be informed that his/her medical records may be examined 
by [CONTACT_91060], by [CONTACT_6667]/IEC members, and by [CONTACT_91061].  
Committees Structure  
As indicated in Section 5.5.[ADDRESS_100491] of the study. Details 
describing the administrative structure for the Steering Committe e are located in the 
Steering Committee Charter.  
As indicated in Section 5.1, an IDMC will convene for review of efficacy and safety 
results at ap propriate intervals. Additional details of the IA will be provided in an IDMC 
Charter.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
259 Publication Policy  
• The results of this study may be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the Sponsor before submission. This allows the Sponsor to protect proprietary 
information  and to provide comments.  
• The Sponsor will comply with the requirements for publication of study results. 
In accordance with standard editorial and ethical practice, the Sponsor will 
generally support publication of multicenter studies only in their entir ety and not 
as individual site data. In this case, a coordinating investigator [INVESTIGATOR_28397].  
• Authorship will be determined by [CONTACT_43217].  
Dissemination of Clinical Study Data  
• Where required by [CONTACT_25435], an investigator signatory 
will be identified for the approval of the clinical study report. The investigator 
will be provided reasonable access to stat istical tables, figures, and relevant 
reports and will have the opportunity to review the complete study results at a 
[COMPANY_004] site or other mutually -agreeable location.  
• [COMPANY_004] will also provide the investigator with the full summary of the study 
results. The inve stigator is encouraged to share the summary results with the 
study participants, as appropriate.  
• The procedures and timing for public disclosure of the results summary and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] 
Polic y. 
• The Sponsor will comply with the requirements for publication of study results 
and will publish the results of each substudy within 12 months of the primary 
completion date (last participant last visit date).  
Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the Sponsor or designee electronically (e.g., 
laboratory data). The investigator is responsible for verifying that data entries 
are accurate and correct by [CONTACT_61530].  
• The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF.  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency  inspections and provide direct access to source data 
documents.  
• The Sponsor or designee is responsible for the data management of this study 
including quality checking of the data.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
260 • Study monitors will perform ongoing source data verification to confirm that 
data entered into the CRF by [CONTACT_1191], complete, 
and verifiable from source documents; that the safety and rights of participants 
are being protected; and that the study is being conducted in accordance with the 
currently  approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
• Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by [CONTACT_1732] 25 years from the issue o f the final 
Clinical Study Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the 
Sponsor. No record s may be transferred to another location or party without 
written notification to the Sponsor.  
• Quality tolerance limits (QTLs) will be pre -defined in the QTL plan to identify 
systematic issues that can impact participant reliability of study results. Thes e 
pre-defined parameters will be monitored during and at the end of the study and 
all deviations from the QTLs and remedial actions taken will be summarized in 
the clinical study report.  
Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source do cuments or the 
discrepancies must be explained. The investigator may need to request previous 
medical records or transfer records, depending on the study. Also, current 
medical records must be available.  
• Definition of what constitutes source data can be fo und in the investigator Site 
File. 
Study and Site Closure  
[COMPANY_004] or its designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of [COMPANY_004] . Study sites will be closed upon study 
completion . A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study  site closure at any time, provided there is reasonable 
cause and suffi cient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_31856]:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by [CONTACT_093]  
• Discontinuation of further study treatment development.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
261 12.5.  Appendix 5: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, 
temporally associated with the use of a study treatment, whether or not considered 
related to the stud y treatment.  
• NOTE:  An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a study treatment.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the  medical and scientific judgment of the investigator (i.e., not 
related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New  conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequ elae of a suspected overdose of either study 
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported r egardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resul ting 
from lack of efficacy will be reported as AE or SAE if they fulfill the definition of 
an AE or SAE.  
 
 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
262 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by 
[CONTACT_19448]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied,  unless more severe than expected for the 
participant’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
 
Definition of SAE  
If an event is not an AE per definition above,  then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study, 
death due to progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if  it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_90961] w ard for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_90962], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the 
AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered  an AE.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
263 d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth d efect  
f. Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_90963]. These events 
should usually be considered serious.  
Examples of such events include invasive or mali gnant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse.  
 
Definition of Cardiovascular Events  
Card iovascular Events (CV) Definition:  
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:  
• Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
•  Revascularization  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
264 Recording AE and SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF.  
• It is not acceptable for  the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] AE/SAE CRF page.  
• There may be instances when copi[INVESTIGATOR_31784]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical i nformation. Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Severity  
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and will assign a grade according to the NCI -CTCAE v5.0 [ NCI, 
2017].  
 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment 
and each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship  conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Pro duct 
Information, for marketed products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE ha s occurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004]. However, it is very 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
265 important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to G SK. 
• The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AE and SAE  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_42383]/or causality of  the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a r ecognized 
follow -up period, the investigator will provide [COMPANY_004] with a copy of any post -
mortem findings including histopathology.  
• New or updated information will be recorded in the originally completed CRF.  
• The investigator will submit any updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.  
 
Reporting of SAE to [COMPANY_004]  
SAE Reporting to [COMPANY_004]  via Electronic Data Collection Tool  
• The primary mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.  
• If the electronic system i s unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is comple ted at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives 
updated data on a previously reported SAE after the electronic data collection tool 
has been taken off -line, then the site can report this information on a paper SAE 
form (see next section) or to the Medical Monitor by [CONTACT_756].  
• Contacts for SAE reporting can be found in the SRM on the Sponsor/Medical 
Monitor Contact [CONTACT_23774].  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
266  
SAE Reporting to [COMPANY_004] via Paper CRF  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the SAE c oordinator to [EMAIL_247].  
• In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by 
[CONTACT_22855].  
• Initial notification via telepho ne does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time 
frames.  
• Contacts for SAE reporting can be found in the SRM.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
267 12.6.  Appendix  6: Contraceptive Guidance and Collection of 
Pregnancy Information  
Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile (see below)  
Women in the following categories are not considered WOCBP  
1. Premenarch al 
2. Premenopausal female with ONE of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
Note:  Documentation can come from the site personnel’s: review of participant’s 
medical records, medical examination, or medical history interview.  
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an 
alternative medical  cause . A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy 
(HRT) . However, in the absence of 12 months of ameno rrhea, a single FSH 
measurement is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highly effective contraception methods if they wish 
to continue their HRT during the study. Otherwise, they must discontinue HRT 
to allow confirmation of postmenopausal status before study enrollment.  
Contraception Guidance  
Male participants  (if required)  
• Male participants with female partners of child -bearing potential are eligible to 
participate if they agree to ONE of the following during the protocol -defined 
time frame in Section 6.1:  
• Are abstinent from penile -vaginal intercourse as their usual and preferred 
lifestyle (abstinent on a long term and persistent basis) and agree to remain 
abstinent  
• Agree to use a male condom plus an additional metho d of contraception 
with a failure rate of <1% per year as described in Table 52 when having 
penile -vaginal intercourse with a woman of childbearing pote ntial  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
268 • Men with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_90964] [ADDRESS_100492] dose of  study treatment.  
• In addition, male participants must refrain from donating sperm for duration of 
study and for at least [ADDRESS_100493] dose of study treatment.  
• If the participant is randomized to the SoC regimen only, then the duration of 
contrac eption is at least [ADDRESS_100494] dose of study treatment (or per 
institutional standard).  
Female participants  
Female participants of childbearing potential are eligible to participate if they agree to 
use a highly effective method of contraception consistently and correctly as described in 
Table 52.  
Table 52 Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependent a 
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationb  
• oral 
• intravaginal  
• transdermal  
Progestogen -only hormonal contraception associated with inhibition of ovulationb  
• injectable  
Highly Effective Methods That Are User Independent  
• Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulationb 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• bilateral tubal occlusion  
Vasectomized partner  
(A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.)  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
269 Highly Effective Methods That Are User Independent  
Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the stud y drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.)   
a. Typi[INVESTIGATOR_35818]. Use should be consistent with 
local regulations regarding the use of contraceptive methods for participants in clinical studies.  
b. Hormonal contraception may be susc eptible to interaction with the study drug, which may reduce the efficacy of the 
contraceptive method. In this case [ADDRESS_100495] dose of study treatment.  
 
Pregnancy Testing  
• WOCBP should only be included after a confirmed menstrual  period and a negative 
highly sensitive serum β -hCG test  
• Additional pregnancy testing should be performed at monthly intervals as indicated 
in the SoA during the treatment period and at for at least [ADDRESS_100496] dose 
of study treatment.  
Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected. Pregnancy testing (serum β -hCG) will be 
performed by [CONTACT_91062].   
Collection of Pregnancy Information.  
Male participants with partners who become pregnant  
• Investigator will attempt to collect pregnancy information on any male participant’s 
female partner of a male study participant who becomes pregnant while participating 
in this study. This applies only to participants who receive study treatment.  
• After obtaining the necessary signed informed consent fr om the pregnant female 
partner directly, the investigator will record pregnancy information on the 
appropriate form and submit it to [COMPANY_004] within 24 hours of learning of the partner’s 
pregnancy.  
• Partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to [COMPANY_004]  
• Generally, follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
270 Female Participants who become pregnant  
• Investigator will collect pregnancy information on any female participant, who 
becomes pregnant while participating in this study.  
• Information will  be recorded on the appropriate form and submitted to [COMPANY_004] within 
24 hours of learning of a participant's pregnancy.  
• Participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on participant and neonate, which will 
be forwarded to [COMPANY_004] Generally, follow -up will not be required for longer than 6 to 8 
weeks beyond the estimated delivery date.  
• Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomal ies) or indication for procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
• A spontaneous abortion is always consid ered to be an SAE and will be reported as 
such.  
• Any SAE occurring as a result of a post -study pregnancy which is considered 
reasonably related to the study treatment by [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix 5 . While the investigator is not obligated to actively seek 
this information in former study participants, he or she may learn of an SAE through 
spontaneous reporting.  
Any female participant who b ecomes pregnant while participating will be discontinued 
from study treatment.  
 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
271 12.7.  Appendix  7: Genetics  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
272 12.8.  Append ix 8: ECOG Performance Status  
Grade  Descriptions  
0 Normal activity. Fully active, able to carry on all pre -disease performance 
without restriction.  
1 Symptoms, but ambulatory. Restricted in physically strenuous activity, but 
ambulatory and able to carry out work of a light or sedentary nature ( e.g., 
light housework, office work).  
2 In bed <50% of the time. Ambulatory and capable of all self -care, but 
unable to carry out any work activities. Up and about more than 50% of 
waking hours.  
3 In bed >50% of the time. Capable of only limited self -care, confined to bed 
or chair more than 50% of waking hours.  
4 100% bedridden. Completely disabled. Cannot carry on any self -care. 
Totally confined to bed or chair.  
5 Dead.  
1. [Oken , 1982]  
 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
273 12.9.  Appendix 9: CKD -EPI [INVESTIGATOR_90844] -Gault Formulas  
CKD -EPI [INVESTIGATOR_90965]: Kidney Disease Outcomes Quality Initiative (KDOQI) CKD stages 3/4/5 
defined by [CONTACT_91063][INVESTIGATOR_10444] (CKD -EPI) formula 
[Levey, 2009] . 
GFR = 141 × min (S cr /κ, 1)α × max(S cr /κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 
1.159 [if black]  
where:  
Scr is serum creatinine in mg/dL,  
κ is 0.7 for females and 0.9 for males,  
α is -0.329 for females and -0.411 for males,  
min indicates the minimum of S cr /κ or 1, and  
max indicates the maximum of S cr /κ or 1.  
Cockcroft -Gault Formula  
The Cockcroft -Gault formula is a commonly -used surrogate marker for actual creatinine 
clearance (CrCl) and employs creatinine measurements and a participant’s weight (kg) to 
predict the clearance.  
If the participant is obese (>30% o ver ideal body weight ), use ideal body weight in 
calculation of estimate CrCl.  
If the participant is below ideal body weight , use actual body weight in calculation of 
estimate CrCl.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
274 Cockcroft -Gault Formula for serum creatinine in mmol/L  
   
CrCl (mL/min)=  Q X (140 -age [years]) X ideal body weight (kg)a 
 72 X serum creatinine (mmol/L)  
Q=0.85 for females  
Q=1.0 for males  
a. Calculation of Ideal Body Weight Using the Devine Formula [ Devine , 1974]  
Male participants:    
 50.0 kg + (2.3 kg X each inch over 5 feet)  
or 
50.0 kg + (0.906 kg X each cm over 152.4 cm)  
Female participants:    
 45.5 kg + (2.3 kg X each inch over 5 feet)  
or 
45.5 kg + (0.906 kg X each cm over 152.4 cm)   
 
Cockcroft -Gault Formula for serum creatinine in mg/dL  
 
 
For example:  
For a male participant with actual body weight = 90.0 kg and height = 68 inches, the 
calculation would be as follows:  
Ideal body weight= 50.0 + (2.3) (68 -60) = 68.4 kg  
This participant’s actual body weight is >30% over ideal body weight. In this case, the 
participant’s ideal body weight of 68.4 kg should be used in calculating estimated 
creatinine clearance.  
 

TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
275 12.10.  Appendix 10: Liver Safe ty: Required Actions and Follow -up 
Assessments and Study Treatment Rechallenge Guidelines  
Phase [ADDRESS_100497] at Baseline:  
Phase 2 Liver Chemistry Stoppi[INVESTIGATOR_90966] -Up Assessments  
Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_42250] - absolute  ALT  5xULN  
ALT Increase  ALT  3xULN persists for 4 weeks  
Bilirubin1, 2 ALT  3xULN and bilirubin  2xULN (>35% direct bilirubin)  
INR2  ALT  3xULN and INR>1.5, if INR measured  
Cannot Monitor  ALT  3xULN and cannot be monitored weekly for 4 weeks  
Symptomatic3 ALT  3xULN associated with symptoms (new or worsening) believed to 
be related to liver injury or hypersensitivity  
Required Actions and Follow -up Assessments Following ANY Liver Stoppi[INVESTIGATOR_53056]*  
Actions  Follow -Up Assessments  
• Immediately discontinue study treatment  
 
• Report the event to [COMPANY_004]  within 24 hours  
• Complete the liver event CRF and complete SAE 
data collection tool if the event also meets the 
criteria for an SAE2 
• Perform liver event follow -up assessments  
• Monitor the participant until liver chemistries resolve, 
stabilize, or return to within baseline (see 
MONITORING  below)  
• Do not restart/rechallenge  participant with study 
treatment unless allowed per protocol and [COMPANY_004] 
Medical Governance approval is granted   
• If restart/rechallenge not allowed per protocol or 
not granted , permanently discontinue study 
treatment and may continue participant in the study 
for any protocol specified follow -up assessments  
  MONITORING:  • Viral hepatitis serology4 
• Obtain INR and recheck with each liver chemistry 
assessment until the transaminases values show 
downward trend  
• Only in those with underlying chronic hepatitis B at 
study entry (identified by [CONTACT_91064] B surface 
antigen) quantitative hepatitis B DNA and hepatitis delta 
antibody5.  
• Blood sample for pharmacokinetic (PK) analysis, 
obtained [ADDRESS_100498] dose6 
• Serum creatine phosphokinase (CPK) and lactate 
dehydrogenase (LDH).  
• Fractionate bilir ubin, if total bilirubin 2xULN  
• Obtain complete blood count with differential to assess 
eosinophilia  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
276 For bilirubin or INR criteria:   
• Repeat liver chemistries (include ALT, AST, alkaline 
phosphatase, bilirubin) and perform liver event 
follow -up assessments within 24 hrs  
• Monitor participants twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline  
• A specialist or hepatology consultatio n is 
recommended  
For All other criteria:   
• Repeat liver chemistries (include ALT, AST, alkaline 
phosphatase, bilirubin) and perform liver event 
follow -up assessments within 24-72 hrs  
• Monitor participants weekly until liver chemistries 
resolve, stabilize or  return to within baseline  
 • Record the appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on the AE 
report form  
• Record use of concomitant medications on  the 
concomitant medications report form including 
acetaminophen, herbal remedies, other over the 
counter medications  
• Record alcohol use on the liver event alcohol intake 
case report form  
For bilirubin or INR criteria:  
• Anti-nuclear antibody, anti -smooth muscle antibody, 
Type 1 anti -liver kidney microsomal antibodies, and 
quantitative total immunoglobulin G (IgG or gamma 
globulins)  
• Serum acetaminophen adduct HPLC assay (quantifies 
potential acetaminophen contribution to liver injury in 
participants with de finite or likely acetaminophen use in 
the preceding week  [James , 2009]). NOTE: not 
required in China   
• Liver imaging (ultrasound, magnetic resonance, or 
computerised tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms  
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant if ALT  3xULN and bilirubin  2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury.  
2. All events of ALT  3xULN and bilirubin  2xULN  (>35% direct bilirubin) or ALT  3xULN and INR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the th reshold 
value stated will not apply to participants receiving anticoagulants  
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, or jaundice) or believed to be relate d to hypersensitivity (such as fever, 
rash or eosinophilia)  
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis 
C RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody ( or if unavailable, obtain 
heterophile antibody or monospot testing); Hepatitis E IgM antibody  
5. If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) Le Gal , 2005].  
6. PK sample may not be required for participants known to be receiving placebo or non -[COMPANY_004] comparator 
treatments.) Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the 
participant’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample 
cannot be coll ected in the time period indicated above, do not obtain a PK sample. Instructions for sample 
handling and shippi[INVESTIGATOR_42253].  
*Study drugs refer to all drugs that comprise a study treatment arm. Refer to the central laboratory manual for 
instructions on sample requirements for follow -up tests performed at central laboratory.  
 
TMF- [ADDRESS_100499] at Baseline:  
Phase 2 Liver Chemistry Stoppi[INVESTIGATOR_90966] -Up Assessments  
Liver Chemistry  Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_90967]  5xULN and 2x baseline value  
ALT Increase  Both  ALT  3xULN and ≥ 1.5x baseline value that persists for 4 weeks  
Bilirubin1, 2 ALT  3xULN and bilirubin  2xULN (>35% direct bilirubin)  
INR2  ALT  3xULN and INR>1.5, if INR measured  
Cannot Monitor  Both  ALT  3xULN and ≥ 1.5x baseline value that cannot be monitored for 4 
weeks  
Symptomatic3 
 Both  ALT  3xULN and ≥ 1.5x baseline value associated with symptoms 
(new or worsening) believed to be related to liver injury or hypersensitivity  
Required Actions and Follow -up Assessments following ANY Liver Stoppi[INVESTIGATOR_53056]*  
Actions  Follow -up Assessments  
• Immediately discontinue study treatment  
 
• Report the event to [COMPANY_004]  within 24 hours  
• Complete the liver event CRF and complete SAE 
data collection tool if the event also meets the 
criteria for an SAE2 
• Perform liver event follow -up assessments  
• Monitor the participant until liver chemistries resolve, 
stabilize, or return to within baseline (see 
MONITORING  below)  
• Do not restart/rechallenge  participant with study 
treatment unless allowed per protocol and [COMPANY_004] 
Medical Governance approval is granted   
• If restart/rechallenge not allowed per protocol or 
not granted , permanently discontinue study 
treatment and may continue participant in the study 
for any protocol specified follow -up assessments  
MONITORING:  
For bilirubin or INR criteria:   
• Repeat liver chemistries (include ALT, AST, alkaline 
phosphatase, bilirubin) and perform liver event 
follow -up assessments within 24 hrs  • Viral hepatitis serology4 
• Obtain INR and recheck with each liver chemistry 
assessment until the transaminases values show 
downward trend  
• Only in those with underlying chronic hepatitis B at study 
entry (identified by  [CONTACT_23977] B surface antigen) 
quantitative hepatitis B DNA and hepatitis delta 
antibody5 
• Blood sample for pharmacokinetic (PK) analysis, 
obtained [ADDRESS_100500] dose6 
• Serum creatine phosphokinase (CPK) and lactate 
dehydrogenase (LDH).  
• Fractio nate bilirubin, if total bilirubin 2xULN  
• Obtain complete blood count with differential to assess 
eosinophilia  
• Record the appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on the AE 
report form  
• Record use of concomitant medications on the 
concomitant medications report form including 
acetaminophen, herbal remedies, other over the counter 
medications  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
278 • Monitor participants twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline  
• A specialist or hepatology  consultation is 
recommended  
For All other criteria:   
• Repeat liver chemistries (include ALT, AST, alkaline 
phosphatase, bilirubin) and perform liver event 
follow -up assessments within 24-72 hrs  
• Monitor participants weekly until liver chemistries 
resolve, stabilize or return to within baseline  
 • Record alcohol use on the liver event alcohol intake 
case report form  
For bilirubin or INR criteria:  
• Anti-nuclear antibody, anti-smooth muscle antibody, 
Type 1 anti -liver kidney microsomal antibodies, and 
quantitative total immunoglobulin G (IgG or gamma 
globulins)  
• Serum acetaminophen adduct HPLC assay (quantifies 
potential acetaminophen contribution to liver injury in 
particip ants with definite or likely acetaminophen use in 
the preceding week  [James , 2009]). NOTE: not 
required in China   
• Liver imaging (ultrasound, magnetic resonance, or 
computerised tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms  
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant if ALT  3xULN and bilirubin  2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin on 
dipstick, indicating direct bilirubin elevations and suggesting liver injury.  
2. All events of ALT  3xULN and bilirubin  2xULN  (>35% direct bilirubin) or ALT  3xULN and INR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis); INR measurement is not required and the th reshold value stated will 
not apply to participants receiving anticoagulants  
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be relate d to hypersensitivity (such as fever, rash or 
eosinophilia)  
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody ( or if unavailable, obtain 
heterophile antibody or monospot testing); Hepatitis E IgM antibody  
5. If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) Le Gal , 2005].  
6. PK sample may not be required for participants known to be receiving placebo or non -[COMPANY_004] comparator 
treatments.) Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to blood sample draw on the CRF. If  the date or time of the last dose is unclear, provide the 
participant’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be collected in the time period indicated above, do not obtain a PK sample. Instruct ions for sample handling and 
shippi[INVESTIGATOR_42253].  
*Study drugs refer to all drugs that comprise a study treatment arm. Refer to the central laboratory manual for 
instructions on sample requirements for follow -up tests performed at central laboratory.  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
279 12.10.3.  Phase 2 Liver Chemistry Increased Monitoring Criteria with 
Continued Therapy  
In the event a participant has an increase in ALT, bilirubin, and/or INR that does not 
require stoppi[INVESTIGATOR_90968] (does not meet liver chemistry stoppi[INVESTIGATOR_90969] 12.10.1  and Section 12.10.2 ), the following guidance for monitoring of 
the increase in ALT, bilirubin, and/or INR should be followed as noted below.   
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event  
Criteria  Actions  
Participant with entry criteria ALT≤2.5x 
ULN 
ALT 3xULN but <5xULN and 
 bilirubin <2xULN, without  symptoms believed 
to be related to liver injury or hypersensitivity 
and who can be monitored weekly for 4 weeks  
Participant with documented  liver 
metastases/tumor infiltratio n at baseline 
AND entry criteria ALT>2.[ADDRESS_100501] but ≤[ADDRESS_100502] 
ALT ≥3x ULN and 1.5x baseline value but ALT 
<5x ULN and 2x baseline value and bilirubin 
<2xULN , without  symptoms believed to be 
related to liver injury, or hypersensitivity and 
who can be monitore d weekly for 4 weeks  
 • Notify the [COMPANY_004] Medical Monitor within 24 hours  
of learning of the abnormality to discuss participant 
safety.  
• Participant can continue study treatment  
• Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline  
• If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described  above  
For participants with entry criteria ALT≤2.[ADDRESS_100503]  
• If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participants twice 
monthly until liver chemistries normalize or return 
to within baseline.  
For participants with documented liver 
metastases/tumor infiltration at baseline AND entry 
criteria ALT>2.[ADDRESS_100504] but ≤[ADDRESS_100505]  
• If, after 4 weeks of monitoring, ALT <3xULN and 
<1.5x baseline value, and bilirubin <2xULN, 
monitor participants twice monthly until liver 
chemistries normalize o r return to within baseline  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
280 12.10.4.  Liver Safety Drug Restart or Rechallenge Guidelines  
[IP_ADDRESS].  Rechallenge Following Liver Stoppi[INVESTIGATOR_42255] -induced liver injury, drug rechallenge is associated with a 13% 
mortality across all drugs in prospective studies [Andrade , 2009 ]. Clinical outcomes 
vary by [CONTACT_9934], with nearly 50% fatality with halothane readministered within 1 month of 
initial injury. However, some drugs seldom result in recurrent liver injury or f atality.  
Risk factors for a fatal drug rechallenge outcome include:  
• Hypersensitivity [ Andrade , 2009] with initial liver injury (e.g. fever, rash, 
eosinop hilia)  
• jaundice or bilirubin >2xULN with initial liver injury (direct bilirubin >35% of 
total)  
• participant currently  exhibits severe liver injury defined by: [CONTACT_42386] 3xULN, 
bilirubin 2xULN (direct bilirubin >35% of total), or INR1.5 
• serious adverse event or fatality has earlier been observed with drug 
rechallenges [ Papay , 2009; Hunt , 2010]  
• evidence of drug -related preclinical liability (e.g. reactive metabolites; 
mitochondrial impairment [ Hunt , 2010])  
Rechallenge refers to resuming study treatment following drug induced liver injury 
(DILI). Because of the risks associated with rechallenge after DILI this should only be 
considered for a participant for whom there is compelling evidence of benefit from a 
critical or life -savin g medicine, there is no alternative approved medicine available, and a 
benefit:risk assessment of rechallenge is considered to be favorable.  
Approval by [CONTACT_42387]:  
• Investigator requests consideration o f rechallenge with study treatment for a 
participant who is receiving compelling benefit (partial response or complete 
response) with study treatment that exceeds risk, and no effective alternative therapy 
is available.  
• The ALT at the time of rechallenge is <3x ULN.  
• The participant did not have additional risk factors for a fatal outcome following the 
initial injury including hypersensitivity, jaundice, bilirubin >2x ULN (direct bilirubin 
>35% of total bilirubin), or INR >1.5.  
• Ethics Committee or Instituti onal Review Board approval for rechallenge with study 
treatment must be obtained, as required.   
• If the rechallenge is approved by [CONTACT_90652], the 
participant must be provided with a clear description of the possible benefits and 
risks of study treatment administration, including the possibility of recurrent, more 
severe liver i njury or death.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
281 • The participant must also provide signed informed consent specifically for the 
rechallenge with study treatment. Documentation of informed consent must be 
recorded in the study chart.  
• Study treatment must be administered at the dose speci fied by [CONTACT_23983].  
• Participants approved by [CONTACT_91065] a week for liver chemistry tests until stable 
liver chemistries have been demonstrated and then standard laboratory monitoring  
may resume as per protocol.  
• If after study treatment rechallenge, participant meets protocol -defined liver 
chemistry stoppi[INVESTIGATOR_3418], study treatment should be permanently discontinued.  
• Medical Monitor, and the Ethics Committee or Institutional Review Board as 
required, must be informed of the participant’s outcome following study treatment 
rechallenge.  
• [COMPANY_004] must be notified of any AEs as per Section 9.4.4 . 
 
[IP_ADDRESS].  Rechallenge Following Transient Liver Stoppi[INVESTIGATOR_90970] a clear underlying cause (other than DILI) of the liver event (e.g., biliary obstruction, 
pancreatic events, hypotension, and acute viral hepatitis). Furthermore, there should be 
no evidence of alcoholic hepatitis or hypersensitivity  
Approval by [CONTACT_42390]:  
• Investigator re quests consideration for study treatment restart if liver chemistries 
have a clear underlying cause (e.g., biliary obstruction, hypotension and liver 
chemistries have improved to normal or are within 1.5 x baseline and ALT 
<3xULN).  
• Possible study treatment -induced liver injury has been excluded by [CONTACT_91066]. This includes the absence of markers of hypersensitivity 
(otherwise unexplained fever, rash, eosinophilia). Where a study treatment has an 
identified genetic marker associated with liver injury (e.g. lapatinib, abacavir, and 
amoxicillin/clavulanate), the presence of the marker should be excluded. If study 
treatment -related liver injury cannot be excluded, the guidance on rechallenge in 
Section [IP_ADDRESS]  will apply.  
• There is no evidence of alcoholic hepatitis.  
• Ethics Committee or Institutional Review Board approval of study treatment restart 
must be obtained, as required.  
• If restart of study treatment is approved by [CONTACT_90652], the 
participant must be provided with a clear description of the possible benefits and 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
282 risks of study treatment administration, including the possibility of recurrent, more 
sever e liver injury or death.  
• The participant must also provide signed informed consent specifically for the study 
treatment restart. Documentation of informed consent must be recorded in the study 
chart.  
• Study treatment must be administered at the dose speci fied by [CONTACT_23983].  
• Participants approved by [CONTACT_91067] a week for liver chemistry tests until stable liver 
chemistries have been demonstrated and then laboratory monitoring may resume as 
per protocol.  
• If after study treatment re -start, participant meets protocol -defined liver chemistry 
stoppi[INVESTIGATOR_3418], follow usual stoppi[INVESTIGATOR_53058].  
• Medical Monitor, and the Ethics Committee or Institutional Review Board as 
required, must be  informed of the participant’s outcome following study treatment 
restart.  
• [COMPANY_004] must be notified of any AEs, as per Section 9.4 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
283 12.11.  Appendix 11: Country -Specific Requirements  
Korea:  Section 6.1, Inclusion Criteria #2: Participants in Korea must be age 19 years or 
older at the time consent is obtained.  
 
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
284 12.12.  Appendix 12: Guidelines for Assessment of Disease, 
Disease Progression and Response Criteria  
12.12.1.  RECIST 1.1 Guidelines  
Please note the following:  
• The same diagnostic method, including use of contrast when applicable, must be 
used throughout the study to evaluate a lesion. Contrast agents must be used in 
accordance with the Image Acqu isition Guidelines.  
• All measurements must be taken and recorded in millimeters (mm), using a ruler 
or calipers.  
• Ultrasound is not a suitable modality of disease assessment. If new lesions are 
identified by [CONTACT_2207], confirmation by [CONTACT_91068].  
• Fluorodeoxyglucose (FDG) -PET is generally not suitable for ongoing assessments 
of disease. However, FDG -PET can be useful in confirming new sites of disease 
where a positive FDG -PET scans correlates with the new site of disease present 
on CT/MRI or when a  baseline FDG -PET was previously negative for the site of 
the new lesion. FDG -PET may also be used in lieu of a standard bone scan 
providing coverage allows interrogation of all likely sites of bone disease and 
FDG -PET is performed at all assessments.  
• If PET/CT is performed then the CT component can only be used for standard 
response assessments if performed to diagnostic quality, which includes the 
required anatomical coverage and prescribed use of contrast. The method of 
assessment must be noted as CT on the eCRF.  
Clinical Examination:  Clinically detected lesions will only be considered measurable 
when they are superficial (e.g., skin nodules). In the case of skin lesions, documentation 
by [CONTACT_6775], including a ruler/calipers to measure the size o f the lesion, is 
required.  
CT and MRI:  Contrast enhanced CT with [ADDRESS_100506] by [CONTACT_91069]. When ever possible, the same 
scanner should be used.  
X-ray: In general, X -ray should not be used for target lesion measurements owing to 
poor lesion definition. Lesions on chest X -ray may be considered measurable if they are 
clearly defined and surrounded by [CONTACT_91070]; however, chest CT is preferred over 
chest X -ray. 
Brain Scan:  If brain scans are required, then contrast enhanced MRI is preferable to 
contrast enhanced CT.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
285 Guidelines for Evaluation of Disease  
Evaluation of Anti -Cancer Activity  
• RECIST version 1.[ADDRESS_100507] target and non -target lesions, and in the disease assessments 
through the duration of the study [ Eisenhauer , 2009].  
• As indicated in RECIST version 1.1 guidelines:  
o Lymph nodes that have a short axis of <[ADDRESS_100508] not be recorded or followed.  
o Pathological lymph nodes with <15  mm, bu t 10 mm short axis are 
considered non -measurable.  
o Pathological lymph nodes with 15 mm short axis are considered measurable 
and can be selected as target lesions; however, lymph nodes should not be 
selected as target lesions when other suitable target les ions are available.  
o Measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target 
lesions, and recorded and measured at baseline. These lesions should be 
selected bas ed on their size (lesions with the longest diameter) and their 
suitability for accurate repeated measurements (either by [CONTACT_91071]).  
Note:  Cystic lesions thought to represent cystic metastases must not be selected as target 
lesions when other suitable target lesions are available.  
Note : Measurable lesions that have been previously irradiated and have not been shown 
to be progressing following irradiation must not be considered as target lesions.  
Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue components, 
that can be evaluated by [CONTACT_462]) can be considered measurable. Bone scans, FDG -
PET scans or X -rays are not considered adequate imaging techniques to measure bone 
lesions.  
• All other lesions (or sites of disease) must be identified as non -target and must 
also be recorded at baseline. Non -target lesions will be grouped by [CONTACT_90628]. 
Measurements of these le sions are not required, but the presence or absence of 
each must be noted throughout follow -up. 
Measurable and Non -Measurable Definitions  
Measurable lesion:  
A non -nodal lesion that can be accurately measured in at least one dimension (longest 
dimension) of  
• [ADDRESS_100509] double the slice thickness (e.g., if the slice thickness is [ADDRESS_100510] be 20 mm).  
• 10 mm caliper/ruler measurement by [CONTACT_91072].  
• [ADDRESS_100511] X -ray. 
• Additionally, lymph nodes can be considered pathologically enlarged and 
measurable if:  
15 mm in the short axis when assessed by C T or MRI (slice thickness recommended to 
be no more than 5  mm). At baseline and follow -up, only the short axis will be measured.  
Non-measurable lesion:  
All other lesions including lesions too small to be considered measurable (longest 
diameter <10  mm or pa thological lymph nodes with ≥10 mm and <15 mm short axis) as 
well as truly non -measurable lesions, which include: leptomeningeal disease, ascites, 
pleural or pericardial effusions, inflammatory breast disease, lymphangitic involvement 
of the skin or lung, abdominal masses/abdominal organomegaly identified by [CONTACT_91073] : The presence of at least 1 measurable lesion. Palpable lesions that 
are not measurable by [CONTACT_91074].  
Non-Measurable only disease : The presence of only non -measurable lesions.  
Note : non -measurable only disease is not allowed per protocol.  
Response Criteria  
Evaluation of target lesions:  
Definitions for assessment of response for target lesion(s) are as follows:  
• Complete Response (CR): Disappearance of all target lesions.  Any pathological 
lymph nodes must be <10mm in the short axis.  
• Partial Response (PR):  At least a 30% decrease in the sum of the diameters of target 
lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change 
from baseline).  
• Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for progressive di sease.  
• Progressive Disease (PD): At least a 20% increase in the sum of the diameters of 
target lesions, taking as a reference, the smallest sum of diameters recorded since the 
treatment started (e.g. percent change from nadir, where nadir is defined as the  
smallest sum of diameters recorded since treatment start). In addition, the sum must 
have an absolute increase from nadir of 5mm.  
• Not Applicable (NA): No target lesions at baseline.  
• Not Evaluable (NE): Cannot be classified by [CONTACT_91075].  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
287 Note:  
• If lymph nodes are documented as target lesions the short axis is added into the sum 
of the diameters (e.g. sum of diameters is the sum of the longest diameters for non -
nodal lesions and the short axis for nodal lesions).  When lymph nodes decrease to 
non-pathological size (short axis <10mm) they should still have a measurement 
reported in order not to overstate progression.  
• If at a given assessment time point all target lesions identified at baseline are not 
assessed, sum of the diameters cannot  be calculated for purposes of assessing CR, 
PR, or SD, or for use as the nadir for future assessments.  However, the sum of the 
diameters of the assessed lesions and the percent change from nadir should be 
calculated to ensure that progression has no t been documented.  If an assessment of 
PD cannot be made, the response assessment should be NE.  
• All lesions (nodal and non -nodal) should have their measurements recorded even 
when very small (e.g. 2 mm).  If lesions are present but too small to measure, 5  mm 
should be recorded and should contribute to the sum of the diameters, unless it is 
likely that the lesion has disappeared in which case 0 mm should be reported.  
• If a lesion disappears and reappears at a subsequent time point it should continue to 
be me asured.  The response at the time when the lesion reappears will depend upon 
the status of the other lesions.  For example, if the disease had reached a CR status 
then PD would be documented at the time of reappearance.  However, if the response 
status was  PR or SD, the diameter of the reappearing lesion should be added to the 
remaining diameters and response determined based on percent change from baseline 
and percent change from nadir.  
Evaluation of non -target lesions:  
Definitions for assessment of respon se for non -target lesions are as follows:  
• Complete Response (CR):  The disappearance of all non -target lesions. All lymph 
nodes identified as a site of disease at baseline must be non -pathological (e.g. <10 
mm short axis).  
• Non-CR/Non -PD:  The persistence o f 1 or more non -target lesion(s) or lymph nodes 
identified as a site of disease at baseline ≥ 10 mm short axis.  
• Progressive Disease (PD): Unequivocal progression of existing non -target lesions.  
• Not Applicable (NA):  No non -target lesions at baseline.  
• Not Evaluable (NE):  Cannot be classified by [CONTACT_91076].  
Note:  
• In the presence of measurable disease, progression on the basis of solely non -target 
disease requires substantial worsening such that even in the presence of SD or PR in 
target disease, the overall tumor burden has increased sufficiently to merit 
discontinuation of therapy.  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
288 • Sites of non -target lesions, which are not assessed at a particular timepoint based on 
the assessment schedule, should be excluded from the response de termination (e.g. 
non-target response does not have to be "Not Evaluable").  
New lesions:  
New malignancies denoting disease progression must be unequivocal.  Lesions identified 
in follow -up in an anatomical location not scanned at baseline are considered n ew 
lesions.  
Any equivocal new lesions should continue to be followed.  Treatment can continue at 
the discretion of the investigator until the next scheduled assessment.  If at the next 
assessment the new lesion is considered to be unequivocal, progression should be 
documented.  
Evaluation of overall response:  
Table 53 presents the overall response at an individual time point for all possible 
combinations of tumor responses in target and non -target lesions with or without the 
appearance of new lesions for su bjects with measurable disease at baseline.  
Table 53 Evaluation of Overall Response for Subjects with Measurable 
Disease at Baseline  
Target Lesions  Non-Target Lesions  New Lesions  Overall Response  
CR CR or NA  No CR 
CR Non-CR/Non -PD or NE  No PR 
PR Non-PD or NA or NE  No PR 
SD Non-PD or NA or NE  No SD 
NE Non-PD or NA or NE  No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR=complete response, PR = partial response, SD=stable disease, PD=progressive disease, NA= Not applicable, 
and NE=Not Evaluable  
 
Note:  
• Subjects with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should 
be classified as having "symptomatic deterioration." Objective response status is 
determined by [CONTACT_91077]. Every effort should be made to 
document the objective progression even after discontinuation of treatment.   
• In some circumstances, it may be difficult to distinguish residual disease from 
normal tissue. When the evaluatio n of CR depends on this determination, it is 
recommended that the residual lesion be investigated (fine needle 
aspi[INVESTIGATOR_337]/biopsy) to confirm the CR.  
TMF- [ADDRESS_100512] overall response:  
The best overall response is the best response recorded from the start o f the treatment 
until disease progression/recurrence and will be determined programmatically by [CONTACT_91078].  
Confirmation Criteria:  
• To be assigned a status of PR or CR, a confirmatory disease as sessment should be 
performed no less than 4 weeks (28 days) after the criteria for response are first met.  
 
12.12.2.  iRECIST Guidelines  
iRECIST is based on RECIST 1.1, but adapted to account for the unique tumor response 
seen with immunotherapeutic drugs. iRECIST w ill be used to assess tumor response and 
progression, and make treatment decisions. When clinically stable and upon approval from 
the Medical Monitor and separate written consent of the participant (See Section 8.1), 
participants may continue treatment until progression is confirmed according to the rules 
described below. This allowance to continue treatment despi[INVESTIGATOR_90971] a transient tumor flare in the 
first few months after the start of immunotherapy, and then experience subsequent disease 
response. These data will be captured in the clinical database.  
Clinical stability  is defined as meeting all of the following:  
• Absence of symptoms and signs indicating clinically significant progression of 
disease  
• No decline in ECOG performance status  
• No requirements for intensified management, including increased analgesia, 
radiation, or other palliative care  
• Absence of rapid disease progression or threat to vital organs or critical anatomical 
sites (e.g., CNS metastasis, respi[INVESTIGATOR_90972], or spi[INVESTIGATOR_90973]) requiring urgent alternative me dical intervention  
• No significant, unacceptable, or irreversible toxicities related to study treatment  
Any participant deemed clinically unstable should be discontinued from study treatment 
at site -assessed radiologic evidence of PD. It is required to ob tain the repeat tumor imaging, 
when feasible, for confirmation of PD by [CONTACT_19393]. The tumor assessment should be 
repeated at least [ADDRESS_100513] and the participant continues to be 
clinically stable, study treatment may continue and follow the regular imaging schedule. If 
PD is confirmed (iCPD), the participant will be d iscontinued from study treatment.  
 
TMF- [ADDRESS_100514] 1.1 the investigator 
will decide in consultation with the Medical Monitor whether to continue a participant on 
study treatment un til repeat imaging is obtained (using iRECIST for participant 
management (see Table 54 and Figure 11). This decision should be based on the 
participant’s overall clinical condition (See discussion of clinical stability in Section 
12.12.1  above). The investigator must obtain approval from the Medical Monitor and 
separate consent from the participant prior to continuing treatment.  
Tumor flare may manifest as any factor causing radiographic progression per RECIST 1.1, 
including:  
• Increase in the sum of diameters of target lesion(s) identified at baseline to ≥20% 
and ≥5  mm from nadir  
o Note:  the iRECIST publication uses the terminology “sum of measurements”, but 
“sum of diameters” will be used in  this protocol, consistent with the original 
RECIST 1.1 terminology.  
• Unequivocal progression of non -target lesion(s) identified at baseline  
• Development of new lesion(s)  
iRECIST defines response categories, including iUPD (unconfirmed progressive disease) 
and iCPD (confirmed progressive disease). For purposes of iRECIST assessment, the first 
visit showing progression according to RECIST 1.1 will be assigned a visit (overall) 
response of iUPD, regardless of which factors caused the progression.  
At this visit , target and non -target lesions identified at baseline by [CONTACT_393] 1.[ADDRESS_100515] 1.1. From m easurable 
new lesions, up to 5 lesions total (up to 2 per organ), may be selected as New Lesions – 
Target. The sum of diameters of these lesions will be calculated and kept distinct from the 
sum of diameters for target lesions at baseline. All other new le sions will be followed 
qualitatively as New Lesions – Non-target.  
Assessment at the Confirmatory Imaging  
At the confirmatory imaging visit assessment, the participant will be classified as 
progression confirmed (with an overall response of iCPD), or as sho wing persistent 
unconfirmed progression (with an overall response of iUPD), or as showing disease 
stability or response (iSD/iPR/iCR). Timing of confirmatory imaging is described in 
Section 9.3.1 . 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
291 Confirmation of Progression  
Progression is considered confirmed, and the overall response will be iCPD, if ANY  of the 
following occurs:  
• Any of the factors that were the basis for the initial iUPD show worsening  
o For target lesions, worsening is a further increase in the sum of diameters of 
≥5 mm, compared to any prior iUPD time point  
o For non -target lesions, worsening is any significant growth in lesions overall, 
compared to a prior iUPD time point; this does not have to meet the 
“unequivocal” standard of RECIST 1.1  
o For new lesions, worsening is any of these:  
▪ An increase in the new lesion sum of diameters by ≥5  mm from a prior 
iUPD time point  
▪ Visible growth of new non -target lesions  
▪ The appearance of add itional new lesions  
• Any new factor appears that would have triggered PD by [CONTACT_393] 1.1  
Persistent iUPD  
Progression is considered not confirmed, and the overall response remains iUPD, if:  
• None of the progression -confirming factors identified above occurs AND  
• The target lesion sum of diameters (initial target lesions) remains above the initial 
PD threshold (by [CONTACT_393] 1.1)  
Additional imaging for confirmation should be scheduled 4 to 8 weeks from the imaging 
on which iUPD is seen. This may correspond to the next  visit in the original visit schedule. 
The assessment of the subsequent confirmation imaging proceeds in an identical manner, 
with possible outcomes of iCPD, iUPD, and iSD/iPR/iCR.  
Resolution of iUPD  
Progression is considered not confirmed, and the overall  response becomes iSD/iPR/iCR, 
if: 
• None of the progression -confirming factors identified above occurs, AND  
• The target lesion sum of diameters (initial target lesions) is not above the initial PD 
threshold.  
The response is classified as iSD or iPR (depending on the sum of diameters of the target 
lesions), or iCR if all lesions resolve.  
In this case, the initial iUPD is considered to be pseudo -progression, and the level of 
suspi[INVESTIGATOR_19367] “reset.” This means that the next visit that show s radiographic 
TMF- [ADDRESS_100516], as assessed by [CONTACT_093], and 
the participant continues to be clinically stable, study treatment may continue and follow 
the regular imaging schedule. If PD is confirmed, participants will be discontinued from 
study treatment.  
Detection  of Progression at Visits after Pseudo -Progression Resolves  
After resolution of pseudo -progression (i.e., achievement of iSD/iPR/iCR), iUPD is 
indicated by [CONTACT_19518]:  
• Target lesions  
o Sum of diameters reaches the PD threshold (≥20% and ≥5  mm increase from 
nadir) either for the first time, or after resolution of previous pseudo -
progression. The nadir is always the smallest sum of diameters seen during the 
entire trial, either before or after an instance of pseudo -progression.  
• Non-target lesio ns 
o If non -target lesions have never shown unequivocal progression, doing so for 
the first -time results in iUPD.  
o If non -target lesions have shown previous unequivocal progression, and this 
progression has not resolved, iUPD results from any significant furt her growth 
of non -target lesions.  
• New lesions  
o New lesions appear for the first time  
o Additional new lesions appear  
o Previously identified new target lesions show an increase of ≥  5 mm in the 
new lesion sum of diameters, from the nadir value of that sum  
o Previ ously identified non -target lesions show any significant growth  
If any of the events above occur, the overall response for that visit is iUPD, and the iUPD 
evaluation process (see Assessment at the Confirmatory Imaging above) is repeated. 
Progression must be confirmed before iCPD can occur.  
The decision process is identical to the iUPD confirmation process for the initial PD, with 
one exception: if new lesions occurred at a prior instance of iUPD, and at the confirmatory 
imaging the burden of new lesions ha s increased from its smallest value (for new target 
lesions, the sum of diameters is ≥5 mm increased from its nadir), then iUPD cannot resolve 
to iSD or iPR. It will remain iUPD until either a decrease in the new lesion burden allows 
resolution to iSD or i PR, or until a confirmatory factor causes iCPD.  
Additional details about iRECIST are provided in the iRECIST publication 
[Seymour , 2017].  
TMF- [ADDRESS_100517] 1.1  Repeat imaging at 
4 to 8 weeks to 
confirm PD.  May continue study 
treatment at the 
investigator’s 
discretion, with 
Medical Monitor 
approval and 
participant consent, 
while awaiting 
confirmatory tumor 
imaging by [CONTACT_91079].  Repeat imaging at 
4 to 8  weeks to 
confirm PD per 
investigator’s 
discretion only.  Discontinue treatment  
Repeat tumor 
imaging confirms 
PD (iCPD) by 
[CONTACT_91080].  Discontinue treatment  No additional 
imaging required.  Not applicable  
Repeat tumor 
imaging shows 
iUPD by [CONTACT_91081] 
4 to 8  weeks to 
confirm PD. May 
occur at next 
regularly 
scheduled 
imaging visit.  Continue study 
treatment at the 
investigator’s 
discretion.  Repeat imaging at 
4 to 8  weeks to 
confirm PD per  
investigator’s 
discretion only.  Discontinue treatment  
Repeat tumor 
imaging shows 
iSD, iPR, or iCR by 
[CONTACT_91082].  Continue regularly 
scheduled 
imaging 
assessments.  Continue study 
treatment at the 
investigator’s 
discretion.  Continue regularly 
scheduled 
imaging 
assessments.  If clinically unstable, 
hold treatment  
 
May consider restart ing 
study treatment only if 
condition has improved 
and/or clinically stable 
per investigator’s 
discretion. Next tumor 
imaging should occur 
accordi ng to the regular 
imaging schedule.  
 
iCPD = iRECIST confirmed progressive disease; iCR = iRECIST complete response; iRECIST = modified 
Response Evaluation Criteria in Solid Tumors 1.1 for immune -based therapeutics; iSD = iRECIST stable disease; 
iUPD = iRECIST unconfirmed progressive disease; PD = progressive disease; RECIST 1.1 = Response 
Evaluation Criteria in Solid Tumors 1.1.  
 
 
 
 
TMF- [ADDRESS_100518] 
Radiologic Evidence of PD Assessed by [CONTACT_91083]- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
295 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
296  
 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
297 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
298 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
299 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
300 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
301 12.14.  Appendix 14: Immune -Related Diseases  
Table 56 Potential Immune -Mediated Diseases  
Neuroinflammatory disorders  Musculoskeletal disorders  Skin disorders  
• Cranial nerve disorders, 
including 
paralyses/paresis (e.g. 
Bell’s palsy)  
• Optic neuritis  
• Multiple sclerosis   
• Transverse myelitis  
• Guillain -Barré syndrome, 
including Miller Fisher 
syndrome and other 
variants  
• Acute disseminated 
encephalomyelitis, 
including site specific 
variants: e.g. non -
infectious encephalitis, 
encephalomyelitis, 
myelitis, 
myeloradiculoneuritis  
• Myasthenia gravis, 
including Lambert -Eaton 
myasthenic syndrome  
• Immune -mediated 
peripheral neuropathies 
and plexopathies, 
(including chroni c 
inflammatory 
demyelinating 
polyneuropathy, 
multifocal motor 
neuropathy and 
polyneuropathies 
associated with 
monoclonal 
gammopathy).  
• Narcolepsy  • Systemic lupus 
erythematosus and 
associated conditions  
• Systemic  Scleroderma  
(Systemic sclerosis) , 
including diffuse 
systemic form and 
CREST syndrome  
• Idiopathic inflammatory 
myopathies, including  
Dermatomyositis , 
Polymyositis , 
• Antisynthetase 
syndrome  
• Rheumatoid arthritis  and 
associated conditions  
including  Juvenile 
chronic arthritis  and 
Still’s disease ) 
• Polymyalgia rheumatica   
• Spondyloarthritis, 
including ankylosing 
spondylitis, reactive 
arthritis (Reiter's 
Syndrome) and 
undifferentiated  
spondyloarthritis  
• Psoriatic arthropathy  
• Relapsing polychondritis  
• Mixed connective tissue 
disorder  • Psoriasis  
• Vitiligo  
• Erythema nodosum  
• Autoimmune bullous skin 
diseases (including 
pemphigus, pemphigoid and 
dermatitis herpetiformis)  
• Alopecia areata  
• Lichen planus  
• Sweet’s syndrome  
• Localized Scleroderma  
(Morphoea ) 
Liver disorders  Gastrointestinal disorders  Endocrine disorders  
• Autoimmune hepatitis  
• Primary biliary cirrhosis  
• Primary sclerosing 
cholangitis  
• Autoimmune cholangitis . • Inflammatory Bowel 
disease, including  
Crohn’s disease , 
ulcerative  colitis , 
microscopic colitis, 
ulcerative  proctitis  
• Celiac disease  
• Autoimmune pancreatitis  • Autoimmune thyroiditis 
(including Hashimoto 
thyroiditis)  
• Grave's or Basedow’s 
disease  
• Diabetes mellitus type I  
• Addison’s disease  
• Polyglandular autoimmune 
syndrome  
• Autoimmune hypophysitis  
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
302 Vasculitides  Blood disorders  Others  
• Large vessels vasculitis 
including: giant cell 
arteritis such as 
Takayasu's arteritis and 
temporal arteritis.  
• Medium sized and/or 
small vessels vasculitis 
including: polyarteritis 
nodosa, Kawasaki's 
disease, microscopic 
polyangiitis, Wegener's 
granulomato sis, Churg –
Strauss syndrome 
(allergic granulomatous 
angiitis), Buerger’s 
disease (thromboangiitis 
obliterans), necrotizing 
vasculitis and anti -
neutrophil cytoplasmic 
antibody (ANCA) positive 
vasculitis (type 
unspecified), Henoch -
Schonlein purpura, 
Behcet's  syndrome, 
leukocytoclastic 
vasculitis.  • Autoimmune hemolytic 
anemia  
• Autoimmune 
thrombocytopenia  
• Antiphospholipid 
syndrome  
• Pernicious anemia  
• Autoimmune aplastic 
anemia  
• Autoimmune 
neutropenia  
• Autoimmune 
pancytopenia  • Autoimmune 
glomerulonephritis (including 
IgA nephropathy, 
glomerulonephritis rapi[INVESTIGATOR_90974], membranous 
glomerulonephritis, 
membranoproliferative 
glomerulonephritis, and 
mesangioproliferative 
glomerulonephritis)  
• Ocular autoimmune 
diseases (including 
autoimmune uveitis and 
autoimmune retinopa thy) 
• Autoimmune 
myocarditis/cardiomyopathy  
• Sarcoidosis  
• Stevens -Johnson  syndrome  
• Sjögren’s syndrome  
• Idiopathic pulmonary fibrosis  
• Goodpasture syndrome  
• Raynaud’s phenomenon  
 
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
303 12.15.  Appendix 15: Protocol Amendment History  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
304 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
305 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
306 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
307  
 
 
 
 
 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
308 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
309 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
310 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
311  
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
312  
 
 
 
 
 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
313 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
314 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
315 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
316  
 
 
 
 
 
 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
317 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
318 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
319 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
320 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
321 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
322 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
323 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
324 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
325 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
326 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
327 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
328 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
329 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
330 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
331 
CCI
TMF- 16073217  CONFIDENTIAL  205801  
  Protocol Amd 10 
332 
CCI